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The quinoline structure is known to be a versatile building block in medicinal chemistry and occurs in 
many biologically active molecules. In antimalarial chemotherapy, 4-aminoquinolines (chloroquine 
and derivatives) represent a potent and well-studied class of compounds. However, the spread of 
multi-drug resistance within Plasmodium falciparum strains has stimulated a continuous research 
interest in the design and synthesis of new antimalarial agents. The aim of this PhD thesis is to move 
away from the well-known 4-aminoquinoline core, and thus to further explore the chemical space 
around the quinoline scaffold en route to innovative, potentially bioactive quinoline derivatives. 
A first approach comprised the synthesis of a variety of 5-, 6- and 8-(4-aminobutyloxy)quinolines 
based on a rhodium-catalyzed hydroformylation and a reductive amination as the key steps. A 
second approach focused on the hybridization of quinolines with a bioactive heterocyclic moiety via 
an aziridine linker. The inherent aziridine reactivity then allowed for further selective transformations 
to provide novel quinoline derivatives. A third approach evolved around the synthesis of N-
functionalized 3-, 5-, 6- and 8-aminoquinolines via intermediate (3-pyrrolin-1-yl)- and (2-
oxopyrrolidin-1-yl)quinolines. In a final approach, novel halogenated 4-quinolones were synthesized 
through initial N-allylation of 4-hydroxyquinolines. In addition to the chemical syntheses, different 
biological assessments (including antiplasmodial activity, cytotoxicity, and antifungal activity studies) 
of the novel quinoline systems were performed, leading to the identification of several bioactive 
compounds with potential for further elaboration in medicinal chemistry programs. 
 
  
 
 
 
 
 
 
 
 
PART I 
INTRODUCTION AND GOALS  
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Quinoline and its derivatives have intrigued chemists since their discovery because of their 
prominent chemical and pharmacological characteristics. The quinoline skeleton 1 is a well-known 
privileged scaffold in many biologically active natural and synthetic compounds with various activities 
like antimalarial,1 anticancer,2, 3 antipsychotic,4 anti-inflammatory,5, 6 anti-HIV,7 antituberculosis,8 
antimicrobial,9 antileishmanial10 and antifungal activity.11, 12 Although quinolines have a very wide 
biological scope, the isolation of the antimalarial alkaloid quinine 2 in 1820 stimulated the 
antiplasmodial evaluation of quinoline-containing classes of compounds. Quinolines have thus grown 
to be among the most important antimalarial drugs ever used.  
 
Figure 1 
Malaria is the most lethal human parasitic infection. The word malaria is the contraction of the Italian 
“mala aria”, meaning “bad air”, a designation that originates from the belief that the disease was 
caused by unwholesome air in swampy districts. In 2012 malaria was transmitted in 103 countries, 
with 3.4 billion people at risk of infection, resulting in an estimated 207 million malaria cases and 
627.000 deaths.13 About 80% of the estimated cases and 90% of the deaths occur in sub-Saharan 
Africa, mostly in children under the age of five, pregnant women or immuno-deficient people.14-16 A 
map of global malaria incidence is depicted below (Figure 2). Malaria is a protozoan disease that is 
transmitted to humans by bites of female Anopheles mosquitoes. There are five Plasmodium species 
that are capable of infecting humans: P. falciparum, P. vivax, P. malariae, P. knowlesi and P. ovale, 
the latter being recently defined as two sympatric forms: P. ovale curtisi and P. ovale wallikeri.17, 18 
Most malaria mortality in sub-Saharan Africa occurs due to P. falciparum infection, while 
considerable morbidity can be caused by P. vivax infection, particularly in South America and 
Southeast Asia.19 Clinical symptoms of malaria vary depending on the infecting parasite species and 
the immune system of the human host, but can range from fever to metabolic acidosis, anemia, 
organ failure, coma and death.20-22  
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Figure 2: Global malaria incidence and country phase 
Global malaria mapper on www.worldmalariareport.org 
 
All Plasmodium parasite species display a complex life cycle that comprises molecular interactions 
with a vertebrate host (e.g. human) and an invertebrate host (Anopheles mosquito). Human infection 
commences after inoculation of the bloodstream of the human host by haploid sporozoites following 
a bite of an infected female Anopheles mosquito. These motile sporozoites travel to the liver and 
invade hepatocytes, where they multiply to form schizonts. These schizonts eventually burst, 
releasing thousands of merozoites into the bloodstream (2-16 days after the initial infection),23 
thereby initiating the asexual cycle. However, P. vivax and P. ovale can remain dormant in the liver as 
hypnozoites and re-emerge months or years after the initial infection to begin a blood-stage infection 
(also known as relapsing malaria). Once the merozoites have reached the bloodstream, they attach 
to and invade erythrocytes and asexually replicate to produce up to 32 new merozoites per red blood 
cell. This growth stage is followed by red blood cell rupture after which the released merozoites re-
invade new erythrocytes, promoting further infection. When the total asexual parasite number in 
circulation reaches about 100 million, symptoms of the disease become apparent. This asexual 
reproduction cycle can persist indefinitely when the illness is not treated. A small fraction of the 
haploid asexual parasites differentiate into male and female gametocytes within the erythrocyte.24 
Until very recently it was unknown what prompted gametocytogenesis, but two recent publications 
reported the necessity of AP2-G DNA-binding proteins for sexual stage initiation.25, 26 These 
gametocytes can persist for weeks and are responsible for the transmission of malaria. Gametocytes 
are taken up by a feeding anopheline mosquito whereupon they differentiate into male and female 
gametes that fuse to form a zygote in the midgut of the mosquito. Meiosis of the zygote causes a 
motile ookinete to develop that later migrates through the gut wall of the mosquito to form an 
Not applicable 
Country malaria classification – © 2014 Global Malaria Mapper 
PART I  INTRODUCTION AND GOALS 
6 
 
oocyst. After several cycles of DNA replication, the oocyst bursts open and liberates thousands of 
haploid sporozoites,27 which migrate to the salivary glands to await transmission at the next human 
blood meal. The entire cycle can take about one month. 
 
Figure 3: Lifecycle of Plasmodium falciparum in the human body and the Anopheles mosquito 
Adjusted figure from Nature reviews: Microbiology 2013, 11, 849 
A first method to control malaria infections comprises prevention, and this can occur on three levels: 
the first level involves vaccination of people in the affected areas in order to stimulate the body and 
develop immune responses that protect against the disease. Unfortunately, there is currently no 
commercially available malaria vaccine, despite decades of intense research. However, over 20 
(subunit) vaccines are presently being evaluated in clinical trials or are in advanced preclinical 
development.13 Another means to prevent malaria is to restrict the transmission of parasite 
sporozoites. This can be attained by vector control, which is achieved by interrupting their life cycle 
or creating a barrier between the mosquito and the human host. In practice, this is realized by the 
use of insecticide-treated mosquito nets, indoor residual spraying and the use of insect repellents 
such as DEET (diethyltoluamide).13 Prophylactic use of medicines (or chemoprevention) is a third 
possibility to prevent malaria infection which is especially useful in the protection of travelers, but it 
is never completely reliable and should be used in combination with the vector control measures. 
Chemoprophylaxis was also recommended for pregnant women in endemic areas,13 but in most of 
these areas resistance has developed against the approved drugs for this application. 
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When preventive measures have failed and a malaria infection has manifested itself, chemotherapy 
affords the only remedy. Today, chemotherapy essentially involves eliminating the asexual parasites 
and boosting the host’s immune system. The aformentioned quinine 2 was the first effective 
treatment for malaria caused by Plasmodium falciparum. Cinchona trees were the primary source for 
quinine until, under wartime pressure, efforts for a total synthesis were undertaken. In 1944 a formal 
synthesis was published,28 but it could not compete with the isolation of the alkaloid from natural 
sources in economic terms. Quinine remained the antimalarial drug of choice until the late 1940s, 
when other drugs, such as chloroquine 3, that had fewer unpleasant side effects, replaced it. 
Chloroquine (CQ) had already been discovered in 1934 by Hans Andersag, who called it Resochin®, 
but at the time it was found to be too toxic for human use.29 Reconsideration during WWII found 
Resochin® to exhibit significant antimalarial activity and it was introduced as chloroquine into clinical 
practice in 1947 for (prophylactic) treatment of malaria.30 Quinine 2, chloroquine 3 and their 
derivatives, such as pamaquine 4, amodiaquine 5 and primaquine 6, dominated the landscape of 
malaria treatment for a while until other synthetic agents like pyrimethamine 7, sulfadoxine 8, 
artemisinin 9, mefloquine 10 and artemether 11 were discovered and widened the choice. 
 
Figure 4 
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Even though the parasite switches between several developmental stages in the human host, all 
disease symptoms sprout from repeated lysis of infected erythrocytes and invasion of formely 
untouched erythrocytes by the asexual blood-stage parasite. Therefore, nearly all therapies focus on 
the blood-stage parasite. When the parasite has entered the erythrocytes, it starts degrading 
hemoglobin in its digestive vacuole to acquire essential amino acids to construct its own proteins. 
Hemoglobin is composed of a protein unit (which is digested by the parasite) and a heme unit (not 
consumed by the parasite). During this degradation process, heme, a toxic and soluble molecule, is 
released and could damage the parasite cell. To avoid destruction by this heme molecule, the 
parasite crystallizes heme to hemozoin, a non-toxic molecule, which collects in the digestive vacuole 
as insoluble crystals. This is, however, the stage where quinine 2, CQ 3 and most of the (4-
amino)quinoline derivatives interfere with the parasite’s lifecycle. When e.g. CQ enters an infected 
erythrocyte, it can enter the parasite’s digestive vacuole by simple diffusion. CQ becomes protonated 
as the digestive vacuole is acidic (pH 4.7), and the protonated CQ cannot leave by diffusion anymore. 
Subsequently, CQ inhibits the parasitic enzyme heme polymerase that converts the toxic heme into 
non-toxic hemozoin, thereby resulting in the accumulation of toxic heme within the parasite. The 
toxic build-up of heme ultimately results in cell lysis and parasite cell autodigestion.31 Only few of the 
available drugs (like pamaquine 4 and primaquine 6) clear the dormant liver forms (hypnozoites) of 
the parasite. These drugs are used to treat P. vivax and P. ovale malaria and prevent relapses, they 
also display gametocytocidal (blood-stage) activity against P. falciparum malaria causing a reduction 
of malaria transmission. However, these drugs also cause hemolytic anemia in people with glucose-6-
phosphate dehydrogenase deficiency, which impedes their use.32 
Unfortunately, resistance has arisen against most of the established drugs and limited their use. 
Chloroquine-resistant P. falciparum initially developed independently in areas in Southeast Asia, 
Oceania and South America in the late 1950s, early 1960s. Since then, chloroquine resistance has 
spread to about every area of the world where Plasmodium falciparum parasites occur. P. falciparum 
has developed resistance against most of the currently available antimalarial drugs (like sulfadoxine 
8, pyrimethamin 7, mefloquine 10 and quinine 2) as well. Resistance against these drugs tends to be 
less geographically widespread, although in some affected areas the impact of multi-drug resistant 
malaria can be significant. Plasmodium vivax has also become chloroquine and sulfadoxine-
pyrimethamine resistant.33, 34 It should be noted that chloroquine resistance is caused by exclusion of 
the drug from the active site and is thus compound specific. By the 1970s, the endoperoxide 
artemisinin 9 and its derivatives (such as artemether 11) supplanted the quinolines and other drugs. 
They were the new benchmark for the design of antimalarials, which has led to the synthesis of 
trioxane and endoperoxide antimalarials. These new drugs appeared to have no resistance liabilities, 
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until in 2008 low-grade resistance to artemisinin-based drugs arose in parts of Southeast Asia.35 To 
counteract the development of widespread artemisinin resistance, the World Health Organisation 
(WHO) demanded to stop the application of artemisinin monotherapies, and to only use this drug in 
combination with other drugs, the so-called artemisinin-combination therapies (ACT). 
The picture below illustrates the evolution of malaria treatment during the last century. Some 
conspicuous turning points are clearly depicted; an immense decrease in annual malaria deaths 
occurred in the 1930s-1940s as a result from the introduction of novel, potent antimalarial drugs 
such as CQ. A further decrease was observed following an intense DDT 
(dichlorodiphenyltrichloroethane) spraying program aiming to kill the anopheline vector. However, 
excessive use of DDT and available drugs rendered both the vector and the parasite resistant, causing 
an incline in malaria mortality around 1970, which persisted until the turn of the century. Since 2000, 
an immense expansion in the financing and coverage of malaria control programs has led to a wide-
scale reduction in malaria incidence and mortality. Worldwide, between 2000 and 2012, estimated 
malaria mortality rates declined by 45% in all age groups.10  
 
Figure 5: Evolution of Malaria Mortality 
Adjusted graph from Clin. Microbiol. Rev. 2002, 15, 564. 
Since there is currently no malaria vaccine available and resistance against most of the established 
drugs is on the rise, there is an urgent need for novel antimalarials. As stated before, the quinoline 
core is a privileged scaffold that displays excellent biological activities and is incorporated in many 
accomplished antiplasmodial drugs. The aim of this PhD thesis consists of the design of novel 
quinoline-containing compounds with potential biological properties, moving away from the 
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extensively scrutinized 4-aminoquinoline core and further exploring the chemical space around the 
quinoline scaffold. It is essential to note that the main focus of this work is put on the elaboration of 
new synthetic approaches toward a broad variety of novel quinoline compounds and preliminary 
assessment of their biological properties. Further hit-to-lead optimization will not be dealth with in 
this thesis. 
In a first chapter of this PhD thesis special attention will be devoted to the synthesis of 4-, 5-, 6- and 
8-(aminobutyloxy)quinolines and 3-, 4-, 5-, 6- and 8-(aminobutylamino)quinolines. These compounds 
would make it possible to evaluate the relationship between the quinoline-side chain position and 
their antiplasmodial potency as well as to assess the influence of replacing amino side chains by their 
oxygen equivalents. More specifically, (2-methyl)allylation of amino- or hydroxyquinolines 12 or 13 
will be evaluated, leading to the formation of (2-methyl)allylamino- or (2-methyl)allyloxyquinolines 
14. These compounds 14 will subsequently be deployed as substrates for a rhodium-catalyzed 
hydroformylation, which could then furnish the corresponding aldehydes 15. The latter substrates 15 
can then be converted toward the premised (aminobutylamino)- or (aminobutyloxy)quinolines 16 by 
reductive amination (Scheme 1). 
 
Scheme 1 
An emerging strategy within drug discovery programs comprises the synthesis of novel chemical 
entities via combination of two biologically relevant moieties. This strategy has been used 
successfully in for example the development of new anticancer, anti-Alzheimer and antiviral 
agents.36-38 The literature review within this PhD thesis will discuss these so-called hybrid molecules 
or chimeras as well, more specifically quinoline-containing hybrids with antiplasmodial activity. It 
should be noted that “hybrid molecules” is an ambiguous term, so to clarify, when this term is used 
in this manuscript, it suggests the covalent coupling of two biologically active moieties, regardless the 
(dual) mode of action of the final product. The promising potential of molecular hybridization 
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inspired the second topic of this thesis, where the quinoline scaffold will be combined with another 
bioactive heteroaromatic moiety via an aziridine linker. Condensation of quinolinecarboxaldehydes 
17 with 2,3-dibromopropylamine hydrobromide should yield the corresponding imines, which could 
be transformed to the desired intermediate ([2-(bromomethyl)aziridin-1-yl]methyl)quinolines 18 by 
hydride reduction.39 Subsequently, nucleophilic substitution of these bromides 18 with various 
bioactive heterocyclic nucleophiles (such as pyrazoles and pyrimidinones) is expected to afford 
quinoline-aziridine-pyrazole/pyrimidinone hybrids 19. The inherent aziridine reactivity can then 
finally allow for further selective transformations (aziridine ring opening) to provide quinoline 
derivatives 20 (Scheme 2). 
 
Scheme 2 
Keeping in mind the initial rationale of exploring the chemical space around the quinoline core, and 
further elaborating on the strategy of linking a reactive heterocycle to a quinoline core, pyrroli(di)ne-
quinoline conjugates will be explored in the final part of this PhD thesis. Further derivatization of 
these pyrrolidine entities could afford side chain lengths equal to that of CQ. Diallylation and 
acylation of 3-, 5-, 6-, and 8-aminoquinolines 12 could furnish diallylaminoquinolines 21 and 4-chloro-
1-(quinolinyl)butyramides 23, respectively, which could afford the desired (3-pyrrolin-1-yl)- and (2-
oxopyrrolidin-1-yl)quinoline intermediates 22 and 24 after ring-closing metathesis and 
intramolecular nucleophilic substitution. Finally a reactivity screening of these intermediates is 
expected to provide a library of the desired functionalized 3-, 5-, 6- and 8-aminoquinolines. 
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Scheme 3 
The above-described strategies should allow for the synthesis of a broad variety of functionalized 
quinolines, in which the side chain is connected to the quinoline core at different positions via a 
nitrogen, oxygen or carbon atom, as eligible substrates for biological activity assessments. 
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The ever-increasing resistance of the Plasmodium parasite against frequently used antimalarial drugs 
such as chloroquine 3 and artemisinin 9 urges scientists to find new approaches to treat and prevent 
malaria infections. Since there is currently no licensed malaria vaccine available to make people 
immune,40 chemotherapy still offers the best solutions. Novel strategies in antimalarial treatment 
include the optimization of therapies with available drugs (e.g. artemisinin combination therapy), 
repurposing of medicines, developing analogs of existing drugs and the evaluation and use of 
chemosensitizers (drug-resistance reversers).41-45 
There is, however, another strategy that has gained much attention in the field of contemporary 
medicinal chemistry. It involves the linking together of two biologically active molecules 
(pharmacophores) into one single hybrid compound with a dual mode of action. These novel hybrid 
molecules have the potential to enhance efficacy, improve safety, be cost-effective and reduce the 
propensity to elicit resistance relative to the parent drugs.46-48 Since molecular hybridization is a hot 
topic in drug development, and not the least in antiplasmodial research, many contributions to this 
topic appeared in the recent literature. 
Several general reviews about antimalarial hybrid drugs have already been published,46-50 but in this 
chapter, a specific literature overview of antimalarial hybrid molecules containing a quinoline core 
will be presented (covering publication between 2009 and 2014).  
Quinoline-based antimalarial hybrids can be categorized into four major classes. The first class 
contains quinolines which are connected to another well-known antimalarial drug, i.e. artemisinin or 
one of its derivatives. A second class involves the coupling of quinoline with a synthetic peroxide. 
Thirdly, quinolines can be linked to synthetic reversal agents (chemosensitizers) and lastly, the fourth 
class of quinoline hybrids consists of quinolines that are connected to new biologically active motifs. 
2.1. Hybrids of quinoline and artemisinin (or derivatives)  
One of the first antimalarial quinoline-artemisinin hybrids has been described by Walsh in 2007, and 
it was one of the simplest in terms of known individual drugs. Dihydroartemisinin (DHA) was coupled 
directly to the carboxylic acid derivative of quinine via an ester linkage, affording hybrid 25. This 
hybrid had superior activity against chloroquine-sensitive (CQS) and chloroquine-resistant (CQR) 
strains of P. falciparum compared to quinine or artemisinin alone and compared to a 1:1 mixture of 
the two.51 This excellent activity suggested a palpable benefit from covalently binding these two 
molecules.  
Prompted by these results, Lombard et al. combined 1-bromo-2-(10β-dihydroartemisinoxy)ethane 
with 7-chloro-4-aminoquinolines through different diamino linkers, resulting in hybrids 26. All these 
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compounds (except two) displayed a higher or comparable in vitro potency than chloroquine.52, 53 
The most potent hybrids exhibited similar in vivo activities to chloroquine (20 nM) against the CQ- 
susceptible strain of P. falciparum and were superior against the resistant strain (20 vs 160 nM).54 
Furthermore, it appeared that cyclic linkers should not be included and that the linker chain should 
be limited to two or three carbon atoms with or without methyl substituent.52, 53 
 
Figure 6 
Since there is a wide range of aminoquinoline antimalarials available, Capela et al. decided to 
hybridize primaquine (PQ, an 8-aminoquinoline) with artemisinin. The synthesis started with the 
conversion of artelinic acid to the corresponding hydroxamate, which was then reduced to the 
aldehyde. Reductive amination using PQ afforded hybrid 27. Further, hybrid 28 was obtained by 
oxidizing the allyl moiety of 10β-allyldeoxoartemisinin to the carboxylic acid, which was subsequently 
coupled to PQ in the presence of TBTU, a peptide coupling reagent, and triethylamine. Hybrids 27 
and 28 were evaluated in vitro against a CQR P. falciparum strain W2. Their antiplasmodial activities 
(IC50 = 13 and 9 nM, respectively) were similar to artemisinin (8 nM) and superior to primaquine (3.3 
µM). Interestingly, even though 28 had a lower in vitro IC50 value than compound 27, it was more 
active in vivo. This suggested enhanced pharmacokinetic properties or stability, which was attributed 
to the replacement of the oxygen at the C-10 position of the artemisinin moiety with a carbon 
atom.55 
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Figure 7 
Another approach involved the use of the Ugi four-component condensation (U-4CC) reaction which 
utilizes an acid, amine, aldehyde and isocyanide, and converts them into an α-acetamidoamide in 
one step. Here the target Ugi adducts 29 have been synthesized by using artelinic acid, 4-amino-7-
chloroquinoline, paraformaldehyde and cyclohexyl or tert-butyl isocyanide.56 These adducts 29 
displayed in vitro antiplasmodial activities (IC50 values between 26 and 35 nM) that were comparable 
to chloroquine’s activity (20 nM) against the CQS D10 strain of P. falciparum and were more potent 
than CQ against the CQR K1 strain of P. falciparum (IC50 values of 19-23 nM and 219 nM, 
respectively). There was no evidence of hybrids 29 exhibiting cross-resistance with chloroquine.56 
 
Figure 8 
A different strategy from the Lombard group involved the design of artemisinin-quinoline hybrid 
dimers 30. Here two 1-bromo-2-(10β-dihydroartemisinoxy)ethane scaffolds were linked to a 4-
amino-7-chloroquinoline scaffold via various spacers, affording conjugates 30.57 The hybrids with a 
short chain diaminolinker (30a and 30b) displayed excellent in vitro antiplasmodial activity against 
CQS (D10) and CQR (Dd2) strains (5-7 nM and 46-28 nM, respectively), exhibiting higher activity than 
CQ against both strains (22 and 158 nM). Hybrids with a chain length of more than three carbon 
atoms (30c) or with a cyclic linker (30d) were less active than CQ. However, all compounds were less 
active than dihydroartemisinin, but showed good selectivity towards P. falciparum.57 In a follow-up 
study by the same group, extra in vitro and in vivo antimalarial assessments of 30b and 30d have 
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been performed.58 The in vitro antiplasmodial activities of hybrid dimers 30b and 30d against CQS 
(3D7) strain of P. falciparum were 9 and 30 nM, respectively, which were equipotent as compared to 
CQ’s activity of 20 nM. Furthermore, these dimers 30b and 30d were able to cure blood parasitemia 
of mice infected by P. vinckei at low doses (25-50 mg/kg), but recrudescence was usually observed 
within 7-18 days as was also the case with artesunate. Modifications to improve bioavailability are 
necessary for these dimers to be used as oral antimalarial treatment agents.58 
 
Figure 9 
As mentioned before, the introduction of a carbon atom at the C-10 position of artemisinin has been 
shown to stabilize the hybrid molecule. The O’Neil group therefore converted DHA into its C-10 
benzoate, which was allowed to react with allyltrimethylsilane, affording the C-10 allyl DHA 
derivative. Subsequent ozonolysis of the double bond and reductive work up resulted in the 
corresponding alcohol, which was oxidized to the aldehyde. Reductive amination of this aldehyde 
with various alkylaminoquinolines afforded hybrids 31. However, oxidation of the alcohol to the 
carboxylic acid followed by treatment with oxalyl chloride and 4-(3-aminopropylamino)quinoline 
resulted in the formation of hybrid 32. All hybrids displayed very good activities against a CQS (3D7) 
strain of P. falciparum (5-22 nM) and excellent activities against a CQR (K1) strain (8-16 nM), which 
are better than CQ (16 and 187 nM, respectively) and in the same order of magnitude as artemisinin 
(11 and 9 nM, respectively).59 
 
Figure 10 
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2.2. Hybrids of quinoline and a synthetic peroxide  
The commercial availability of artemisinin (and consequently its semi-synthetic derivatives) is limited 
by the fact that it is a natural product isolated from the plant Artemisia annua. Unfortunately, fully 
synthetic peroxidic antimalarial drugs are not yet available for clinical application. Limitations 
associated with semi-synthetic artemisinins include chemical availability, purity, cost, bioavailability 
and pharmacokinetics, which all limit their therapeutical potential.60, 61 Consequently, scientists have 
been engaged in extensive research into synthetic endoperoxide antimalarials in order to find 
structurally simplified molecules with better bioavailability that are also synthetically accessible and 
have a low overall production cost. This has led to the assembly of some totally synthetic peroxide 
analogs such as 1,2,4-trioxolanes, 1,2,4-trioxanes and 1,2,4,5-tetraoxanes, which all carry the critical 
endoperoxide bond that bestows activity to artemisinins.62-66  
An innovation in this field was the design of antimalarials specifically acting on multiple targets 
(covalent biotherapy) in which a trioxane or trioxolane motive was linked to a quinoline entity. These 
chimeric molecules were referred to as trioxaquines and trioxolaquines.59, 67 The first trioxaquine 33 
has been synthesized by Meunier and co-workers in 2000 and showed high in vitro activity against a 
CQR strain of P. falciparum.  
 
Figure 11 
More recently, the O’Neill group produced synthetic 1,2,4-trioxolaquines 35,59 in a three-step 
synthesis starting from adamantan-2-one. The first step involved the transformation of 
adamantanone to a methyl oxime, which in a second step underwent ozonolysis in the presence of 
1,4-cyclohexadione toward intermediate 34. Finally, reductive amination of 34 with aminoquinoline 
derivatives afforded trioxolaquines 35. These hybrids 35 displayed significant antiplasmodial activity 
in vitro against a CQS (3D7) strain of P. falciparum (IC50 = 6-13 nM) and were equally active against a 
CQR (K1) strain (IC50 = 3-26 nM), which made them more potent than CQ (18 and 240 nM, 
respectively). Again, increasing the linker length or introducing cyclic linkers slightly reduced activity, 
but more interestingly, ketone 34 showed superior activity than conjugates 35 indicating that the 
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presence of the additional hematin-binding unit (aminoquinoline) does not enhance antimalarial 
activity in this case.59 
 
Figure 12 
Instead of coupling an aminoquinoline to a synthetic peroxide moiety in order to obtain trioxaquine 
hybrid antimalarials, Robert et al. reported the synthesis of trioxaferroquines 37 and 38, hybrids 
containing a 1,2,4-trioxane moiety that was covalently linked to ferroquine (FQ) 36, a synthetic 
ferrocenyl quinoline. The synthesis involved an initial reduction of the N,N-dimethylamino 
substituent of FQ 36, resulting in the primary amine derivative of FQ. This primary amine was then 
coupled to a trioxane moiety in different manners, affording trioxaferroquines 37 and 38. The 1,2-
disubstituted ferrocene moiety possesses planar chirality and hence trioxaferroquines are chiral 
compounds. The possibility of stereoisomerism complicates the development of trioxaferroquines as 
potential drugs, therefore iso-trioxaferroquine 39 was synthesized as well.68 In vitro antiplasmodial 
activity of trioxaferroquines 37 and 38 and iso-trioxaferroquine 39 was evaluated against two CQR 
strains (FcB1 and FcM29) of P. falciparum. All compounds showed IC50 values in the range from 16 to 
71 nM, which makes them more active than CQ (145 and 735 nM against FcB1 and FcM29, 
respectively), equally active as artemisinin (10 and 18 nM, respectively), but slightly less active than 
FQ (6 and 7 nM, respectively). Furthermore, in vivo antimalarial evaluation of compound 37a 
revealed that when administered orally at low dose (10 mg/kg/day), it was able to clear parasitemia 
below detectable level in P. vinckei petteri infected mice.68 
 
Figure 13 
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In order to prepare the fully synthetic derivative of the aforementioned artemisinin-PQ hybrids, the 
Lopes group linked synthetic 1,2,4,5-tetraoxane derivatives with PQ, using TBTU and methyl 
chloroformate as coupling agents, affording hybrids 40 and 41. These chimeras were screened for 
antiplasmodial activity against a CQR (W2) strain of P. falciparum and they all inhibited the growth of 
the parasite with IC50 values ranging from 21 to 45 nM, suggesting that the linker length between the 
two active sites does not considerably affect activity. To evaluate the ability of hybrids 40 and 41 to 
inhibit liver cell infection by malaria parasites, they were evaluated using an in vitro infection model 
that utilizes a human hepatoma cell line (Huh7) and malaria parasite P. berghei. They displayed high 
potency against the liver forms of the parasite as well, exhibiting IC50 values between 330 and 1000 
nM, which was significantly higher than PQ (7500 nM) and the equimolar mixture of PQ and 
artemisinin (9714 nM). Furthermore, none of the conjugates considerably affected Huh7 cell 
proliferation, indicating that the chimeras were selective and nontoxic antiplasmodial agents. The in 
vivo efficacy of compound 41a was evaluated using P. berghei infected mice; conjugate 41a was 
administered intraperitoneally at 30 mg/kg/day for 5 days and completely and irreversibly cleared 
the parasitemia by day 8. All treated mice survived until the end of the experiment.69  
 
Figure 14 
2.3. Hybrids of quinoline and a synthetic reversal agent 
CQR Plasmodium falciparum strains exhibit no changes in the process of heme detoxification, but 
resistance develops from mutations and alterations in the expression levels of membrane proteins 
located in the membrane of the parasitic digestive vacuole. Crucial to chloroquine resistance are 
mutant forms of a protein known as PfCRT.70, 71 This protein transports chloroquine and lowers its 
concentration in the digestive vacuole, allowing hemozoin formation to resume unhindered and 
thereby causing resistance. It has been known for a long time that calcium channel blockers like 
verapamil, nifedipine, dibenzazepines and their analogs (imipramine, plant-derived alkaloids, 
phenothiazines, dibenzylmethylamines (dibemethins), dihydroanthracenes, primaquine, etc.) can 
restore chloroquine sensitivity in various resistant strains of P. falciparum, and these molecules are 
known as chemosensitizers or reversal agents.72-75 This knowledge resulted in the development of 
dual-function antimalarials that incorporate both, an active antimalarial (CQ) and a resistance 
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reversing chemosensitizer. The covalent bonding of CQ to a reversal agent produced a single 
molecule that was termed ‘reversed-CQ’ (RCQ). 76, 77  
The first example 42 has been reported in 2006 and involved the merging of 4-amino-7-
chloroquinoline to imipramine via an alkyl linker. Hybrid 42 was very effective against both CQS (D6) 
and CQR (Dd2) strains of P. falciparum (3 and 5 nM, respectively), and was able to eliminate 
parasitemia from a mouse model to less than 1% via oral dosing. However, compound 42 was not 
retained for further drug development because of its high lipophilicity.78 
 
Figure 15 
In a follow-up study the linker and aromatic groups of RCQ have been varied, which involved the 
evaluation of the linker length and flexibility as well as the evaluation of the bridging between the 
two aromatic rings of the chemosensitizer. All hybrids 43-46 were tested and displayed significant 
activity against CQS D6 (2-52 nM) and CQR Dd2 (5-115 nM) strains of P. falciparum. Noteworthy was 
the fact that changing terminal amines to amides reduced lipophilicity (cLogP) to values comparable 
to CQ (a factor that is important in improving solubility), as well as the fact that the reversal agent 
portion of the molecule could be considerably varied without severe loss of activity. All compounds 
43-46 also exhibit large selectivity towards malaria parasites.79 
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Figure 16 
Subsequent research performed by the same team involved further variations to both the linker and 
the aromatic head groups of the reversal agent moiety. The linkage was now a piperazinyl ring which 
was supposed to make the compounds more stable to metabolic cleavage. Replacing the diphenyl- or 
dibenzylamino head group with groups such as benzhydryl, adamantyl, triphenylmethyl, 
benzhydrylmethyl and pyridin-2-ylmethyl resulted in hybrids 47 and 48. The in vitro testing results 
from hybrids 47 against CQS D6 (0.5-21 nM) and CQR Dd2 (1-15 nM) strains of P. falciparum were 
superior to CQ (7 and 102 nM, respectively). Interestingly, changing the head group had a relatively 
limited influence on the activity against either strain of the parasite. Remarkably, more fluctuation in 
activity was observed against the CQR 7G8 strain (2-56 nM) of P. falciparum; the activity against 7G8 
was four- to five-fold weaker than against the D6 or Dd2 strains. This 7G8 strain stems from South-
America and differs enough from the African D6 and Dd2 strains so that the chemosensitizer 
verapamil only has a weak influence on it, which could account for the decrease in activity. Also 
notable were derivatives 48 where the head group was replaced with pyridinyl groups. They were 
equally potent against all three tested strains but were substantially less lipophilic, which improved 
their solubility and potentially lowered their toxicity. Indeed, compounds 48 were found to have 
good oral activity in a Plasmodium berghei mouse model and reduced parasitemia by more than 
99.9% with four doses of 44 or 46 mg/kg and cured three out of three and nine out of ten treated 
mice (hybrids 48a and 48b, respectively).77, 80  
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Figure 17 
The acridine skeleton has also been coupled to CQ to produce related RCQ structures.81 Acridine 
attached to quinoline with ethylene- and propylene-functionalized piperazine afforded hybrids 49, 
while linkage via meta- or para-phenylenediamine resulted in conjugates 50. These quinoline-
acridine derivatives 49 and 50 were in vitro evaluated for their antimalarial activity against a CQS 
(NF54) strain of P. falciparum. Contrary to previous studies, the tested concentration was recorded 
as the minimum inhibitory concentration (MIC), which is the lowest concentration of an antimalarial 
that will inhibit the complete maturation of ring stage parasite into the schizont stage after 40 h 
incubation. Hybrids 49 and 50 displayed MIC values between 0.25 and 1 µg/mL, which were higher 
than CQ (MIC = 0.125 µg/mL). Compound 50b was also tested in vivo against a CQR N67 strain of P. 
yoelii in Swiss mice and showed complete clearance of parasitemia on day 4 at doses of 50 mg/kg per 
day, but none of the mice survived beyond day 28.81 
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Figure 18 
The astemizole scaffold possesses two aryl groups closely linked to each other causing it to resemble 
the initial reversal agent, imipramine. Another set of chimeras has been obtained by linking 
astemizole derivatives with an (amino)quinoline via a piperazine or an aminopiperidine linker. In vitro 
antiplasmodial activity of these hybrids 51, 52 and 53 was determined against a CQR (K1) strain of 
the P. falciparum parasite, and compounds 51b, 52 and 53 were three to ten times more active than 
CQ (23-64 nM vs 230 nM), compound 51a was less active (IC50 = 610 nM).
82 Interestingly, the hybrids 
with conformationally constrained aminopiperidine linkers also delivered potent K1 activity, which is 
in contrast with previously discribed CQ derivatives where acyclic linkers were found to be more 
potent than constrained cyclic linker.58, 59 Furthermore, the hybrid analogs exhibited a good 
cytotoxicity profile and the in vivo antiplasmodial activity of compounds 52 and 53 against a 
Plasmodium berghei mouse malaria model was established. Both compounds showed in vivo activity 
(>80% clearance of parasitemia at doses of 20-50 mg/kg/day), although neither was as active as CQ.82 
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Figure 19 
An elevation of glutathione (GSH) content in P. falciparum appeared to lead to an increased 
resistance to CQ, while GSH depletion in resistant strains restored CQ sensitivity.83 Since GSH levels 
depend on the efficient reduction of glutathione disulfide by glutathione disulfide reductase (GR), 
novel GR inhibitors have been developed to reverse CQ resistance. Subsequently, the Biot group 
prepared secondary amine FQ analogs from FQ by nucleophilic substitution. The basic terminal 
nitrogen atom of FQ was quaternized with methyl iodide and the resulting quaternary ammonium 
unit was then replaced by the appropriate amine, resulting in the secondary amine FQ analogs. 
Subsequently, linking these ferroquine (FQ) derivatives to a GR inhibitor or GSH depletor afforded 
hybrids 54 and 56 where FQ was linked to a GR inhibitor and hybrids 55 and 57 where FQ was linked 
to a GSH depletor. The antimalarial activity of all dual molecules 54-57 was assessed against both 
CQS (NF54) and CQR (K1) strains of P. falciparum. Compounds 54, 55 and 57 were able to counter CQ 
resistance and showed good antimalarial activity with IC50<160 nM against both CQS and CQR strains. 
Compounds 56, however, displayed decreased antimalarial activities (IC50 values between 36 and 445 
nM) and could not counter CQ resistance. Overall, conjugates 54, 55 and 57 were more active than 
CQ, but all hybrid molecules 54-57 were less active than FQ.84 
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Figure 20 
The class of dual-function quinolines with resistance-reversing activity has been extended by 
dibemequines 58-60 which were synthesized in a single step by reaction of 4,7-dichloroquinoline 
with an appropriate dibemethin (dibenzylmethylamine) motif in the presence of potassium 
carbonate and triethylamine. The dibemethin side chain itself reversed chloroquine resistance and 
inhibited chloroquine transport by PfCRT. The in vitro antimalarial activity of hybrids 58-60 was 
evaluated against CQS (D10) and CQR (K1) strains of the parasite. All compounds exhibited activities 
between 20 and 180 nM against the D10 strain and activities between 26 and 1130 nM against the 
K1 strain. The whole series showed no significant cross-resistance with CQ. The three most active 
compounds (59a, 60a and 60d) were found to be very potent against both CQS and CQR strains, with 
IC50 values below 50 nM. The activity of the most potent compound 60a against four CQR strains (K1, 
Dd2, W2 and RSA11) was similar to that of CQ against CQS strains. The three most active compounds 
were found to have low cytotoxicity and possessed significant in vivo antimalarial activity in the P. 
berghei mouse malaria model; two of the three compounds were therapeutic with three or four oral 
doses of 100 mg/kg, rendering parasites undetectable after 30 days of treatment with 100% survival 
of the mice.85 
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Figure 21 
The design of novel antimalarial hybrid drugs that combine the 4-aminoquinoline pharmacophore of 
chloroquine with that of clotrimazole-based compounds has been described by the Gemma group. 
The synthesis commenced with the substitution of 4-(bromomethyl)benzophenone with various 
heterocycles after which the carbonyl function was reduced with sodium borohydride, followed by 
activation of the resulting alcohols to the corresponding chlorides. These latter compounds were 
reacted with the appropriate 4-aminoquinolines, furnishing hybrids 61 and 62 bearing various 
heterocycles at the benzhydryl system. Heterocycles such as imidazole, piperazine, pyrrolidine and 
morpholine were employed because they are basic at the pH of the digestive vacuole (pH 5.5) and 
because they are able to coordinate metals such as iron. These hybrids 61 and 62 were in vitro 
assessed as racemates against the P. falciparum CQS strains D10 and NF54 and the CQR strains W2 
and K1. Almost all compounds displayed IC50 values lower than 100 nM against all evaluated strains. 
The pyrrolidine and imidazole derivatives 61a and 61c appeared to exhibit low-level cross-resistance 
with CQ, which was determined by calculating their resistance index: RI = IC50(CQR strain)/IC50(CQS 
strain) (RI = 1.6 and 1.9). Piperazine derivative 61d displayed more severe cross-resistance (RI = 2.8), 
indicating that not only the quinoline core but also the heterocyclic side chain influences cross-
resistance with CQ. Hybrids carrying a pyrrolidine functionality proved to be more potent than 
compounds with the less basic morpholine skeleton in the side chain. Furthermore, introduction of 
an additional electron-withdrawing or -donating group (X = Cl, F, OMe) onto the benzhydryl side 
chain only had little effect on the antimalarial potency. Substitution of the quinoline core was found 
to be more pivotal for activity, 7-chloro-4-aminoquinolines issue greater antiplasmodial properties 
than 6-methoxy- or 7-trifluoromethyl-4-aminoquinolines. In vivo antimalarial activity of the most 
potent compounds (61d, 61f and 62h) was evaluated using a P. berghei mouse model. A single dose 
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of 61d or 61f at 30 mg/kg substantially prolonged mouse survival and administration of three or four 
doses extended the survival of all mice until day 30.86  
 
Figure 22 
In the same study a trityl derivative 63 has been prepared, as well as some piperazine-tethered 
derivatives 64 and quinoline dimers 65 and 66. Their in vitro antiplasmodial activity was evaluated 
against the aforementioned P. falciparum strains. Piperazine-tethered derivatives 64 displayed poor 
activity against all tested strains (IC50 values between 10 and 735 nM),
86 confirming the theory that 
direct conjugation between the polyarylmethyl system and the iron-coordinating and electron-
transfer moiety (4-aminoquinoline) is necessary for optimal activity.87, 88 Dimers 65 and 66 displayed 
moderate activities (IC50 values between 10 and 190 nM) and trityl derivative 63 proved to be quite 
potent against the CQS strains of P. falciparum with IC50 values ranging from 10 to 26 nM and against 
the CQR strains with IC50 values between 8 and 52 nM. Hence, compound 63 was evaluated in vivo 
using the P. berghei mouse model but was unable to significantly improve survival of the mice.86  
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Figure 23 
Sulfonamides are competitive inhibitors of the DHPS enzyme (deoxyhypusine synthase),89 which 
catalyses the conversion of para-aminobenzoic acid to dihydropteroate, a fundamental step in folate 
synthesis.90 Sulfadoxine 8 is a metabolically stable sulfonamide and can be used for malaria 
treatment in combination with pyrimethamine.91 Therefore, novel piperazine-tethered chloroquine-
based sulfonamide hybrids 67 have been designed. They were synthesized by nucleophilic aromatic 
substitution of piperazine on the commercially available 4,7-dichloroquinoline. Subsequent addition 
of different sulfonyl chlorides, using triethylamine as a base, afforded hybrids 67. Evaluation of their 
antiplasmodial activity against the CQR FCR-3 strain of P. falciparum revealed that all compounds 
exhibited intrinsic in vitro antimalarial properties with IC50 values between 1.2 and 8.5 µM, but this is 
at least ten-fold less than quinine. Hybrid 67h was the most potent and was able to inhibit β-hematin 
formation as potently as chloroquine. Although the antimalarial activity of most conjugates did not 
correlate with their ability to inhibit β-hematin formation, several compounds did display enough 
interesting properties to be considered as lead compounds in antimalarial drug development. 92 
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Figure 24 
A number of CQ-related compounds are equally active against CQS and CQR strains, which can be 
attributed to the fact that these compounds are not recognized or translocated by the PfCRT-
enzyme, and can thus evade the resistance mechanism caused by the mutant protein. An example of 
such an analog is piperaquine, a dimer that consists of two 7-chloroquinoline cores coupled via an 
amine-containing side chain. Piperaquine does not display cross-resistance with CQ and testing in an 
oocyte system showed that piperaquine was unable to inhibit transport of CQ via PfCRT. This 
indicated that piperaquine could bypass the CQ resistance mechanism because it doesn’t interact 
with CQR forms of PfCRT.93, 94 This spurred the hypothesis that dimers of other quinoline drugs might 
also evade the CQ resistance mechanism, which led to the design and antiplasmodial evaluation of 
dimeric quinine agents 68-71 linked via ester, carbamate or amide bonds. The ability of these dimeric 
molecules to inhibit the transport of CQ via PfCRT was evaluated using the Xenopus oocyte system. 
All the compounds reduced the accumulation of CQ in oocytes to levels significantly below (1-6 µM) 
those measured in the presence of verapamil (30 µM), quinine (48 µM) or saquinavir (13 µM), 
indicating that the activity of quinine dimers 68-71 is not simply due to a doubling in amount of 
quinine in the digestive vacuole but is a consequence, at least in part, of an enhanced ability to 
inhibit PfCRT. The antiplasmodial activity of compounds 68a and 71 was evaluated in vitro against the 
CQS HB3 strain of P. falciparum and CQR Dd2, FCB and P31 strains. The quinine dimers were 
significantly more active against the CQR strains than CQ (2- to 5-fold), but neither compound was 
more effective than quinine against the CQS strain. Compound 71 was also found to be a potent 
reverser of CQ resistance in vitro, while compound 68a displayed an in vivo antimalarial activity 
comparable to quinine when orally administered to P. berghei infected mice.95 
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Figure 25 
  
2.4. Hybrids of quinoline and a new motif 
Finally, the fourth class of antiplasmodial quinoline hybrids has been explored most frequently in the 
last years and involves the coupling of a quinoline unit to a novel motif with demonstrated biological 
(antimalarial) activity. This should lead to dual inhibitors or “double drugs” which could potentially 
inhibit hemozoin formation (activity caused by the CQ input) and another target within P. falciparum 
(activity caused by the novel motif) and would not be recognized by the proteins involved in drug 
efflux, making them very desirable for treatment of drug resistant strains. 
2.4.1. 4-Aminoquinoline-tetrazole/triazole/triazine hybrids 
The Chibale group has reported the synthesis and biological evaluation of a series of 
deoxyamodiaquine-tetrazole derivatives 72 and 73. The design involved the incorporation of the 
tetrazole moiety and basic nitrogen(s) onto the deoxyamodiaquine scaffold. Therefore, 2-, 3- or 4-[(7-
chloroquinolin-4-yl)amino]benzaldehyde was subjected to the TMSN3-Ugi multi-component reaction 
strategy, resulting in a tetrazole-amodiaquine hybrid 72a-j. Acid-mediated de-tert-butylation of the 
latter compounds afforded hybrids 73a-e. The interest in tetrazole-containing hybrids originated 
from the fact that pharmaceuticals containing this moiety possess excellent absorption, distribution, 
metabolism and excretion (ADME) properties.96, 97 Tetrazole-containing compounds exhibit a broad 
spectrum of biological activity,98-100 and moreover, the tetrazole ring is able to coordinate with the 
iron centre of heme in the design of heme oxygenase inhibitors.101 In vitro antimalarial assay of 
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hybrids 72-73 against CQS (3D7) and CQR (K1 and W2) strains of P. falciparum revealed that 
conjugates 72b-c and 72j (IC50 values between 6 and 12 nM) were 2- to 6-fold more active than 
amodiaquine and chloroquine (IC50 = 27 and 36 nM, respectively) against the resistant Plasmodium 
strain. Furthermore, compounds 72a-e, 72j and 73c displayed superior activity than amodiaquine 
against the W2 strain. All over, para-analog 72j appeared to be the most potent across all tested 
strains, but due to its poor solubility, only compounds 72b and 72c were in vitro profiled for 
microsomal stability. Both hybrids were rapidly metabolized in microsomes and had high metabolic 
clearance. Compound 72c then showed a relatively poor pharmacokinetic profile and low 
bioavailability in vivo, preventing in vivo activity determination.102 
 
Figure 26 
4-Aminoquinoline-tetrazole derivatives have likewise been the subjects of a study by Pandey et al. 
This group examined variations in the tetrazole-containing side chain of 4-aminoquinoline 
pharmacophores and evaluated their antiplasmodial activity. Tetrazole-quinoline hybrids 74 were 
obtained via a TMSN3-Ugi multi-component reaction. These hybrids 74 contained an extra aryl group 
next to the tetrazole moiety in order to increase the molecule’s lipophilicity, and different 
diaminolinkers were evaluated. All hybrids 74 were evaluated for their in vitro antimalarial efficacy 
against CQS (3D7) and CQR (K1) strains of P. falciparum and displayed moderate activity against the 
CQ susceptible strain with IC50 values ranging from 10 to 216 nM. Thirteen compounds were found to 
be more active (IC50 values between 74 and 234 nM) than CQ (IC50 = 254 nM) when screened against 
the resistant K1 strain. A structure-activity relationship study on these hybrids suggested that their 
antiplasmodial potencies were greatly influenced by the type of linker (aromatic linkers resulted in a 
manifold increase of activity), substitutions on the aromatic ring (introduction of halogens have a 
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positive influence) as well as substitution on the tetrazole ring. Compounds 74j and 74k were found 
to be the most potent in vitro against the 3D7 strain and were also very promising against the K1 
strain. Subsequently, the 11 most potent compounds were evaluated for their in vivo antimalarial 
potency against P. yoelii, and again compounds 74j and 74k displayed the best activities, exhibiting 
99.99% parasitemia suppression on day 4 and 60 to 80% survival on day 28 of treatment at a dose of 
50 mg/kg/day for 4 days.103 The Chibale group reported analogous molecules with similar 
activities.104 
 
Figure 27 
Triazoles are similar to tetrazoles and also represent a renowned class of compounds known to 
display various biological activities such as antimicrobial, antifungal and antitubercular activity.105-108 
Consequently, the Egan group designed a series of quinoline-triazole-amide analogs 75 using click 
chemistry to synthesize the triazole moiety. Several hybrids (75h-n) were based on a 4-amino-7-
cyanoquinoline core instead of a 4-amino-7-chloroquinoline scaffold (75a-g); these conjugates (75h-
n) were proposed to be the less lipophilic analogs that might show improved toxicity levels. All 
compounds 75 were tested for their in vitro antimalarial activity against CQS (D10) strain and CQR 
(K1) strain of P. falciparum and displayed inherent antiplasmodial activities (IC50 values between 0.3 
and 13 µM) against the susceptible D10 strain. Replacement of the 7-Cl group with a 7-CN group 
resulted in a significant increase in polarity, but didn’t render the hybrids inactive. The 7-CN series 
also had much lower levels of cross-resistance, pointing out that the 4-amino-7-chloroquinoline core 
itself is part of the pharmacophore involved in the resistance mechanism. Overall it may be possible 
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to further improve the activities of compounds 75 by reducing the amido groups to the 
corresponding amines.109 
 
Figure 28 
The Kumar group proposed to introduce 1H-1,2,3-triazole-tethered 7-chloroquinoline-isatin 
conjugates 76 and 77. The triazole functionality was introduced because of its favorable properties 
(hydrogen bonding capacity, rigidity and stability under in vivo conditions, etc.), which account for its 
range of biological activities. Furthermore, isatin (1H-indole-2,3-dione) is a heterocyclic moiety that 
has promising activity profiles and is well tolerated in humans.110 Trifunctional conjugates 76 and 77 
were synthesized by Cu-mediated click chemistry of N-propargylated isatins with varied substitutions 
and 7-chloroquinoline-based azides with or without a well-modulated alkyl chain. Hybrids 76 and 77 
have been evaluated for their in vitro antiplasmodial profiles against a CQR (W2) strain of P. 
falciparum. Hybrids 76 appeared to be inactive at tested concentrations, while compounds 77 
displayed low micromolar activity against W2. The activity profiles indicated an influence of the 
length of the alkyl side chain as well as of the substituent at the C-5 position of isatin. Hybrid 77h 
proved to be the most potent analog.111 Compounds 76 and 77 in Figure 29 are depicted the way 
they were presented in the original article. However, it should be noted that compounds 77 are 
(most likely) incorrectly displayed as the 1,5-disubstituted triazole regioisomers, since a copper-
catalyzed click reaction should specifically afford 1,4-disubstituted regioisomers.  
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Figure 29 
In a study of Pereira et al. 27 7-chloroquinoline-triazole derivatives 78 with the triazole ring directly 
linked to the C-4 quinoline position by the N-1 have been synthesized by Cu(I)-catalyzed azide-alkyne 
1,3-dipolar cycloaddition (click chemistry) of 4-azido-7-chloroquinoline to different alkynes. These 
hybrids 78 have been assessed for their antimalarial activity against a CQR (W2) strain of P. 
falciparum. Five compounds exhibited moderate antiplasmodial potency with IC50 lower than 50 µM, 
the other hybrids displayed very low activities (IC50 > 80 µM). The overall disappointing activity profile 
of these hybrids can be explained by the low resonance contribution of the triazole ring to stabilize 
the acidic quinoline form, decreasing the pKa of the protonated quinoline nitrogen atom which is 
known to be important for the heme detoxification in the malaria parasite. This work illustrated the 
importance of a spacer between the quinoline and the triazole core as well as the significance of the 
triazole side chain for antiplasmodial activity.112 
 
Figure 30 
Research by Manohar has been focused on the synthesis of dimeric and even trimeric hybrid 
compounds, more specifically 4-aminoquinoline-1,2,3-triazoles 79 and 4-aminoquinoline-1,2,3-
triazole-1,3,5-triazines 80. The biological importance of 4-aminoquinolines and 1,2,3-triazoles has 
already been established in this literature overview, but triazines are biologically privileged 
structures as well. Cycloguanil is an example of a triazine-based antimalarial compound that operates 
by inhibiting the plasmodial dihydrofolate reductase (DHFR) enzyme, proving that triazines are 
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interesting moieties to incorporate in hybrid molecules. Hybrids 79 and 80 were thus tested for in 
vitro antimalarial activity against a CQS (D6) and CQR (W2) strain of P. falciparum. All compounds 
displayed mild to moderate antiplasmodial activity (IC50 < 12 µM) against both strains. The most 
potent derivatives 79a-e and 80a-e exhibited IC50 values between 0.6 and 1.7 µM and proved to be 
interesting antimalarial hit compounds.113 
 
Figure 31 
This brings us to a next class of hybrid molecules, the aminoquinoline-triazine dual conjugates. As 
mentioned before, 1,3,5-triazines should enhance antimalarial activity by their ability to inhibit the 
DHFR enzyme. Therefore, hybrid derivatives 81 have been synthesized by linking 4-amino-7-
chloroquinoline with various monosubstituted 1,3,5-triazines (which was accomplished by ipso 
nucleophilic substitution of the chloro atom of cyanuric chloride) via an appropriate linker, followed 
by treatment with more nucleophilic amines. These hybrids 81 were evaluated for their in vitro 
antimalarial activities against CQS (3D7) strain of P. falciparum. All compounds displayed nanomolar 
activity profiles (IC50 = 5-164 nM), which were in the same order of magnitude as CQ (IC50 = 5 nM). 
The most potent compounds (81d, 81i and 81k) were subsequently evaluated for their in vivo 
potency against the CQR N67 strain of P. yoelii in Swiss mice at 50 mg/kg/day for 4 days by 
intraperitoneal route (ip), but were found to be toxic against this strain.114 
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Figure 32 
A simular study by Manohar et al. has led to the synthesis of very similar hybrid compounds 82. In 
vitro antimalarial activity against a CQS (D6) and a CQR (W2) clone of P. falciparum was determined. 
Mammalian cell cytotoxicity against LLC-PK11 (pig kidney epithelial cells), HepG2 (human hepatoma 
cells) and Vero (fibroblasts) was evaluated as well. Compounds 82c, 82f, 82o and 82v were most 
potent against both Plasmodium strains, with IC50 values ranging from 0.21 to 0.48 µM. However, 
hybrids 82c, 82f and 82v had a much higher selectivity than 82o. The activity profile indicated that 
the activity of conjugates 82 depends on the length of the diamino linker. A chain length of two or 
three carbon atoms retained potency, while increasing the chain length to four or five methylene 
groups resulted in activity loss. However, when the linker length was even higher (eight carbon 
atoms), activity was retained. Cytotoxicity of most of the conjugates appeared at considerably higher 
concentrations than the concentrations responsible for their antiplasmodial potency, some were not 
even cytotoxic at the highest tested concentration of 48 µM, indicating their safety in mammalian 
systems.115 
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Figure 33 
The Kumar group followed up on these studies with the design of 4-anilinoquinoline-triazine chimeric 
compounds 83 and 84, which were in vitro evaluated for antimalarial activity against a CQS (3D7) 
strain of P. falciparum and proved to exhibit good to excellent antiplasmodial activity, with IC50 
values ranging from 3 to 300 nM. The five most potent compounds 83 (with para-substituted aniline 
linker) even displayed activities between 3 and 7 nM, which makes them more potent than CQ (IC50 = 
8 nM). A cytotoxicity assessment was established against VERO cells and revealed that most 
conjugates 83 showed promising selectivity indices: the most potent compounds 83a-e possessed 
selectivity indices ranging from 92 to 610, demonstrating the compound’s safe activity profile. 
Compounds with good in vitro antimalarial activity were selected for in vivo testing in Swiss mice 
infected with the CQR (N67) strain of the P. yoelii parasite. Compounds 83c, 83f and 83g provided 
100% protection to the mice treated for four days at 50 mg/kg/day via intraperitoneal route while 
the rest only managed to suppress the parasite. These hybrids were further tested for their oral 
activity and compounds 83f and 83g again provided 100% protection for the mice treated with 100 
mg/kg/day for four days, whereas compound 83c was found to be inactive at this concentration. 
Even though the efficacy of orally active hybrids 83f and 83g was only modest they still represent 
promising lead compounds for the development of potent antimalarials.116 
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Figure 34 
Finally, work of Bhat focused on hybrid quinoline-triazine molecules 85 employing 2-(piperazin-1-
yl)ethylamine as a linker to covalently connect the 4-aminoquinoline and 1,3,5-triazine scaffolds. 
Hybrids 85 were subsequently screened for antiplasmodial activity against CQS (3D7) and CQR (RKL2) 
strains. It appeared that the aromatic derivatives displayed mild to moderate activity, while the 
aliphatic derivatives exhibited good potency against the CQS strain. Compounds 85a, 85f and 85g 
displayed enhanced activity against the CQR strain, however, all hybrids 85 were less potent than CQ. 
Introduction of basic moieties like piperidine, 1,3-diaminopropane and morpholine (85e, 85h and 
85j) on the 1,3,5-triazine heterocyclic ring enhanced antimalarial activity and confirmed the necessity 
of basic moieties for antimalarial potency.117 
  
Figure 35 
 
2.4.2. 7-Chloroquinoline-pyrimidine hybrids 
Pyrimidine-based compounds are well-known for their role in the nucleic acid synthesis118 but also 
for their wide range of biological activities, including herbicidal, analgesic, fungicidal, anti-
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inflammatory, antimalarial and anticancer activity.118-123 Furthermore, pyrimethamine, a pyrimidine 
analog, has been used for malaria treatment with varying success.124 Pyrimidine is thus a promising 
moiety to include in potential antimalarial hybrid systems by linking it to a quinoline core. 
The pyrimidine and quinoline moieties have been connected via an aniline or phenol linker by the 
Chauhan group. Firstly, ipso-nucleophilic substitution of 4-chloro- or 4,7-dichloroquinoline with 4-
hydroxy- or 4-amino acetophenone afforded intermediate quinoline derivatives which were 
condensed with different aldehydes by a standard Claisen-Schmidt aldol condensation reaction. 
Subsequently, the obtained chalcones were reacted with guanidine hydrochloride, affording hybrid 
molecules 86. All conjugates 86 were screened in vitro against a CQS (NF54) strain of P. falciparum. 
The 4-oxo-linked analogs were found to be inactive, while their 4-amino-linked derivatives showed 
inherent activity but were four times less active than CQ.125 
 
Figure 36 
This topic was likewise the focus of research by Manohar. Pyrimidine derivatives have been linked via 
flexible diaminoalkane linkers to a quinoline scaffold, affording dual molecules 87, 88 and 89. The 
previous study had shown that when 4-aminoquinoline-pyrimidine conjugates were linked through 
an aromatic ring, they displayed only moderate biological activity.125 That is why in this research a 
flexible linker was preferred. Subsequently, in vitro antiplasmodial assessment of all conjugates 87, 
88 and 89 was performed against CQS (D6) and CQR (W2) strains of P. falciparum. Most of the 
compounds displayed very promising activities against both CQS (IC50 values between 5 and 440 nM) 
and CQR (IC50 between 16 and 1170 nM) strains, 11 compounds were more potent than CQ (IC50 = 40 
nM) against the sensitive strain and most of them retained potency against the resistant strain. Some 
of the most active hybrids (89d, 89h and 89l) showed slight toxicity against the three tested cell lines 
(VERO, LLC-PK11 and HepG2), but their selectivity indices were still considerably high, meaning that 
cytotoxicity of these conjugates appeared at much higher concentrations than those responsible for 
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antimalarial activity. All other derivatives were not cytotoxic even up to the highest tested 
concentrations (60 µM), pointing to their biological potential. Two of the most potent compounds 
(89i and 89m) were evaluated for their in vivo antimalarial activity against P. berghei infected mice. 
They both displayed excellent in vivo activity without any toxicity, hybrid 89i was more potent than 
89m and even than CQ; three doses of 30 mg/kg caused almost complete suppression of the 
parasitemia and cured 80% of the treated mice.126 
 
Figure 37 
Further exploration of the influence of the linker on the antiplasmodial activity of quinoline-
pyrimidine hybrids has been the aim of a next project. Dehydrogenation of 3,4-dihydropyrimidin-
2(1H)-ones using pyridinium chlorochromate furnished the corresponding pyrimidinones, which were 
subsequently treated with POCl3, yielding chloropyrimidines. These chloropyrimidines gave upon 
nucleophilic aromatic substitution with appropriate 4-amino-7-chloroquinoline the envisioned 
hybrids 90. The in vitro antimalarial activities of compounds 90 have been determined in a screening 
assay against CQS (3D7) and CQR (K1) strains of P. falciparum. Compounds 90a, 90l, 90m and 90r 
displayed good activity against the CQS strain (IC50 < 100 nM) and hybrids 90a, 90b, 90c, 90l, 90p and 
90r were more potent than CQ (IC50 = 202 nM) against the resistant strain. The activity profile also 
revealed a significant decrease in antiplasmodial activity when the spacer contained more than 4 
methylene groups or when a non-flexible or substituted linker was utilized. Hybrid 90r was found to 
be the most active compound in this series with IC50 = 4 nM against the CQR strain, rendering it 55 
times more potent than CQ (IC50 = 202 nM) and equipotent to artesunate (IC50 = 3 nM).
127 
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Figure 38 
The same group further focused on pyrimidine-5-carboxylate hybrids in a follow-up study. It had 
been established in the previous study that the 4-aminoquinoline-pyrimidine conjugates tethered by 
a diaminoalkyl spacer displayed optimum potency when the flexible linker consisted of three or four 
carbon atoms. Futhermore, the introduction of a nitro substituent at the ortho position of the phenyl 
ring rendered the most potent compound. These observations led to further exploration of this class 
of compounds by incorporating electron-withdrawing substituents at the C-4 position of the phenyl 
ring as well as varying the ester substituent and altering the basicity of the diaminoalkyl spacer, 
affording hybrid conjugates 91. Antimalarial evaluation of these compounds 91 against CQS (D10) 
and CQR (Dd2) strains of P. falciparum revealed only moderate activities against both strains (IC50 
values between 150 and 2760 nM). Hybrids 91 were also evaluated for their toxicity against various 
cell cultures, and the results revealed that all molecules were cytotoxic against MDCK cell cultures.128 
 
Figure 39 
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Another strategy comprised the design of hybrids by linking a 4-aminoquinoline unit to pyrimidine 
which afforded hybrid compounds 92 and 93 whose synthesis was described in the literature,126 but 
some additional derivatives 94 and 95 have been synthesized by replacement of the chloro 
substituent with different heterocyclic amines, in order to further explore side chain diversity by 
varying the length and basicity of the spacer as well as to evaluate the influence of the substitution 
pattern. An in vitro antiplasmodial assay of hybrids 92, 93, 94 and 95 against a CQS (D10) and CQR 
(Dd2) strain of P. falciparum depicted nanomolar activity for all derivatives. Compound 94b exhibited 
the lowest IC50 values against both the sensitive and resistant strain, 23 and 43 nM, respectively. 
Furthermore, these conjugates exhibited high selectivity toward the parasite and low toxicity against 
the tested cell lines (HeLa, VERO, CRFK, Hel and MDCK). The test results confirmed that increasing 
the length of the methylene spacer had a significant effect on the antimalarial activity, as well as 
replacing a more basic diaminoalkyl linker with a relatively less basic alkoxyalkylamino linker.129 
 
Figure 40 
The following paper focused even further on the exploration of side chain diversity (length and 
basicity). Functionalized aminoquinoline intermediates (with various side chains) were treated with 
2,6-diamino-4-chloropyrimidine, which yielded hybrids 96 and 97. The compounds were tested in 
vitro against a CQS (D10) and a CQR (Dd2) strain of P. falciparum and all exhibited antiplasmodial 
activity. Hybrids 96e and 97 displayed similar potency (IC50 = 157 and 70 nM, respectively) as CQ (IC50 
= 40 nM) against the CQS strain, while these conjugates, together with 96i, were more potent (IC50 = 
210, 157 and 107 nM, respectively) than CQ (IC50 = 417 nM) against the resistant parasite strain. 
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Overall, compounds 96i and 97 stood out as most active hybrids with comparable activities against 
the Dd2 strain. However, evaluation of their resistance indices (0.49 and 2.36, respectively) 
concluded that 96i carried its antiplasmodial activity against D10 over to Dd2, where 97 knew a 
fivefold loss of activity. Most of these hybrids displayed high SI values for the parasitic cells in the 
presence of Chinese Hamster Ovarian (CHO) cells, meaning that they were non-toxic to the 
mammalian cells. However, hybrid 96i exhibited the lowest SI value of all and thus appeared to be 
less selective. Statistical data also confirmed that its cytotoxicity was not only the highest, but also 
statistically significantly different from that of the other compounds.130 
 
Figure 41 
 
2.4.3. 7-Chloroquinoline-chalcone hybrids 
Chalcones or 1,3-diarylprop-2-en-1-ones are bioprecursors of flavonoids and have been inspiring 
medicinal chemists for a long time. Their analogs exhibit a broad range of biological activities such as 
antifungal,131 antiparasitic,132 antitumor and antioxidant,133 immunomodulatory,134 antileishmanial,135 
antimitotic,136 anti-invasive,137, 138 anti-inflammatory139-142 and antimalarial activity.143, 144 These 
systems display antiplasmodial activity by inhibiting either cysteine proteases or plasmodial aspartate 
proteases,145 and they also proved to inhibit the parasite-induced channels146 and cause severe 
membrane disruptions of erythrocytes.147 Licochalcone-A was the first potent antimalarial chalcone 
with activity against CQR P. falciparum.148 This has led to the synthesis of new synthetic analogs and 
hybrid molecules. 
In a first approach, chalcones have been connected to a quinoline core either via an oxo-linker or via 
an amino-linker. Nucleophilic substitution of 4-chloro- or 4,7-dichloroquinoline with 4-hydroxy- or 4-
aminoacetophenone afforded iquinoline intermediates which were subsequently condensed with 
different aldehydes by an aldol condensation reaction, yielding conjugates 98. These compounds 
were screened in vitro against the CQS NF54 strain of P. falciparum and the 4-oxo-linked quinoline-
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chalcone hybrids were found to be inactive, while the 4-amino-linked derivatives displayed only very 
mild antimalarial activity.125 
 
Figure 42 
Another group focused on the amino-linked derivatives but varied the substituents of the 
benzaldehydes used for the Claisen-Schmidt aldol condensation, thereby affording hybrid molecules 
99. These compounds were in vitro evaluated for their effects as inhibitors of β-hematin formation. 
Since inhibitions of more than 90% are considered significant (CQ: 94% inhibition), five hybrids 99a-e 
were retained as they exhibited satisfactory inhibition (94-95%). However, none of them indicated 
effective inhibition of hemoglobin proteolysis in an in vitro assay which used trophozoyte-rich extract 
to digest the native hemoglobin of mice.149 
 
Figure 43 
Hybridization of the chalcone moiety with a quinoline core via a triazole linker has been discussed by 
Guantai et al. Hybrids 100 and 101 were synthesized by a click reaction of acetylenic chalcones and 4-
azido-7-chloroquinoline. The synthesis of the acetylenic chalcones involved the propargylation of 
vanillin and acetovanillone with propargyl bromide, followed by a base-catalyzed Claisen-Schmidt 
condensation with methoxylated acetophenone or benzaldehyde, respectively. Conjugates 100 and 
101 were evaluated for their in vitro antimalarial activity against the CQS D10 and the CQR Dd2 and 
W2 strains of P. falciparum. All compounds displayed moderate to good in vitro activity across all 
three strains, with IC50 values in the lower micromolar to high nanomolar range. Three conjugates 
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100b-c and 101b had submicromolar potency, compound 100b was the most active with IC50 values 
of 40, 70 and 90 nM against the D10, Dd2 and W2 strains of P. falciparum, respectively. Hybrid 100b 
was also evaluated for its cytotoxicity against the CHO (mammalian) cell line and no cytotoxicity was 
observed at the highest concentration tested (100 µM). 150 
 
Figure 44 
Inspired by these results, the Sashidhara group pursued a hybridization strategy that combined two 
known antiplasmodial moieties, CQ and ketoenamine chalcones. The Duff reaction on ortho alkyl- 
substituted phenols in the presence of hexamethylenetetraamine and TFA gave aromatic 
dicarbaldehydes, which on coupling with appropriate acetophenones afforded para-condensed 
chalcones. These chalcones were connected to appropriate 4-aminoquinolines, furnishing hybrids 
102. Antimalarial assessment of these compounds 102 against the CQS 3D7 strain of P. falciparum 
revealed that two hybrids (102b and 102g) out of 28 derivatives displayed comparable activity (3.63 
and 4.64 ng/mL, respectively) to CQ (2.45 ng/mL) and 5 compounds showed IC50 values lower than 10 
ng/mL. The difference in activity (3 to 380 ng/mL) in general could be attributed to different factors 
such as length and nature of the linker and substitutions on the chalcone ring. Furthermore, the 10 
most potent compounds were also evaluated in vivo against the CQR N67 strain of P. yoelii in Swiss 
mice and results revealed that these derivatives were highly active and able to clear parasitemia 
below detectable levels in mice when orally administered in doses of 100 mg/kg. However, a 
complete cure was not obtained at the tested dose.151 
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Figure 45 
As a continuation of the previous research, the Sashidhara group reported on a new class of CQ-
chalcone-based hybrid molecules 103 which were synthesized by substitution of 4-chloro- or 4,7-
dichloroquinoline with hydrazine hydrate, followed by condensation with 4-hydroxybenzaldehyde 
and nucleophilic substitution using 4-chlorophenacyl bromide. Finally, hybrids 103 were obtained by 
Claisen-Schmidt condensation with the appropriate aldehydes. The in vitro antiplasmodial activity of 
hybrids 103 was assessed against a CQS (3D7) and a CQR (K1) strain of P. falciparum. Most 
compounds exhibited potent antimalarial activity against the susceptible strain (IC50 values between 
30 and 300 nM), but more importantly, all conjugates were more potent (IC50 values between 80 and 
315 nM) than CQ (IC50 = 463 nM) against the resistant K1 Plasmodium strain. Compound 103f was 
found to be the most potent against both strains. Cytotoxicity of hybrids 103 was evaluated against 
VERO cells and all compounds displayed SI values ranging between 387 and 6200. Since compounds 
with a SI value higher than 50 are generally considered as safe, these hybrids 103 are worth 
considering as promising lead compounds. Mechanistic studies also revealed that these hybrids acted 
through heme polymerization targets.152 
 
Figure 46 
The N’Da group continued this research by connecting a chalcone moiety (with 5-methylfuran as 
aromatic A-ring) to a 7-chloroquinoline pharmacophore through amide bond formation between the 
PART II  LITERATURE REVIEW 
48 
 
carboxylic acid of the chalcone and the free amine of the aminoquinolines, using CDI as a coupling 
agent, yielding chimeras 104. In vitro antimalarial screens showed that all hybrids 104 proved to be 
active with IC50 values between 0.05-0.53 µM against the CQS 3D7 strain and IC50 values between 
0.07-1.8 µM against the CQR W2 strain of the Plasmodium parasite. However, amide-hybrids 104 
exhibited a loss of activity against the resistant strain compared to the CQ sensitive strain, which 
implied that chloroquine resistance was not overcome with these compounds. They also displayed 
moderate to high toxicity towards mammalian cells (WI-38 cell line, normal human fetal lung 
fibroblast). Hybrid 104e was found to be the most potent against both strains and was up to two 
times more active than CQ against the resistant parasite strain.153 
 
Figure 47 
 
2.4.4. 7-Chloroquinoline-β/γ-lactam hybrids 
Since their discovery β-lactam antibiotics have continued to be very effective chemotherapeutics 
combining a broad activity spectrum with low toxicity.154 Interest in this class of compounds has led 
to the design and synthesis of classical β-lactams such as penicillins and cephalosporins but also non-
classical substrates like carbapenems and monobactams.155-157 More recently β-lactam research 
focused on modifications of the β-lactam ring in order to obtain compounds with very diverse 
pharmacological activities such as vasopressin V1a antagonist activity, cholesterol absorption 
inhibitory activity, thrombin and chymase inhibitory activity and antiparkinsonian, antidiabetic, 
antitubercular, anti-inflammatory and anti-HIV activity.158-161 A related class of compounds concerns 
the γ-lactams; these systems appear in many natural products and bioactive derivatives.162-164 Since 
β- and γ-lactams clearly represent biologically active scaffolds, they could serve as excellent motifs to 
include in hybrid molecules, where dual functionality could be beneficial for the overall activity. 
This is exactly what the group of Kumar envisioned when they designed 1,2,3-triazole-tethered β-
lactam and 7-chloroquinoline bifunctional hybrids 105 and 106. Therefore, 3-amino-2-azetidinone 
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was mono- or di-N-alkylated using propargyl bromide. The reaction products were treated with 4-
azido-7-chloroquinoline, which afforded hybrids 105 and 106 after 1,3-dipolar cycloaddition (Click 
reaction). In vitro antimalarial activities of conjugates 105 and 106 were evaluated against a CQR 
(W2) strain of P. falciparum. These compounds were less active than CQ, but with the exception of 
105a and 105c, all hybrids displayed moderate antiplasmodial activity with IC50 values ranging from 1 
to 6 µM. The bis-compounds 106 mostly were more potent than the corresponding mono-scaffolds 
105. The increase in activity might be attributed to either solubility-enhancing properties of triazole 
rings or increased heme-binding of 7-chloroquinolines.165 
 
Figure 48 
The Kumar group further focused on this strategy and synthesized a library of 4-aminoquinoline-β-
lactam hybrids tethered via alkyl chain linkers (conjugates 107) as well as through amide 
functionalities (conjugates 108). Compounds 107 and 108 have been evaluated for their in vitro 
antimalarial profiles against the CQR W2 strain of P. falciparum. Most hybrids showed high 
nanomolar activities and when comparing the potencies among the alkyl chain and amide-tethered 
series, the alkyl chain-linked compounds displayed better efficacy in inhibiting P. falciparum. Again it 
seemed that varying the length of the alkyl linker chain had a distinct influence on the conjugate’s 
activity. Hybrids 107a, 108c and 108d exhibited the best activity profiles with IC50 values ranging 
between 80 and 94 nM, which are comparable to the potency of CQ (IC50 = 99 nM) against the W2 
parasite strain.166 
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Figure 49 
The Kumar group further extended this research toward the design of β-lactam-4-aminoquinoline 
conjugates 109 and 110 having urea/oxalamide linkers and a well-modulated alkyl chain length. 
Groups like amides, sulfonamides, ureas and thioureas have shown to improve pharmacological 
activities against both CQS and CQR strains of P. falciparum,51, 167-169 while oxalamide groups have 
proven to enhance antiplasmodial potency due to stronger hydrogen bonding ability.170, 171 The 3-
carbamic acid ethyl ester and 3-oxalamic acid ethyl ester-2-azetidinone intermediates were 
synthesized diastereoselectively by treating cis-3-amino-2-azetidinones with ethyl chloroformate or 
ethyl oxalylchloride. The desired hybrids 109 and 110 were subsequently prepared by heating the 
latter intermediates in the presence of the appropriate aminoquinolines. The in vitro antimalarial 
potency of hybrids 109 and 110 was determined against the CQR W2 strain of P. falciparum. The 
urea-tethered compounds 109 displayed IC50 values ranging from 42 to 193 nM, while the conjugates 
110, linked through an oxalamido group, exhibited a slight improvement in activity with IC50 values 
ranging from 34-120 nM, which are good antiplasmodial activities (CQ: IC50 = 59 nM). A concise SAR 
study clearly pointed out that an N-aryl substituent has a profound effect on the activity at shorter 
chain lengths (n = 2, 3), while the effect reverses in favor of the cyclohexyl substituent when higher 
alkyl chain lengths are considered (n = 4, 6). The cytotoxicity of the most potent compounds 109h 
and 110d was evaluated against HeLa cells and both hybrids displayed no apparent toxicity.172 
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Figure 50 
Aside from β-lactams, γ-lactams have also emerged as excellent substrates for molecular 
hybridization. Recent research reported on the synthesis of fluoroalkylated γ-hydroxy-γ-lactam-4-
aminoquinoline hybrids 111 and 112, also called quinolac hybrids. Therefore, γ-ketothioesters were 
treated with diisopropylamine to give rise to γ-lacton sulfides, which, after mCPBA oxidation, 
resulted in the corresponding sulfones. Coupling reaction of appropriate aminoquinolines with γ-
lactones (lactamization) furnished the desired conjugates 111 and 112. In vitro antimalarial 
assessment of derivatives 111 and 112 against CQS (3D7) and CQR (W2) strains of P. falciparum 
revealed eight compounds exhibiting reasonable potency (IC50<100 nM) against both strains. The 
citric acid salt of compounds 111b and 112a exhibited the highest activities (26 and 19 nM, 
respectively) against the 3D7 strain, which was comparable to CQ (IC50 = 30 nM) and potencies 
between 49 and 42 nM, respectively, against the resistant strain. Overall, the length of the spacer 
had a major impact on the antiplasmodial activity, with three carbon atoms being favored over four 
or six. Also, the insertion of a basic nitrogen in the spacer greatly improved the activity against both 
strains. The most active representatives were also evaluated against a mammalian cell line (HUVECs), 
but no significant cytotoxicity was determined at the tested concentrations (0.01-100 µM).173 
 
Figure 51 
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2.4.5. 7-Chloroquinoline-cinnamic acid hybrids 
Cinnamic acid is a naturally occurring organic acid in plants, has low toxicity and a broad biological 
activity spectrum. Many cinnamic acid derivatives, especially those with a phenolic hydroxyl group, 
are well-known antioxidants. Cinnamic acid derivatives, both isolated from plant material and 
synthesized, have been reported to display antibacterial, antiviral and antifungal properties,174, 175 but 
have also proven to exhibit antimalarial activity.176 Cinnamic acid is thus a valuable motif to include in 
hybrid molecules. 
Keeping this in mind, HEterocyclic-DIpeptide-CINnamic (HEDICIN) acid conjugates 113 have been 
synthesized by linking a 4-amino-7-chloroquinoline core to a trans-cinnamic acid moiety through a 
dipeptide spacer. This was achieved by subsequently linking two amino acids to a 4-amino-7-
chloroquinoline core, followed by coupling of this quinolinyldipeptide with cinnamic acid using 
PyBOP as a coupling agent. Analogs of these hybrids lacking the dipeptide spacer, HEterocyclic-
CINnamic (HECIN) acid derivatives 114 were also prepared by the Gomes group through direct 
coupling of aminoquinoline to cinnamic acid derivatives with PyBOP as a coupling agent. Compounds 
113 and 114 were evaluated for their in vitro antimalarial activity against the blood-stage CQR W2 
strain of P. falciparum. The resulting activity profile revealed a complete lack of activity for HECIN-
hybrids 114, which correlated with their inability to inhibit heme polymerization. Furthermore, 
HEDICIN-hybrids 113 inhibited heme polymerization in vitro and displayed IC50 values between 1 and 
11 nM, suggesting that this inhibitory activity is at least in part accountable for their antimalarial 
activity. Hybrids 113 and 114 were also evaluated in vitro for inhibition of falcipains. HECINs 113 
generally exhibited more potent inhibition of falcipain than HEDICINs 114 did, so these falcipain 
inhibition results do not allow the identification of a correlation between these inhibitory capacities 
and the hybrid’s antimalarial potency.177 
 
Figure 52 
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This research group continued their efford towards the design of N-cinnamoylated chloroquine 
analogs. Since the previous study proved that a spacer between the heterocycle and the cinnamoyl 
motif was required for antimalarial potency, the cinnamoyl moiety was linked to a 4-aminoquinoline 
core through a flexible and more hydrophobic butylamine/butyloxy chain, affording hybrids 115. 
Since primaquine (an 8-aminoquinoline) remains the only drug in clinical use that acts against the 
liver stages of all Plasmodium species, the Gomes group also synthesized an N-cinnamoylated 
primaquine hybrid 116 through a single amide coupling step between the parent drug PQ and 
cinnamic acid; cinnamic acid was first activated by TBTU in the presence of DIEA, followed by 
addition of PQ. These conjugates were evaluated for their in vitro antimalarial potency and hybrids 
115 displayed activities between 15-141 nM against the sensitive 3D7 parasite strain and between 
11-111 nM against the resistant W2 strain of P. falciparum, which are higher potencies than CQ (IC50 
(W2) = 138 nM). The cinnamoyl core thus appears to be a valuable pharmacophore to enhance the 
antiplasmodial potency of chloroquine. The primaquine analog 116, however, completely lacked 
activity. The compounds’ activities were also evaluated against liver stage P. berghei parasites and 
most conjugates displayed outstanding potency against both erythrocytic and liver stages of the 
parasite. They were found to be non-cytotoxic against Huh7 human hepatoma cells as well. The most 
potent compounds 115c and 115e were confirmed to be active in vivo against a blood-stage infection 
in a P. berghei rodent malaria model, as they extended survival with two to seven days when treated 
with doses of 30 mg/kg/day for two days. Hybrid 115c was highly toxic when administered in doses 
of 100 mg/kg/day, while hybrid 115e did not appear to be toxic at any tested dosage.178 
 
Figure 53 
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2.4.6. Quinoline-HDAC inhibitor hybrids 
Histone deacetylases (HDACs) are important zinc-dependent enzymes that affect post-translational 
modifications of proteins by altering the acetylation state of lysine side chains of histones.179-181 
HDACs control the proliferation of transformed cells associated with many diseases as well as 
epigenetic variations that trigger cell transformations.182, 183 These enzymes are validated drug 
targets since they have been widely evaluated for their cytotoxic, anticancer, antimalarial and other 
potential therapeutic properties.184, 185 The malaria parasite P. falciparum contains at least five HDAC 
homologs and their presence raises the possibility that the parasite uses histone modulation to 
regulate gene expression, which makes them attractive targets for novel antimalarial drugs that 
could then act via a different mechanism than current antimalarial agents. 
HDAC inhibitors normally possess a zinc binding group, a linker region and a cap group. Most 
alterations that have been made to HDAC inhibitors in connection to enhance their activity have 
involved altering the cap or linker region. Apicidin 117 was one of the first HDAC inhibitors found to 
exhibit cytotoxic activity against Plasmodium species,186 and the Andrews group made derivatives of 
this compound by exchanging the tryptophan group by a quinoline group, affording hybrids 119 and 
120. Suberoylanilide hydroxamic acid 118 is a simpler, achiral compound capable of inducing 
differentiation, cell growth arrest or apoptosis in a wide variety of cells at low concentrations.184, 187 
2-Aminosuberic acid-quinoline conjugates 121 have been designed in this study as derivatives with 
potentially better antimalarial potency. These hybrids were evaluated for their in vitro antimalarial 
activity against CQS (3D7) and CQR (Dd2) strains of P. falciparum. They proved to be very potent with 
IC50 values between 13-81 nM against the sensitive strain and between 33-71 nM against the 
resistant strain. This indicates that these derivatives are very valuable lead compounds and no cross-
resistance was observed.188 In a later report of this group another quinoline-HDAC inhibitor hybrid 
122 was described, it exerted nanomolar activity (IC50 values between 10-40 nM) and displayed a 
reasonable selectivity index between 30 and 120.189 
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Figure 54 
 
2.4.7. Hybrids of 4-aminoquinolines and thiourea 
The thiourea moiety is a privileged pharmacophore that is present in many biologically active 
compounds and that can act as an electrophilic warhead.190-194 Thioureas have proven to be useful in 
the design of enzyme inhibitors195 and as an alternative for amide bonds in peptidomimetics.196 
This information has led to the introduction of the thiourea functionality in the side chain of 4-
aminoquinoline derivatives, which afforded antimalarial compounds.192 The Katti group attempted to 
further optimize these antiplasmodial agents by designing hybrid derivatives 123 that linked a variety 
of substituted thioureas with 4-aminoquinoline. This was achieved by treating N-(7-chloroquinolin-4-
yl)propane-1,3-diamine with carbon disulfide in the presence of alkali, followed by methylation with 
dimethyl sulfate. This product was further subjected to nucleophilic substitution with a variety of 
amines (primary, secondary and cyclic). Bis(4-aminoquinoline) derivative 124 connected through a 
thiourea linker was also synthesized. Dual systems 123 and 124 were screened in vitro for 
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antimalarial activity against CQS (D6) and CQR (Dd2) P. falciparum strains. Three compounds (123e, 
123j and 123k) displayed IC50 values between 24 and 59 nM, while the rest exhibited values between 
103 and 333 nM against the CQ susceptible strain. The earlier mentioned compounds were more 
potent against the resistant Plasmodium strain as well (IC50(D6) = 14-68 nM, IC50(Dd2) = 104-778 nM). 
The consistency of the antimalarial potency against both CQS and CQR strains of the parasite is 
remarkable. However, only one compound 123e was more potent than CQ against the resistant 
strain (IC50 = 14 vs 51 nM). Conjugate 123e also displayed a low resistance factor (RI = 0.59), which 
means that the chances of the parasite developing resistance is not likely.193 
 
Figure 55 
 
The report of Sunduru also discussed the conjugation of 4-aminoquinolines with several thioureas; 
amination of 4,7-dichloroquinolines with α,γ-diaminoalkanes resulted in N-(7-chloroquinol-4-
yl)diaminoalkanes, which after treatment with different isothiocyanates yielded hybrid molecules 
125. The in vitro antiplasmodial activity of these compounds 125 has been assessed against a CQS 
(3D7) strain of P. falciparum. Thiourea derivatives 125 displayed good antimalarial activities with IC50 
values ranging from 6 to 42 ng/mL. Consequently, their cytotoxicity was evaluated against VERO cells 
and results showed that hybrids 125 displayed good to excellent selectivity indices (SI: 332-1113). 
Based on these selectivity indices, compounds 125b and 125h were screened in an in vivo model 
against CQR (N67) strain of P. yoelii in Swiss mice at 50 mg/kg/day for four days by intraperitoneal 
route. Compound 125b was found to be the most active with 99.3% suppression of parasitemia on 
day 4.169 
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Figure 56 
Since not only thiourea, but also polyamine conjugates are well-known for their pharmaceutical 
applications,197 the Smith group opted to explore the combination of both in the design of thiourea-
4-amino-7-chloroquinoline hybrid 126 and polyamine-thiourea conjugates 127, 128 and 129. The 
synthesis of hybrid 126 commenced with the preparation of N-(7-chloroquinolin-4-yl)propane-1,3-
diamine, which was treated with carbon disulfide in the presence of potassium hydroxide followed 
by the addition of methyl iodide, affording a methylcarbamodithioate. Finally, substitution of the 
latter with propylamine gave rise to hybrids 126. On the other hand, refluxing 
methylcarbamodithioate with 1,3-diaminopropane, tris(2-amino)ethylamine or N,N,N’,N’-tetrakis(3-
aminopropyl)-1,4-butanediamine afforded hybrids 127-129. Hereby the effect of increasing the 
number of active pharmacophores (and molecule size) on the biological activity was investigated, as 
well as the effect of polyamine formation on the antimalarial potency. All conjugates were screened 
for in vitro antimalarial efficacy against CQS (NF54) and CQR (Dd2) strains of P. falciparum and 
proved to be potent against the drug susceptible parasite strain (IC50 values between 0.09-0.34 µM) 
as well as against the resistant strain (IC50 between 0.23-0.52 µM), but activities remained lower than 
those of CQ (0.02 and 0.14 µM, respectively). Furthermore, there does not seem to be a clear 
correlation between increasing the number of active moieties and antiplasmodial activity. According 
to β-hematin inhibition studies there did appear to be a relationship between the size of the 
molecules and their ability to inhibit heme aggregation; the larger tetrameric compound 129 was 
able to inhibit β-hematin formation more than the monomeric derivative 126, but overall, no 
unambiguous correlation could be observed between β-hematin formation and in vitro 
antiplasmodial potency.198 
PART II  LITERATURE REVIEW 
58 
 
 
  Figure 57 
 
2.4.8. Hybrids of 4-aminoquinolines and various heterocycles 
Many heterocyclic systems are considered to be biologically privileged scaffolds and have 
applications in agriculture, medicine, etc.199, 200 Heterocycles such as pyrimidines, tetrazoles, triazoles 
and triazines have already been discussed, but there are also oxygen-, sulfur- and other nitrogen-
containing heterocycles such as thiazolidinones, oxazoles, imidazoles, thiazoles, etc. Their biological 
potential renders them promising moieties for molecular hybridization studies. 
The Chauhan group focused on connecting entities like thiazolidinedione and thioparabanic acid onto 
the 4-aminoalkyl chain of 7-chloroquinolines. The synthesis started with the amination of 4,7-
dichloroquinolines with α,γ-diaminoalkanes resulting in N-(7-chloroquinolin-4-yl)diaminoalkanes, 
which, after treatment with different isothiocyanates and cyclization with oxalyl chloride and ethyl 
chlorooxoacetate, yielded hybrids 130 and 131. These compounds were evaluated for their in vitro 
antimalarial activity against CQS (3D7) strain of P. falciparum. Thiazolidinedione analogs 130 and 
thioparabanic acid hybrids 131 exhibited a moderate antimalarial profile with IC50 values ranging 
from 11 to 111 ng/mL and from 33 to 199 ng/mL, which was good in comparison with CQ (IC50 = 5 
ng/mL). The conjugates were evaluated for cytotoxicity against VERO cells as well, and 
thiazolidinedione derivatives 130 displayed somewhat better selectivity indices (SI: 256-637) 
compared to thioparabanic acid analogs 130 (SI: 3-406). Based on these selectivity indices, 
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compound 130d was screened in an in vivo model against CQR (N67) strain of P. yoelii in Swiss mice 
administered in doses of 50 mg/kg/day for four days by intraperitoneal route. Merely 5% suppression 
of the parasitemia was obtained on day 4.169 
 
Figure 58 
Thiazolidin-4-ones are heterocyclic scaffolds that display diverse biological activities and these 
compounds are well tolerated in humans.201, 202 Therefore, this heterocyclic moiety has been 
incorporated in a CQ-hybrid system. A one-pot three component reaction with N-(7-chloroquinolin-4-
yl)diaminoalkanes, an aldehyde (furfuraldehyde, thiophene carboxaldehyde or benzaldehydes) and 
α-mercaptoacetic acid afforded the desired conjugates 132. All conjugates 132 were evaluated for 
their activity against a sensitive 3D7 and a resistant Dd2 strain of the P. falciparum malaria parasite 
under in vitro conditions. None of the compounds was found to be more potent than CQ against the 
CQS strain, but hybrid 132l was proven to be more active than CQ (IC50 = 0.44 and 0.50 µM, 
respectively) against the resistant Plasmodium strain. Compound 132p showed comparable activity 
(IC50 = 0.54 µM) to CQ. Cytotoxicity against J774 murine macrophages was observed in seven 
compounds and two compounds showed to be cytotoxic for HepG2 cells. The most potent hybrids 
132l and 132p were evaluated for their in vivo activity and inhibited 80 and 100%, respectively, of the 
parasite growth in P. berghei infected mice treated with a dose of 10 mg/kg/day.203 
 
Figure 59 
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Oxazoles have likewise been recognized for their potent biological activity,204-206 which has led to the 
design and synthesis of quinoline-oxazoline hybrids 133. Conjugates 133 were synthesized by 
adapting a Pd-mediated cross-coupling procedure involving 7-chloro-4-iodoquinoline and an 
appropriate aniline with a meta- or para-located 1,3-oxazoline substituent. Compounds 133 were 
screened on cultures of P. falciparum clones 3D7 (CQS) and K1 (CQR) to evaluate their antiplasmodial 
activities. The hybrids displayed activities between 0.083 and 0.192 µM against the susceptible strain 
and between 0.711 and 1 µM against the resistant strain, with compound 133c being the most 
promising. Treatment of human peripheral blood mononuclear cells (MNL) with hybrids 133 resulted 
in a significant degree of cell death, and this toxicity was consistent with 5 to 500 µM applications.207 
 
Figure 60 
The Sparatore group has focused on the hybridization of the 4-amino-7-chloroquinoline core with 
imidazoles, oxazoles and thiazoles, resulting in the synthesis of compounds 134, 135, 136, 137 and 
138. All conjugates were assessed in vitro against CQS (D10) and CQR (W2) strains of P. falciparum, 
and they all exhibited moderate to high potency against the sensitive strain (6-399 nM). Even 17 out 
of 25 hybrids displayed an IC50 lower than 100 nM, which made them interesting compounds for 
further evaluation. Ten compounds exhibited strong activities against the resistant strain as well (21- 
61 nM), rendering them 5 to 15 times more active than CQ (317 nM). These results confirmed that 
the introduction of these heteroaromatic systems was associated with antiplasmodial activity, 
provided that an additional basic centre, besides the quinolinic system, was present. The most 
potent compounds were thienyl derivative 136b, N-methylimidazolyl derivative 138e and 
arylimidazolyl compound 137e. They displayed very strong antimalarial activity, a low resistance 
index and no or very low cytotoxicity against a human endothelial cell line. These hybrids are thus 
very promising lead compound for further antimalarial drug research.208 
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Figure 61 
The amount of reports on pyrazolines reflects the wide range of biological activities associated with 
this class of heterocycles and anti-inflammatory, antitumor, antimycobacterial and antimicrobial 
activities are just a few of the applications that have been described.209-213 The Insuasty group has 
focused on the design of novel pyrazoline derivatives 139 containing a 4-amino-7-chloroquinoline 
moiety and the assessment of their antimalarial and cytotoxic activities. Nucleophilic aromatic 
substitution of 4,7-dichloroquinoline with 3- and 4-aminoacetophenones, followed by a Claisen-
Schmidt condensation of the ketones led to the formation of quinoline-chalcone conjugates. 
Reactions of these chalcones with hydrazine hydrate in acetic acid or formic acid furnished the 
desired hybrids 139. Antiplasmodial activity of these conjugates 139 was evaluated in vitro against a 
CQS (NF54) strain of the Plasmodium falciparum parasite. Only four compounds (139b, 139c, 139d 
and 139g) showed more than 30% inhibition of the parasite at concentrations of 20 µg/mL. 
Compound 139g displayed the highest antimalarial activity (IC50 = 14 µg/mL), but was still a lot less 
potent than CQ (IC50 = 0.02 µg/mL).
214 
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Figure 62 
Research by the Sparatore group has proved that substituting the phenolic ring of amodiaquine with 
another (heterocyclic) aromatic ring, such as the biologically active pyrrole nucleus, afforded 
compounds with biological activity.215 To further improve the potency of such compounds, their 
lipophilicity was increased by adding a substituted aryl group to the structure, which afforded hybrids 
140. Synthesis of conjugates 140 was achieved through condensation of the appropriate ethyl α-(4-
substituted-phenacyl)acetoacetate with 7-chloro-4-hydrazinequinoline. The obtained quinoline-
pyrrole carboxylate intermediates were converted to amides by adding relevant amines 
(diethylamine and pyrrolidine) in the presence of trimethylaluminium. The amides were then 
reduced to the corresponding amino compounds 140 by means of diphenylsilane in the presence of 
tris(triphenylphosphine) rhodium(I)carbonylhydride. These conjugates were tested in vitro against 
CQS (D10) and CQR (W2) strains of P. falciparum and their cytotoxicity was determined against 
mammalian cell lines of both humane and murine origine. All compounds 140 exhibited high activity 
against the susceptible parasite strain, with IC50 values ranging from 23 to 62 nM, which was in the 
same order of magnitude as CQ (IC50 = 25 nM). Five compounds (140a, 140b, 140d, 140e and 140f) 
appeared to be very potent against the resistant strain with activities 5- to 7-fold higher than CQ (IC50 
values of 55-80 nM vs 441 nM, respectively). The other compounds also displayed activities lower 
than or similar to CQ, but they showed evident cross resistance (resistance index between 6 and 11). 
The most active compounds displayed moderate to low toxicity against three different human cell 
lines (HMEC1, K562 and WEHI13) and one mouse cell line (HDF), and have therapeutic indices 
(calculated on the W2 strain) ranging from 21 to 233. Furthermore, a multivariate analysis of these 
results suggested a good correlation (R² = 0.975) between antiplasmodial activity and lipophilicity, 
which was mainly determined by the presence of a hydrophilic substituent on the phenyl ring. 216 
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Figure 63 
Compounds that release nitric oxide (NO) are interesting from a biological viewpoint; nitric oxide 
appears to be involved in the regulation of the immune response against P. falciparum and thus 
stimulates antiplasmodial activity.217-221 3-Cyano-4-phenyl-1,2,5-oxadiazole-2-oxide or furoxan is an 
entity that is able to release NO and is known to display activity against malaria and other parasitic 
diseases.218, 219, 222, 223 Based upon these results, furoxan-amodiaquine hybrids 141 have been 
designed, aiming to provide a small molecule that is active against parasitic diseases. Compounds 141 
were tested in vitro against the CQS (3D7) clonal line of P. falciparum in a SYBR green I assay and in a 
luciferase reporting delayed death assay. The activity of oxime precursor 141a decreased nearly 50-
fold between the two assays (0.024 vs 1.07 µM), while N-nitroso compound 141b displayed reduced 
activity in the SYBR green assay and was basically inactive in the delayed death assay (0.113 vs > 15 
µM). Although it is widely accepted that a basic nitrogen at the NR’ location is indispensable to 
promote accumulation of the compound in the parasitic digestive vacuole,224 this could account for 
the drop in activity. However, this rationale was not confirmed by the results of hybrid 141c; it 
displayed potency in both assays (40 and 630 nM, respectively), but a drop in activity could still be 
observed.225 
 
Figure 64 
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The 4-aminophenol moiety of AQ has been identified as a “structural alert” for toxicity since 
bioactivation of AQ to the reactive quinone imine is determined to be the likely cause of AQ-induced 
hepatotoxicity.226, 227 In an effort to find ways to prevent the formation of such imines, the Chibale 
group has anticipated that AQ derivatives 142 in which the hydroxyl group and the side chain were 
cyclized into benzothiazole, benzoxazole or benzimidazole heterocyclic ring systems would not form 
reactive metabolites. Furthermore, analogs 143 in which the aromatic ring was replaced with a 
pyridyl ring that includes an aminoalkyl side chain but no hydroxyl group, were conceived to lack the 
essential fuctional group for bioactivation, which should diminish cytotoxicity. The antiplasmodial 
activity of hybrids 142 and 143 was determined in vitro against two CQR (K1 and W2) P. falciparum 
strains and cytotoxicity was evaluated against rat myoblast (L6) cells. Results showed that the 
benzimidazole series (compounds 142h-j) were less potent against the W2 strain (200-4580 nM) 
compared to the other analogs; the pyridine derivatives 143 displayed good activity against the W2 
parasite strain (21-41 nM) but lower activity against the K1 strain (73-92 nM). Benzothiazole 
compounds 142b, 142c, 142e and benzoxazole 142g exhibited excellent activity against both strains 
with IC50 values ranging from 7 to 22 nM. Of the most potent compounds, hybrid 142g displayed the 
highest selectivity index (SI: 1088) and most other compounds displayed moderate to low 
cytotoxicity. The resistance indices were relatively low, suggesting that all compounds exhibit a low 
level of cross resistance.228 
 
Figure 65 
2.4.9. Hybrids of (amino)quinolines and other various motifs 
The classes of hybrids that have been discussed so far have been described in at least two 
publications and have proven their value in antimalarial drug design. There are, however, also a 
variety of antimalarial quinoline hybrids that have only once been mentioned in the literature in 
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recent years. This can be due to disappointing biological activities, or they can be promising classes 
that have just recently been discovered. This last section of this literature review will cover these 
specific classes of hybrids. 
As was previously mentioned, the 8-aminoquinoline primaquine (PQ) is active against liver-stage 
schizonts, it is also the only compound that eradicates hypnozoites and thus prevents relapses.229-231 
Primaquine is active against the clinical silent liver stage and could obstruct the disease before 
symptoms appear. CQ and most other antimalarial drugs inhibit the blood stage of the Plasmodium 
parasite and act during the clinical phase of the disease. The perfect remedy would be a non-toxic 
compound that is active against all stages of the Plasmodium life cycle that can be used 
prophylactically. This train of thought led to the design of bifunctional hybrid 144 where two 
approved antimalarial drugs CQ and PQ were combined in one dual compound by a neat coupling 
reaction at high temperature (120 °C). This conjugate 144 was tested for its antiplasmodial activity on 
the asexual blood stages of three P. falciparum strains: 3D7 (CQS), Dd2 (CQR) and K1 (CQR). Hybrid 
144 was less efficient than CQ against 3D7 (0.64 vs 0.03 µM) and the combined application of CQ and 
PQ (1:1) also showed no additional effect, this implied that PQ had no synergistic effect on the 3D7 
strain. However, compound 144 exhibited a moderate inhibitory effect against CQR strains Dd2 (IC50 
= 0.58 µM) and significantly inhibited the resistant K1 strain (IC50 = 0.08 µM). The combined 
equimolar administration of CQ and PQ was slightly more potent than hybrid 144 against Dd2, but 
was less active against K1. This indicated a resistance-reversing effect of PQ. This conjugate 144 
showed promising in vitro effects against the liver stages post-invasion in human hepatoma cells and 
was proven to be potent in vivo as well. This hybrid 144 thus inhibits the liver and blood stages of 
mammalian Plasmodium infection in vitro and in vivo and can be considered a very valuable lead in 
antiplasmodial research.232 
 
 
Figure 66 
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Since the work of Köpf-Maier reported on the anticancer activity of ferrocenium complexes,233 there 
has been a growing interest in metallocenes and their potential application in medicinal chemistry. 
Many ferrocene-containing compounds or functionalized ferrocenes have been designed and tested 
for their potential biological activity such as anticancer,234-236 antituberculosis,237-239 antimalarial 
activity,240-243 etc. Following these results a series of quinoline-ferrocene hybrids 145 with various 
spacers has been described. Condensation of various diamines with 4,7-dichloroquinoline afforded 
primary and secondary amino-functionalized quinolines. Subsequently, reductive amination of 
ferrocenic aldehyde with the functionalized quinolines furnished the desired hybrids 145. These 
metallocenes 145 were screened against CQS (D10) and CQR (Dd2) strains of P. falciparum, and 
hybrids containing a flexible hydrocarbon spacer (145a, 145b, 145f and 145g) were found to be the 
most active against both strains (IC50 between 0.09-0.13 µM for D10 and between 0.01-0.02 µM for 
Dd2). The compounds’ potency against the sensitive strain was comparable to that of CQ (0.05 µM), 
but was higher than CQ against the resistant strain (CQ: IC50 = 0.15 µM). Furthermore, all tested 
conjugates (except for 145a and 145b) displayed good selectivity towards Chinese Hamster Ovarium 
cell-types, implying low cytotoxicity.244 
 
Figure 67 
Triclosan is a diarylether which is well established as an antibacterial agent with mild in vitro 
antimalarial potency,245, 246 and this entity has been selected by Mishra et al. to be included in 
quinoline-based hybrids 146. The synthesis commenced with the coupling of 2- or 4-
fluoronitrobenzene with 2,5-dichlorophenol or 4-methoxyphenol, affording the diarylethers. 
Reducing the nitro group with iron and acetic acid furnished the respective substituted anilines, 
which were treated with different aryl isothiocyanates, affording the corresponding thioureides. 
Thiourea derivatives were transformed to the desired hybrids 146 by reaction with different 4-
aminoquinolines in the presence of mercury chloride and triethylamine. A total of 58 triclosan-4-
amino-7-chloroquinoline derivatives 146 have been synthesized and assessed for their in vitro 
antiplasmodial activity against CQS (3D7) and CQR (K1) strains of P. falciparum. Thirty-six out of the 
58 hybrids 146 displayed IC50 values lower than 100 nM against the sensitive 3D7 strain, but even the 
most active compound (IC50 = 20 nM) was less potent than CQ (IC50 = 7 nM). However, 28 conjugates 
146 were more active (IC50 between 41 and 329 nM) than CQ (IC50 = 352 nM) against the resistant K1 
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strain. Overall, hybrids 146 exhibited significant antimalarial potency when compounds had the 
triclosan-ether linkage para to the guanidino group, a 3-chloro-substitution (R2) on the phenyl ring 
and a propyl spacer between the 4-aminoquinoline moiety and the guanidine unit. Further selectivity 
and toxicity studies should disclose whether or not more research should be performed toward this 
type of compounds.247 
 
Figure 68 
Azithromycin has been the central compound in the hybridization study of the Perić group. 
Azithromycin is an azalide antibiotic, semi-synthetically derived from the macrolide erythromycin, 
that demonstrated in vitro and in vivo activity in malaria prophylaxis and experimental models.248-250 
In the Starčević study a 4-amino-7-chloroquinoline moiety has been linked to a C-3’ modified 15-
membered macrolide azalide, yielding hybrid molecules 147. These compounds 147 were profiled for 
their in vitro antiplasmodial activity against CQS (3D7) and CQR (W2) strains of P. falciparum. The five 
most potent compounds displayed IC50 values between 3 and 104 nM against the susceptible 
parasite strain and between 2 and 48 nM against the resistant strain. The high in vitro activities and 
the high selectivity of these macrolides render them interesting lead compounds for further 
investigation.251 
 
Figure 69 
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In the literature some examples of aminoquinoline-steroid conjugates have been reported to have 
good in vitro potencies against Leishmania major and Mycobacterium tuberculosis,252 which 
presented the incentive to design hybrids 148 of Cinchona alkaloids (quinine, quinidine, cinchonine 
and cinchonidine) and bile acids. The choice for bile acids was based on their easy accessibility, their 
role as drug transporters and the wide range of steroids that exhibit antiparasitic activity.253-255 
Reaction of peracetylated chenodeoxycholic or lithocholic acids with 2-mercaptopyridine N-oxide 
and N,N’-dicyclohexylcarbodiimide (DCC) afforded Barton esters, which were subsequently subjected 
to photolytic decarboxylation in the presence of a large excess of a protonated Cinchona alkaloid. 
These peracetylated hybrids were finally treated with a sodium hydroxide solution, furnishing 
conjugates 148. Hybrids 148 were assessed for their in vitro antiplasmodial activity against a CQS 
(3D7) strain of P. falciparum and cytotoxicity was evaluated against a human normal fibroblast cell 
line (WI38). Although none of the conjugates 148 were more active in vitro than the corresponding 
Cinchona alkaloids, they all exhibited activities with IC50 < 6 µg/mL, most of them even < 1 µg/mL. 
Moreover, hybrids 148 showed good selectivity indices.256 
 
Figure 70 
Squaric acid has been identified in the literature as a compound with good antiplasmodial 
properties257, 258 and was therefore utilized as active moiety in hybrid molecules. Linking squarate to 
4-amino-7-chloroquinoline (CQ derivative) afforded hybrids 149 and 150, while the connection of 
squarate and 8-amino-6-methoxyquinoline (PQ derivative) yielded conjugates 151 and 152. These 
compounds were examined for their ability to inhibit a CQR (W2) strain of P. falciparum, and most of 
them displayed antiplasmodial activities in a range from 0.1 to 2 µM. Hybrids 150, containing two CQ 
moieties, were clearly the most potent with IC50 values ranging from 0.1 to 0.2 µM. Therefore, the 
activity profiles of hybrids 149 and 150 were compared with those of P. falciparum-infected red 
blood cell that were incubated with a 1:1 and 2:1 mixture of CQ and squaric acid. The results 
revealed that the 1:1 mixture was equipotent to CQ (IC50 values of 138 and 140 nM, respectively), but 
considerably more active than conjugates 149. The 2:1 mixture on the other hand exhibited potency 
comparable to that of hybrids 150, implying that the 4-aminoquinoline moiety significantly 
PART II  LITERATURE REVIEW 
69 
 
contributes to the overall hybrid activity. The cytotoxicity was evaluated using NIH 3T3 and Hek 293T 
cell lines, most of the derivatives were non-cytotoxic at the tested concentrations (up to 50 µM).259 
 
Figure 71 
The rhodanine scaffold is a known synthon for the synthesis of various heterocyclic units with a range 
of pharmacological activities.260-264 The combination of the two intrinsically bioactive moieties 4-
aminoquinoline and rhodanine afforded hybrid molecules 153 and 154. 4,7-Dichloroquinolines were 
condensed with various diamines, and addition-elimination reaction of these products with carbon 
disulfide and ethylbromo acetate provided cyclized intermediate 3-(7-chloroquinolin-4-yl)alkyl-2-
thioxothiazolidin-4-ones 153. Knoevenagel condensation with appropriate aldehydes furnished 
hybrids 154. These compounds have been assessed for in vitro antiplasmodial efficacy against CQS 
(3D7) and CQR (K1) stains of P. falciparum. Derivatives 154 (except 154h, 154s and 154t) displayed 
promising activities against the sensitive Plasmodium strain (IC50 < 100 nM) and were even more 
potent than CQ (IC50 = 254 nM) against the resistant strain. Furthermore, all compounds were also 
assessed for their cytotoxicity toward the VERO cell line and compounds 154e, 154m and 154o 
exhibited very high selectivity indices (>2000), indicating no cytotoxicity.265 
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Figure 72 
Thiopurines, like 6-mercaptopurines, are cytotoxic prodrugs that hinder nucleic acid synthesis by 
inhibiting enzymes involved in the de novo purine synthetic pathway,266 and they are often used in 
cancer treatment and as immunosupressors.267, 268 Conjugation of the sodium salt of 6-
mercaptopurine with either 4,7-dichloroquinoline or (7-chloroquinolin-4-ylamino)alkyl 
methanesulfonate afforded hybrids 155 and 156, respectively, which were evaluated in vivo against 
P. berghei in a murine malaria model to determine their antiplasmodial efficacy. Compound 155 
displayed the best antimalarial profile, after 7 days there was more than 70% inhibition of parasite 
multiplication (when using doses of 5 mg/kg/day for 4 days). Cytotoxicity evaluation was also 
performed in an in vitro peritoneal macrophage model and none of the tested compounds displayed 
toxicity for mammalian cells at the maximum concentration tested (100 µg/mL).269 
 
Figure 73 
Iron plays an important role in the development of the malaria parasite, meaning that disruptions in 
the iron concentration can hamper parasite proliferation. 3-Hydroxypyridin-4-ones have been 
reported to chelate iron,270 which would lead to the loss of iron and cause the parasite to diminish, 
but only if the hydroxypyridinones are able to access the parasitic digestive vacuole, which would be 
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possible using CQ transport systems. Therefore, 4-aminoquinoline-3-hydroxypyridin-4-one hybrid 
derivatives 157 have been synthesized by Michael addition of N-(7-chloroquinolin-4-
yl)diaminoalkanes to benzylated pyranones. These protected conjugates were deprotected by 
catalytic hydrogenolysis at high pressure or by acid hydrolysis. Hybrids 157 have been assessed for in 
vitro antiplasmodial efficacy against CQS 3D7 strain and CQR K1 and W2 strains of P. falciparum. 
Fifteen out of 20 compounds 157 displayed IC50 values < 1 µM against the sensitive strain, compound 
157f was more potent (IC50 = 4 nM) than CQ (IC50 = 10 nM). Nine compounds exhibited superior 
activity than CQ against the resistant strains (K1 and W2). Cytotoxicity studies in mammalian KB cell 
line revealed that most of the tested hybrids were not toxic up to concentrations of 30 µM.271 
 
Figure 74 
Paclitaxel (Taxol) is an antimicrotubular drug272 that also displays potential antiplasmodial efficacy,273 
and consists of two structural moieties, (2R,3S)-N-benzoyl-3-phenylisoserine and baccatin III, thus it 
can be considered a hybrid molecule. It has been proven that both structural components are 
essential for the antimicrotubular potency, since individually they are devoid of any activity.274 As 
these structural nuclei act synergistically in Taxol, they suggest themselves as potential templates for 
the design of novel biologically active hybrid entities. In a study of Njogu et al., a (2R,3S)-N-benzoyl-3-
phenylisoserine moiety has been coupled to a quinoline scaffold via ester, amide or triazole linkers, 
affording hybrid compounds 158 and 159. All conjugates were evaluated in vitro for efficacy against 
two CQR (K1 and W2) strains of P. falciparum. Compounds 158 displayed IC50 values between 0.22 -
1.00 µM against the K1 strain and between 0.13 and 0.56 µM against the W2 strain, while IC50 values 
of compounds 159 ranged from 0.39 to 3.24 µM and from 0.28 to 2.71 µM against K1 and W2, 
respectively. Hybrids 158c and 158d were the most potent against W2 (IC50 = 0.13 and 0.16 µM, 
respectively), but were still less active than CQ (IC50 = 0.05 µM). These results suggested that the 
inherent antimalarial activity of the 4-amino-7-chloroquinoline was retained, but hybridization with 
(2R,3S)-N-benzoyl-3-phenylisoserine did not improve antimalarial potency as anticipated.275  
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Figure 75 
Reports have indicated that malaria and HIV co-infection may work synergistically in regions where 
they co-exist.276-279 The concept of hybrid drugs has led to the development of hybrid antimalarial 
and hybrid anti-HIV drugs, but a novel, interesting approach from the Chibale group consisted of the 
design of dual molecules targeting HIV and P. falciparum simultaneously. Therefore, hybrid 
molecules that incorporate derivatives of clinically approved antimalarial drugs (e.g. CQ) and anti-HIV 
drugs (azidothymidine) have been designed. 4-Aminoquinoline-based intermediates were reacted 
with N-protected aminothymidine intermediates and afforded conjugates 160 and 161. Quinoline-
based hybrids 162 and 163 were obtained by substitution with appropriate 4-aminoquinolines at the 
N-3 position of azidothymidine. This series of obtained compounds was evaluated for their inhibitory 
activity against CQS (3D7) and CQR (Dd2) strains of P. falciparum and were screened for cytotoxicity 
against HeLa cells at various concentrations (1-50 µM). Eleven of the hybrids displayed IC50 values in 
nanomolar range against both Plasmodium strains, while compounds 160a, 160d and 161d showed 
significant reduction in the growth of HeLa cells. Compounds 160d and 161d appeared to be the 
most active (IC50 = 0.08 µM) against the resistant strain and they were 7- to 8-fold more potent than 
CQ (IC50 = 0.71 µM). Since the hybrids also exhibited moderate to strong inhibition of HIV-1 this study 
proved that the concept of using molecular hybrid molecules to inhibit two non-related organisms 
could find applications in the treatment of HIV/malaria co-infections.280 
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Figure 76 
Quinolone antibiotics are very well known for the treatment of life-threatening bacterial 
infections.281 Quinolones and fluoroquinolones have also been reported to exhibit antiplasmodial 
activity against CQS and CQR P. falciparum.282-284 Consequently, the Katritzky group looked into 
linking quinine-amino acid conjugates to quinolone antibiotics in order to obtain hybrids 164 with 
potentially enhanced antimalarial activity. Quinine-amino acid conjugates were utilized because 
amino acids can be employed as carriers for drugs since they are able to be built into mammalian 
tissue later on. Hybrids 164 were assessed for in vitro antiplasmodial efficacy against a CQS (3D7) 
strain of P. falciparum and all compounds displayed nanomolar activity with IC50 values ranging from 
12 to 207 nM, with compounds 164f and 164g (IC50 = 16 and 12 nM, respectively) being the most 
potent ones. This proves that conjugates 164 retained antimalarial activity, similar to quinine (IC50 = 
18 nM).285 
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Figure 77 
N-acylhydrazones are a well-known group of antiparasitic agents which possess antiamoebic and 
antimalarial properties.286, 287 In view of these characteristics, it was envisaged to link 4-
aminoquinoline with N-acylhydrazone via an appropriate linker, resulting in hybrid molecules 165. 
Nucleophilic aromatic substitution of 4,7-dichloroquinoline with piperazine afforded 7-chloro-4-
piperazin-1-ylquinoline, which was subsequently reacted with methyl acrylate under neat conditions. 
The obtained ester was treated with hydrazine hydrate and further reacted with various aldehydes to 
give N-acylhydrazone hybrids 165. All compounds 165 were screened for antimalarial activity against 
CQR W2 strain of P. falciparum and cytotoxicity was determined against mouse splenocytes. Only the 
compounds that showed Plasmodium inhibition higher than 90% were further evaluated, and they 
displayed IC50 values between 0.2 and 4.5 µM making them a lot less potent than the reference drug 
mefloquine (IC50 = 0.04 µM). These compounds were also not selective toward the parasite with 
selectivity indices between 0.03 and 0.7, which implies they are very cytotoxic.288 
 
Figure 78 
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In a final approach, molecular hybridization of 4-amino-7-chloroquinoline derivatives with 
substituted aryl/heteroaryl piperazines, tetrahydroisoquinoline and 4-cyano-4-aryl-piperidine, 
respectively, yielded hybrid molecules 166, 167 and 168. In vitro antiplasmodial assessment of these 
compounds against a CQ susceptible NF54 parasite strain revealed MIC-values > 10 µg/mL for most 
compounds, except hybrids 166f, 167a, 167b and 168b, which amounted to 0.125 µg/mL, 2 µg/mL, 
0.031 µg/mL and 2 µg/mL, respectively. Conjugates 166f and 167b were equally to more potent than 
CQ (MIC = 0.125 µg/mL) and where subsequently evaluated in vivo against CQR N67 strain of P. yoelii 
in Swiss infected mice. Hybrid 166f, containing the pyridine nucleus in the side chain, displayed a 
curative response when administered at doses of 50 mg/kg/day for four days by intraperitoneal 
route as well as when administered orally at doses of 100 mg/kg/day for four days. Compound 167b 
did suppress 100% of the parasitemia on day four, but there was no mice survival on day 28. 
Pyridine-containing conjugate 166f thus represents a promising lead compound for future 
antiplasmodial drug research.81 
 
Figure 79 
 
2.5. Conclusions 
The extent of this literature review demonstrates the high interest in the field of quinoline hybrid 
formation, but also illustrates the high antiplasmodial potential of most of the described chimeras. 
Quinoline hybrid formation has proven to be a valuable approach in the development of novel 
antimalarial lead compounds. As a benchmark, the five most potent compounds that were dicussed 
in this literature review are depicted in Figure 80. 
PART II  LITERATURE REVIEW 
76 
 
 
Figure 80: Promising quinoline-containing antimalarial agents.  
In this PhD thesis, the potential of hybrid formation around the quinoline core will be explored with 
the intention to provide new entries toward biologically interesting functionalized quinolines.
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3.1.  
Synthesis and biological evaluation of  
(4-aminobutyloxy)quinolines 
 
 
 
 
Abstract: A variety of 5-, 6- and 8-(4-aminobutyloxy)quinolines as novel oxygen analogs of known 4- 
and 8-(4-aminobutylamino)quinoline antimalarial drugs was generated from hydroxyquinolines via a 
three-step approach with a rhodium-catalyzed hydroformylation and a reductive amination as the 
key steps. Antiplasmodial assays of these new quinolines revealed micromolar potency for all 
representatives against a chloroquine-sensitive strain of Plasmodium falciparum, and three 
compounds displayed submicromolar activity against a chloroquine-resistant strain of P. falciparum 
with IC50 values ranging between 150-680 nM. Antifungal assessment of these quinolines revealed a 
significant susceptibility of the tested fungi and yeast strains (Candida albicans, Rhodotorula 
bogoriensis, Aspergillus flavus and Fusarium solani) toward different halo-substituted 8-(4-
aminobutyloxy)quinolines. The six most potent compounds exhibited antifungal activities similar to 
those of established antifungal agents such as Amphotericin B, Fluconazole and Itraconazole. One 
compound also displayed a promising broad-spectrum antifungal profile.  
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3.1.1. Introduction 
Quinolines, and especially the potent, inexpensive chloroquine (CQ), have a long history in the 
treatment of malaria. However, the rise of chloroquine resistance within Plasmodium falciparum 
strains has complicated medicinal treatment in the affected areas. Many important antimalarial 
drugs comprise a quinoline system as the core unit and systematic synthetic modifications of these 
structures have led to a variety of antimalarial drugs and hit-to-lead candidates with diverse 
substitutions around the quinoline ring.289-292 Literature reports on CQ analogs reveal that 
replacement of the nitrogen atom at the 4-position of the quinoline ring by oxygen results in 
compounds with lower antiplasmodial potency.291 The introduction of oxygen, however, has also 
been suggested to cause a significant reduction of the quinolyl nitrogen’s basicity, inflicting the 4-O 
analogs to be monoprotic weak bases compared to the diprotic weakly basic 4-aminoquinoline 
derivatives. In spite of the lower antimalarial potency of these compounds, an improved resistance 
index (RI) was observed.290, 291 Since the rise of chloroquine resistance, especially the potency of 4-
substituted (amino)quinolines has been extensively unravelled.290-295 Other, but far less thorough 
studies have been performed concerning the synthesis and antimalarial evaluation of 8-substituted 
quinolines,296, 297 although the elaboration of this class has mainly focused on the derivatization of 
known 8-aminoquinoline antiplasmodial drugs such as pamaquine and primaquine.296-299 In both 
cases the modification of the quinoline side chain has been well examined,49, 81, 114, 207, 292, 294, 295, 300 
however, substitution of the amino group by oxygen equivalents has only been described for 4-
substituted quinolines so far.290, 291 Given the fact that 4-O analogs displayed improved RI’s and 
toxicological advantages compared to 4-amino derivatives,291 and knowing that the decrease in 
antimalarial activity of 4-O CQ derivatives correlates to the decrease in basicity of the quinolyl 
nitrogen as a result of a particular substitution pattern (i.e., para-positioning),291 the introduction of a 
functionalized alkoxy side chain at a more remote position with respect to the quinoline nitrogen 
atom might result in an overall beneficial effect with regard to the antiplasmodial activity of these 
novel structures. Thus, in the present chapter, the preparation of new 8-(4-aminobutyloxy)- and 8-(4-
aminobutylamino)quinolines is described, as well as the assessment of their antiplasmodial and 
antimicrobial activity. In addition, the scope of this study was further extended toward the synthesis 
and biological evaluation of novel 5- and 6-(4-aminobutyloxy) and 5- and 6-(4-
aminobutylamino)quinolines as well.  
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3.1.2. Design and synthesis of 5-, 6- and 8-(4-aminobutyloxy)quinolines 
The synthesis of 4-substituted quinolines can easily be accomplished through nucleophilic aromatic 
substitution on commercially available 4-haloquinolines. Unfortunately, this method is less or not 
effective toward the preparation of the desired quinolines bearing a functionalized side chain at, for 
example, the 5-, 6- or 8-position, which made a novel approach of side chain introduction necessary. 
3.1.2.1. Synthesis of 3-, 5-, 6- and 8-allyloxy- and allylaminoquinolines 
A variety of allyloxy- and allylaminoquinolines 169 and 170 was prepared through O- or N-allylation 
of 3-, 5-, 6- or 8-hydroxy- or aminoquinolines 13 and 12 upon treatment with 1.5 equiv of allyl 
bromide or 2-methylallylbromide (in order to induce structural diversity) in the presence of 3 equiv 
of potassium carbonate. An initial solvent screening showed that this reaction was not selective in 
dimethylformamide (DMF) under reflux, affording a mixture of mono- and diallylaminoquinolines or 
propagating Claisen rearrangement of allyloxyquinolines. Selective O-allylation was achieved when 
the reaction was performed in acetone and stirred for 24 h at reflux temperature. Exclusive mono-N-
allylation of aminoquinolines 12 could not be accomplished, although reaction in a DMF/acetone 1:1 
solvent mixture afforded allylaminoquinolines 170 as the major products, column chromatography 
yielded pure compounds 170a,h-j,k,r-t (Scheme 4).  
 
 
Scheme 4 
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Table 1: Substitution pattern and yields of quinolines 169 and 170 
 Quinolin- R
1 
R
2 
Yield 
(%) 
169  
Yield 
(%) 
170 
 Quinolin- R
1 
R
2 
Yield 
(%) 
169 
Yield 
(%) 
170 
a  8-yl H H  91 66 k 8-yl H CH3 92 54 
b  8-yl 5-Cl H  82 - l 8-yl 5-Cl CH3 79 - 
c  8-yl 5-Cl,7-I H  78 - m 8-yl 5-Cl,7-I CH3 71 - 
d 8-yl 2,7-di-Cl H 78 - n 8-yl 2,7-di-Cl CH3 58 - 
e  8-yl 2,7-di-I H  70 - o 8-yl 2,7-di-I CH3 71 - 
f  8-yl 2,7-di-Br H  82 - p 8-yl 2,7-di-Br CH3 57 - 
g 8-yl 2-CH3,5,7-di-Cl H  78 - q 8-yl 2-CH3,5,7-di-Cl CH3 76 - 
h  6-yl H H  76 25 r 6-yl H CH3 88 63 
i  5-yl H H  97 30 s 5-yl H CH3 82 40 
j  3-yl H H  - 50 t 3-yl H CH3 - 62 
 
3.1.2.2. Rhodium-catalyzed hydroformylation of allyloxy- and allylaminoquinolines 
The obtained quinolines 169 and 170 were evaluated for the first time as substrates for a rhodium-
catalyzed hydroformylation toward the corresponding linear aldehydes 172 and 173. These reactions 
were performed during a research stay at Eindhoven University of Technology under the supervision 
of Prof. D. Vogt. Initially, quinolines 169 and 170 were subjected to standard hydroformylation 
conditions, i.e., applying syngas (20 bar CO/H2, 1:1) using (acetylacetonato)dicarbonylrhodium(I) 
[Rh(acac)(CO)2] as a catalyst precursor (substrate/Rh = 500) and xantphos as a ligand (ligand/Rh = 4) 
in toluene at 80 °C (2h preformation, 20 h reaction).301 This method gave satisfying results for non- or 
mono-substituted (2-propenyloxy)quinolines (R1 = H, Cl), but when di- or tri-substituted (2-
propenyloxy)quinolines 169 (R1 = 2 × Cl, I, Br) were used as substrates, only partial conversion was 
obtained (~50%). Prolonging the reaction time (40-115h), changing the solvent (2-Me-THF) or 
elevating the reaction temperature (120 °C) had a varying influence on the conversion (5-76%) (Table 
2). It seemed that steric hindrance (by both the halogen and the R2 substituents) prevented the 
catalyst to reach the double bond in these cases. Subsequently, triphenylphosphine, a typical 
monodentate ligand which is less rigid than the bidendate xantphos, was used, but unfortunately 
conversion dropped further (5-15%), even when large quantities of the ligand were employed (20-40 
equiv). However, changing the solvent to 2-methyltetrahydrofuran seemed to be beneficial in this 
case, affording 85% conversion. The use of tris(2,4-di-tert-butylphenyl)phospite (P(OR)3),
302, 303 a 
ligand that is typically used for hydroformylation of internal and sterically more demanding olefins,304 
gave no conversion at all. Other ligands known to be very selective toward the formation of linear 
aldehydes are bidendate phosphordiamidite ligands.305 Thus in a final attempt, the pyrrole-
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containing phosphordiamidite ligand DPBO (Figure 81) was used, a ligand with a 2,2’-binaphthol 
backbone that has recently been evaluated for the hydroformylation of styrene.306  
   
Figure 81: Structure of DPBO-ligand, X-ray published by Boymans, et al.
306
 
Fortunately, the use of this DPBO-ligand resulted in good to excellent conversion (65-99%) of non-
substituted (R1 = H) as well as substituted [(2-methyl-)2-propenyloxy]quinolines 169 (R1 = Cl, I, Br) 
into the corresponding 4-(quinolinyloxy)butyraldehydes 172 under standard hydroformylation 
reaction conditions (20 bar, CO/H2 (1:1), substrate/Rh = 500, ligand/Rh = 4, toluene, 80 °C, 20-24h) 
(Scheme 5, Table 2). In analogy with the results described in the literature,306 this ligand was selective 
toward the formation of linear aldehydes, and no branched aldehydes were formed. The (2-
propenylamino)quinolines 170, however, were unstable under all tested reaction conditions and 
decomposed; only minute fractions of the desired product were formed and could not be isolated 
(Table 2). 
 
Scheme 5 
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Scheme 6 
The mechanism of the hydroformylation reaction is depicted in Scheme 6. The reaction starts with 
the generation of a coordinatively unsaturated metal hydrido carbonyl complex (preformation), after 
which this species binds alkenes (step A). The resulting complex undergoes a migratory insertion 
reaction to form an alkyl complex (step B). After this alkyl formation a second migratory insertion 
converts the alkyl into an acyl ligand (steps C and D), after which an oxidative addition of a hydrogen 
molecule fills the vacant site on the metal (step E). Finally, one of these hydrides takes part in the 
reductive elimination to form the desired aldehyde with recovery of the activated catalyst (step F).  
Table 2: Different reaction conditions of Rh-catalyzed hydroformylation 
Substrate  Ligand  Solvent  Temperature (°C)  Time (h)  Conversion (%)
* 
169a xantphos (4 eq)  toluene  80  20  99 
169l xantphos (4 eq)  toluene  80  20  95 
169i xantphos (4 eq)  toluene  80  20  88 
169b xantphos (4 eq) toluene 80 20 98 
169d xantphos (4 eq) toluene 80 20/66  50/58  
169
e
 xantphos (4 eq) toluene  80 62 <5 
169f xantphos (4 eq) toluene  80 40 <5 
169c xantphos (4 eq) toluene  80 90 <5 
169g xantphos (4 eq) toluene  80 60 76 
169
e
 xantphos (4 eq) 2-MeTHF 80 87 <5 
169l PPh3 (20 eq) toluene 80 20 11 
169l PPh3 (20 eq) toluene 120 20 9 
169l PPh3 (20 eq) toluene 120 115 5 
169r  PPh3 (40 eq) toluene 80 20 8 
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169r PPh3 (20 eq) 2-MeTHF 80 20 85 
169l P(OR)3 (20 eq) toluene  80 20 0 
169a DPBO (2 eq)  toluene  80  20  85 
169b DPBO (2 eq) toluene 80 20 90 
169c DPBO (2 eq) toluene 80 20 89 
169d DPBO (2 eq) toluene 80 20 82 
169k DPBO (2 eq) toluene 80 20 99 
169l DPBO (2 eq) toluene  80 20 65 
169m DPBO (2 eq) toluene 80 20 99 
169n DPBO (2 eq) toluene 80 20 97 
169o DPBO (2 eq) toluene 80 20 90 
169p DPBO (2 eq) toluene 80 20 96 
169q DPBO (2 eq) toluene 80 24 95 
169r DPBO (2 eq) toluene 80 20 95 
169s DPBO (2 eq) toluene 80 20 98 
      170a xantphos (4 eq) toluene 80 20 14 
170a xantphos (4 eq) 2-MeTHF 80 20 5 
170j P(OR)3 (2 eq) toluene  80 20 0 
170k DPBO (2 eq) toluene  80 20 13 
170i DPBO (2 eq) 2-MeTHF 80 20 17  
*
 Conversion measured via GC analysis 
In conclusion, this hydroformylation step proved to be an efficient method for the generation of a 4-
oxobutyloxy side chain as an anchor point for further derivatization and comprises the first example 
of the successful integration of homogenous catalysis within the synthesis of 
aminoalkyloxyquinolines as potential antimalarial candidates. 
3.1.2.3. Reductive amination of 4-(quinolinyloxy)butyraldehydes 
The introduction of an aldehyde functionality within the side chain created a myriad of possibilities 
for further synthetic elaboration. In light of the target compounds (chloroquine and pamaquine 
analogs), imination of aldehydes 172 followed by a reduction toward the corresponding amines 
comprised the next synthetic steps. Diethylamine and 4-chlorobenzylamine were selected as the 
amines to undergo condensation with aldehydes 172. The choice for diethylamine is evident from 
the established importance of the diethylamino moiety in many antimalarial agents, whereas 4-
chlorobenzylamine was selected based on previous studies in which the incorporation of this group 
had shown to be advantageous with respect to antiplasmodial activity.307, 308 When performing the 
reductive amination of 4-(quinolinyloxy)butyraldehydes 172 in a one-pot reaction using 2 equiv of 
diethylamine and 2 equiv of sodium cyanoborohydride in the presence of 5 equiv of acetic acid in 
methanol at room temperature, full conversion to the desired [4-(diethylamino)butyloxy]quinolines 
174 was obtained in moderate to excellent yields (56-95%) (Scheme 7). However, when the primary 
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amine 4-chlorobenzylamine was utilized, the same reaction conditions did not result in full 
conversion to the desired amines 175, but dimerization occurred, causing tertiary amines to be 
formed. Fortunately, this was easily overcome by performing the reductive amination in a stepwise 
fashion. Firstly, aldehydes 172 were treated with 1.05 equiv of 4-chlorobenzylamine in the presence 
of 1.5 equiv of magnesium sulphate in dichloromethane under reflux for 1 h to afford the 
corresponding imines, which were immediately reduced using 2 equiv of sodium borohydride in 
methanol under reflux for 1 h, furnishing the desired [4-(4-chlorobenzylamino)butyloxy]quinolines 
175 in moderate to excellent yields (48-94%) (Scheme 7). 
 
Scheme 7 
After an initial attempt to hydroformylate compound 169l using (acetoacetonato) 
dicarbonylrhodium(I) as a catalyst and xantphos as a ligand, no aldehyde formation was observed. On 
the other hand, the elevated reaction temperature (80 °C) had caused (2-methyl-2-
propenyloxy)quinoline 169l to undergo a Claisen rearrangement, yielding 5-chloro-7-(2-methyl-2-
propenyl)quinolin-8-ol 176 in quantitative yield. It should be noted that no Claisen rearrangement 
was observed when allyl ether 169l was heated at 80 °C in toluene for 18h without catalyst present. 
Subsequently, compound 176 was evaluated as an alternative substrate for hydroformylation using 
DPBO as the ligand. In this way, 4-(5-chloro-8-hydroxyquinolin-7-yl)-3-methylbutyraldehyde 177 was 
obtained as the sole reaction product in 73% yield. Finally, aldehyde 177 was subjected to reductive 
amination using diethylamine and sodium cyanoborohydride in methanol in the presence of acetic 
acid, rendering 5-chloro-7-(4-diethylamino-2-methylbutyl)quinolin-8-ol 178 in high yield and purity 
(Scheme 8). 
PART III  RESULTS AND DISCUSSION 
87 
 
 
Scheme 8 
3.1.3. Antiplasmodial assay of novel (4-aminobutyloxy)quinolines 
The newly synthesized quinolines 174, 175 and 178 were screened for their in vitro antiplasmodial 
activity at the University of Cape Town, South Africa (Prof. P. J. Smith and Prof. K. Chibale). Only 
those samples showing promising antimalarial activity (IC50 < 5 µM) were tested against a CQR strain 
of P. falciparum (Dd2) and screened for in vitro cytotoxicity against a mammalian cell-line, Chinese 
Hamster Ovarian (CHO) cells, using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT)-assay. The MTT-assay was used as a colorimetric assay for cellular growth and survival, and 
compares well with other available assays.309, 310 The tetrazolium salt MTT was used to measure all 
growth and chemosensitivity.  
The results of the biological evaluation are summarized in Table 3. This study shows that all 
representatives display micromolar potencies against the CQS D10 strain of P. falciparum, with 12 of 
the 19 samples having IC50 values between 10 and 1 µM. Interestingly, the most active compounds 
were more potent against the CQR Dd2 strain of the parasite (IC50 = 150-680 nM). While 175q 
exhibits moderate cytotoxicity (SI = 2), quinolines 174q, 175h and 175i have good to very good 
selectivity indices at the concentrations tested (SI = 29-57), as a reference, the selectivity index of CQ 
is about 50. Overall, compound 178 appeared to be the most active against both parasite strains 
(IC50(D10) = 1.01 µM, IC50 (Dd2) = 0.15 µM) with a SI of 5. 
With regard to structure-activity relationships, this assay shows that the presence of a methyl group 
in the side chain or the presence of at least one chlorine atom on the quinoline core is salutary for 
the antiplasmodial activity of these compounds, and that both the diethylamino group and the 4-
chlorobenzylamino group at the terminus of the side chain can be of interest with regard to their 
antimalarial properties. Based on the observations made in this work, it can be concluded that the 
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introduction of substituents bearing a β-methyl group (instead of the usual α-methyl group in known 
antimalarial drugs) at the less explored 5-, 6- or 8-positions of the quinoline nucleus might provide 
promising prospects and opportunities within antimalarial drug design. Finally, it appears that 
compound 178, recovered after a Claisen rearrangement, gives the best overall results, which could 
be attributed to the intermolecular hydrogen bonding between the 8-hydroxyl group and the target 
enzyme.  
 
Table 3: IC50 values of quinolines 174, 175 and 178 tested for in vitro antimalarial activity and cytotoxicity 
Compound D10: IC50 (µM) Dd2: IC50 (µM) CHO: IC50 (µM) SI
a 
RI
b 
174a 49.19 ND ND ND ND 
174b 17.18 ND ND ND ND 
174c 9.02 ND ND ND ND 
174h 6.02 ND ND ND ND 
174i 10.24 ND ND ND ND 
174k 100.20 ND ND ND ND 
174m 12.97 ND ND ND ND 
174n 8.08 ND ND ND ND 
174o 13.89 ND ND ND ND 
174p 8.65 ND ND ND ND 
174q 3.95 0.68 224.46 57 0.17 
175b 9.99 ND ND ND ND 
175h 7.29 (n=6) >1 211.45 29 ND 
175i 7.01 (n=6) ND 237.35 34 ND 
175k 5.64 (n=6) ND ND ND ND 
175o 9.15 ND ND ND ND 
175q 2.44 0.26 4.11 2 0.11 
175s 23.08 ND ND ND ND 
178 1.01 (n=6) 0.15 4.80 5 0.15 
CQ 0.04 (n=28) 0.34 ND ND 8 
Emetine ND ND 0.17 ND ND 
ND = not determined; n = number of replicates; 
a
 SI (Selectivity Index) = IC50 CHO/IC50 D10; 
b
 RI (Resistance 
Index) = IC50 Dd2/IC50 D10. 
 
3.1.4. Antimicrobial assessment of novel (4-aminobutyloxy)quinolines 
Until the 1970s, the number of fungal infections (mycoses) worldwide was relatively low and could 
be held steady for many years. Most of these infections were easily cured and mainly superficial, 
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resulting in the fact that there was one ‘golden standard’ in antifungal chemotherapy: Amphotericin 
B 179 (Figure 82).311  
 
Figure 82: structure of Amphotericin B 
However, the incidence and severity of fungal infections has increased considerably over the years, 
causing significant morbidity and mortality (particularly in patients with impaired immunity due to 
diabetes, AIDS, cancer, etc.).312-315 Nowadays there are many types of mycoses, which can be caused 
by opportunistic pathogens (endogenous or acquired from the environment) or invasive fungal 
infections, and these mycoses are often associated with corticosteroid therapy, antibiotic 
treatments, diabetes, surgery, etc.316, 317 Even though mycoses are becoming more frequent, they are 
still difficult to clinically diagnose.313, 318 In addition, another important issue to be addressed 
concerns the emergence of (cross)resistance against the most frequently used antifungal drugs, 
necessitating a continuous input of novel antifungal drug candidates with high efficacy rates and low 
toxicity, especially in the treatment of some invasive fungal infections such as aspergillosis and 
fusariosis.313-315, 318, 319 Consequently, a lot of research is being performed in order to discover novel 
and potent antifungal agents.311, 312, 320 Polyenes, azoles, cyclic lipopeptides, allylamines and 
thiocarbamates are the most frequently encountered structural units within antifungal drug 
research, but also quinoline-based systems have emerged as an important class of antifungal 
agents.11 Chemical derivatization of 8-hydroxyquinoline, a simple fungistatic compound known since 
the early 1920s,321 has been intensively evaluated in the literature in order to augment its antifungal 
activity. Chlorinated, brominated and bulky (halo-)substituted derivatives have therefore been 
synthesized and revealed improved fungitoxicity in comparison with the parent molecule 8-
hydroxyquinoline.322-329 These derivatization studies mainly focused on the introduction of various 
substitutions on the quinoline ring. On the other hand, O-functionalization of 8-hydroxyquinoline has 
hardly been examined so far, and only a few 8-alkoxyquinolines have been described as antifungal 
agents.330 Elaboration of O-functionalized quinolines as a potential new class of antifungals can thus 
be considered as a relevant challenge within antimicrobial research. Following this train of thought, 
the evaluation of the antifungal properties of the above-mentioned types of quinolines 174 and 175 
was performed. 
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The antifungal activity of the 18 compounds was tested on two yeast strains (Candida albicans (IHEM 
374) and Rhodotorula bogoriensis (MUCL 11796)) and two mould strains (Aspergillus flavus (ATCC 
44310) and Fusarium solani (CBS 230.34)) at the Centre of Expertise for Industrial Biotechnology and 
Biocatalysis, Ghent University (Prof. T. Desmet). In a preliminary screening test, the antifungal activity 
of these 18 compounds was studied on the aforementioned fungi by using the Disk diffusion 
susceptibility test.331 The results of these antifungal assessments are depicted in Table 4. 
 
Table 4: Results of the Disk diffusion susceptibility test  
(diameter of antifungal zone (mm) – 2 µL of 0.1 mg/µL per disc) 
Compound Candida 
albicans 
Rhodotorula  
bogoriensis 
Aspergillus  
flavus 
Fusarium  
solani 
174a 0 0 0 0 
174b 12 0 0 0 
174c 0 14 7 0 
174h 0 0 0 0 
174i 0 0 0 0 
174k 0 0 0 0 
174m 7 30 10 0 
174n 10 32 12 0 
174o 12 26 7 0 
174p 20 28 7 0 
174q 20 30 10 20 
175b 8 30 0 0 
175h 0 0 0 0 
175i 0 0 0 0 
175k 0 15 0 0 
175o 7 10 0 0 
175q 0 32 0 8 
175s 0 7 0 0 
DMSO 0 0 0 0 
 
It is important to note that all tested strains appear to be susceptible only toward the 8-(4-
aminobutyloxy)quinolines 174a-c,k,m-q and 175b,k,o,q. This implies that moving the aminobutyloxy 
side chain to the 5- or 6-position of the quinoline ring is detrimental for antifungal activity. Moreover, 
in agreement with previous research,322-324, 326, 330 these results demonstrate that the antifungal 
activity of 8-(4-aminobutyloxy)quinolines increases with the degree of substitution of the quinoline 
ring. It also seems that compounds bearing a 4-(diethylamino)butyloxy side chain display antifungal 
activity against yeasts (C. albicans and R. bogoriensis) and moulds (A. flavus), while compounds with 
a 4-(chlorobenzylamino)butyloxy side chain appear to be active only against yeast strains. The 
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introduction of an extra methyl group within the side chain does not seem to affect the compounds’ 
antifungal potencies. In the end, the six most active compounds of the 8-(4-aminobutyloxy)quinoline 
class (174m-q and 175q) were subjected to a Minimum Inhibitory Concentration (MIC) determination 
test via microdilution, and the MIC values are reported in Table 5. 
 
Table 5: MIC values  
Compound Candida albicans Rhodotorula bogoriensis   Aspergillus flavus  Fusarium solani 
 (mg/L) (µM)        (mg/L)     (µM) (mg/L) (µM) (mg/L) (µM) 
174m 4.00 8.95 0.25 0.56 4.00 8.95 ND ND 
174n 0.50 1.41 0.25 0.70 0.50 1.41 ND ND 
174o 0.50 0.93 0.50 0.93 4.00 7.43 ND ND 
174p 0.25 0.56 0.50 1.13 2.00 4.50 ND ND 
174q 0.25 0.68 0.12 0.32 0.50 1.35 0.50 1.35 
175q ND ND 0.25 0.57 ND ND 8.00 18.27 
Amphotericin B <0.195 <0.2 <0.195 <0.2 3.125 34.0 ND ND 
ND = not determined 
 
The MIC values correspond well with the results of the preliminary screening test and prove that all 
six tested compounds exhibit considerable antifungal activity. Compound 174n in particular displays 
low MIC values for C. albicans, R. bogoriensis and A. flavus, indicating that both yeasts and moulds 
are susceptible to this compound. Compounds 174o and 174p on the other hand prove to be more 
selective toward yeasts, while compounds 174m and 175q show specific activity toward Rhodotorula 
bogoriensis. Finally, molecule 174q exhibits antifungal activity against yeasts as well as moulds. 
Furthermore, its antifungal activity in terms of MIC values is comparable to or lower than that of 
standard, commercially available antifungal reagents such as Itraconazole, Fluconazole or 
Amphotericin B (MIC values between 0.01 and 16 mg/L).312, 332-335 Therefore, compound 174q can be 
considered as a promising novel broad-spectrum antifungal lead compound that can significantly 
suppress growth of pathogenic yeasts and moulds.  
 
As can be expected, the (calculated) molecular parameters of the most promising compounds 174m-
q and 175q correspond very well with those of the established quinoline antimalarial drugs 
chloroquine and pamaquine.   
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3.1.5. Conclusions 
In conclusion, the preparation of 5-, 6- and 8-(4-aminobutyloxy)quinolines as a new class of quinoline 
derivatives was established in a three-step pathway consisting of (i) O-allylation, (ii) rhodium-
catalyzed hydroformylation of the thus obtained [(2-methyl-)2-propenyloxy]quinolines and (iii) 
reductive amination. Furthermore, the biological relevance of this novel class of compounds was 
demonstrated by evaluation of its in vitro antiplasmodial activity and cytotoxicity. Three compounds 
showed submicromolar activity against a chloroquine-resistant strain of P. falciparum, pointing to the 
promising potential of these new structures as novel antimalarial pharmacophores. Antifungal 
assessment of these quinolines resulted in the identification of six 8-(4-aminobutyloxy)quinolines 
displaying antifungal activity, with one compound showing a significant potential as a novel broad-
spectrum antifungal candidate. The introduction of an aminoalkoxy side chain on a halo-substituted 
hydroxyquinoline core at the 8-position might thus provide a new perspective within the search for 
new antifungal agents.  
3.1.6. Experimental section 
3.1.6.1. General methods 
All reagents were purchased from commercial suppliers (Sigma-Aldrich, Acros, TCI), and were used as 
received without any purification, unless otherwise noted. Solvents were dried with sodium (THF) or 
calcium hydride (dichloromethane), and distilled before use. Toluene and 2-methyltetrahydrofuran 
were dried and deoxygenated using custom-made solvent purification columns filled with Al2O3. 
Other solvents were purchased from commercial suppliers and used as supplied. The petroleum 
ether used during product purification steps had a boiling range of 40-60 °C. The hydroformylation 
reactions were carried out under an argon atmosphere (using modified Schlenk techniques), in 
glassware and autoclaves that ware dried prior to use by heating under vacuum. Crude reaction 
mixtures were analysed by LC/MS/UV. Thin-layer chromatography was carried out on silica gel 
60F254 plates (Merck). Column chromatography was performed in a glass column with silica gel 
(particle size 70-200 µm, pore diameter 60Å). Preperative TLC was executed with 2000 µm 20 × 20 
cm TLC plates. High-resolution 1H and 13C magnetic resonance (NMR) spectra were recorded with Jeol 
Eclipse+ 300 NMR spectrometer in CDCl3, unless otherwise noted. Chemical shifts were calibrated 
using tetramethylsilane, which was used as an internal reference, unless otherwise indicated. Peak 
assignments were obtained with the aid of HSQC spectra. Attenuated total reflection (ATR) IR spectra 
were recorded with a Perkin-Elmer Spectrum BX spectrometer, equipped with a ZnSe crystal, at room 
temperature (neat). Low-resolution mass spectra were recorded with an Agilent Technologies 1100 
series VL mass spectrometer (ESI, 70 eV). High resolution mass spectra were obtained with an HPLC 
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coupled to an Agilent Technologies 6210 series time-of-flight mass spectrometer equipped with an 
ESI/APCI-multimode source. Melting points were measured with a Büchi B-540 apparatus. 
 
3.1.6.2. Synthesis of (2-methyl-2-propenyloxy)quinolines 
General procedure: To a solution of hydroxyquinoline 13 (7 mmol) and 2-methylallyl bromide (10.5 
mmol, 1.5 equiv) in acetone (30 mL) was added potassium carbonate (21 mmol, 3 equiv). After 
stirring for 24 h at reflux temperature, the reaction mixture was poured into water (15 mL) and 
extracted with dichloromethane (3 × 15 mL). The combined organic extracts were dried over 
anhydrous magnesium sulfate. Filtration of the drying agent and removal of the solvent in vacuo 
afforded the crude products 169a-n, which were purified by recrystallization. 
 
8-(2-Propenyloxy)quinoline 169a (91%) 
Spectral data of 8-(2-propenyloxy)quinoline 169a corresponded with data described in the 
literature.336  
 
5-Chloro-8-(2-propenyloxy)quinoline 169b (82%) 
Spectral data of 5-chloro-8-(2-propenyloxy)quinoline 169b corresponded with data described in the 
literature.337  
 
5-Chloro-7-iodo-8-(2-propenyloxy)quinoline 169c (78%) 
Spectral data of 5-chloro-7-iodo-8-(2-propenyloxy)quinoline 169c corresponded with data described 
in the literature.338  
 
5,7-Dichloro-8-(2-propenyloxy)quinoline 169d (78%) 
Spectral data of 5,7-dichloro-8-(2-propenyloxy)quinoline 169d corresponded with data described in 
the literature.337  
 
5,7-Diiodo-8-(2-propenyloxy)quinoline 169e (70%) 
Spectral data of 5,7-diiodo-8-(2-propenyloxy)quinoline 169e corresponded with data described in the 
literature.339  
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5,7-Dibromo-8-(2-propenyloxy)quinoline 169f (82%) 
Spectral data of 5,7-dibromo-8-(2-propenyloxy)quinoline 169f corresponded with data described in 
the literature.340  
 
5,7-Dichloro-2-methyl-8-(2-propenyloxy)quinoline 169g (78%) 
 White crystals. Mp = 68.5 °C. Recrystallization from acetone. 1H NMR (300 MHz, 
CDCl3): δ 2.79 (3H, s, CH3); 4.96 (2H, d, J = 6.1 Hz, CH2O); 5.23 (1H, dd, J = 9.9, 1.7 
Hz, (HCH)=CH); 5.38 (1H, dd, J = 17.1, 1.7 Hz, (HCH)=CH); 6.18-6.31 (1H, m, 
CH2=CH); 7.38 (1H, d, J = 8.8 Hz, CHarom); 7.56 (1H, s, CHarom); 8.37 (1H, d, J = 8.8 Hz, 
CHarom). 
13C NMR (75.6 MHz, Ref = CDCl3): δ 25.6 (CH3); 76.0 (CH2O); 118.5 
(CH2=CH); 122.9 (HCarom); 124.6 (OCqCqCl); 126.0 (CHCqCqCl); 126.86 (HCarom); 
126.91 (CHCqCqCl); 133.4 (HCarom); 134.1 (CH2=CH); 143.5 (CqCqN); 149.9 (CqO); 
160.0 (CH3CqN). IR (cm
-1): νmax = 3069, 1589, 1441, 1413, 1398, 1313, 1256, 1231, 1094, 970, 945, 931, 
917, 908, 794, 777. MS (70eV): m/z (%): 268/70/72 (M++1, 100). HRMS (ESI) calcd for C13H12Cl2NO 
268.0291 [M+H]+, found 268.0289. 
 
6-(2-propenyloxy)quinoline 169h (76%) 
Spectral data of 6-(2-propenyloxy)quinoline 169h corresponded with data described in the 
literature.341  
 
5-(2-propenyloxy)quinoline 169i (97%) 
Spectral data of 5-(2-propenyloxy)quinoline 169i corresponded with data described in the 
literature.336 
  
8-(2-methyl-2-propenyloxy)quinoline 169k (92%) 
Spectral data of 8-(2-methyl-2-propenyloxy)quinoline 169k corresponded with data described in the 
literature.342 
  
5-Chloro-8-(2-methyl-2-propenyloxy)quinoline 169l (79%) 
Green crystals. Mp = 41.9 °C. Recrystallization from absolute EtOH. 1H NMR (300 MHz, 
CDCl3): δ 1.87 (3H, s, CH3); 4.79 (2H, s, CH2O); 5.04 (1H, s, C=(HCH)); 5.15 (1H, s, 
C=(HCH)); 6.99 (1H, d, J = 8.3 Hz, CHarom); 7.49 (1H, d, J = 8.3 Hz, CHarom); 7.54 (1H, dd, J = 
8.3, 4.4 Hz, CHarom); 8.53 (1H, d, J = 8.3 Hz, CHarom); 9.00 (1H, dd, J = 4.4, 1.7 Hz, CHarom). 
13C NMR (75.6 MHz, Ref = CDCl3): δ 19.4 (CH3); 72.9 (CH2O); 109.6 (HCarom); 113.2 (CH2Cq); 
122.3 (HCarom); 122.4 (HCarom); 126.4 (CqCl); 127.2 (CqCqCl); 133.0 (HCarom); 140.3 (CqCH2); 
141.0 (CqN); 149.9 (HCarom); 153.8 (CqO). IR (cm
-1): νmax = 3084, 2974, 2916, 1498, 1382, 
1362, 1310, 1237, 1226, 1090, 930, 899,811, 786. MS (70eV): m/z (%): 234/6 (M++1, 100). HRMS (ESI) 
calcd for C13H13ClNO 234.0680 [M+H]
+, found 234.0683. 
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5-Chloro-7-iodo-8-(2-methyl-2-propenyloxy)quinoline 169m (71%) 
Light-yellow crystals. Mp = 62.5 °C. Recrystallization from acetone. 1H NMR (300 MHz, 
CDCl3): δ 2.02 (3H, s, CH3); 4.83 (2H, s, CH2O); 5.04 (1H, s, C=(HCH)); 5.28 (1H, s, 
C=(HCH)); 7.54 (1H, dd, J = 8.8, 4.4 Hz, CHarom); 7.97 (1H, s, CHarom); 8.51 (1H, dd, J = 8.8, 
1.7 Hz, CHarom); 8.96 (1H, dd, J = 4.4, 1.7 Hz, CHarom). 
13C NMR (75.6 MHz, Ref = CDCl3): δ 
20.3 (CH3); 73.5 (CqI); 78.5 (CH2O); 113.6 (CH2Cq); 122.3 (HCarom); 126.4 (CqCl); 127.6 
(CqCqCl); 133.5 (HCarom); 135.3 (HCarom); 141.4 (CqCH2); 142.6 (CqN); 150.4 (HCarom); 155.1 
(CqO). IR (cm
-1): νmax = 3081, 2977, 2953, 2917, 1573, 1483, 1448, 1376, 1358, 1345, 1208, 1086, 984, 
965, 936, 889, 882, 872, 843, 787, 741, 698. MS (70eV): m/z (%): 360/2 (M++1, 100). HRMS (ESI) calcd 
for C13H12ClINO 359.9647 [M+H]
+, found 359.9655. 
 
5,7-Dichloro-8-(2-methyl-2-propenyloxy)quinoline 169n (58%) 
 White crystals. Mp = 50.9 °C. Recrystallization from absolute EtOH. 1H NMR (300 
MHz, CDCl3): δ 1.99 (3H, s, CH3); 4.85 (2H, s, CH2O); 5.00 (1H, s, C=(HCH)); 5.19 (1H, s, 
C=(HCH)); 7.52 (1H, dd, J = 8.3, 3.9 Hz, CHarom); 7.64 (1H, s, CHarom); 8.51 (1H, dd, J = 
8.3, 1.7 Hz, CHarom); 8.99 (1H, dd, J = 3.9, 1.7 Hz, CHarom). 
13C NMR (75.6 MHz, Ref = 
CDCl3): δ 20.0 (CH3); 78.8 (CH2O); 113.9 (CH2Cq); 122.0 (HCarom); 126.0 (OCqCqCl); 126.3 
(CHCqCqCl); 126.7 (CqCl); 128.0 (HCarom); 133.4 (HCarom); 141.5 (CqCH2 + CqN); 143.9 
(CqO); 150.7 (HCarom). IR (cm
-1): νmax = 3078, 2968, 1581, 1450, 1347, 1090, 965, 940, 
901, 881, 869, 788, 753. MS (70eV): m/z (%): 268/70/72 (M++1, 86). HRMS (ESI) calcd for C13H12Cl2NO 
268.0290 [M+H]+, found 268.0296.  
 
5,7-Diiodo -8-(2-methyl-2-propenyloxy)quinoline 169o (71%) 
 Light-yellow crystals. Mp = 71.4 °C. Recrystallization from acetone. 1H NMR (300 MHz, 
CDCl3): δ 1.94 (3H, s, CH3); 4.84 (2H, s, CH2O); 5.03 (1H, s, C=(HCH)); 5.27 (1H, s, 
C=(HCH)); 7.46-7.51 (1H, m, CHarom); 8.31 (1H, dd, J = 6.6, 1.7 Hz, CHarom); 8.44 (1H, d, J 
= 1.7 Hz, CHarom); 8.86 (1H, d, J = 6.6 Hz, CHarom). 
13C NMR (75.6 MHz, Ref = CDCl3): δ 
20.3 (CH3); 73.9 (OCqCqI); 78.5 (CH2O); 91.9 (CHCqCqI); 113.7 (CH2Cq); 123.2 (HCarom); 
131.4 (CHCqCqI); 140.8 (HCarom); 141.3 (CH2Cq); 142.9 (CqN); 145.3 (HCarom); 150.4 
(HCarom); 156.8 (CqO). IR (cm
-1): νmax = 2971, 2916, 2865, 1561, 1476, 1442, 1359, 1341, 
1226, 1218, 1088, 1022, 989, 905, 897, 872, 843, 786, 726. MS (70eV): m/z (%): 452 (M++1, 100). 
HRMS (ESI) calcd for C13H12I2NO 451.9003 [M+H]
+, found 451.9011. 
 
5,7-Dibromo-8-(2-methyl-2-propenyloxy)quinoline 169p (57%) 
 Light-yellow crystals. Mp = 62.8 °C. Recrystallization from acetone. 1H NMR (300 
MHz, CDCl3): δ 2.00 (3H, s, CH3); 4.85 (2H, s, CH2O); 5.02 (1H, s, C=(HCH)); 5.23 (1H, s, 
C=(HCH)); 7.52 (1H, dd, J = 8.8, 4.4 Hz, CHarom); 7.98 (1H, s, CHarom); 8.46 (1H, dd, J = 
8.8, 1.7 Hz, CHarom); 8.94 (1H, dd, J = 4.4, 1.7 Hz, CHarom). 
13C NMR (75.6 MHz, Ref = 
CDCl3): δ 20.1 (CH3); 78.6 (CH2O); 113.8 (CH2Cq); 116.1 (OCqCqBr); 116.4 (CHCqCqBr); 
122.5 (HCarom); 128.1 (CHCqCqBr); 133.7 (HCarom); 136.0 (HCarom); 141.4 (CH2Cq); 143.9 
(CqN); 150.6 (HCarom); 152.7 (CqO). IR (cm
-1): νmax = 2980, 2952, 1574, 1449, 1376, 
1343, 1212, 1089, 984, 964, 921, 888, 873, 856, 808, 788, 736. MS (70eV): m/z (%): 356/58/60 (M++1, 
100). HRMS (ESI) calcd for C13H12Br2NO 355.9280 [M+H]
+, found 355.9286. 
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5,7-Dichloro-2-methyl-8-(2-methyl-2-propenyloxy)quinoline 169q (76%) 
 White crystals. Mp = 66.8 °C. Recrystallization from acetone. 1H NMR (300 MHz, 
CDCl3): δ 2.02 (3H, s, CH3); 2.79 (3H, s, NCqCH3); 4.85 (2H, s, CH2O); 4.99 (1H, s, 
C=(HCH)); 5.17 (1H, s, C=(HCH)); 7.37 (1H, d, J = 8.8 Hz, CHarom); 7.55 (1H, s, CHarom); 
8.36 (1H, d, J = 8.8 Hz, CHarom). 
13C NMR (75.6 MHz, Ref = CDCl3): δ 20.0 (CH3CqCH2); 
25.6 (CH3CqN); 78.8 (CH2O); 114.0 (CH2Cq); 122.9 (HCarom); 124.6 (OCqCqCl); 125.9 
(CHCqCqCl); 126.6 (CHCqCqCl); 126.9 (HCarom); 133.4 (HCarom); 141.8 (CqCH2) 143.4 
(CqCqN); 150.2 (CqO); 159.8 (CH3CqN). IR (cm
-1): νmax = 3077, 2976, 2916, 1588, 1445, 
1423, 1368, 1316, 1236, 1092, 985, 960, 945, 926, 890, 791, 776. MS (70eV): m/z (%): 282/4/5 (M++1, 
100). HRMS (ESI) calcd for C14H14Cl2NO 282.0447 [M+H]
+, found 282.0452. 
 
5-(2-Methyl-2-propenyloxy)quinoline 169s (82%) 
 Yellow oil. Rf (SiO2) = 0.33 (hexane/EtOAc 2/1) . 
1H NMR (300 MHz, CDCl3): δ 1.90 (3H, s, 
CH3); 4.60 (2H, s, CH2O); 5.05 (1H, s, C=(HCH)); 5.19 (1H, s, C=(HCH)); 6.84 (1H, d, J = 8.3 
Hz, CHarom); 7.37 (1H, dd, J = 8.3, 4.4 Hz, CHarom); 7.58 (1H, t, J = 8.3 Hz, CHarom); 7.70 (1H, 
d, J = 8.3 Hz, CHarom); 8.62 (1H, dd, J = 8.3, 1.7 Hz, CHarom), 8.90 (1H, dd, J = 4.4, 1.7 Hz, 
CHarom). 
13C NMR (75.6 MHz, Ref = CDCl3): δ 19.6 (CH3); 72.2(CH2O); 105.5 (HCarom); 113.0 
(CH2Cq); 120.3 (HCarom); 121.1 (CqCqO); 121.8 (HCarom); 129.4 (HCarom); 130.9 (HCarom); 140.6 
(CqCH2); 149.2(CqN); 150.8 (HCarom); 154.2 (CqO). IR (cm
-1): νmax = 1588, 1574, 1261, 1089, 793. MS 
(70eV): m/z (%): 200 (M++1, 100). HRMS (ESI) calcd for C13H13NO 200.1070 [M+H]
+, found 200.1075.  
 
3.1.6.3. Synthesis of 4-(quinolinyloxy)butyraldehydes 
General procedure for the hydroformylation of [(2-methyl-)2-propenyloxy]quinolines 169: In a typical 
experiment, a stainless steel autoclave (100 mL) was dried overnight under vacuum at 100 °C and 
afterward filled with argon, whereupon the autoclave was flushed 20 times with argon to remove 
oxygen traces. The autoclave was charged with a solution of Rh(acac)(CO)2 (0.008 mmol) and the 
DPBO phosphordiamidite ligand (0.032 mmol) in degassed toluene (3 mL) under argon. The 
atmosphere was further exchanged with a 1:1 mixture of CO/H2 and the reactor was heated to 80 °C 
and pressurized with the syngas to 20 bar. The catalyst was preformed at 20 bar (CO/H2) and 80 °C 
for 1-2 h at 2000 rpm (mechanical stirring). Subsequently, the substrate 169 (4 mmol), dissolved in 
degassed toluene (5 mL), was added from a dropping funnel, followed by hydroformylation at 20 bar 
(CO/H2) and 80 °C for 20 h at 2000 rpm. The reaction was stopped by cooling the reactor to room 
temperature and venting. The catalyst was removed by filtration over silica gel and the solvent was 
evaporated in vacuo, affording the linear aldehydes 172a-n in high purity (>95% based on NMR) 
which were used as such in the next step. These aldehydes 172 were considered as intermediates 
and were not characterized. 
 
 
N
O
PART III  RESULTS AND DISCUSSION 
97 
 
3.1.6.4. Synthesis of [4-(4-N,N-diethylamino)butyloxy]quinolines 
General procedure: To a solution of 4-(quinolinyloxy)butyraldehyde 172 (5 mmol) and diethylamine 
(10 mmol, 2 equiv) in methanol (30 mL) was added acetic acid (25 mmol, 5 equiv). After stirring for 2 
h at room temperature, sodium cyanoborohydride (10 mmol, 2 equiv) was added and the mixture 
was stirred an additional 16 h at room temperature. Afterward, the reaction mixture was poured into 
an aqueous solution of sodium hydroxide (1M, 15 mL), extracted with dichloromethane (3 × 15 mL) 
and washed with brine (3 × 15 mL). The combined organic layers were dried over anhydrous 
magnesium sulfate. Filtration of the drying agent and removal of the solvent in vacuo afforded the 
crude products 174a-c,h-i,k,m-q, which were purified by means of column chromatography on silica 
gel. 
 
8-[(4-N,N-diethylamino)butyloxy]quinoline 174a (56%) 
Brown oil. Rf (SiO2) = 0.10 (CH2Cl2/MeOH 95/5). 
1H NMR (300 MHz, CDCl3): δ 1.04 (6H, 
t, J = 7.7 Hz, (CH2CH3)2); 1.72 (2H, quint, J = 7.7 Hz, NCH2CH2); 2.05 (2H, quint, J = 7.7 
Hz, OCH2CH2); 2.53-2.60 (6H, m, N(CH2)3); 4.27 (2H, t, J = 7.7 Hz, CH2O); 7.07 (1H, d, J = 
7.7 Hz, CHarom); 7.36-7.48 (3H, m, 3 × CHarom); 8.12 (1H, dd, J = 8.3, 1.7 Hz, CHarom); 8.94 
(1H, dd, J = 3.9, 1.7 Hz, CHarom). 
13C NMR (75.6 MHz, Ref = CDCl3): δ 11.6 (2 × CH3); 23.7 
(CH2CH2N); 27.1 (CH2CH2O); 46.9 (2 × CH2CH3); 52.7 (CH2N); 68.9 (CH2O); 108.8 
(HCarom); 119.5 (HCarom); 121.6 (HCarom); 126.8 (HCarom); 129.6 (CHCqCH); 135.9 (HCarom); 
140.5 (CqN); 149.4 (HCarom); 154.9 (CqO). IR (cm
-1): νmax = 2966, 2934, 1500, 1466, 1376, 1316, 1260, 
1105, 1078, 821, 791, 748, 729. HRMS (ESI) calcd for C17H25N2O 273.1961 [M+H]
+, found 273.1965. 
 
5-Chloro-8-[(4-N,N-diethylamino)butyloxy]quinoline 174b (57%) 
Orange-brown oil. 1H NMR (300 MHz, CDCl3): δ 1.03 (6H, t, J = 6.6 Hz, (CH2CH3)2); 1.70 
(2H, quint, J = 7.7 Hz, NCH2CH2); 2.03 (2H, quint, J = 7.7 Hz, OCH2CH2); 2.53 (6H, t, J = 
7.7 Hz, N(CH2)3); 4.26 (2H, t, J = 7.7 Hz, CH2O); 7.00 (1H, d, J = 8.3 Hz, CHarom); 7.50-
7.56 (2H, m, 2 × CHarom); 8.52 (1H, dd, J = 8.3, 1.7 Hz, CHarom); 8.99 (1H, dd, J = 4.4, 1.7 
Hz, CHarom). 
13C NMR (75.6 MHz, Ref = CDCl3): δ 11.7 (2 × CH3); 23.7 (CH2CH2N); 27.0 
(CH2CH2O); 46.9 (2 × CH2CH3); 52.6 (CH2N); 69.2 (CH2O); 108.6 (HCarom); 121.9 (CqCl); 
122.3 (HCarom); 126.5 (HCarom); 127.1 (CqCqCl); 132.9 (HCarom); 141.0 (CqN); 149.8 
(HCarom); 154.1 (CqO). IR (cm
-1): νmax = 2966, 2934, 1499, 1463, 1380, 1363, 1307, 1238, 
1094, 813, 787, 739. HRMS (ESI) calcd for C17H24ClN2O 307.1572 [M+H]
+, found 307.1576. 
 
5-Chloro-8-[(4-N,N-diethylamino)butyloxy]-7-iodoquinoline 174c (75%) 
Viscous brown oil. 1H NMR (300 MHz, CDCl3): δ 1.04 (6H, t, J = 6.6 Hz, (CH2CH3)2); 
1.70-1.81 (2H, m, NCH2CH2); 1.89-2.02 (2H, m, OCH2CH2); 2.52-2.60 (6H, m, N(CH2)3); 
4.38 (2H, t, J = 6.6 Hz, CH2O); 7.53 (1H, dd, J = 8.3, 4.4 Hz, CHarom); 7.95 (1H, s, CHarom); 
8.50 (1H, dd, J = 8.3, 1.7 Hz, CHarom); 8.94 (1H, dd, J = 4.4, 1.7 Hz, CHarom). 
13C NMR 
(75.6 MHz, Ref = CDCl3): δ 11.8 (2 × CH3); 23.6 (CH2CH2N); 28.7 (CH2CH2O); 47.0 (2 × 
CH2CH3); 52.8 (CH2N); 75.5 (CH2O); 90.5 (CqI); 122.3 (HCarom); 126.3 (CqCl); 127.6 
(CqCqCl); 133.5 (HCarom); 135.2 (HCarom); 142.6 (CqN); 150.5 (HCarom); 155.6 (CqO). IR 
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(cm-1): νmax = 2967, 1444, 1362, 1347, 940, 907, 790, 728. HRMS (ESI) calcd for C17H23ClIN2O 433.0538 
[M+H]+, found 433.0541. 
 
6-[(4-N,N-diethylamino)butyloxy]quinoline 174h (91%) 
Yellow oil. Rf (SiO2) = 0.05 (100% EtOAc). 
1H NMR (300 MHz, CDCl3): δ 
1.04 (6H, t, J = 7.2 Hz, (CH2CH3)2); 1.62-1.73 (2H, m, NCH2CH2); 1.83-1.92 
(2H, m, OCH2CH2); 2.49-2.59 (6H, m, N(CH2)3); 4.10 (2H, t, J = 6.6 Hz, 
CH2O); 7.06 (1H, d, J = 2.8 Hz, CHarom); 7.32-7.39 (2H, m, 2 × CHarom); 7.99 (1H, d, J = 8.8 Hz, CHarom); 
8.03 (1H, dd, J = 8.8, 1.7 Hz, CHarom); 8.76 (1H, dd, J = 4.4, 1.7 Hz, CHarom). 
13C NMR (75.6 MHz, Ref = 
CDCl3): δ 11.8 (2 × CH3); 23.8 (CH2CH2N); 27.4 (CH2CH2O); 46.9 (2 × CH2CH3); 52.7 (CH2N); 68.2 (CH2O); 
105.9 (HCarom); 121.4 (HCarom); 122.7 (HCarom); 129.4 (CHCqCH); 130.9 (HCarom); 134.8 (HCarom); 144.4 
(CqN); 147.9 (HCarom); 157.3 (CqO). IR (cm
-1): νmax = 2966, 2933, 1499, 1378, 1226, 833. HRMS (ESI) 
calcd for C17H25N2O 273.1961 [M+H]
+, found 273.1965. 
 
5-[(4-N,N-diethylamino)butyloxy]quinoline 174i (60%) 
Brown oil. Rf (SiO2) = 0.12 (100% EtOAc). 
1H NMR (300 MHz, CDCl3): δ 1.03 (6H, t, J = 
7.2 Hz, (CH2CH3)2); 1.67-1.77 (2H, m, NCH2CH2); 1.89-1.99 (2H, m, OCH2CH2); 2.51-2.59 
(6H, m, N(CH2)3); 4.15 (2H, t, J = 6.6 Hz, CH2O); 6.84 (1H, d, J = 7.7 Hz, CHarom); 7.36 
(1H, dd, J = 8.8, 4.4 Hz, CHarom); 7.48-7.71 (2H, m, 2 × CHarom); 8.59 (1H, dd, J = 8.8, 1.7 
Hz, CHarom); 8.89 (1H, dd, J = 4.4, 1.7 Hz, CHarom). 
13C NMR (75.6 MHz, Ref = CDCl3): δ 
11.7 (2 × CH3); 23.9 (CH2CH2N); 27.4 (CH2CH2O); 46.9 (2 × CH2CH3); 52.7 (CH2N); 68.3 
(CH2O); 105.0 (HCarom); 120.2 (HCarom); 121.0 (CqCqO); 121.4 (HCarom); 129.5 (HCarom); 
131.0 (HCarom); 149.2 (CqN); 150.7 (HCarom); 154.6 (CqO). IR (cm
-1): νmax = 2965, 2930, 1588, 1575, 1465, 
1263, 1091, 794, 731. HRMS (ESI) calcd for C17H25N2O 273.1961 [M+H]
+, found 273.1967. 
 
8-[(4-N,N-diethylamino)-3-methylbutyloxy]quinoline 174k (89%) 
Orange oil. Rf (SiO2) = 0.04 (100% EtOAc). 
1H NMR (300 MHz, CDCl3): δ 1.01 (6H, t, J = 
7.2 Hz, (CH2CH3)2); 1.15 (3H, d, J = 6.6 Hz, CHCH3); 1.39-1.51 (1H, m, CH2(HCH)CH); 
1.71-1.82 (1H, m, CH2(HCH)CH); 2.22-2.36 (1H, oct, J = 6.6 Hz, CHCH3); 2.49-2.60 (6H, 
m, N(CH2)3); 4.01 (1H, dd, J = 9.4, 7.7 Hz, (HCH)O); 4.17 (1H, dd, J = 9.4, 6.1 Hz, 
(HCH)O); 7.08 (1H, dd, J = 7.2, 1.1 Hz, CHarom); 7.35-7.47 (3H, m, 3 × CHarom); 8.11 (1H, 
dd, J = 8.3, 1.7 Hz, CHarom); 8.94 (1H, dd, J = 4.4, 1.7 Hz, CHarom). 
13C NMR (75.6 MHz, 
Ref = CDCl3): δ 11.7 (2 × CH3); 17.6 (CH3CH); 31.0 (CH2CH2N); 31.4 (CHCH3); 46.8 (2 × 
CH2CH3); 50.6 (CH2N); 74.3 (CH2O); 109.0 (HCarom); 119.4 (HCarom); 121.5 (HCarom); 126.7 (HCarom); 129.5 
(CHCqCH); 135.8 (HCarom); 140.6 (CqN); 149.2 (HCarom); 155.1 (CqO). IR (cm
-1): νmax = 2965, 2929, 1499, 
1463, 1376, 1316, 1261, 1105, 820, 790, 747, 729. HRMS (ESI) calcd for C18H27N2O 287.2118 [M+H]
+, 
found 287.2120. 
 
5-Chloro-8-[(4-N,N-diethylamino)-3-methylbutyloxy]-7-iodoquinoline 174m (89%) 
Brown oil. 1H NMR (300 MHz, CDCl3): δ 1.04 (6H, t, J = 7.2 Hz, (CH2CH3)2); 1.21 (3H, d, 
J = 6.6 Hz, CHCH3); 1.40-1.52 (1H, m, CH2(HCH)CH); 1.87-1.98 (1H, m, CH2(HCH)CH); 
2.13-2.23 (1H, oct, J = 6.6 Hz, CHCH3); 2.53-2.67 (6H, m, N(CH2)3); 4.20 (1H, dd, J = 
8.8, 6.6 Hz, (HCH)O); 4.25 (1H, dd, J = 8.8, 6.1 Hz, (HCH)O); 7.52 (1H, dd, J = 8.8, 4.4 
Hz, CHarom); 7.95 (1H, s, CHarom); 8.49 (1H, dd, J = 8.8, 1.7 Hz, CHarom); 8.93 (1H, dd, J = 
4.4, 1.7 Hz, CHarom). 
13C NMR (75 MHz, Ref = CDCl3): δ 11.9 (2 × CH3); 17.6 (CH3CH); 
30.6 (CH2CH2N); 33.1 (CHCH3); 47.0 (2 × CH2CH3); 50.7 (CH2N); 80.4 (CH2O); 90.0 (CqI); 
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122.3 (HCarom); 126.1 (CqCl); 127.6 (CqCqCl); 133.5 (HCarom); 135.2 (HCarom); 142.5 (CqN); 150.2 (HCarom); 
155.6 (CqO). IR (cm
-1): νmax = 2966, 2928, 1571, 1483, 1443, 1381, 1361, 1346, 1205, 1083, 941, 908, 
789, 730. HRMS (ESI) calcd for C18H25ClIN2O 447.7608 [M+H]
+, found 447.0703. 
 
5,7-Dichloro-8-[(4-N,N-diethylamino)-3-methylbutyloxy]quinoline 174n (89%) 
Brown oil. 1H NMR (300 MHz, CDCl3): δ 1.03 (6H, t, J = 7.2 Hz, (CH2CH3)2); 1.17 (3H, 
d, J = 7.2 Hz, CHCH3); 1.38-1.50 (1H, m, CH2(HCH)CH); 1.84-1.96 (1H, m, 
CH2(HCH)CH); 2.05-2.18 (1H, m, CHCH3); 2.52-2.63 (6H, m, N(CH2)3); 4.18 (1H, dd, 
J = 8.3, 6.6 Hz, (HCH)O); 4.24 (1H, dd, J = 8.3, 6.6 Hz, (HCH)O); 7.49 (1H, dd, J = 
8.8, 3.9 Hz, CHarom); 7.61 (1H, s, CHarom); 8.47 (1H, dd, J = 8.8, 1.7 Hz, CHarom); 8.96 
(1H, dd, J = 3.9, 1.7 Hz, CHarom). 
13C NMR (75.6 MHz, Ref = CDCl3): δ 11.8 (2 × CH3); 
17.3 (CH3CH); 30.4 (CH2CH2N); 33.0 (CHCH3); 46.9 (2 × CH2CH3); 50.7 (CH2N); 80.4 
(CH2O); 121.9 (HCarom); 125.7 (OCqCqCl); 126.3 (CHCqCqCl); 126.5 (CHCqCqCl); 128.0 
(HCarom); 133.3 (HCarom); 143.9 (CqN); 150.6 (HCarom); 151.2 (CqO). IR (cm
-1): νmax = 
2965, 2931, 1450, 1367, 1349, 1088, 945, 880, 790, 732. HRMS (ESI) calcd for C18H25Cl2N2O 355.1338 
[M+H]+, found 355.1347. 
 
8-[(4-N,N-diethylamino)-3-methylbutyloxy]-5,7-diiodoquinoline 174o (61%) 
Brown oil. Rf (SiO2) = 0.10 (EtOAc 100%) . 
1H NMR (300 MHz, CDCl3): δ 1.05 (6H, t, J = 
7.2 Hz, (CH2CH3)2); 1.20 (3H, d, J = 7.2 Hz, CHCH3); 1.40-1.53 (1H, m, CH2(HCH)CH); 
1.87-2.00 (1H, m, CH2(HCH)CH); 2.11-2.23 (1H, m, CHCH3); 2.53-2.66 (6H, m, 
N(CH2)3); 4.21 (1H, dd, J = 8.8, 6.6 Hz, (HCH)O); 4.26 (1H, dd, J = 8.8, 6.6 Hz, (HCH)O); 
7.47 (1H, dd, J = 8.8, 4.4 Hz, CHarom); 8.30 (1H, dd, J = 8.8, 1.7 Hz, CHarom); 8.43 (1H, s, 
CHarom); 8.84 (1H, dd, J = 4.4, 1.7 Hz, CHarom). 
13C NMR (75.6 MHz, Ref = CDCl3): δ 
11.8 (2 × CH3); 17.6 (CH3CH); 30.5 (CH2CH2N); 33.1 (CHCH3); 46.9 (2 × CH2CH3); 50.7 
(CH2N); 80.4 (CH2O + OCqCqI); 91.7 (CHCqCqI); 123.2 (HCarom); 131.4 (CHCqCqCl); 140.7 
(HCarom); 142.8 (CqN); 145.3 (HCarom); 150.3 (HCarom); 157.2 (CqO). IR (cm
-1): νmax = 2965, 2925, 1433, 
1340, 1082, 904, 754, 730. HRMS (ESI) calcd for C18H25I2N2O 539.0051 [M+H]
+, found 539.0053. 
 
5,7-Dibromo-8-[(4-N,N-diethylamino)-3-methylbutyloxy]quinoline 174p (95%) 
Brown oil. 1H NMR (300 MHz, CDCl3): δ 1.04 (6H, t, J = 7.2 Hz, (CH2CH3)2); 1.19 (3H, 
d, J = 6.6 Hz, CHCH3); 1.38-1.50 (1H, m, CH2(HCH)CH); 1.85-1.97 (1H, m, 
CH2(HCH)CH); 2.07-2.20 (1H, m, CHCH3); 2.52-2.68 (6H, m, N(CH2)3); 4.20 (1H, dd, J 
= 8.8, 6.6 Hz, (HCH)O); 4.26 (1H, dd, J = 8.8, 6.1 Hz, (HCH)O); 7.51 (1H, dd, J = 8.8, 
4.4 Hz, CHarom); 7.97 (1H, s, CHarom); 8.45 (1H, dd, J = 8.8, 1.7 Hz, CHarom); 8.93 (1H, 
dd, J = 4.4, 1.7 Hz, CHarom). 
13C NMR (75.6 MHz, Ref = CDCl3): δ 11.8 (2 × CH3); 17.4 
(CH3CH); 30.5 (CH2CH2N); 33.0 (CHCH3); 46.9 (2 × CH2CH3); 50.7 (CH2N); 80.4 
(CH2O); 115.8 (OCqCqBr); 116.2 (CHCqCqBr); 122.4 (HCarom); 128.1 (CHCqCqBr); 133.7 
(HCarom); 136.0 (HCarom); 143.9 (CqN); 150.5 (HCarom); 153.2 (CqO). IR (cm
-1): νmax = 2966, 2931, 1448, 
1362, 1345, 1084, 919, 788, 730. HRMS (ESI) calcd for C18H25Br2N2O 443.0328 [M+H]
+, found 
443.0327. 
 
5,7-Dichloro-8-[(4-N,N-diethylamino)-3-methylbutyloxy]-2-methylquinoline 174q (60%) 
Brown oil. Rf (SiO2) = 0.10 (CH2Cl2/MeOH 95/5). 
1H NMR (300 MHz, CDCl3): δ 1.03 (6H, t, J = 7.2 Hz, 
(CH2CH3)2); 1.19 (3H, d, J = 6.6 Hz, CHCH3); 1.33-1.52 (1H,m, CH2(HCH)CH); 1.83-1.95 (1H, m, 
CH2(HCH)CH); 2.03-2.18 (1H, m, CHCH3); 2.52-2.64 (6H, m, N(CH2)3); 2.76 (3H, s, CqCH3); 4.16 (1H, dd, 
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J = 8.8, 6.6 Hz, (HCH)O); 4.25 (1H, dd, J = 8.8, 5.5 Hz, (HCH)O); 7.36 (1H, d, J = 8.8 
Hz, CHarom); 7.54 (1H, s, CHarom); 8.35 (1H, d, J = 8.8 Hz, CHarom). 
13C NMR (75.6 MHz, 
Ref = CDCl3): δ 11.8 (2 × CH3); 17.5 (CH3CH); 25.6 (CH3Cq); 30.4 (CH2CH2N); 33.0 
(CHCH3); 46.9 (2 × CH2CH3); 50.7 (CH2N); 80.2 (CH2O); 122.8 (HCarom); 124.6 
(OCqCqCl); 125.7 (CHCqCqBr); 126.4 (HCarom); 126.9 (CHCqCqBr); 133.3 (HCarom); 143.4 
(OCqCqN); 150.6 (CqO); 159.8 (CqCH3). IR (cm
-1): νmax = 2966, 2928, 2873, 2798, 
1605, 1587, 1441, 1382, 1315, 1236, 1090, 947, 926, 795, 774. HRMS (ESI) calcd 
for C19H27Cl2N2O 369.1495 [M+H]
+, found 369.1502. 
 
3.1.6.5. Synthesis of [4-(4-chlorobenzylamino)butyloxy]quinolines 
General procedure: To a solution of 4-(quinolinyloxy)butyraldehyde 172 (5 mmol) and 4-
chlorobenzylamine (5.25 mmol, 1.05 equiv) in dichloromethane (30 mL) was added anhydrous 
magnesium sulfate (7.5 mmol, 1.5 equiv). After stirring for 1 h at reflux temperature, the reaction 
mixture was filtered to remove the drying agent and the solvent was removed in vacuo. The acquired 
crude imine was then dissolved in methanol and sodium borohydride (10 mmol, 2 equiv) was added 
while stirring at 0 °C. After additional stirring for 1 h at reflux temperature, the reaction mixture was 
poured into ice water (15 mL) and extracted with dichloromethane (3 × 15 mL). The combined 
organic layers were dried over anhydrous magnesium sulfate. Filtration of the drying agent and 
removal of the solvent in vacuo afforded the crude products 175b,h-i,k,o,q,s which were purified by 
means of column chromatography on silica gel. 
 
5-Chloro-8-[4-(4-chlorobenzylamino)butyloxy]quinoline 175b (53%) 
Light-brown oil. Rf (SiO2) = 0.06 (100% EtOAc). 
1H NMR (300 MHz, CDCl3): δ 1.76 (2H, 
quint, J = 7.2 Hz, CH2CH2NH); 2.07 (2H, quint, J = 7.2 Hz, CH2CH2O); 2.72 (2H, t, J = 7.2 
Hz, CH2CH2NH); 3.76 (2H, s, CqCH2NH); 4.24 (2H, t, J = 7.2 Hz, CH2O); 6.96 (1H, d, J = 
8.8 Hz, CHarom); 7.24-7.27 (4H, m, 4 × CHarom); 7.51 (1H, d, J = 8.8 Hz, CHarom); 7.54 
(1H, dd, J = 8.8, 4.4 Hz, CHarom); 8.53 (1H, dd, J = 8.8, 1.7 Hz, CHarom); 8.97 (1H, dd, J = 
4.4, 1.7 Hz, CHarom). 
13C NMR (75.6 MHz, Ref = CDCl3): δ 26.7 (CH2CH2NH); 26.8 
(CH2CH2O); 48.9 (CH2NH); 53.2 (CqCH2NH); 69.0 (CH2O); 108.6 (HCarom); 122.0 
(CqCqCl); 122.4 (HCarom); 126.5 (HCarom); 127.1 (CqCqCl); 128.5 (2 × HCarom); 129.5 (2 × 
HCarom); 132.6 (CHCqCl); 133.0 (HCarom); 138.9 (CH2Cq); 140.9 (CqN); 149.8 (HCarom); 
154.0 (CqO). IR (cm
-1): νNH = 3428, νmax = 2926, 1364, 1307, 1093, 813, 787, 730. HRMS (ESI) calcd for 
C20H21Cl2N2O 375.1025 [M+H]
+, found 375.1034. 
 
6-[4-(4-chlorobenzylamino)butyloxy]quinoline 175h (58%) 
Orange oil. Rf (SiO2) = 0.07 (100% EtOAc). 
1H NMR (300 MHz, CDCl3): δ 
1.46 (1H, br. s., NH); 1.68-1.78 (2H, m, CH2CH2NH); 1.87-1.96 (2H, m, 
CH2CH2O); 2.72 (2H, t, J = 7.2 Hz, CH2CH2NH); 3.78 (2H, s, CqCH2NH); 
4.09 (2H, t, J = 6.6 Hz, CH2O); 7.04 (1H, d, J = 2.8 Hz, CHarom); 7.23-7.37 
(6H, m, 6 × CHarom); 7.99 (1H, d, J = 8.8, CHarom); 8.03 (1H, d, J = 8.8, 
CHarom); 8.76 (1H, dd, J = 4.4, 1.7 Hz, CHarom). 
13C NMR (75.6 MHz, Ref = 
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CDCl3): δ 26.7 (CH2CH2NH); 27.0 (CH2CH2O); 49.0 (CH2NH); 53.3 (CqCH2NH); 68.1 (CH2O); 105.9 
(HCarom); 121.4 (HCarom); 122.6 (HCarom); 128.6 (2 × HCarom); 129.4 (CHCqCH); 129.5 (2 × HCarom); 130.9 
(HCarom); 132.7 (CqCl); 134.8 (HCarom); 139.0 (CH2Cq); 144.5 (CqN); 148.0 (HCarom); 157.2 (CqO). IR (cm
-1): 
νNH = 3028, νmax = 2928, 1499, 1226, 833, 801, 732. HRMS (ESI) calcd for C20H22ClN2O 341.1415 [M+H]
+, 
found 341.1422. 
 
5-[4-(4-chlorobenzylamino)butyloxy]quinoline 175i (56%) 
Brown oil. Rf (SiO2) = 0.05 (100% EtOAc). 
1H NMR (300 MHz, CDCl3): δ 1.73-1.86 (2H, 
m, CH2CH2NH); 1.94-2.06 (2H, m, CH2CH2O); 2.74 (2H, t, J = 7.2 Hz, CH2CH2NH); 3.79 
(2H, s, CqCH2NH); 4.16 (2H, t, J = 6.1 Hz, CH2O); 6.83 (1H, d, J = 7.7 Hz, CHarom); 7.21-
7.32 (4H, m, 4 × CHarom); 7.36 (1H, dd, J = 8.3, 4.4 Hz, CHarom); 7.59 (1H, t, J = 8.3 Hz, 
CHarom); 7.68 (1H, d, J = 8.3 Hz, CHarom); 8.57 (1H, dd, J = 8.3, 1.7 Hz, CHarom); 8.90 (1H, 
dd, J = 4.4, 1.7 Hz, CHarom). 
13C NMR (75.6 MHz, Ref = CDCl3): δ 26.9 (CH2CH2NH); 27.1 
(CH2CH2O); 49.0 (CH2NH); 53.3 (CqCH2NH); 68.2 (CH2O); 105.0 (HCarom); 120.2 
(HCarom); 121.0 (OCqCq); 121.4 (HCarom); 128.6 (2 × HCarom); 129.6 (2 × HCarom); 131.0 
(HCarom); 132.8 (CqCl); 138.8 (CH2Cq); 149.1 (CqN); 150.7 (HCarom); 154.5 (CqO). IR (cm
-1): νNH = 3040, νmax 
= 2929, 1588, 1575, 1464, 1264, 1091, 795, 735. HRMS (ESI) calcd for C20H22ClN2O 341.1415 [M+H]
+, 
found 341.1422. 
 
8-[4-(4-chlorobenzylamino)-3-methylbutyloxy]quinoline 175k (94%) 
Yellow-orange oil. Rf (SiO2) = 0.06 (100% EtOAc). 
1H NMR (300 MHz, CDCl3): δ 1.12 
(3H, d, J = 6.6 Hz, CH3); 1.50-1.62 (1H, m, CH2(HCH)CH); 1.81-2.00 (1H, m, 
CH2(HCH)CH); 2.36 (1H, quint, J = 6.6 Hz, CHCH3); 2.68-2.84 (2H, m, CH2CH2N); 3.77 
(2H, d, J = 2.2 Hz, CqCH2NH); 4.03 (1H, dd, J = 9.4, 7.2 Hz, (HCH)O); 4.09 (1H, dd, J = 
9.4, 7.2 Hz, (HCH)O); 7.05 (1H, dd, J = 7.7, 1.7 Hz, CHarom); 7.10-7.47 (7H, m, 7 × 
CHarom); 8.12 (1H, dd, J = 8.3, 1.7 Hz, CHarom); 8.90 (1H, dd, J = 4.4, 1.7 Hz, CHarom). 
13C 
NMR (75.6 MHz, Ref = CDCl3): δ 17.5 (CH3); 31.1 (CH2CH2NH); 34.4 (CHCH3); 47.1 
(CH2NH); 53.3 (CqCH2NH); 74.3 (CH2O); 109.0 (HCarom); 119.6 (HCarom); 121.6 (HCarom); 
126.7 (HCarom); 128.5 (2 × HCarom); 129.6 (2 × HCarom); 132.6 (CHCqCH); 135.86 (CqCl); 135.93 (HCarom); 
138.9 (CH2Cq); 140.6 (CqN); 149.4 (HCarom); 155.0 (CqO). IR (cm
-1): νNH = 3042, νmax = 2922, 1261, 1105, 
820, 790, 730. HRMS (ESI) calcd for C21H24ClN2O 355.1572 [M+H]
+, found 355.1578. 
 
8-[4-(4-chlorobenzylamino)-3-methylbutyloxy]-5,7-diiodoquinoline 175o (76%) 
Brown oil. Rf (SiO2) = 0.10 (100% EtOAc). 
1H NMR (300 MHz, CDCl3): δ 1.16 (3H, d, J 
= 7.2 Hz, CH3); 1.55-1.67 (1H, m, CH2(HCH)CH); 1.91-2.02 (1H, m, CH2(HCH)CH); 
2.21-2.32 (1H, m, CHCH3); 2.41 (1H, br. s., NH); 2.73-2.90 (2H, m, CH2CH2N); 3.80 
(2H, s, CqCH2NH); 4.17 (1H, dd, J = 8.8, 6.1 Hz, (HCH)O); 4.24 (1H, dd, J = 8.8, 6.1 
Hz, (HCH)O); 7.21-7.27 (4H, m, 4 × CHarom); 7.46 (1H, dd, J = 8.8, 4.4 Hz, CHarom); 
8.29 (1H, dd, J = 8.8, 1.7 Hz, CHarom); 8.42 (1H, s, CHarom); 8.77 (1H, dd, J = 4.4, 1.7 
Hz, CHarom). 
13C NMR (75.6 MHz, Ref = CDCl3): δ 17.6 (CH3); 32.7 (CH2CH2NH); 34.0 
(CHCH3); 47.3 (CH2NH); 53.3 (CqCH2NH); 80.2 (CH2O); 91.8 (OCqCqI); 92.0 (CHCqCqI); 
123.2 (HCarom); 128.5 (2 × HCarom); 129.7 (2 × HCarom); 131.4 (CqCqI); 132.7 (CqCl); 
138.8 (CH2Cq); 140.8 (HCarom); 142.8 (CqN); 145.3 (HCarom); 150.4 (HCarom); 157.1 (CqO). IR (cm
-1): νNH = 
2927, νmax = 1478, 1443, 1359, 1340, 1083, 905, 788, 727, 647. HRMS (ESI) calcd for C21H22ClI2N2O 
606.9505 [M+H]+, found 606.9508. 
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8-[4-(4-Chlorobenzylamino)-3-methylbutyloxy]-5,7-dichloro-2-methylquinoline 175q (48%) 
Orange oil. Rf (SiO2) = 0.10 (100% EtOAc). 
1H NMR (300 MHz, CDCl3): δ 1.16 
(3H, d, J = 6.6 Hz, CHCH3); 1.51-1.63 (1H, m, CH2(HCH)CH); 1.90-2.01 (1H, 
m, CH2(HCH)CH); 2.19 (1H, quint, J = 6.6 Hz, CHCH3); 2.74 (3H, s, CqCH3); 
2.70-2.87 (2H, m, CH2CH2N); 3.79 (2H, s, CqCH2NH); 4.15 (1H, dd, J = 8.8, 6.1 
Hz, (HCH)O); 4.22 (1H, dd, J = 8.8, 5.5 Hz, (HCH)O); 7.24-7.26 (4H, m, 4 × 
CHarom); 7.36 (1H, d, J = 8.8 Hz, CHarom); 7.55 (1H, s, CHarom); 8.36 (1H, d, J = 
8.8 Hz, CHarom). 
13C NMR (75.6 MHz, Ref = CDCl3): δ 17.5 (CH3); 25.5(CH3Cq); 
32.6 (CH2CH2NH); 33.9 (CHCH3); 47.3 (CH2NH); 53.4 (CqCH2NH); 79.9 
(CH2O); 122.7 (HCarom); 124.5 (OCqCqCl); 125.6 (CHCqCqCl); 126.3 
(CHCqCqCl); 126.8 (HCarom); 128.4 (2 × HCarom); 129.5 (2 × HCarom); 132.4 
(CHCHCqCl); 133.1 (HCarom); 139.1 (CH2Cq); 143.2 (CqN); 150.5 (CqO); 159.7 
(CqCH3). IR (cm
-1): νNH = 2956, νmax = 2926, 1491, 1442, 1234, 1090, 947, 908, 822, 796, 774, 731. 
HRMS (ESI) calcd for C22H24Cl3N2O 437.0949 [M+H]
+, found 437.0957. 
 
5-[4-(4-chlorobenzylamino)-3-methylbutyloxy]quinoline 175s (84%) 
Brown oil. Rf (SiO2) = 0.10 (100% EtOAc). 
1H NMR (300 MHz, CDCl3): δ 1.13 (3H, d, J = 
6.6 Hz, CH3); 1.50-1.62 (1H, m, CH2(HCH)CH); 1.77-1.91 (1H, m, CH2(HCH)CH); 2.15-
2.25 (1H, m, CHCH3); 2.67-2.81 (2H, m, CH2CH2N); 3.76 (2H, s, CqCH2NH); 3.89-4.02 
(2H, m, CH2O); 6.81 (1H, d, J = 7.7 Hz, CHarom); 7.22-7.28 (4H, m, 4 × CHarom); 7.35 (1H, 
ddd, J = 8.8, 4.4, 1.7 Hz, CHarom); 7.58 (1H, t, J = 7.7 Hz, CHarom); 7.68 (1H, d, J = 8.8 Hz, 
CHarom); 8.57 (1H, d, J = 8.8 Hz, CHarom); 8.89 (1H, dd, J = 4.4, 1.7 Hz, CHarom). 
13C NMR 
(75.6 MHz, Ref = CDCl3): δ 17.5 (CH3); 31.5 (CH2CH2NH); 34.2 (CHCH3); 47.2 (CH2NH); 
53.5 (CqCH2NH); 73.3 (CH2O); 105.0 (HCarom); 120.2 (HCarom); 121.0 (CqCqO); 121.5 
(HCarom); 128.6 (2 × HCarom); 129.5 (2 × HCarom); 130.9 (HCarom); 132.7 (CqCl); 139.0 (CH2Cq); 149.2 (CqN); 
150.8 (HCarom); 154.6 (CqO). IR (cm
-1): νNH = 3039, νmax = 2921, 1264, 1090, 795, 735. HRMS (ESI) calcd 
for C21H24ClN2O 355.1572 [M+H]
+, found 355.1579. 
 
3.1.6.6. Synthesis of 5-chloro-7-(4-diethylamino-2-methylbutyl)quinolin-8-ol 
The procedure for the synthesis of compounds 174a-k was also applied for the preparation of 5-
chloro-7-(4-diethylamino-2-methylbutyl)quinolin-8-ol 178. The crude product was purified by means 
of column chromatography on silica gel. 
 
5-Chloro-7-[(4-N,N-diethylamino)-3-methylbutyloxy]-8-hydroxyquinoline 178 (81%) 
Viscous red-brown oil. Rf (SiO2) = 0.08 (100% EtOAc). 
1H NMR (300 MHz, 
CDCl3): δ 0.95 (3H, d, J = 6.6 Hz, CHCH3); 1.02 (6H, t, J = 7.2 Hz, (CH2CH3)2); 
1.38-1.48 (1H, m, CH2(HCH)CH); 1.52-1.64 (1H, m, CH2(HCH)CH); 1.86-2.02 
(1H, m, CHCH3); 2.43-2.60 (6H, m, N(CH2)3); 2.61 (1H, dd, J = 13.2, 8.3 Hz, 
(HCH)Cq); 2.86 (1H, dd, J = 13.2, 6.1 Hz, (HCH)Cq); 7.40 (1H, s, CHarom); 7.48 
(1H, dd, J = 8.3, 4.4 Hz, CHarom); 8.46 (1H, dd, J = 8.3, 1.7 Hz, CHarom); 8.80 
(1H, dd, J = 4.4, 1.7 Hz, CHarom). 
13C NMR (75.6 MHz, Ref = CDCl3): δ 11.6 (2 × CH3CH2); 19.9 (CH3); 32.6 
(CH2CH2NH); 33.8 (CHCH3); 37.3 (CH2Cq); 46.9 (2 × CH2CH3); 50.7 (CH2N); 119.6 (CqCH2); 121.7 (HCarom); 
123.7 (CqCqCl); 124.8 (CqCl); 130.0 (HCarom); 133.2 (HCarom); 138.8 (CqN); 148.4 (HCarom); 149.0 (CqO). IR 
(cm-1): νmax = 2965, 2926, 1459, 1391, 1367, 1264, 1201, 1153, 943, 786, 738, 718. HRMS (ESI) calcd 
for C18H26ClN2O 321.1728 [M+H]
+, found 321.1732. 
N
O
NH
Cl
Cl
Cl
N
O
H
N
Cl
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3.1.6.7. Antiplasmodial and cytotoxicity testing procedures 
Antiplasmodial assessment 
All samples were tested against a CQS strain of P. falciparum (D10). Continuous in vitro cultures of 
asexual erythrocyte stages of P. falciparum were maintained using a modified method of Trager and 
Jensen,343 and quantitative assessment of antiplasmodial activity in vitro was determined via the 
parasite lactate dehydrogenase assay using a modified method described by Makler.344 The samples 
were tested in triplicate on one occasion. The test samples were prepared to a 20 mg/mL stock 
solution in 100% DMSO. Stock solutions were stored at -20 °C. Further dilutions were prepared in 
complete medium on the day of the experiment. Samples were tested as a suspension if not 
completely dissolved. CQ was used as the reference. A full dose-response was performed for all 
compounds to determine the concentration inhibiting 50% of parasite growth (IC50 value). Test 
samples were tested at a starting concentration of 100 µg/mL, which was then serially diluted 
twofold in complete medium to give 10 concentrations; with the lowest concentration being 0.2 
µg/mL. The same dilution technique was used for all samples. CQ was tested at a starting 
concentration of 100 ng/mL against a CQS strain and 1000 ng/mL against the CQR strain. The highest 
concentration of solvent to which the parasites were exposed to had no measurable effect on the 
parasite viability. 
Cytotoxicity assessment 
The test samples were tested in triplicate on one occasion. The test samples were prepared to a 2 
mg/mL stock solution in 10% DMSO and were tested as a suspension. Test compounds were stored 
at -20 °C until use. Dilutions were prepared on the day of the experiment. Emetine was used as the 
reference drug in all experiments. The initial concentration of emetine was 100 µg/mL, which was 
serially diluted in complete medium with 10-fold dilutions to give 6 concentrations, the lowest being 
0.001 µg/mL. The same dilution technique was applied to all test samples. The highest concentration 
of solvent to which the cells were exposed to had no measurable effect on the cell viability. The 50% 
inhibitory concentration (IC50) values were obtained from full dose-response curves, using a non-
linear dose-response curve fitting analysis via GraphPad Prism v.4 software. 
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3.1.6.8. Antimicrobial testing procedures 
Disk diffusion susceptibility test 
These strains were subcultured onto potato dextro medium (Oxoid) at 25 °C and the inocula were 
prepared by suspending and diluting a fresh and mature culture of each strain in a 0.85% sterile 
saline solution for desired density, equivalent to 0.5 McFarland standard (stock inocula). The fungal 
inocula were spread out on a PDA (Oxaid) plate by a sterile glass hockey. The empty 6 mm disc (BBLTM 
Sensi-DiscTM) containing 0.2 mg of the antifungal compound dissolved in DMSO was dispensed on the 
plate. The control disk was dispensed with 2 µL of the pure solvent (DMSO). All the plates were 
incubated at 25 °C and antifungal activity was measured after 24 h of incubation for yeasts and after 
48 h of incubation for filamentous fungi. The microbial inhibition was determined by measuring the 
diameter of the clear zone around microbial colonies. These experiments were repeated three times. 
MIC determination via microdilution 
The MIC values of antifungal reagents were determined by a microdilution test which was performed 
in 96-well microtiter plates. The RPMI-1640 medium supplemented with glutamine and a pH 
indicator, but without bicarbonate, was employed to prepare a dilution series (0-500 mg/L) of the 
antifungal agents. The previously prepared inoculi were diluted ten times in distilled water. Each well 
of the microtiter plate contained 100 µL of antifungal dilution and 100 µL inoculum. The 
microdilution plates were subsequently incubated without agitation at 37 °C for 24h, 48h or 72h for 
yeast, A. flavus or F. solani, respectively. The plates were read with a microtiter plate 
spectrophotometer (Bio-rad) at 530 nm. The MIC value evalution was based on the guidelines of 
EUCAST protocols. 
 
  
 
 
3.2.  
Synthesis, synthetic elaboration and biological  
assessment of aziridine-(iso)quinoline hybrids 
 
 
 
 
 
Abstract: Aziridine-(iso)quinoline hybrid systems were prepared as novel synthetic intermediates en 
route to functionalized (iso)quinolines with potential antimalarial activity. Various 
quinolinecarboxaldehydes were converted into quinoline-aziridine-pyrazole, -pyridazinone or  
-pyrimidinone hybrids, and the three-membered azaheterocyclic moiety in these compounds was 
finally subjected to ring opening by either methanol or water to provide the corresponding 
functionalized quinolines. In addition, 5-hydroxyisoquinoline was used for the preparation of 
isoquinoline-aziridine chimeras, which were further transformed into a variety of functionalized 
isoquinolines via regioselective aziridine ring opening by various nucleophiles. Antiplasmodial 
evaluation of these new aziridine-(iso)quinoline hybrids and their ring-opening products revealed 
micromolar potency (0.22-30 µM) for all representatives against a chloroquine-sensitive strain of the 
malaria parasite Plasmodium falciparum. The six most potent compounds also showed micromolar 
activity against a chloroquine-resistant strain of P. falciparum with IC50 values ranging between 1.02 
and 17.58 µM. 
 
 
 
Parts of the work described in this chapter have been published: 
Stéphanie Vandekerckhove, Sofie De Moor, Dries Segers, Carmen de Kock, Peter J. Smith, Kelly Chibale, Norbert De Kimpe, 
Matthias D’hooghe. Synthesis and antiplasmodial evaluation of aziridine-(iso)quinoline hybrids and their ring-opening 
products. Med. Chem. Commun. 2013, 4, 724-730. 
Stéphanie Vandekerckhove, Matthias D’hooghe. Exploration of aziridine- and β-lactam-based hybrids as both bioactive 
substances and synthetic intermediates in medicinal chemistry. Bioorg. Med. Chem. 2013, 21, 3643-3647. 
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3.2.1. Introduction 
An emerging strategy within drug discovery programs comprises the synthesis of novel chemical 
entities via combination of two biologically relevant moieties. This strategy has recently been used in 
the development of various drugs, such as anticancer, anti-Alzheimer and antiviral agents.36-38, 345 The 
literature review section of this PhD thesis provides an extensive overview of recent advances in the 
development of hybrid quinoline-containing antimalarial drugs, emphasizing the relevance of this 
strategy in current medicinal chemistry. An important motive for the application of molecular 
hybridization is the development of active drugs which can obviate drug resistance. By linking 
bioactive units to other important scaffolds, the resulting conjugates can be transported into the 
desired cells, but are not recognized by the resistance mechanism. In addition to these biological 
perspectives, molecular hybridization also allows for selective modification of the more reactive 
entity within the hybrid system, thus providing easy access to new functionalized compounds with 
biological interest because of the conservation of the second bioactive moiety.38 The importance of 
the quinoline class of compounds in the treatment of malaria has unequivocally been established and 
has been a source of inspiration for medicinal chemists for many years.296  
Although less frequently encountered as the core structure in bioactive substances as compared to 
quinolines, isoquinolines have also been associated with a range of biological activities such as 
anticancer, anti-inflammatory, antidiabetes, anti-HIV, etc.346-350 In addition, diverse studies have 
ratified the antimalarial properties of isoquinoline derivatives, making these systems attractive 
templates in antimalarial research as well.289, 350 The combination of a(n) (iso)quinoline scaffold with 
a bioactive heterocyclic moiety in a hybrid system via an aziridine linker and the study of their 
applications comprises an unexplored field of research. As (iso)quinolines are known to be suitable 
templates for the synthesis of antimalarial agents, antimalarial evaluation of novel aziridine-
(iso)quinoline chimeras could potentially provide new leads in this field. Moreover, the inherent 
reactivity of the aziridine nucleus allows for selective transformations of these hybrids to provide 
novel functionalized (iso)quinoline derivatives.351-358 Hence, the objective of this study comprises the 
design, synthesis and antiplasmodial evaluation of a set of new aziridine-(iso)quinoline systems and 
the corresponding aziridine ring-opening products. 
 
3.2.2. Design and synthesis of aziridine-(iso)quinoline hybrids and their ring-opening products 
3.2.2.1. Synthesis of aziridine-quinoline hybrids and their ring-opening products 
The synthetic strategy used to construct aziridine-quinoline chimeras consists of the initial synthesis 
of {[2-(bromomethyl)aziridin-1-yl]methyl}quinolines starting from quinolinecarboxaldehydes. From a 
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synthetic perspective, the 2-(bromomethyl)aziridine core has proven to be an excellent synthon in 
organic chemistry,359, 360 especially toward the preparation of functionalized aminopropanes, which 
are known to possess a wide variety of biological activities (β-blockers, antibiotics, antimalarials, 
anticancer agents, etc).307, 308, 361-369 Condensation of quinoline-3- and quinoline-4-carboxaldehydes 17 
with 2,3-dibromopropylamine hydrobromide in dichloromethane in the presence of magnesium 
sulfate and triethylamine resulted in the formation of dibromoimines 180 after 5 h stirring under 
reflux conditions. However, a more efficient procedure was obtained when the reaction was 
performed in a closed recipient at 90 °C applying microwave irradiation for 15-20 min. Due to the 
inherent reactivity of imines toward water, these imines 180 were immediately treated with sodium 
borohydride in methanol in order to produce {[2-(bromomethyl)aziridin-1-yl]methyl}quinolines 181. 
Evaluation of the reaction conditions showed that sequential addition of sodium borohydride (4 × 2 
equiv) and a total reaction time of 8h (4 × 2h) yielded the desired aziridines 181 in very good yields 
(93-96%). However, the use of microwave irradiation again improved the reaction efficiency 
considerably. Imines 180 were therefore dissolved in methanol in a closed vessel and were treated 
with sodium borohydride and stirred for 90 min at 65 °C under microwave irradiation (Scheme 9, 
Table 6). Further optimization of the reaction conditions showed that full conversion was only 
obtained when the reducing agent was sequentially added (2 × 1.5 equiv, with an interval of 45 min). 
This method afforded aziridines 181 in excellent yields (96-98%) and purities (> 95%, NMR).  
 
 
Scheme 9 
 
All newly synthesized [2-(bromomethyl)aziridin-1-yl]methyl}quinolines 181 appeared to be rather 
unstable, even when stored at low temperatures (-20 °C), so further synthetic modification of these 
hybrids 181 was immediately performed through bromide substitution with heteroaromatic 
nucleophiles. Three nucleophiles, i.e., 2-methyl-5-trifluoromethyl-2H-pyrazol-3-ol 182, 4-
trifluoromethyl-1H-pyrimidin-2-one 183 and 4,5-dichloro-2H-pyridazin-3-one 184, were selected 
because of their known antimalarial potency,370 which could be beneficial within the concept of 
biological hybrid formation. To accomplish the desired bromide displacement reaction, one equiv of 
nucleophile 182, 183 or 184 was first treated with 2 equiv of sodium hydroxide in DMF at room 
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temperature under inert atmosphere (N2). After one hour, (aziridin-1-ylmethyl)quinolines 181 and 
0.1 equiv of sodium iodide (inspired by the Finkelstein reaction)371 were added to the mixture, and 
further stirring for 60 h at room temperature afforded the desired novel quinoline-aziridine-
pyrazole/pyrimidinone/pyridazinone hybrid compounds 185, 186 and 187 in moderate to good yields 
(37-82%). Finally, column chromatography on silica gel was performed to afford analytically pure 
samples for spectroscopic analyses and biological testing, although this purification step accounted 
for reduced yields (10-45%) due to the strong polarity of these novel compounds 185, 186 and 187 
(Scheme 10, Table 6). Literature reports show that deprotonation of pyrimidin-2-one 183 and 
pyridazin-3-one 184 leads to selective N-alkylation, supporting the formation of N-functionalized 
pyrimidinones 186 and pyridazinones 187.372-375  
 
Scheme 10 
 
An interesting feature of these novel hybrid structures 185, 186 and 187 comprises attachment of 
the quinoline ring to the heteroaromatic moiety (pyrazole, pyrimidine or pyridazine) by an aziridine 
linker. This small azaheterocycle represents a useful synthon since the strained three-membered ring 
can be opened toward functionalized aminopropanes, a moiety which has already proven its broad 
therapeutic relevance in the past.307, 308, 361-369 Therefore, {[2-(1-methyl-3-trifluoromethyl-1H-pyrazol-
5-yloxymethyl)aziridin-1-yl]methyl}quinolines 185 and 4,5-dichloro-2-[1-(quinolinylmethyl)aziridin-2-
ylmethyl]-2H-pyridazin-3-ones 187 were selected for further elaboration and subjected to two types 
of regioselective ring opening. In the first approach, the aziridine ring was activated by protonation 
with an equimolar amount of para-toluenesulfonic acid followed by regioselective ring opening by 
water at the less sterically hindered aziridine carbon atom,376 affording the desired functionalized 
aminopropanes 188a-b and 189a-c (R’ = H) in good yields (60-82%) after 24 h stirring at room 
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temperature in a THF/water (1/1) mixture (Scheme 11, Table 6). Cumbersome column 
chromatography on silica gel was performed in order to obtain analytically pure samples, resulting in 
low overall yields of 8-38% after purification. To evaluate a second approach toward the ring opening 
of azaheterocycles 185 and 187, the aziridine ring was activated using the Lewis acid BF3·Et2O. 
Aziridine-quinoline conjugates 185 and 187 were thus treated with 0.5 equiv of BF3·Et2O in methanol 
at reflux temperature for 20 h, affording functionalized aminopropanes 188c and 189d (R’ = Me) 
through regioselective ring opening by methanol in good yields (74-83%). It should be noted that 
lower Lewis acid loadings (< 0.5 equiv) resulted in longer reaction times and/or lower overall yields. 
Once more, a troublesome purification step affected the overall yields (10-24%) of the finally 
obtained products (Scheme 11, Table 6). 
 
Scheme 11 
 
Notably, the BF3·Et2O-mediated ring opening of aziridine-quinoline-pyrazole hybrid 185b (R = Cl) 
under microwave irradiation (MeOH, 90 °C, 1 h) yielded quinoline 188c (R = Cl, 11%) only as the 
minor product, while the major product 188d (R = OMe, 38%) was formed through replacement of 
chloride by methanol at the 2-position of the quinoline ring. Similar reactions have been reported in 
the literature.377 
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Table 6: Substitution pattern and isolated yields of quinolines 181, 185, 186, 187, 188 and 189 
 
 
3.2.2.2. Synthesis of aziridine-isoquinoline hybrids and their ring-opening products 
A second approach toward aziridine-containing hybrids as intermediates for the synthesis of 
potential novel antimalarials was based on the use of the isoquinoline template. As mentioned 
above, the antiplasmodial activity of isoquinoline derivatives has by far not been described as 
extensively as that of the quinoline class, although diverse literature reports have mentioned their 
antimalarial properties.289, 350 Therefore, functionalization of the isoquinoline nucleus via molecular 
hybridization was considered a new and interesting tool to provide an entry to new representatives 
of this class of compounds. In order to achieve this objective, a reactive moiety had to be introduced 
and, in analogy with the first part of this work, a strained aziridine ring was proposed.  
As an isoquinoline source, the readily available 5-hydroxyisoquinoline 194 was employed and was 
added to 1-arylmethyl-2-(bromomethyl)aziridines 193, which were prepared according to literature 
procedures.359, 360 This synthesis commenced with the condensation of benzaldehydes 190a-g with 
allylamine in the presence of the drying agent magnesium sulfate in dry dichloromethane, and 
stirring for 1 h at reflux temperature afforded N-allylimines 191a-g. These imines 191a-g were 
Compound 
Quinolin- 
3- or 4-yl 
R R’ Yield (%) 
181a 3-yl H - 96 
181b 3-yl Cl - 98 
181c 4-yl H - 96 
185a 3-yl H - 10 
185b 3-yl Cl - 28 
185c 4-yl H - 12 
186a 3-yl H - 45 
186b 3-yl Cl - 12 
187a 3-yl H - 32 
187b 3-yl Cl - 21 
187c 4-yl H - 34 
188a 3-yl H H 11 
188b 3-yl Cl H 24 
188c 3-yl Cl CH3 12 
188d 3-yl OMe CH3 38 
189a 3-yl H H 8 
189b 3-yl Cl H 9 
189c 4-yl H H 11 
189d 4-yl H CH3 10 
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subsequently treated with 1.05 equiv of bromine in dry dichloromethane, furnishing N-(benzylidene)-
2,3-dibromopropylamines 192a-g after stirring for 1 h at room temperature. In a final step, imines 
192a-g were treated with 2 equiv sodium borohydride in methanol affording the desired 1-
arylmethyl-2-(bromomethyl)aziridines 193a-g via reductive ring closure after stirring for 1 h at reflux 
temperature (Scheme 12, Table 7). 
 
Scheme 12 
 
Table 7: Substitution pattern and yields of 1-arylmethyl-2-(bromomethyl)aziridines 193 
Compound R Yield (%) Compound R Yield (%) 
193a H 99 193e 4-OMe 71 
193b 4-Cl 72 193f 2,4-di-Cl 85 
193c 4-F 84 193g 4-CF3 88 
193c 2-Cl 69 193h 2-OMe 95 
 
The hydroxyl group of the 5-hydroxyisoquinoline 194 was first deprotonated using sodium hydroxide, 
and nucleophilic substitution then occurred after adding 1 equiv of an 1-arylmethyl-2-
(bromomethyl)aziridine 193. Reaction for 2-4 h in DMF at 100 °C thus afforded novel 5-(aziridin-2-
ylmethoxy)isoquinolines 195 in good yields (65-90%) (Scheme 13, Table 8). 
 
 
Scheme 13 
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In a next step different strategies for the opening of the constrained ring in these aziridine-
isoquinoline hybrids 195 were evaluated. Firstly, the aziridine system in compound 195 was activated 
by N-protonation using para-toluenesulfonic acid in a THF/water (1/1) solvent mixture. Reaction at 
reflux for 6 h caused water to regioselectively open the activated aziridine ring at the less substituted 
position, which afforded isoquinoline-aminopropanols 196 in high yields (85-94%) (Scheme 14, Table 
8). Secondly, the aziridine was activated by complexation of its nitrogen atom with a Lewis acid (e.g., 
boron trifluoride etherate BF3·Et2O). Adding 2 equiv of BF3·Et2O to hybrids 195 in methanol and 
stirring for 24 h at reflux temperature afforded isoquinolines 197 in moderate yields (42-45%). 
However, in order to render the reaction more efficient, the reaction conditions were altered and it 
appeared that 0.5 equiv of BF3·Et2O allowed the strained-three membered ring to be opened at the 
less hindered aziridine carbon atom by the solvent methanol after 30 min at 90 °C under microwave 
irradiation,376 yielding functionalized isoquinolines 197 in high yields (75-91%). In addition to the 
oxygen-based nucleophiles H2O and MeOH, aniline was used as a nitrogen nucleophile to induce ring 
opening of aziridines 195 en route to 1,2-diaminopropanes. To that end, aziridine-isoquinoline 
hybrids 195 were dissolved in dichloromethane in the presence of 0.5 equiv of BF3·Et2O, after which 
1.1 equiv of aniline was added. Reaction occurred after stirring for 16 h at reflux temperatures or 
under microwave irradiation (1 h at 65 °C), providing new isoquinoline derivatives 198 in high yields 
(91-92%). As reported in the literature, Lewis acid-mediated ring opening of 2-alkylaziridines by 
aromatic amines occurred via nucleophilic attack at the less substituted aziridine carbon atom.376 
Furthermore, the efficiency of different Lewis acids was assessed, and when ytterbium triflate 
Yb(OTf)3 was used instead of BF3·Et2O under the same reaction conditions, yields dropped to 68%, 
while copper triflate Cu(OTf)2 did not result in conversion at all. The final method that was evaluated 
to activate the aziridine moiety in hybrid systems 195 involved alkylation of the aziridine nitrogen 
atom. However, upon addition of 1 equiv of benzyl bromide to aziridine-isoquinoline chimeras 195 in 
CH3CN, selective alkylation of the isoquinoline nitrogen atom was observed, resulting in the 
formation of isoquinolinium salt 199.350 Still containing a reactive aziridine linker, this isoquinolinium 
bromide 199 was again treated with an equimolar amount of benzyl bromide in acetonitrile for 5 h at 
reflux temperature, affording the ring-opened product, i.e., β-bromoamine 200, in excellent yield 
(98%) (Scheme 14, Table 8). According to the literature, ring opening of N,N-dialkylaziridinium salts 
by bromide proceeds at the more hindered aziridine carbon atom.376, 378, 379 It should be noted that 
isoquinolinium salts have been reported to exhibit potent antiplasmodial activities.350  
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Scheme 14 
 
Table 8: Substitution pattern and isolated yields of isoquinolines 195, 196, 197, 198, 199 and 200 
 
 
 
 
 
 
 
 
3.2.3. Antiplasmodial assay of aziridine-(iso)quinoline hybrids and their ring-opening products 
With a small library of aziridine-(iso)quinoline chimeras 185a-c, 186a-b, 187a-c, 195a-g, 199 and their 
ring-opening products 188a-d, 189a-d, 196a,b,f,g, 197a,c-e, 198a-b, 200 in hand, antiplasmodial 
screening was undertaken at the University of Cape Town, South Africa (Prof. P. J. Smith and Prof. K. 
Chibale). All samples were tested in triplicate against a CQS strain of Plasmodium falciparum (NF54). 
Subsequently, only those samples showing promising antiplasmodial activity were tested against a 
Compound R Yield (%) Compound R Yield (%) 
195a H 90 196g 4-CF3 93 
195b 4-Cl 80 197a H 91 
195c 4-F 75 197c 4-F 79 
195d 2-Cl 74 197d 2-Cl 82 
195e 4-OMe 77 197e 4-OMe 85 
195f 2,4-di-Cl 82 197h 2-OMe 75 
195g 4-CF3 84 198a H 92 
195h 2-OMe 65 198b 4-Cl 91 
196a H 94 199 - 97 
196b 4-Cl 85 200 - 98 
196f 2,4-di-Cl 89    
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CQR strain of P. falciparum (Dd2) and screened for in vitro cytotoxicity against a mammalian cell-line, 
Chinese Hamster Ovarian (CHO), using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT)-assay. The MTT-assay was used to measure all growth and survival, and compares 
well with other available assays.309, 310 The tetrazolium salt MTT was used to measure growth and 
chemosensitivity.  
Table 9: IC50 values of aziridine-(iso)quinoline hybrids 185a-c, 186a-b, 187a-c, 195a-g, 199 and their ring-opening products 
188a-d, 189a-d, 196a,b,f,g, 197a,c-e, 198a-b, 200 tested for in vitro antimalarial activity and cytotoxicity 
Compound NF54: IC50 (µM) Dd2: IC50 (µM) CHO: IC50 (µM) SI
a 
RI
b 
185a >27.60 ND ND ND ND 
185b >25.20 ND ND ND ND 
185c 9.66 ND ND ND ND 
186a >27.75 ND ND ND ND 
186b 9.12 ND ND ND ND 
187a 12.73 ND ND ND ND 
187b 22.75 ND ND ND ND 
187c 26.85 ND ND ND ND 
188a 4.73 15.25 181.14 38 3.22 
188b >24.11 ND ND ND ND 
188c 17.02 ND ND ND ND 
188d >23.56 ND ND ND ND 
189a 15.29 ND ND ND ND 
189b 14.99 ND ND ND ND 
189c 24.52 ND ND ND ND 
189d 14.49 ND ND ND ND 
195a 9.99 ND ND ND ND 
195b >30.79 ND ND ND ND 
195c 15.89 ND ND ND ND 
195d 12.93 ND ND ND ND 
195e 9.99 ND ND ND ND 
195f >27.84 ND ND ND ND 
195g >27.90 ND ND ND ND 
195h 5.29 8.46 52.27 10 1.60 
196a 6.81 17.58 148.19 22 2.58 
196b 22.75 ND ND ND ND 
196f >26.51 ND ND ND ND 
196g 11.69 ND ND ND ND 
197a 13.03 ND ND ND ND 
197c 24.38 ND ND ND ND 
197d 16.53 ND ND ND ND 
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197e >28.37 ND ND ND ND 
197h >28.38 ND ND ND ND 
198a 4.69 8.21 237.03 51 1.75 
198b 10.53 ND ND ND ND 
199 1.09 1.02 51.80 48 0.94 
200 0.22 1.17 45.06 205 5.32 
CQ (n=14) 0.03 0.53 ND ND 21.25 
Artunesate (n=8) 0.02 ND ND ND ND 
Emetine ND ND 0.40 ND ND 
ND = not determined; CQ = chloroquine; n = number of replicates; 
a
 SI (Selectivity Index) = IC50 CHO/IC50 NF54;  
b
 RI (Resistance Index) = IC50 Dd2/IC50 NF54. 
 
The results of the antimalarial evaluation are summarized in Table 9. All compounds exhibited 
micromolar potencies against a chloroquine-sensitive NF54 strain of P. falciparum, with 21 of the 37 
samples having IC50 values beween 220 nM and 20 µM. Subsequently, the activity of the six most 
potent compounds (IC50 < 7 µM) was determined against a chloroquine-resistant strain of P. 
falciparum (Dd2), again resulting in micromolar activities with IC50 values ranging between 1.02 and 
17.58 µM. Isoquinolinium salts 199 and 200 in particular displayed promising in vitro activities (1.09 
µM and 220 nM against a NF54 strain and 1.02 µM and 1.17 µM against a Dd2 strain, respectively). 
These six representatives also appear to have moderate to high selectivity indices toward P. 
falciparum and low resistance indices, illustrating the potential of these compounds as novel 
templates in antimalarial drug design.  
 
From a structure-activity relationship viewpoint, a few observations can be made. Firstly, it is clear 
that isoquinolinium-based hybrids display the most potent antiplasmodial activities and that this 
class of compounds holds the most promising potential upon further investigation. Secondly, 
aziridine ring opening by both water and aniline mostly results in more active compounds as 
compared to methanol-induced ring-opening products, although the difference is very small. Finally, 
both the introduction of a chloro atom at the 2-position of the quinoline ring and the choice of the 
heterocyclic moiety (pyrazole, pyrimidinone or pyridazinone) in quinoline-based hybrids does not 
seem to have a pronounced effect on the antimalarial activity. 
 
3.2.4. Immunological testing 
Immunosuppressants are an important class of clinical drugs used in prevention of transplant 
rejection and in the treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis and 
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systemic lupus erythematosus. Even though known immunosuppressive drugs (like cyclosporine A, 
Rapamycin or Tacrolimus) have been successfully employed for organ transplantations and 
treatment of autoimmune diseases in the clinic, their side effects (including cardiovascular toxicity, 
liver toxicity, nephrotoxicity, etc.) cannot be neglected.380-383 Recently, quinoline derivatives have 
been identified as a novel class of immunosuppressive lead compounds.384 Subsequently, a selection 
of novel quinoline hybrids, described in the previous paragraph, was evaluated for their 
immunosuppressive activity in a Mixed Lymphocyte Reaction (MLR)-assay and a B-cell-assay at the 
Interface Valorisation Platform, KU Leuven.  
Table 10: Immunosuppressant activity of quinoline hybrids (µM) 
Compound MLR: IC50 
(µM) 
B-cell: IC50 
(µM) 
Compound MLR: IC50 
(µM) 
B-cell: IC50 
(µM) 185a >10 4.4 195a 6.3 4.9 
185c >10 >10 196a >10 >10 
188a >10 6.9 197a >10 7.1 
188d >10 >10 198a 7.9 5.2 
 
The activities of each compound in the MLR (T-cell assay) and IgG production (B-cell assay) are 
summarized in Table 10. Five compounds displayed moderate activity (IC50 values ranging from 4.4 to 
7.9 µM) in one or both of the assays. These results ratified the statement that quinolines can be seen 
as a potential class of immunosuppressive lead compounds, as well as isoquinolines. 
 
3.2.5. Antimicrobial testing 
The antifungal activity of a selection of novel quinoline hybrids was tested on two yeast strains 
(Candida albicans and Rhodotorula bogoriensis) and three filamentous fungi (Aspergillus niger, 
Fusarium solani and Colletotrichum lindemuthianum) at the Centre of Expertise for Industrial 
Biotechnology and Biocatalysis, Ghent University (Prof. T. Desmet) by using the Disk diffusion 
susceptibility test.331 The novel compounds displayed no activity against any of the tested strains. 
 
3.2.6. Conclusion 
A new approach to functionalize (iso)quinolines via molecular hybridization with a (small) reactive 
heterocycle, i.e., a strained aziridine ring, was elaborated. With aziridines being useful synthons in 
organic synthesis, further functionalization of these novel aziridine-(iso)quinoline conjugates was 
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effected by ring opening of the aziridine moiety by water, methanol, aniline or bromide affording 
new functionalized (iso)quinolines and isoquinolinium salts. Furthermore, the antiplasmodial activity 
and cytotoxicity of the novel aziridine-(iso)quinoline class of compounds and their ring-opening 
products was demonstrated. All tested compounds displayed micromolar activity against a 
chloroquine-sensitive strain of P. falciparum, and six compounds also showed micromolar activity 
against a chloroquine-resistant strain of P. falciparum. High selectivity indices asserted the low 
cytotoxicity of these compounds, demonstrating the promising potential of these new compounds as 
potential novel antimalarial lead structures. In addition, moderate immunosuppressant activity was 
observed for some of these hybrid molecules. 
 
3.2.7. Experimental section 
3.2.7.1. General methods 
All reagents were purchased from commercial suppliers (Sigma-Aldrich, Acros, TCI), and were used as 
received without any purification, unless otherwise noted. Solvents were dried with sodium (THF) or 
calcium hydride (dichloromethane), and distilled before use. Other solvents were purchased from 
commercial suppliers and used as supplied. The petroleum ether used during product purification 
steps had a boiling range of 40-60 °C. Crude reaction mixtures were analysed by LC/MS/UV. Thin-
layer chromatography was carried out on silica gel 60F254 plates (Merck). Column chromatography 
was performed in a glass column with silica gel (particle size 70-200 µm, pore diameter 60Å). 
Preperative TLC was executed with 2000 µm 20 × 20 cm TLC plates. High-resolution 1H and 13C 
magnetic resonance (NMR) spectra were recorded with Jeol Eclipse+ 300 NMR spectrometer in 
CDCl3, unless otherwise noted. Chemical shifts were calibrated using tetramethylsilane, which was 
used as an internal reference, unless otherwise indicated. Peak assignments were obtained with the 
aid of HSQC spectra. Attenuated total reflection (ATR) IR spectra were recorded with a Perkin-Elmer 
Spectrum BX spectrometer, equipped with a ZnSe crystal, at room temperature (neat). Low-
resolution mass spectra were recorded with an Agilent Technologies 1100 series VL mass 
spectrometer (ESI, 70 eV). High resolution mass spectra were obtained with an HPLC coupled to an 
Agilent Technologies 6210 series time-of-flight mass spectrometer equipped with an ESI/APCI-
multimode source. Melting points were measured with a Büchi B-540 apparatus. 
 
3.2.7.2. Synthesis of {[2-(bromomethyl)aziridin-1-yl]methyl}quinolines 
General procedure: In a microwave recipient of 80 mL, quinoline-3-carboxaldehyde 17 (2 mmol), 
triethylamine (2 mmol, 1 equiv), magnesium sulfate (3 mmol, 1.5 equiv) and 2,3-
dibromopropylamine hydrobromide (2.2 mol, 1.1 equiv) were dissolved in dichloromethane (40 mL). 
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After stirring for 15-20 min at 90 °C under microwave irradiation, the reaction mixture was poured 
into water (30 mL) and extracted with dichloromethane (3 × 15 mL). The combined organic extracts 
were dried over anhydrous magnesium sulfate. Filtration of the drying agent and removal of the 
solvent in vacuo afforded the crude imine products 180a-c. Because of their instability, these 
compounds were immediately used for the subsequent reaction step. In a microwave recipient of 80 
mL, imine 180 (2 mmol) was dissolved in methanol (40 mL), and sodium borohydride (3 mmol, 1.5 
equiv) was added slowly to this solution. After stirring for 15-45 min at 65 °C under microwave 
irradiation, the reaction mixture was cooled down to room temperature, after which a second 
portion of sodium borohydride (3 mmol, 1.5 equiv) was added slowly. After stirring again for 15-45 
min at 65 °C under microwave irradiation, the reaction mixture was poured into brine (30 mL) and 
extracted with dichloromethane (3 × 15 mL). The combined organic extracts were dried over 
anhydrous magnesium sulfate, and filtration of the drying agent and removal of the solvent in vacuo 
afforded {[2-(bromomethyl)aziridin-1-yl]methyl}quinolines 181a-c.  
 
3-{[2-(Bromomethyl)aziridin-1-yl]methyl}quinoline 181a (96%) 
Brown crystals. Mp = 57 °C. Rf (SiO2) = 0.11 (hexane/EtOAc 1/1). 
1H NMR 
(300 MHz, CDCl3): δ 1.72 (1H, d, J = 6.1 Hz, (HCH)CHN); 1.90 (1H, d, J = 3.3 
Hz, (HCH)CHN); 1.99-2.07 (1H, m, CH2CHN); 3.27 (1H, dd, J = 10.2, 7.4 Hz, 
(HCH)Br); 3.39 (1H, dd, J = 10.2, 5.5 Hz, (HCH)Br); 3.63 (1H, d, J = 13.8 Hz, N(HCH)Ar); 3.71 (1H, d, J = 
13.8 Hz, N(HCH)Ar); 7.52-7.57 (1H, m, CHarom); 7.67-7.72 (1H, m, CHarom); 7.80-7.84 (1H, m, CHarom); 
8.10 (1H, d, J = 8.3 Hz, CHarom); 8.19 (1H, d, J = 1.1 Hz, CHarom); 8.88 (1H, d, J = 2.2 Hz, CHarom). 
13C NMR 
(75.6 MHz, ref = CDCl3): δ 35.2 (CH2Br); 35.9 (NCH2CH); 40.6 (NCH2CH); 61.6 (NCH2Ar); 126.7 (HCarom); 
127.8 (HCarom); 127.9 (Carom,quat); 129.2 (2 × HCarom); 131.5 (Carom,quat); 134.6 (HCarom); 147.5 (Carom,quat); 
151.0 (HCarom). IR (cm
-1): νmax = 3050, 2988, 2964, 2924, 2863, 1236, 743, 631. MS (70 eV): m/z (%): 
277/279 (M++1, 100). HRMS (ESI) calcd for C13H14BrN2 277.0335 [M+H]
+, found 277.0333.  
 
3-{[2-(Bromomethyl)aziridin-1-yl]methyl}-2-chloroquinoline 181b (98%) 
Light yellow crystals. Mp = 136 °C. 1H NMR (300 MHz, CDCl3): δ 1,75 (1H, d, J 
= 6.6 Hz, (HCH)CHN); 2.02 (1H, d, J = 3.3 Hz, (HCH)CHN); 2.06-2.14 (1H, m, 
CH2CHN); 3.35 (1H, dd, J = 10.5, 7.7 Hz, (HCH)Br); 3.53 (1H, dd, J = 10.5, 5.0 
Hz, (HCH)Br); 3.68 (1H, d, J = 16.0 Hz, N(HCH)Ar); 3.80 (1H, d, J = 16.0 Hz, N(HCH)Ar); 7.54-7.60 (1H, 
m, CHarom); 7.68-7.74 (1H, m, CHarom); 7.88 (1H, dd, J = 8.3, 1.1 Hz, CHarom); 8.02 (1H, d, J = 8.3 Hz, 
CHarom); 8.55 (1H, s, CHarom). 
13C NMR (75.6 MHz, ref = CDCl3): δ 35.1 (CH2Br); 36.1 (NCH2CH); 41.0 
(NCH2CH); 60.8 (NCH2Ar); 127.2 (HCarom); 127.5 (Carom,quat); 127.7 (HCarom); 128.3 (HCarom); 130.2 
(HCarom); 130.9 (Carom,quat); 137.3 (HCarom); 146.8 (Carom,quat); 149.7 (Carom,quat). IR (cm
-1): νmax = 3059, 
2979, 2963, 2929, 2856, 1323, 1234, 1030, 746. MS (70 eV): m/z (%) 311/313/315 (M++1, 100). HRMS 
(ESI) calcd for C13H13BrClN2 310.9945 [M+H]
+, found 310.9941.  
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4-{[2-(Bromomethyl)aziridin-1-yl]methyl}quinoline 181c (96%) 
Brown viscous oil. Rf (SiO2) = 0.21 (hexane/EtOAc 1/1). 
1H NMR (300 MHz, 
CDCl3): δ 1.71 (1H, d, J = 6.6 Hz, (HCH)CH); 1.97 (1H, d, J = 3.3 Hz, (HCH)CH); 
2.02-2.10 (1H, m, CH2CHN); 3.34 (1H, dd, J = 10.5, 7.7 Hz, (HCH)Br); 3.44 (1H, dd, 
J = 10.5, 5.5 Hz, (HCH)Br); 3.79 (1H, d, J = 14.9 Hz, N(HCH)Ar); 4.15 (1H, d, J = 
14.9 Hz, N(HCH)Ar); 7.54-7.61 (2H, m, 2 × CHarom); 7.69-7.75 (1H, m, CHarom); 8.00 
(1H, dd, J = 8.3, 1.1 Hz, CHarom); 8.13 (1H, d, J = 7.7 Hz, CHarom); 8.91 (1H, d, J = 4.4 Hz, CHarom). 
13C NMR 
(75.6 MHz, ref = CDCl3): δ 35.0 (CH2Br); 36.3 (NCH2CH); 40.8 (NCH2CH); 60.7 (NCH2Ar); 119.9 (HCarom); 
123.2 (HCarom); 126.69 (Carom,quat); 126.73 (HCarom); 129.3 (HCarom); 130.2 (HCarom); 144.2 (Carom,quat); 
148.0 (Carom,quat); 150.5 (HCarom). IR (cm
-1): νmax = 3034, 2986, 2918, 2842, 1594, 848, 754. MS (70 eV): 
m/z (%): 277/279 (M++1, 100).  
 
3.2.7.3. Synthesis of {[2-(1-methyl-3-trifluoromethyl-1H-pyrazole-5-yloxymethyl)aziridinyl]methyl} 
quinolines 
General procedure: To a solution of {[2-(bromomethyl)aziridin-1-yl]methyl}quinoline 181 (6 mmol) in 
DMF (40 mL), sodium iodide (0.6 mmol, 0.1 equiv), 2-methyl-5-trifluoromethyl-2H-pyrazole-3-ol (6 
mmol, 1 equiv) and sodium hydroxide (12 mmol, 2 equiv) were added. After stirring for 60 h at room 
temperature under nitrogen atmosphere, the reaction mixture was poured into brine (50 mL) and 
extracted with dichloromethane (3 × 20 mL). The combined organic layers were washed with brine 
(10 × 20 mL) and dried over anhydrous magnesium sulfate. Filtration of the drying agent and removal 
of the solvent in vacuo afforded {[2-(1-methyl-3-trifloromethyl-1H-pyrazole-5-yloxymethyl)aziridin-1-
yl]methyl} quinolines 185a-c, which were purified by means of column chromatography on silica gel, 
preparative thin layer chromatography or recrystallization. 
 
3-{[2-(1-Methyl-3-trifluoromethyl-1H-pyrazole-5-yloxymethyl)aziridin-1-yl]methyl}quinoline 185a 
(10%) 
Yellow oil. Rf (SiO2) = 0.12 (EtOAc 100%). 
1H NMR (300 MHz, 
CDCl3): δ 1.64 (1H, d, J = 6.6 Hz, (HCH)CHN); 1.93 (1H, d, J = 3.3 
Hz, (HCH)CHN); 2.06-2.13 (1H, m, CH2CHN); 3.63 (1H, d, J = 14.0 
Hz, N(HCH)Ar); 3.75 (1H, d, J = 14.0 Hz, N(HCH)Ar); 3.78 (3H, s, 
CH3N); 4.01 (1H, dd, J = 11.0, 7.2 Hz, (HCH)O); 4.27 (1H, dd, J = 
11.0, 4.4 Hz, (HCH)O); 5.91 (1H, s, OCqCHCq); 7.52-7.57 (1H, m, CHarom); 7.67-7.72 (1H, m, CHarom); 7.81 
(1H, d, J = 7.7 Hz, CHarom); 8.10 (1H, d, J = 8.3 Hz, CHarom); 8.23 (1H, s, CHarom); 8.87 (1H, d, J = 2.2 Hz, 
CHarom). 
13C NMR (75.6 MHz, ref = CDCl3): δ 31.5 (NCH2CH); 37.3 (CH3N); 37.8 (NCH2CH); 61.3 
(NCH2Ar); 71.1 (CH2O); 92.3 (OCqCHCq); 119.4 (q, J = 268.8 Hz, CF3), 126.4 (HCarom); 127.6 (HCarom); 
127.8 (Carom,quat); 128.9 (HCarom); 129.0 (HCarom); 131.8 (Carom,quat); 132.1 (q, J = 38.5 Hz, CqCF3); 134.2 
(HCarom); 147.3 (Carom,quat); 150.8 (HCarom); 160.7 (Carom,quat);. 
19F NMR (282 MHz, CDCl3): δ -60,80 (3F, s, 
CF3). IR (cm
-1): νmax = 2988, 2946, 2835, 1493, 1273, 1187, 1123, 1018, 752, 728. MS (70 eV): m/z (%): 
363 (M++1, 100). HRMS (ESI) calcd for C18H18F3N4O 363.1427 [M+H]
+, found 363.1434.  
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2-Chloro-3-[2-(1-methyl-3-trifluoromethyl-1H-pyrazole-5-yloxymethyl)aziridin-1-ylmethyl] 
quinoline 185b (28%) 
Light yellow crystals. Mp = 87.7 °C. Recrystallization from 
ethanol. 1H NMR (300 MHz, CDCl3): δ 1.70 (1H, d, J = 6.6 Hz, 
(HCH)CHN); 2,03 (1H, d, J = 3.3 Hz, (HCH)CHN); 2.09-2.16 (1H, m, 
CH2CHN); 3.58 (1H, d, J = 16.2 Hz, N(HCH)Ar); 3.88 (1H, d, J = 
16.2 Hz, N(HCH)Ar); 3.81 (3H, s, CH3N); 4.04 (1H, dd, J = 11.0, 7.7 
Hz, (HCH)O); 4.43 (1H, dd, J = 11.0, 3.9 Hz, (HCH)O); 5.96 (1H, s, OCqCHCq); 7.55-7.59 (1H, m, CHarom); 
7.69-7.74 (1H, m, CHarom); 7.84 (1H, d, J = 8.3 Hz, CHarom); 8.01 (1H, d, J = 8.3 Hz, CHarom); 8.62 (1H, s, 
CHarom). 
13C NMR (75.6 MHz, ref = CDCl3): δ 31.7 (NCH2CH); 37.6 (CH3N); 38.4 (NCH2CH); 60.5 
(NCH2Ar); 71.4 (CH2O); 92.5 (OCqCHCq); 119.6 (q, J = 267.7 Hz, CF3); 127.1 (HCarom); 127.60 (Carom,quat); 
127.64 (HCarom); 128.2 (HCarom); 130.0 (HCarom); 131.2 (Carom,quat); 132.7 (q, J = 39.2 Hz, CqCF3), 137.0 
(HCarom); 146.7 (Carom,quat); 149.7 (Carom,quat); 161.0 (Carom,quat);. 
19F NMR (282 MHz, CDCl3): δ -60.69 (3F, 
s, CF3). IR (cm
-1): νmax = 2941, 2928, 1492, 1272, 1113, 1023. MS (70 eV): m/z (%): 397/399 (M
++1, 
100). HRMS (ESI) calcd for C18H17ClF3N4O 397.1037 [M+H]
+, found 397.1040.  
 
4-{[2-(1-Methyl-3-trifluoromethyl-1H-pyrazole-5-yloxymethyl)aziridin-1-yl]methyl}quinoline 185c 
(12%) 
Yellow oil. Rf (SiO2) = 0.15 (hexane/EtOAc 1/3). 
1H NMR (300 MHz, 
CDCl3): δ 1.64 (1H, d, J = 6.6 Hz, (HCH)CHN); 1.99 (1H, d, J = 3.3 Hz, 
(HCH)CHN); 2.07-2.14 (1H, m, CH2CHN); 3.80 (3H, s, CH3N); 3.98 (2H, 
s, NCH2Ar); 4.08 (1H, dd, J = 11.0, 7.2 Hz, (HCH)O); 4.31 (1H, dd, J = 
11.0, 4.4 Hz, (HCH)O); 5.98 (1H, s, (OCqCHCq); 7.52-7.57 (1H, m, 
CHarom); 7.68-7.74 (2H, m, 2 × CHarom); 7.94 (1H, d, J = 7.7 Hz, CHarom); 8.13 (1H, d, J = 8.8 Hz, CHarom); 
8.90 (1H, d, J = 4.4 Hz, CHarom). 
13C NMR (75.6 MHz, ref = CDCl3): δ 32.0 (NCH2CH); 37.6 (CH3N); 38.3 
(NCH2CH); 60.5 (NCH2Ar); 71.3 (CH2O); 92.6 (OCqCHCq); 119.57 (q, J = 270.0 Hz, CF3), 119.60 (HCarom); 
123.0 (HCarom); 126.61 (Carom,quat); 126.63 (HCarom); 129.2 (HCarom); 130,2 (HCarom); 132,7 (q, J = 39,2 Hz, 
CqCF3), 144,6 (Carom,quat); 147,9 (Carom,quat); 150,5 (HCarom); 161.0 (Carom,quat). 
19F NMR (282 MHz, CDCl3): d 
-60.68 (3F, s, CF3). IR (cm
-1): νmax = 2987, 2950, 1492, 1273, 1187, 1124, 1019, 755, 729. MS (70 eV): 
m/z (%): 363 (M++1, 100). HRMS (ESI) calcd for C18H18F3N4O 363.1427 [M+H]
+, found 363.1432. 
 
3.2.7.4. Synthesis of 2-(quinolinylmethyl)amino-3-(1-methyl-3-trifluoromethyl-1H-pyrazole-5-
yloxy)propan-1-ols 
General procedure: To a solution of {[2-(1-methyl-3-trifluoromethyl-1H-pyrazole-5-
yloxymethyl)aziridin-1-yl]methyl}quinoline 185 (2 mmol) in a tetrahydrofuran/water (1/1) solvent 
mixture (30 mL), para-toluenesulfonic acid (2 mmol, 1 equiv) was added. After stirring for 24 h at 
room temperature, the reaction mixture was poured into water (30 mL) and extracted with 
dichloromethane (3 × 15 mL). The combined organic layers were subsequently dried over anhydrous 
magnesium sulfate. Filtration of the drying agent and removal of the solvent in vacuo afforded the 
crude products 188a-b, which were purified by means of column chromatography on silica gel or 
recrystallization in ethanol. 
PART III  RESULTS AND DISCUSSION 
121 
 
2-(Quinolin-3-ylmethyl)amino-3-(1-methyl-3-trifluoromethyl-1H-pyrazole-5-yloxy)propan-1-ol 188a 
(11%) 
Viscous dark yellow oil. Rf (SiO2) = 0.12 (EtOAc/Et3N 97/3). 
1H 
NMR (300 MHz, CDCl3): δ 3.14 (1H, quint, J = 5.5 Hz, CHNH); 3.60-
3.83 (2H, m, CH2OH); 3.79 (3H, s, CH3N); 4.10 (2H, d, J = 2.2 Hz, 
NCH2Ar); 4.24 (1H, dd, J = 10.6, 5.5 Hz, (HCH)OCq); 4.31 (1H, dd, J 
= 10.6, 5.2 Hz, (HCH)OCq); 5.99 (1H, s, OCqCHCq); 7.52-7.57 (1H, 
m, CHarom); 7.65-7.72 (1H, m, CHarom); 7.79 (1H, d, J = 8.3 Hz, CHarom); 8.10 (1H, d, J = 8.3 Hz, CHarom); 
8.91 (1H, d, J = 2.2 Hz, CHarom). 
13C NMR (75.6 MHz, ref = CDCl3): δ 37.3 (CH3N); 48.8 (NCH2Ar); 57.8 
(CHNH); 61.0 (CH2OH); 69.1 (CH2OCq); 92.2 (OCqCHCq); 119.4 (q, J = 268.8 Hz, CF3), 126.5 (HCarom); 
127.5 (HCarom); 127.8 (Carom,quat); 128.7 (HCarom); 128.9 (HCarom); 132.3 (q, J = 39.2 Hz, CqCF3), 133.2 
(Carom,quat); 134.5 (HCarom); 147.0 (Carom,quat); 151.2 (HCarom); 161.0 (Carom,quat). 
19F NMR (282 MHz, CDCl3): 
δ -60.76 (3F, s, CF3). IR (cm
-1): νNH, OH = 3284, νmax = 2932, 2878, 1493, 1459, 1273, 1187, 1122, 1078, 
1038, 751. MS (70 eV): m/z (%): 381 (M++1, 100). HRMS (ESI) calcd for C18H20F3N4O2 381.1533 [M+H]
+, 
found 381.1542.  
 
2-(2-Chloroquinolin-3-ylmethyl)amino-3-(1-methyl-3-trifluoromethyl-1H-pyrazole-5-yloxy)propan-
1-ol 188b (24%) 
White crystals. Mp = 120.1 °C. Recrystallization from ethanol. 1H 
NMR (300 MHz, CDCl3): δ 3.17 (1H, quint, J = 5.5 Hz, CHNH); 3.65 
(1H, dd, J = 11.1, 5.2 Hz, (HCH)OH); 3.81 (1H, dd, J = 11.1, 5.0 Hz, 
(HCH)OH); 3.77 (3H, s, CH3N); 4.13 (2H, s, NCH2Ar); 4.26 (1H, dd, 
J = 10.9, 5.8 Hz, (HCH)OCq); 4.32 (1H, dd, J = 10.9, 5.0 Hz, 
(HCH)OCq); 5.99 (1H, s, OCqCHCq); 7.53-7.59 (1H, m, CHarom); 7.69-7.75 (1H, m, CHarom); 7.81 (1H, d, J = 
7.7 Hz, CHarom); 8.01 (1H, d, J = 8.8 Hz, CHarom); 8.23 (1H, s, CHarom). 
13C NMR (75.6 MHz, ref = CDCl3): δ 
37.7 (CH3N); 48.5 (NCH2Ar); 57.8 (CHNH); 61.1 (CH2OH); 68.9 (CH2OCq); 92.6 (OCqCHCq); 119.5 (q, J = 
268.8 Hz, CF3), 127.3 (HCarom); 127.41 (Carom,quat); 127.44 (HCarom); 128.3 (HCarom); 130.3 (HCarom); 131.7 
(Carom,quat); 133.1 (q, J = 78.5 Hz, CqCF3), 137.5 (HCarom); 146.9 (Carom,quat); 150.6 (Carom,quat); 161.1 
(Carom,quat). 
19F NMR (282 MHz, CDCl3): δ -60.75 (3F, s, CF3). IR (cm
-1): νNH, OH = 3270, νmax = 2954, 2830, 
1482, 1270, 1163, 1154, 1114, 1033. MS (70 eV): m/z (%): 415/417 (M++1, 100). HRMS (ESI) calcd for 
C18H19ClF3N4O2 415.1143 [M+H]
+, found 415.1152.  
 
3.2.7.5. Synthesis of N-[(2-chloroquinolin-3-yl)methyl]-1-methoxy-3-(1-methyl-3-trifluoromethyl-1H-
pyrazole-5-yloxy)propane-2-amine 
General procedure: To a solution of 2-chloro-3-{[2-(1-methyl-3-trifluoromethyl-1H-pyrazole-5-
yloxymethyl)aziridin-1-yl]methyl}quinoline 185b (1 mmol) in methanol (20 mL) was added boron 
trifluoride etherate (0.5 mmol, 0.5 equiv). After stirring for 20 h at reflux temperature, the reaction 
mixture was poured into water (30 mL) and extracted with dichloromethane (3 × 15 mL). The 
combined organic layers were subsequently dried over anhydrous magnesium sulfate. Filtration of 
the drying agent and removal of the solvent in vacuo afforded the crude product 188c, which was 
purified by means of column chromatography on silica gel. 
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N-[(2-chloroquinolin-3-yl)methyl]-1-methoxy-3-(1-methyl-3-trifluoromethyl-1H-pyrazole-5-
yloxy)propane-2-amine 188c (12%) 
Yellow oil. Rf (SiO2) = 0.23 (hexane/EtOAc 1/1). 
1H NMR (300 
MHz, CDCl3): δ 3.24 (1H, quint, J = 5.5 Hz,CHNH); 3.38 (3H, s, 
CH3OCH2); 3.51-3.61 (2H, m, CH3OCH2); 3.77 (3H, s, CH3N); 4.15 
(2H, s, NCH2Ar); 4.23 (2H, d, J = 5.5 Hz, CH2OCq); 6.01 (1H, s, 
OCqCHCq); 7.52-7.57 (1H, m, CHarom); 7.67-7.73 (1H, m, CHarom); 
7.80 (1H, d, J = 8.3 Hz, CHarom); 8.00 (1H, d, J = 8.3 Hz, CHarom); 8.30 (1H, s, CHarom). 
13C NMR (75.6 MHz, 
ref = CDCl3): δ 37.6 (CH3N); 48.6 (NCH2Ar); 56.2 (CHNH); 59.2 (CH2OCH3); 69.2 (CH2OCq); 72.5 
(CH2OCH3); 92.4 (OCqCHCq); 119.5 (q, J = 268.8 Hz, CF3); 127.0 (HCarom); 127.4 (HCarom); 127.6 
(Carom,quat); 128.2 (HCarom); 130.0 (HCarom); 131.2 (Carom,quat); 132.6 (q, J = 39.2 Hz, CqCF3), 137.3 (HCarom); 
146.7 (Carom,quat); 150.6 (Carom,quat); 161.1 (Carom,quat). 
19F NMR (282 MHz, CDCl3): δ -60.70 (3F, s, CF3). IR 
(cm-1): νNH = 3330, νmax = 2929, 2896, 1493, 1458, 1274, 1188, 1129, 1038, 1029. MS (70 eV): m/z (%): 
429/431 (M++1, 100). HRMS (ESI) calcd for C19H21ClF3N4O2 429.1300 [M+H]
+, found 429.1300.  
 
3.2.7.6. Synthesis of N-[(2-chloroquinolin-3-yl)methyl]-1-methoxy-3-(1-methyl-3-trifluoromethyl-1H-
pyrazole-5-yloxy)propane-2-amine 
General procedure: To a solution of 2-chloro-3-{[2-(1-methyl-3-trifluoromethyl-1H-pyrazole-5-
yloxymethyl)aziridin-1-yl]methyl}quinoline 185b (1 mmol) in methanol (20 mL) was added boron 
trifluoride etherate (0.5 mmol, 0.5 equiv). After stirring for 1 h at 90 °C under microwave irradiation, 
the reaction mixture was poured into water (30 mL) and extracted with dichloromethane (3 × 15 mL). 
The combined organic layers were subsequently dried over anhydrous magnesium sulfate. Filtration 
of the drying agent and removal of the solvent in vacuo afforded products 188c and 188d, which 
were separated by means of column chromatography on silica gel. 
 
N-[(2-methoxyquinolin-3-yl)methyl]-1-methoxy-3-(1-methyl-3-trifluoromethyl-1H-pyrazole-5-
yloxy)propane-2-amine 188d (38%) 
Yellow oil. Rf (SiO2) = 0.14 (hexane/EtOAc 1/1). 
1H NMR (300 
MHz, CDCl3): δ 3.19 (1H, quint, J = 5.5 Hz, CHNH); 3.35 (3H, s, 
CH3OCH2); 3.52 (2H, d, J = 5.5Hz, CH3OCH2); 3.76 (3H, s, CH3N); 
3.99 (2H, s, NCH2Ar); 4.09 (3H, s, CH3OCq); 4.19 (2H, d, J = 5.5 Hz, 
CH2OCq); 5.99 (1H, s, OCqCHCq); 7.33-7.38 (1H, m, CHarom); 7.52-
7.61 (1H, m, CHarom); 7.67-7.70 (1H, m, CHarom); 7.82 (1H, d, J = 8.3 Hz, CHarom); 7.98 (1H, s, CHarom). 
13C 
NMR (75.6 MHz, ref = CDCl3): δ 37.6 (CH3N); 46.7 (NCH2Ar); 53.5 (CHNH); 55.7 (CH3OCq); 59.1 
(CH2OCH3); 69.3 (CH2OCq); 72.5 (CH2OCH3); 92.4 (HCarom); 119.6 (q, J = 268.8 Hz, CF3); 124.1 (HCarom); 
124.4 (Carom,quat); 125.4 (Carom,quat); 126.9 (HCarom); 127.3 (HCarom); 129.0 (HCarom); 132.6 (q, J = 39.2 Hz, 
CqCF3), 136.5 (HCarom); 145.8 (Carom,quat); 160.8 (Carom,quat); 161.2 (Carom,quat). 
19F NMR (282 MHz, CDCl3): δ 
-60.68 (3F, s, CF3). IR (cm
-1): νNH = 3333, νmax = 2952, 2897, 1494, 1274, 1188, 1147, 1126. MS (70 eV): 
m/z (%): 425 (M++1, 100). HRMS (ESI) calcd for C20H24F3N4O3 425.1795 [M+H]
+, found 425.1795.  
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3.2.7.7. Synthesis of 1-[1-(quinolinylmethyl)aziridin-2-ylmethyl]-4-trifluoromethyl-1H-pyrimidin-3-ones 
The procedure for the synthesis of compounds 185a-c was applied for the preparation of 1-[1-
(quinolinylmethyl)aziridin-2-ylmethyl]-4-trifluoromethyl-1H-pyrimidin-3-ones 186a-b. The crude 
products 186a-b were purified by column chromatography on silica gel. 
 
1-(1-Quinolin-3-ylmethylaziridin-2-ylmethyl)-4-trifluoromethyl-1H-pyrimidin-2-one 186a (45%)  
Dark yellow oil. Rf (SiO2) = 0.08 (CH2Cl2/MeOH 9/1). 
1H NMR (300 
MHz, CDCl3): δ 1.82 (1H, d, J = 6.6 Hz, (HCH)CHN); 1.98 (1H, d, J = 
3.3 Hz, (HCH)CHN); 2.33-2.56 (1H, m, CH2CHN); 2.90 (1H, d, J = 12.7 
Hz, N(HCH)Cq); 2.90 (1H, dd, J = 13.2, 8.8 Hz, CH(HCH)N); 4.08 (1H, d, J = 12.7 Hz, N(HCH)Cq); 4.70 (1H, 
dd, J = 13.2, 2.8 Hz, CH(HCH)N); 5.84 (1H, d, J = 6.6 Hz, CHarom); 7.52-7.58 (2H, m, 2 × CHarom); 7.70-
7.81 (3H, m, 3 × CHarom); 8.06 (1H, d, J = 8.3 Hz, CHarom); 8.87 (1H, d, J = 2.2 Hz, CHarom). 
13C NMR (100.6 
MHz, ref = CDCl3): δ 33.2 (NCH2CH); 37.1 (NCH2CH); 52.6 (NCH2CHN); 61.6 (CqCH2N); 98.5 (q, J = 2.0 
Hz, CHCqCF3); 118.7 (q, J = 277.9 Hz, CF3); 127.3 (HCarom); 127.4 (Carom,quat); 127.5 (HCarom); 129.0 
(HCarom); 129.7 (HCarom); 131.2 (Carom,quat); 134.8 (HCarom); 147.3 (Carom,quat); 151.0 (HCarom); 151.4 
(HCarom); 154.7 (Carom,quat); 162.8 (q, J = 36.7 Hz, CqCF3). 
19F NMR (282 MHz, CDCl3): δ -71.41 (3F, s, CF3). 
IR (cm-1): νmax =3062, 2993, 1662, 1312, 1192, 1153. MS (70 eV): m/z (%): 361 (M
++1, 100). HRMS (ESI) 
calcd for C18H16F3N4O 361.1271 [M+H]
+, found 361.1276.  
 
1-[1-(2-Chloroquinolin-3-ylmethyl)aziridin-2-ylmethyl]-4-trifluoromethyl-1H-pyrimidin-2-one 186b 
(12%) 
Orange-brown oil. Rf (SiO2) = 0.02 (CHCl3/MeOH 9/1). 
1H NMR (300 
MHz, CDCl3): δ 1.78 (1H, d, J = 6.6 Hz, (HCH)CHN); 2.03 (1H, d, J = 
3.3 Hz, (HCH)CHN); 2.31-2.37 (1H, m, CH2CHN); 3.17 (1H, dd, J = 
13.2, 7.7 Hz, CH(HCH)N); 3.22 (1H, d, J = 13.8 Hz, N(HCH)Cq); 3.89 (1H, d, J = 13.8 Hz, N(HCH)Cq); 4.64 
(1H, dd, J = 13.2, 3.3 Hz, CH(HCH)N); 6.14 (1H, d, J = 6.6 Hz, CHarom); 7.54 (1H, t, J = 7.7 Hz, CHarom); 
7.69-7.75 (2H, m, 2 × CHarom); 7.88-8.02 (3H, m, 3 × CHarom). 
13C NMR (75.6 MHz, ref = acetone-d6): δ 
32.8 (NCH2CH); 36.9 (NCH2CH); 53.9 (NCH2CHN); 60.3 (CqCH2N); 98.7 (HCarom); 119.6 (q, J = 276.9 Hz, 
CF3), 127.3 (HCarom); 127.4 (Carom,quat); 127.8 (HCarom); 127.9 (HCarom); 130.3 (HCarom); 131.5 (Carom,quat); 
137.9 (HCarom); 146.8 (Carom,quat); 150.1 (Carom,quat); 153.6 (HCarom); 154.6 (Carom,quat); 161.9 (q, J = 35.8 Hz, 
CqCF3). 
19F NMR (282 MHz, CDCl3): δ -71.35 (3F, s, CF3). IR (cm
-1): νmax = 2923, 2854, 1671, 1320, 1902, 
1154, 1140, 755, 733. MS (70 eV): m/z (%): 395/7 (M++1, 100). HRMS (ESI) calcd for 
C19H21ClF3N4O2 395.0881 [M+H]
+, found 395.0876.  
 
3.2.7.8. Synthesis of 4,5-dichloro-2-[1-(quinolinylmethyl)aziridin-2-ylmethyl]-2H-pyridazin-3-ones 
The procedure for the synthesis of compounds 185a-c was applied for the preparation of 4,5-
dichloro-2-[1-(quinolinylmethyl)aziridin-2-ylmethyl]-2H-pyridazin-3-ones 187a-c. The crude products 
187a-c were purified by column chromatography on silica gel or recrystallization from ethanol. 
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4,5-Dichloro-2-[1-(quinolin-3-ylmethyl)aziridin-2-ylmethyl]-2H-pyridazin-3-one 187a (32%) 
White crystals. Mp = 106 °C. Recrystallization from ethanol. 1H NMR 
(300 MHz, CDCl3): δ 1.76 (1H, d, J = 6.1 Hz, (HCH)CHN); 2.06 (1H, d, J 
= 3.3 Hz, (HCH)CHN); 2.21-2.28 (1H, m, CH2CHN); 2.87 (1H, d, J = 12.7 
Hz, N(HCH)Cq); 4.17 (1H, d, J = 12.7 Hz, N(HCH)Cq); 3.61 (1H, dd, J = 
13.2, 8.8 Hz, (HCH)NCO); 4.52 (1H, dd, J = 13.2, 3.9 Hz, (HCH)NCO); 7.34 (1H, s, CHarom); 7.52-7.58 (1H, 
m, CHarom); 7.68-7.77 (2H, m, 2 × CHarom); 7.90 (1H, d, J = 2.2 Hz, CHarom); 8.09 (1H, d, J = 8.3 Hz, 
CHarom); 8.78 (1H, d, J = 2.2 Hz, CHarom). 
13C NMR (75.6 MHz, ref = CDCl3): δ 33.9 (NCH2CH); 36.1 
(NCH2CH); 56.4 (CH2NCO); 61.9 (NCH2Cq); 127.1 (HCarom); 127.7 (HCarom + Carom,quat); 129,3 (HCarom); 
129,5 (HCarom); 131,5 (Carom,quat); 133,4 (Carom,quat); 134,9 (HCarom); 135.3 (HCarom); 136.4 (Carom,quat); 147.2 
(Carom,quat); 151.5 (HCarom); 156.2 (Carom,quat). IR (cm
-1): νmax = 3034, 2986, 1646, 748, 721. MS (70 eV): 
m/z (%): 361/363/365 (M++1, 100). HRMS (ESI) calcd for C17H15Cl2N4O 361.0617 [M+H]
+, found 
361.0615.  
 
4,5-Dichloro-2-[1-(2-chloroquinolin-3-ylmethyl)aziridin-2-ylmethyl]-2H-pyridazin-3-one 187b (21%) 
White crystals. Mp = 129,9 °C. Recrystallization from ethanol. 1H 
NMR (300 MHz, CDCl3): δ 1.71 (1H, d, J = 6.6 Hz, (HCH)CHN); 2.11 
(1H, d, J = 3.3 Hz, (HCH)CHN); 2.24-2.32 (1H, m, CH2CHN); 3.33 (1H, 
d, J = 14.1 Hz, N(HCH)Cq); 3.93 (1H, d, J = 14.1 Hz, N(HCH)Cq); 3.95 
(1H, dd, J = 13.2, 7.7 Hz, (HCH)NCO); 4.50 (1H, dd, J = 13.2, 4.4 Hz, (HCH)NCO); 7.54 (1H, s, CHarom); 
7.54-7.60 (1H, m, CHarom); 7.70-7.75 (1H, m, CHarom); 7.79-7.82 (1H, m, CHarom); 8.01 (1H, d, J = 9.4 Hz, 
CHarom); 8.22 (1H, s, CHarom). 
13C NMR (75.6 MHz, ref = CDCl3): δ 33.4 (NCH2CH); 36.8 (NCH2CH); 55.9 
(CH2NCO); 61.0 (NCH2Cq); 127.3 (Carom,quat); 127.4 (HCarom); 127.5 (HCarom); 128.3 (HCarom); 130.4 
(HCarom); 130.9 (Carom,quat); 133.9 (Carom,quat); 135.5 (HCarom); 136.6 (Carom,quat); 137.7 (HCarom); 146.8 
(Carom,quat); 150.2 (Carom,quat); 156.5 (Carom,quat). IR (cm
-1): νmax = 3044, 2923, 1646, 1047, 963, 753. MS 
(70 eV): m/z (%): 395/397/399/401 (M++1, 100). HRMS (ESI) calcd for C17H14Cl3N4O 395.0228 [M+H]
+, 
found 395.0222.  
 
4,5-Dichloro-2-[1-(quinolin-4-ylmethyl)aziridin-2-ylmethyl]-2H-pyridazin-3-one 187c (34%) 
Yellow oil. Rf (SiO2) = 0.06 (hexane/EtOAc 1/3). 
1H NMR (300 MHz, CDCl3): 
δ 1.78 (1H, d, J = 6.6 Hz, (HCH)CHN); 2.11 (1H, d, J = 3.3 Hz, (HCH)CHN); 
2.21-2.27 (1H, m, CH2CHN); 3.05 (1H, d, J = 12.9 Hz, N(HCH)Cq); 4.51 (1H, 
d, J = 12.9 Hz, N(HCH)Cq); 3.62 (1H, dd, J = 13.2, 8.8 Hz, (HCH)NCO); 4.47 
(1H, dd, J = 13.2, 5.0 Hz, (HCH)NCO); 6.93 (1H, s, CHarom); 7.20 (1H, d, J = 
4.4 Hz, CHarom); 7.56-7.61 (1H, m, CHarom); 7.69-7.74 (1H, m, CHarom); 8.10 
(1H, d, J = 8.3 Hz, CHarom); 8.18 (1H, d, J = 8.3 Hz, CHarom); 8.79 (1H, d, J = 4.4 Hz, CHarom). 
13C NMR (75.6 
MHz, ref = CDCl3): δ 34.4 (NCH2CH); 35.8 (NCH2CH); 55.9 (CH2NCO); 61.1 (NCH2Cq); 120.9 (HCarom); 
124.3 (HCarom); 126.4 (HCarom); 126.5 (Carom,quat); 129.0 (HCarom); 129.8 (HCarom); 133.1 (Carom,quat); 134.5 
(HCarom); 136.0 (Carom,quat); 143.8 (Carom,quat); 147.6 (Carom,quat); 150.0 (HCarom); 155.7 (Carom,quat). IR (cm
-1): 
νmax = 3062, 2984, 2950, 1650, 760, 750, 722. MS (70 eV): m/z (%): 361/363/365 (M
++1, 100). HRMS 
(ESI) calcd for C17H15Cl2N4O 361.0617 [M+H]
+, found 361.0624.  
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3.2.7.9. Synthesis of 4,5-dichloro-2-{3-hydroxy-2-[(quinolinylmethyl)amino]propyl}-2H-pyridazin-3-
ones 
The procedure for the synthesis of compounds 188a-b was also applied for the preparation of 4,5-
dichloro-2-{3-hydroxy-2-[(quinolinylmethyl)amino]propyl}-2H-pyridazin-3-ones 189a-c. The crude 
products 189a-c were purified by means of column chromatography on silica gel and preparative thin 
layer chromatography. 
 
4,5-Dichloro-2-{3-hydroxy-2-[(quinolin-3-ylmethyl)amino]propyl}-2H-pyridazin-3-one 189a (8%) 
Yellow oil. Rf (SiO2) = 0.10 (EtOAc 100%). 
1H NMR (300 MHz, CDCl3): δ 
3.14-3.20 (1H, m, CHNH); 3.51 (1H, dd, J = 11.8, 4.7 Hz, (HCH)OH); 
3.69 (1H, dd, J = 11.8, 4.1 Hz, (HCH)OH); 4.02 (1H, d, J = 13.8 Hz, 
N(HCH)Cq); 4.09 (1H, d, J = 13.8 Hz, N(HCH)Cq); 4.31 (1H, dd, J = 13.2, 
6.1 Hz, HC(HCH)N); 4.39 (1H, dd, J = 13.2, 6.1 Hz, HC(HCH)N); 7.52-
7.57 (1H, m, CHarom); 7.67-7.80 (3H, m, 3 × CHarom); 8.05 (1H, d, J = 1.7 Hz, CHarom); 8.09 (1H, d, J = 8.8 
Hz, CHarom); 8.85 (1H, d, J = 2.2 Hz, CHarom). 
13C NMR (75.6 MHz, ref = CDCl3): δ 48.8 (NCH2Cq); 53.3 
(CHCH2N); 57.7 (CHNH); 61.3 (CH2OH); 126.9 (HCarom); 127.7 (HCarom); 127.9 (Carom,quat); 129.1 (HCarom); 
129.3 (HCarom); 132.8 (Carom,quat); 134.3 (Carom,quat); 134.8 (HCarom); 136.2 (HCarom); 136.9 (Carom,quat); 
147.3 (Carom,quat); 151.4 (HCarom); 157.5 (Carom,quat). IR (cm
-1): νNH, OH = 3306, νmax = 3059, 3008, 2937, 
2856, 1654, 1579, 959, 748. MS (70 eV): m/z (%): 379/381/383 (M++1, 100). HRMS (ESI) calcd for 
C17H17Cl2N4O2 379.0723 [M+H]
+, found 379.0725.  
 
4,5-Dichloro-2-{3-hydroxy-2-[(2-chloroquinolin-3-ylmethyl)amino]propyl}-2H-pyridazin-3-one 189b 
(9%) 
Viscous yellow oil. Rf (SiO2) = 0.11 (hexane/EtOAc 2/3). 
1H NMR (300 
MHz, CDCl3): δ 3.16-3.22 (1H, m, CHNH); 3.58 (1H, dd, J = 11.6, 4.4 
Hz, (HCH)OH); 3.75 (1H, dd, J = 11.6, 3.9 Hz, (HCH)OH); 3.97 (1H, d, J 
= 15.1 Hz, N(HCH)Cq); 4.09 (1H, d, J = 15.1 Hz N(HCH)Cq); 4.27 (1H, 
dd, J = 13.2, 6.6 Hz, CH(HCH)N); 4.40 (1H, dd, J = 13.2, 6.1 Hz, 
CH(HCH)N); 7.51-7.56 (1H, m, CHarom); 7.66-7.72 (2H, m, 2 × CHarom); 7.76 (1H, d, J = 7.7 Hz, CHarom); 
7.96 (1H, d, J = 8.3 Hz, CHarom); 8.11 (1H, s, CHarom). 
13C NMR (75.6 MHz, ref = CDCl3): δ 48.5 (NCH2Cq); 
53.5 (CHCH2N); 57.7 (CHNH); 61.5 (CH2OH); 127.3 (HCarom + Carom,quat); 127.5 (HCarom); 128.2 (HCarom); 
130.3 (HCarom); 131.5 (Carom,quat); 134.3 (Carom,quat); 136.1 (HCarom); 136.8 (Carom,quat); 137.7 (HCarom); 
146.8 (Carom,quat); 150.6 (Carom,quat); 157.4 (Carom,quat). IR (cm
-1): νNH, OH = 3329, νmax = 3062, 2932, 2890, 
2872, 1654, 1030, 959, 752, 730. MS (70 eV): m/z (%): 413/415/417/419 (M++1, 100). HRMS (ESI) 
calcd for C17H16Cl3N4O2 413.0333 [M+H]
+, found 413.0339.  
 
4,5-Dichloro-2-{3-hydroxy-2-[(quinolin-4-ylmethyl)amino]propyl}-2H-pyridazin-3-one 189c (11%) 
Colorless oil. Rf (SiO2) = 0.11 (EtOAc 100%). 
1H NMR (300 MHz, CDCl3): δ 3.20-3.23 (1H, m, CHNH); 
3.57 (1H, dd, J = 11.4, 4.1 Hz, (HCH)OH); 3.78 (1H, dd, J = 11.4, 3.3 Hz, (HCH)OH); 4.15-4.43 (4H, m, 
NCH2Cq + CHCH2N); 7.33 (1H, d, J = 3.9 Hz, CHarom); 7.50-7.55 (2H, m, 2 × CHarom); 7.67-7.72 (1H, m, 
CHarom); 8.00 (1H, d, J = 8.3 Hz, CHarom); 8.09 (1H, d, J = 8.8 Hz, CHarom); 8.79 (1H, d, J = 4.4 Hz, CHarom). 
13C NMR (75.6 MHz, ref = CDCl3): δ 47.8 (NCH2Cq); 53.4 (CHCH2N); 57.8 (CHNH); 61.2 (CH2OH); 120.5 
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(HCarom); 123.4 (HCarom); 126.7 (HCarom); 126.8 (Carom,quat); 129.4 (HCarom); 
130.2 (HCarom); 134.2 (Carom,quat); 135.9 (HCarom); 136.6 (Carom,quat); 145.2 
(Carom,quat); 148.2 (Carom,quat); 150.2 (HCarom); 157.4 (Carom,quat). IR (cm
-1): νNH, OH 
= 3313, νmax = 3088, 3060, 2916, 2862, 1651, 1579, 958, 751, 729. MS (70 
eV): m/z (%): 379/381/383 (M++1, 100). HRMS (ESI) calcd for C17H17Cl2N4O2 
379.0723 [M+H]+, found 379.0726.  
 
3.2.7.10. Synthesis of 4,5-dichloro-2-{3-methoxy-2-[(quinolin-4-ylmethyl)amino]propyl}-2H- 
        pyridazin-3-one 
The procedure for the synthesis of compound 188c was also applied for the preparation of 4,5-
dichloro-2-{3-methoxy-2-[(quinoline-4-ylmethyl)amino]propyl}-2H-pyridazin-3-one 189d. The crude 
product was purified by means of preparative thin layer chromatography on silica gel. 
 
4,5-Dichloro-2-{3-methoxy-2-[(quinolin-4-ylmethyl)amino]propyl}-2H-pyridazin-3-one 189d (10%) 
Colorless oil. Rf (SiO2) = 0.50 (EtOAc 100%). 
1H NMR (300 MHz, CDCl3): δ 
3.24-3.33 (1H, m, CHNH); 3.39 (3H, s, CH3O); 3.46 (1H, dd, J = 9.9, 5.0 Hz, 
(HCH)OMe); 3.61 (1H, dd, J = 9.9, 5.0 Hz, (HCH)OMe); 4.04 (1H, dd, J = 13.2, 
7.7 Hz, CH(HCH)N); 4.39 (1H, dd, J = 13.2, 5.0 Hz, CH(HCH)N); 4.14 (1H, d, J = 
14.3 Hz, N(HCH)Cq); 4.40 (1H, d, J = 14.3 Hz, N(HCH)Cq); 7.31 (1H, d, J = 4.4 
Hz, CHarom); 7.40 (1H, s, CHarom); 7.47-7.53 (1H, m, CHarom); 7.66-7.72 (1H, m, 
CHarom); 8.01 (1H, dd, J = 8.3, 1.1 Hz, CHarom); 8.09 (1H, d, J = 8.3 Hz, CHarom); 8.81 (1H, d, J = 4.4 Hz, 
CHarom). 
13C NMR (75.6 MHz, ref = CDCl3): δ 48.2 (NCH2Cq); 54.1 (CHCH2N); 55.9 (CHNH); 59.3 (CH3O); 
72.5 (CH2OMe); 120.8 (HCarom); 123.7 (HCarom); 126.5 (HCarom); 126.9 (Carom,quat); 129.2 (HCarom); 130.2 
(HCarom); 134.0 (Carom,quat); 135.2 (HCarom); 136.2 (Carom,quat); 145.4 (Carom,quat); 148.2 (Carom,quat); 150.2 
(HCarom); 157.0 (Carom,quat). IR (cm
-1): νNH = 3327, νmax = 1658, 1581, 1136, 1113, 960, 751. MS (70 eV): 
m/z (%): 393/395/397 (M++1, 100). HRMS (ESI) calcd for C18H21Cl2N4O2 393.0880 [M+H]
+, found 
393.0872. 
 
3.2.7.11. Synthesis of 5-{[1-(arylmethyl)aziridin-2-yl]methoxy}isoquinolines 
General procedure: To a solution of 5-hydroxyisoquinoline 194 (1 mmol) in dimethylformamide (20 
mL) was added sodium hydroxide (1.5 mmol, 1.5 equiv). After stirring for 1 h at room temperature, 1-
aryl-2-(bromomethyl)aziridine (1 mmol) was added and the mixture was stirred again for 2-4 h at 100 
°C. Subsequently, the reaction mixture was poured into brine (30 mL) and extracted with diethyl 
ether (3 × 20 mL). The combined organic layers were washed with brine (3 × 20 mL) and 
subsequently dried over anhydrous magnesium sulfate. Filtration of the drying agent and removal of 
the solvent in vacuo afforded the crude products 195a-h, which were purified by means of column 
chromatography on silica gel or recrystallization. 
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5-[(1-Benzylaziridin-2-yl)methoxy]isoquinoline 195a (90%) 
Dark brown viscous oil. Rf (SiO2) = 0.22 (hexane/EtOAc 1/3). 
1H NMR (300 MHz, 
CDCl3): δ 1.66 (1H, d, J = 6.6 Hz, (HCH)CHN); 1.93 (1H, d, J = 3.9 Hz, (HCH)CHN); 
2.07-2.14 (1H, m, CHN); 3.30 (1H, d, J = 13.2 Hz, N(HCH)Cq); 3.75 (1H, d, J = 13.2 
Hz, N(HCH)Cq); 3.91 (1H, dd, J = 10.5, 7.7 Hz, (HCH)O); 4.24 (1H, dd, J = 10.5, 4.4 Hz, 
(HCH)O); 6.91 (1H, d, J = 7.2 Hz, CHarom); 7.26-7.49 (6H, m, 6 × CHarom); 7.45 (1H, d, J 
= 7.7 Hz, CHarom); 7.75 (1H, d, J = 6.1 Hz, CHarom); 8.46 (1H, d, J = 6.1 Hz, CHarom); 
9.16 (1H, s, CHarom). 
13C NMR (75.6 MHz, Ref = CDCl3): δ 31.8 (NCH2CH); 37.8 (CHN); 64.5 (NCH2Cq); 
70.8 (CH2O); 108.5 (HCarom); 115.4 (HCarom); 119.4 (HCarom); 127.3 (HCarom); 127.4 (HCarom); 128.3 (2 × 
HCarom); 128.5 (Carom,quat); 128.6 (2 × HCarom); 129.5 (Carom,quat); 138.9 (Carom,quat); 142.6 (HCarom); 151.8 
(HCarom); 153.5 (Carom,quat). IR (cm
-1): νmax = 3027, 2985, 2924, 2833, 1583, 1277, 1249, 1109, 830, 735, 
697. MS m/z (%): 291 (M++1, 100). HRMS (ESI) calcd for C19H19N2O: 291.1497 [M+H]
+, found: 
291.1491.  
 
5-{[1-(4-Chlorobenzyl)aziridin-2-yl]methoxy}isoquinoline 195b (80%) 
Orange crystals. Mp = 80.4 °C. Recrystallization from ethanol. 1H NMR (300 
MHz, CDCl3): δ 1.67 (1H, d, J = 6.6 Hz, (HCH)CHN); 1.95 (1H, d, J = 3.3 Hz, 
(HCH)CHN); 2.07-2.14 (1H, m, CHN); 3.24 (1H, d, J = 13.2 Hz, N(HCH)Cq); 3.76 
(1H, d, J = 13.2 Hz, N(HCH)Cq); 3.89 (1H, dd, J = 10.5, 7.7 Hz, (HCH)O); 4.27 (1H, 
dd, J = 10.5, 3.9 Hz, (HCH)O); 6.92 (1H, d, J = 6.6 Hz, CHarom); 7.28-7.52 (6H, m, 
6 × CHarom); 7.70 (1H, d, J = 6.6 Hz, CHarom); 8.52 (1H, d, J = 6.6 Hz, CHarom); 9.18 
(1H, s, CHarom). 
13C NMR (75.6 MHz, Ref = CDCl3): δ 31.8 (NCH2CH); 37.8 (NCH); 63.8 (NCH2Cq); 70.7 
(CH2O); 108.5 (HCarom); 115.2 (HCarom); 119.5 (HCarom); 127.3 (HCarom); 128.4 (Carom,quat); 128.7 (2 × 
HCarom); 129.5 (Carom,quat); 129.7 (2 × HCarom); 133.1 (Carom,quat); 137.4 (Carom,quat); 142.7 (HCarom); 151.9 
(HCarom); 153.5 (Carom,quat). IR (cm
-1): νmax = 3062, 2986, 2904, 2836, 1587, 1493, 1282, 1171, 1087, 818, 
802, 756, 750. MS m/z (%): 325/7 (M++1, 100). HRMS (ESI) calcd for C19H18ClN2O: 325.1108 [M+H]
+, 
found: 325.1100.  
 
5-{[1-(4-Fluorobenzyl)aziridin-2-yl]methoxy}isoquinoline 195c (75%) 
Yellow viscous oil. Rf (SiO2) = 0.20 (hexane/EtOAc 1/3). 
1H NMR (300 MHz, 
CDCl3): δ 1.66 (1H, d, J = 6.6 Hz, (HCH)CHN); 1.93 (1H, d, J = 3.3 Hz, (HCH)CHN); 
2.07-2.15 (1H, m, CHN); 3.28 (1H, d, J = 13.2 Hz, N(HCH)Cq); 3.71 (1H, d, J = 13.2 
Hz, N(HCH)Cq); 3.90 (1H, dd, J = 10.2, 7.7 Hz, (HCH)O); 4.26 (1H, dd, J = 10.2, 3.9 
Hz, (HCH)O); 6.93 (1H, d, J = 7.7 Hz, CHarom); 6.99-7.05 (2H, m, 2 × CHarom); 7.35-
7.52 (4H, m, 4 × CHarom); 7.74 (1H, d, J = 6.1 Hz, CHarom); 8.50 (1H, d, J = 6.1 Hz, 
CHarom); 9.18 (1H, s, CHarom). 
13C NMR (75.6 MHz, Ref = CDCl3): δ 31.8 (NCH2CH); 
37.8 (CHN); 63.8 (NCH2Cq); 70.7 (CH2O); 108.5 (HCarom); 115.2 (HCarom); 115.4 (d, J = 20.8 Hz, 2 × 
HCarom); 119.5 (HCarom); 127.4 (HCarom); 128.4 (Carom,quat); 129.5 (Carom,quat); 129.9 (d, J = 8.1 Hz, 2 × 
HCarom); 134.7 (Carom,quat); 142.7 (HCarom); 151.9 (HCarom); 153.5 (Carom,quat); 162.2 (d, J = 244.6 Hz, CqF). 
19F NMR (282 MHz, Ref = CDCl3): -115.34 (1F, s, CqF). IR (cm
-1): νmax = 3044, 2985, 2928, 2842, 1583, 
1502, 1493, 1282, 1254, 1215, 1116, 1004, 867, 827, 816, 798, 780, 747. MS m/z (%): 309 (M++1, 
100). HRMS (ESI) calcd for C19H18FN2O: 309.1398 [M+H]
+, found: 309.1398.  
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5-{[1-(2-Chlorobenzyl)aziridin-2-yl]methoxy}isoquinoline 195d (74%) 
Brown viscous oil. Rf (SiO2) = 0.19 (hexane/EtOAc 1/3). 
1H NMR (300 MHz, CDCl3): 
δ 1.72 (1H, d, J = 6.6 Hz, (HCH)CHN); 1.99 (1H, d, J = 3.3 Hz, (HCH)CHN); 2.16-2.23 
(1H, m, CHN); 3.48 (1H, d, J = 14.9 Hz, N(HCH)Cq); 3.84 (1H, d, J = 14.9 Hz, 
N(HCH)Cq); 3.98 (1H, dd, J = 10.5, 7.7 Hz, (HCH)O); 4.32 (1H, dd, J = 10.5, 3.9 Hz, 
(HCH)O); 6.98 (1H, dd, J = 7.7, 1.1 Hz, CHarom); 7.21-7.27 (2H, m, 2 × CHarom); 7.34-
7.37 (1H, m, CHarom); 7.43-7.53 (2H, m, 2 × CHarom); 7.73-7.76 (1H, m, CHarom); 7.87 
(1H, d, J = 6.1 Hz, CHarom); 8.49 (1H, d, J = 6.1 Hz, CHarom); 9.19 (1H, s, CHarom). 
13C 
NMR (75.6 MHz, Ref = CDCl3): δ 31.7 (NCH2CH); 38.1 (CHN); 61.2 (NCH2Cq); 70.9 
(CH2O); 108.6 (HCarom); 115.3 (HCarom); 119.5 (HCarom); 127.0 (HCarom); 127.4 (HCarom); 128.3 (HCarom); 
128.5 (Carom,quat); 129.3 (HCarom); 129.5 (Carom,quat); 129.6 (HCarom); 133.1 (Carom,quat); 136.7 (Carom,quat); 
142.7 (HCarom); 151.9 (HCarom); 153.5 (Carom,quat). IR (cm
-1): νmax = 3059, 2984, 2922, 2855, 1583, 1277, 
1248, 1109, 829, 747. MS m/z (%): 325/7 (M++1, 100). HRMS (ESI) calcd for C19H18ClN2O: 325.1108 
[M+H]+, found: 325.1101.  
 
5-{[1-(4-Methoxybenzyl)aziridin-2-yl]methoxy}isoquinoline 195e (77%) 
Orange viscous oil. Rf (SiO2) = 0.21 (hexane/EtOAc 1/3). 
1H NMR (300 MHz, 
CDCl3): δ 1.67 (1H, d, J = 6.6 Hz, (HCH)CHN); 1.92 (1H, d, J = 3.3 Hz, 
(HCH)CHN); 2.08-2.15 (1H, m, CHN); 3.22 (1H, d, J = 13.2 Hz, N(HCH)Cq); 3.74 
(1H, d, J = 13.2 Hz, N(HCH)Cq); 3.81 (3H, s, CH3O); 3.91 (1H, dd, J = 10.5, 7.7 
Hz, (HCH)O); 4.26 (1H, dd, J = 10.5, 4.4 Hz, (HCH)O); 6.85-6.91 (2H, m, 2 × 
CHarom); 6.93 (1H, dd, J = 7.7, 1.1 Hz, CHarom); 7.30-7.35 (2H, m, 2 × CHarom); 
7.41-7.52 (2H, m, 2 × CHarom); 7.73 (1H, d, J = 6.1 Hz, CHarom); 8.47 (1H, d, J = 6.1 Hz, CHarom); 9.18 (1H, 
s, CHarom). 
13C NMR (75.6 MHz, Ref = CDCl3): δ 31.8 (NCH2CH); 37.6 (CHN); 55.3 (CH3O); 64.0 (NCH2Cq); 
70.8 (CH2O); 108.5 (HCarom); 113.9 (2 × HCarom); 115.4 (HCarom); 119.4 (HCarom); 127.4 (HCarom); 128.5 
(Carom,quat); 129.5 (Carom,quat); 129.6 (2 × HCarom); 131.0 (Carom,quat); 142.6 (HCarom); 151.8 (HCarom); 153.6 
(Carom,quat); 159.0 (Carom,quat). IR (cm
-1): νmax = 3048, 3000, 2984, 2934, 2840, 1581, 1509, 1278, 1252, 
1242, 1110, 1030, 989, 825, 818, 802, 756, 745. MS m/z (%): 321 (M++1, 100). HRMS calcd for 
C20H21N2O2: 321.1598 [M+H]
+, found: 321.1598.  
 
5-{[1-(2,4-Dichlorobenzyl)aziridin-2-yl]methoxy}isoquinoline 195f (82%) 
White crystals. Mp = 107.1 °C. Recrystallization from ethanol. 1H NMR (300 
MHz, CDCl3): δ 1.72 (1H, d, J = 6.6 Hz, (HCH)CHN); 2.01 (1H, d, J = 3.3 Hz, 
(HCH)CHN); 2.15-2.20 (1H, m, CHN); 3.42 (1H, d, J = 14.9 Hz, N(HCH)Cq); 3.80 
(1H, d, J = 14.9 Hz, N(HCH)Cq); 3.96 (1H, dd, J = 10.5, 7.7 Hz, (HCH)O); 4.34 (1H, 
dd, J = 10.5, 3.3 Hz, (HCH)O); 6.98 (1H, d, J = 8.3 Hz, CHarom); 7.21 (1H, dd, J = 
8.3, 1.7 Hz, CHarom); 7.38 (1H, d, J = 1.7 Hz, CHarom); 7.44-7.55 (2H, m, 2 × 
CHarom); 7.69 (1H, d, J = 8.3 Hz, CHarom); 7.84 (1H, d, J = 5.5 Hz, CHarom); 8.53 (1H, 
d, J = 5.5 Hz, CHarom); 9.21 (1H, s, CHarom). 
13C NMR (75.6 MHz, Ref = CDCl3): δ 
31.7 (NCH2CH); 38.1 (CHN); 60.6 (NCH2Cq); 70.7 (CH2O); 108.6 (HCarom); 115.1 (HCarom); 119.6 (HCarom); 
127.3 (HCarom); 127.4 (HCarom); 128.4 (Carom,quat); 129.0 (HCarom); 129.5 (Carom,quat); 130.5 (HCarom); 133.5 
(Carom,quat); 133.7 (Carom,quat); 135.4 (Carom,quat); 142.8 (HCarom); 152.0 (HCarom); 153.4 (Carom,quat). IR (cm
-1): 
νmax = 3020, 2982, 2945, 2831, 1586, 1393, 1279, 1252, 1113, 992, 836, 824, 806, 797, 751, 744. MS 
m/z (%): 359/361/363 (M++1, 100). HRMS (ESI) calcd for C19H17Cl2N2O: 359.0718 [M+H]
+, found: 
359.0716.  
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5-{[1-(4-(Trifluoromethyl)benzyl)aziridin-2-yl]methoxy}isoquinoline 195g (84%) 
Orange crystals. Mp = 96.8 °C. Recrystallization from ethanol. 1H NMR (300 
MHz, CDCl3): δ 1.69 (1H, d, J = 6.6 Hz, (HCH)CHN); 1.99 (1H, d, J = 3.3 Hz, 
(HCH)CHN); 2.10-2.18 (1H, m, CHN); 3.40 (1H, d, J = 13.8 Hz, N(HCH)Cq); 3.81 
(1H, d, J = 13.8 Hz, N(HCH)Cq); 3.95 (1H, dd, J = 10.5, 7.7 Hz, (HCH)O); 4.29 
(1H, dd, J = 10.5, 3.9 Hz, (HCH)O); 6.95 (1H, dd, J = 7.7, 1.1 Hz, CHarom); 7.42-
7.61 (6H, m, 6 × CHarom); 7.77 (1H, d, J = 5.5 Hz, CHarom); 8.47 (1H, d, J = 5.5 Hz, 
CHarom); 9.19 (1H, s, CHarom); 
13C NMR (75.6 MHz, Ref = CDCl3): δ 31.8 (NCH2CH); 38.1 (CHN); 63.9 
(NCH2Cq); 70.7 (CH2O); 108.6 (HCarom); 115.1 (HCarom); 119.7 (HCarom); 124.3 (q, J = 272.7 Hz, CF3), 
125.38 (Carom,quat); 125.42 (HCarom); 125.48 (HCarom); 125.53 (Carom,quat); 127.4 (HCarom); 128.4 (2 × 
HCarom); 129.6 (q, J = 32.3 Hz, CqCF3); 142.7 (HCarom); 142.9 (Carom,quat); 151.9 (HCarom); 153.4 (Carom,quat). 
19F NMR (282 MHz, Ref = CDCl3): -62.24 (3F, s, CF3). IR (cm
-1): νmax = 3062, 2906, 1322, 1162, 1121, 
1108, 1064, 828. MS m/z (%): 359 (M++1, 100). HRMS (ESI) calcd for C20H18F3N2O: 359.1371 [M+H]
+, 
found: 359.1369.  
 
5-[1-(2-Methoxybenzyl)aziridin-2-ylmethoxy]isoquinoline 195h (65%) 
Brown oil. Rf (SiO2) = 0.26; CH2Cl2/MeOH (95/5). 
1H NMR (300 MHz, CDCl3): δ 1.70 
(1H, d, J = 6.6 Hz, (HCH)CHN); 1.94 (1H, d, J = 3.3 Hz, (HCH)CHN); 2.12-2.21 (1H, 
m, CHN); 3.37 (1H, d, J = 13.2 Hz, N(HCH)Cq); 3.78 (1H, d, J = 13.2 Hz, N(HCH)Cq); 
3.81 (3H, s, CH3O)); 3.98 (1H, dd, J = 10.5, 7.7 Hz, (HCH)O); 4.28 (1H, dd, J = 10.5, 
4.4 Hz, (HCH)O); 6.86 (1H, d, J = 8.3 Hz, CHarom); 6.93-6.98 (2H, m, 2 × CHarom); 
7.25-7.31 (1H, m, CHarom); 7.41-7.58 (3H, m, 3 × CHarom); 7.84 (1H, d, J = 6.1 Hz, 
CHarom); 8.48 (1H, d, J = 6.1 Hz, CHarom); 9.18 (1H, s, CHarom). 
13C NMR (75.6 MHz, 
ref = CDCl3): δ 31.8 (NCH2CH); 37.8 (CHN); 55.4 (CH3O); 58.6 (NCH2Cq); 70.9 
(CH2O); 108.6 (HCarom); 110.2 (HCarom); 115.4 (Carom,quat); 119.3 (HCarom); 120.7 (HCarom); 127.3 
(Carom,quat); 127.4 (HCarom); 128.3 (HCarom); 129.51 (HCarom); 129.53 (HCarom); 142.6 (HCarom); 151.8 
(HCarom); 153.6 (Carom,quat); 157.1 (Carom,quat); 162.6(Carom,quat). IR (cm
-1): νmax = 2933, 2836, 1672, 1584, 
1492, 1277,1241, 1108, 1028, 752. MS (70 eV): m/z (%): 321 (M++1, 100). HRMS (ESI) calcd for 
C20H21N2O2 321.1598 [M+H]
+, found 321.1601.  
 
3.2.7.12. Synthesis of 2-arylmethylamino-3-(isoquinolin-5-yloxy)propane-1-ols 
General procedure: To a solution of 5-[(1-arylmethylaziridin-2-yl)methoxy]isoquinoline 195 (1 mmol) 
in a THF/water (1/1) solvent mixture (25 mL), para-toluenesulfonic acid (1 mmol, 1 equiv) was added. 
After stirring for 3 h at reflux temperature, the reaction mixture was neutralized with sodium 
bicarbonate, poured into water (30 mL) and extracted with dichloromethane (3 × 20 mL). The 
combined organic layers were washed with distilled water (3 × 20 mL) and subsequently dried over 
anhydrous magnesium sulfate. Filtration of the drying agent and removal of the solvent in vacuo 
afforded the crude products 196a,b,f,g, which were purified by means of column chromatography on 
silica gel. 
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2-Benzylamino-3-(isoquinolin-5-yloxy)propan-1-ol 196a (94%) 
 Yellow viscous oil. Rf (SiO2) = 0.21 (EtOAc/MeOH 95/5). 
1H NMR (300 MHz, 
CDCl3): δ 3.27 (1H, quint, J = 5.5 Hz, CHNH); 3.76 (1H, dd, J = 11.0, 5.0 Hz, 
(HCH)OH); 3.89 (1H, dd, J = 11.0, 4.4 Hz, (HCH)OH); 3.95 (2H, s, CH2NH); 4.18 (2H, 
dd, J = 5.5, 1.7 Hz, CH2O); 6.94 (1H, t, J = 4.4 Hz, CHarom); 7.25-7.44 (7H, m, 7 × 
CHarom); 7.80 (1H, d, J = 6.1 Hz, CHarom); 8.41 (1H, d, J = 6.1 Hz, CHarom); 9.08 (1H, s, 
CHarom). 
13C NMR (75.6 MHz, Ref = CDCl3): δ 51.6 (CH2NH); 57.6 (CHNH); 61.1 
(CH2OH); 68.1 (CH2O); 108.7 (HCarom); 115.0 (HCarom); 119.7 (HCarom); 127.3 
(HCarom); 127.5 (HCarom); 128.2 (2 × HCarom); 128.3 (Carom,quat); 128.7 (2 × HCarom); 129.4 (Carom,quat); 140.1 
(Carom,quat); 142.4 (HCarom); 151.8 (HCarom); 153.3 (Carom,quat). IR (cm
-1): νNH,OH = 3227, νmax = 1584, 1392, 
1276, 1249, 1110, 828, 732, 698. MS m/z (%): 309 (M++1, 100). HRMS (ESI) calcd for C19H21N2O2: 
309.1603 [M+H]+, found: 309.1604.  
 
2-(4-Chlorobenzyl)amino-3-(isoquinolin-5-yloxy)propan-1-ol 196b (85%) 
Yellow viscous oil. Rf (SiO2) = 0.20 (EtOAc/MeOH 95/5). 
1H NMR (300 MHz, 
CDCl3): δ 3.25 (1H, quint, J = 5.5 Hz, CHNH); 3.76 (1H, dd, J = 11.0, 5.5 Hz 
(HCH)OH); 3.89 (1H, dd, J = 11.0, 5.0 Hz, (HCH)OH); 3.92 (2H, s, CH2NH); 4.19 
(2H, dd, J = 5.5, 2.8 Hz, CH2O); 6.99 (1H, dd, J = 5.5, 3.3 Hz, CHarom); 7.25-7.32 
(4H, m, 4 × CHarom); 7.44-7.48 (2H, m, 2 × CHarom); 7.80 (1H, d, J = 6.1 Hz, 
CHarom); 8.44 (1H, d, J = 6.1 Hz, CHarom); 9.10 (1H, s, CHarom). 
13C NMR (75.6 
MHz, Ref = CDCl3): δ 50.8 (CH2NH); 57.5 (CHNH); 61.2 (CH2OH); 68.0 (CH2O); 
108.7 (HCarom); 114.9 (HCarom); 119.8 (HCarom); 127.5 (HCarom); 128.3 (Carom,quat); 128.8 (2 × HCarom); 
129.4 (Carom,quat); 129.5 (2 × HCarom); 133.0 (Carom,quat); 138.6 (Carom,quat); 142.5 (HCarom); 151.9 (HCarom); 
153.3 (Carom,quat). IR (cm
-1): νNH,OH = 3222, νmax = 1492, 1276, 1249, 1110, 1088, 828, 800, 748, 734. MS 
m/z (%): 343/5 (M++1, 100). HRMS (ESI) calcd for C19H19ClN2O2: 343.1213 [M+H]
+, found: 343.1215.  
 
2-(2,4-Dichlorobenzyl)amino-3-(isoquinolin-5-yloxy)propan-1-ol 196f (89%) 
Yellow viscous oil. Rf (SiO2) = 0.19 (EtOAc/MeOH 95/5). 
1H NMR (300 MHz, 
CDCl3): δ 3.28 (1H, quint, J = 5.5 Hz, CHNH); 3.73 (1H, dd, J = 11.0, 4.4 Hz, 
(HCH)OH); 3.92 (1H, dd, J = 11.0, 5.0 Hz, (HCH)OH); 4.01 (2H, s, CH2NH); 4.19 
(1H, dd, J = 9.9, 6.1 Hz, (HCH)O); 4.24 (1H, dd, J = 9.9, 5.0 Hz, (HCH)O); 6.98 
(1H, dd, J = 7.7, 1.1 Hz, CHarom); 7.21 (1H, dd, J = 8.3, 1.7 Hz, CHarom); 7.36-7.38 
(2H, m, 2 × CHarom); 7.45-7.56 (2H, m, 2 × CHarom); 7.88 (1H, d, J = 6.1 Hz, 
CHarom); 8.52 (1H, d, J = 6.1 Hz, CHarom); 9.20 (1H, s, CHarom). 
13C NMR (75.6 
MHz, Ref = CDCl3): δ 48.5 (CH2NH); 57.8 (CHNH); 61.1 (CH2OH); 68.1 (CH2O); 108.7 (HCarom); 115.1 
(HCarom); 119.7 (HCarom); 127.2 (HCarom); 127.5 (HCarom); 128.2 (Carom,quat); 129.3 (Carom,quat); 129.4 
(HCarom); 130.9 (HCarom); 133.5 (Carom,quat); 134.4 (Carom,quat); 136.2 (Carom,quat); 142.1 (HCarom); 151.6 
(HCarom); 153.2 (Carom,quat). IR (cm
-1): νNH,OH = 3215, νmax = 1585, 1391, 1276, 1249, 1110, 1046, 827, 800, 
748. MS m/z (%): 377/379/381 (M++1, 100). HRMS (ESI) calcd for C19H19Cl2N2O2: 377.0824 [M+H]
+, 
found: 377.0826.  
 
3-(Isoquinolin-5-yloxy)-2-{[4-(trifluoromethyl)benzyl]amino}propan-1-ol 196g (93%)  
Yellow viscous oil. Rf (SiO2) = 0.20 (EtOAc/MeOH 95/5). 
1H NMR (300 MHz, CDCl3): δ 3.28 (1H, quint, J 
= 5.5 Hz, CHNH); 3.77 (1H, dd, J = 11.0, 5.5 Hz, (HCH)OH); 3.91 (1H, dd, J = 11.0, 5.0 Hz, (HCH)OH); 
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4.03 (2H, s, CH2NH); 4.17-4.27 (2H, m, CH2O); 6.99 (1H, dd, J = 7.2, 1.1 Hz, 
CHarom); 7.44-7.59 (6H, m, 6 × CHarom); 7.84 (1H, d, J = 6.1 Hz, CHarom); 8.48 
(1H, d, J = 6.1 Hz, CHarom); 9.15 (1H, d, J = 1.1 Hz, CHarom). 
13C NMR (100.6 
MHz, Ref = CDCl3): δ 50.9 (CH2NH); 57.6 (CHNH); 61.3 (CH2OH); 68.0 (CH2O); 
108.6 (HCarom); 114.7 (HCarom); 119.9 (HCarom); 124.1 (q, J = 279.5 Hz, CF3), 
125.5 (q, J = 3.7 Hz, 2 × CHCqCF3); 127.4 (HCarom); 128.3 (2 × HCarom); 129.4 (2 
× Carom,quat); 129.6 (q, J = 32.3 Hz, CqCF3); 142.7 (HCarom); 144.1 (Carom,quat); 
151.9 (HCarom); 153.2 (Carom,quat). 
19F NMR (282 MHz, Ref = CDCl3): -62.30 (3F, s, CF3); IR (cm
-1): νNH,OH = 
3242, νmax = 1323, 1277, 1160, 1110, 1065, 828, 749. MS m/z (%): 377 (M
++1, 100). HRMS (ESI) calcd 
for C20H20F3N2O2: 377.1477 [M+H]
+ , found: 377.1481.  
 
3.2.7.13. Synthesis of N-arylmethyl-1-(isoquinolin-5-yloxy)-3-methoxypropane-2-amines 
General procedure: To a solution of 5-[(1-arylmethylaziridin-2-yl)methoxy]isoquinoline 195 (1 mmol) 
in methanol (4 mL) in a microwave recipient of 6 mL, boron trifluoride diethyl etherate (0.5 mmol, 
0.5 equiv) was added slowly. After microwave irradiation for 30 min at 90 °C, the reaction mixture 
was neutralized with sodium hydroxide (pH = 7) and then poured into water (30 mL) and extracted 
with diethyl ether (3 × 20 mL). The combined organic layers were washed with distilled water (3 × 20 
mL) and subsequently dried over anhydrous magnesium sulfate. Filtration of the drying agent and 
removal of the solvent in vacuo afforded the crude products 197a,c-e,h, which were purified by 
means of column chromatography on silica gel. 
 
N-Benzyl-1-(isoquinolin-5-yloxy)-3-methoxypropane-2-amine 197a (91%) 
 Yellow viscous oil. Rf (SiO2) = 0.23 (EtOAc/MeOH 9/1). 
1H NMR (300 MHz, CDCl3): 
δ 1.95 (1H, br s, NH); 3.29-3.40 (1H, m, CHNH); 3.39 (3H, s, CH3O); 3.60 (1H, dd, J 
= 9.4, 5.5 Hz, (HCH)OMe); 3.67 (1H, dd, J = 9.4, 5.5 Hz, (HCH)OMe); 3.97 (2H, s, 
CH2NH); 4.19 (2H, d, J = 5.5 Hz, CH2O); 7.00 (1H, dd, 7.2, 1.1 Hz, CHarom); 7.23-7.40 
(5H, m, 5 × CHarom); 7.46-7.56 (2H, m, 2 × CHarom); 7.94 (1H, d, J = 5.5 Hz, CHarom); 
8.53 (1H, d, J = 5.5 Hz, CHarom); 9.21 (1H, s, CHarom). 
13C NMR (75.6 MHz, Ref = 
CDCl3): δ 51.9 (CH2NH); 56.1 (CHNH); 59.3 (CH3O); 68.5 (CH2O); 72.4 (CH2OMe); 
108.7 (HCarom); 115.0 (HCarom); 119.6 (HCarom); 127.2 (HCarom); 127.5 (HCarom); 128.2 (2 × HCarom); 128.5 
(Carom,quat); 128.6 (2 × HCarom); 129.5 (Carom,quat); 140.4 (Carom,quat); 142.8 (HCarom); 152.0 (HCarom); 153.6 
(Carom,quat). IR (cm
-1): νmax = 1583, 1433, 1391, 1276, 1249, 1108, 1068, 828, 732, 698. MS m/z (%): 323 
(M++1, 100). HRMS (ESI) calcd for C20H23N2O2: 323.1759 [M+H]
+, found: 323.1761.  
 
N-(4-Fluorobenzyl)-1-(isoquinolin-5-yloxy)-3-methoxypropane-2-amine 197c (79%)  
Yellow viscous oil. Rf (SiO2) = 0.22 (EtOAc/MeOH 9/1). 
1H NMR (300 MHz, 
CDCl3): δ 1.90 (1H, br s, NH); 3.23 (1H, quint, J = 5.5 Hz, CHNH); 3.29 (3H, s, 
CH3O); 3.50 (1H, dd, J = 9.4, 5.5 Hz, (HCH)OMe); 3.57 (1H, dd, J = 9.4, 5.5 Hz, 
(HCH)OMe); 3.84 (2H, s, CH2NH); 4.08 (2H, d, J = 5.5 Hz, CH2O); 6.88-6.94 (3H, 
m, 3 × CHarom); 7.22-7.26 (2H, m, 2 × CHarom); 7.36-7.46 (2H, m, 2 × CHarom); 7.85 
(1H, d, J = 5.5 Hz, CHarom); 8.44 (1H, d, J = 5.5 Hz, CHarom); 9.11 (1H, s, CHarom). 
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13C NMR (75.6 MHz, Ref = CDCl3): δ 51.2 (CH2NH); 56.1(CHNH); 59.3 (CH3O); 68.4 (CH2O); 72.4 
(CH2OMe); 108.7 (HCarom); 115.0 (d, J = 19.6 Hz, 2 × HCarom); 115.5 (HCarom); 119.6 (HCarom); 127.5 
(HCarom); 128.5 (Carom,quat); 129.5 (Carom,quat); 129.7 (d, J = 8.1 Hz, 2 × HCarom); 136.2 (Carom,quat); 142.8 
(HCarom); 152.0 (HCarom); 153.5 (Carom,quat); 162.0 (d, J = 244.6 Hz,CqF). 
19F NMR (282 MHz, Ref = CDCl3): -
115.67 (1F, s, CqF); IR (cm
-1): νmax = 1583, 1508, 1276, 1248, 1218, 1108, 827, 802, 748. MS m/z (%): 
341 (M++1, 100). HRMS (ESI) calcd for C20H22FN2O2: 341.1665 [M+H]
+, found: 341.1670.  
 
N-(2-Chlorobenzyl)-1-(isoquinolin-5-yloxy)-3-methoxypropane-2-amine 197d (82%) 
Yellow viscous oil. Rf (SiO2) = 0.22 (EtOAc/MeOH 9/1). 
1H NMR (300 MHz, CDCl3): 
δ 2.17 (1H, br s, NH); 3.35 (1H, m, CHNH); 3.39 (3H, s, CH3O); 3.62 (1H, dd, J = 9.4, 
5.5 Hz, (HCH)OMe); 3.66 (1H, dd, J = 9.4, 5.5 Hz, (HCH)OMe); 4.06 (2H, d, J = 1.7 
Hz, CH2NH); 4.20 (2H, d, J = 5.5 Hz, CH2O); 7.00 (1H, d, J = 7.7 Hz, CHarom); 7.16-
7.26 (2H, m, 2 × CHarom); 7.34-7.37 (1H, m, CHarom); 7.45-7.55 (3H, m, 3 × CHarom); 
7.95 (1H, d, J = 6.1 Hz, CHarom); 8.52 (1H, d, J = 6.1 Hz, CHarom); 9.20 (1H, s, CHarom). 
13C NMR (75.6 MHz, Ref = CDCl3): δ 49.5 (CH2NH); 56.1 (CHNH); 59.3 (CH3O); 68.6 
(CH2O); 72.5 (CH2OMe); 108.7 (HCarom); 115.0 (HCarom); 119.6 (HCarom); 127.0 (HCarom); 127.5 (HCarom); 
128.5 (Carom,quat); 128.6 (HCarom); 129.5 (Carom,quat); 129.7 (HCarom); 130.2 (HCarom); 133.8 (Carom,quat); 
137.7 (Carom,quat); 142.8 (HCarom); 152.0 (HCarom); 153.5 (Carom,quat). IR (cm
-1): νmax = 1584, 1434, 1276, 
1249, 1108, 828, 748. MS m/z (%): 357/9 (M++1, 100). HRMS (ESI) calcd for C20H21ClN2O2: 357.1370 
[M+H]+, found: 357.1375.  
 
1-(Isoquinolin-5-yloxy)-3-methoxy-N-(4-methoxybenzyl)propane-2-amine 197e (85%) 
Yellow viscous oil. Rf (SiO2) = 0.20 (EtOAc/MeOH 9/1). 
1H NMR (300 MHz, 
CDCl3): δ 2.03 (1H, br s, NH); 3.34 (1H, quint, J = 5.5 Hz, CHNH); 3.38 (3H, s, 
CH3OCH2); 3.59 (1H, dd, J = 9.4, 5.5 Hz, (HCH)OMe); 3.66 (1H, dd, J = 9.4, 5.5 
Hz, (HCH)OMe); 3.79 (3H, s, CH3OCq); 3.90 (2H, s, CH2NH); 4.17 (2H, d, J = 
5.5 Hz, CH2O); 6.86 (2H, d, J = 8.8 Hz, 2 × CHarom); 6.99 (1H, d, J = 7.7 Hz, 
CHarom); 7.27-7.31 (2H, m, 2 × CHarom); 7.45-7.55 (2H, m, 2 × CHarom); 7.94 
(1H, d, J = 6.1 Hz, CHarom); 8.52 (1H, d, J = 6.1 Hz, CHarom); 9.20 (1H, s, CHarom). 
13C NMR (75.6 MHz, Ref = CDCl3): δ 51.4 (CH2NH); 55.4 (CH3OCq); 56.0 (CHNH); 59.3 (CH3O); 68.5 
(CH2O); 72.5 (CH2OMe); 108.7 (HCarom); 114.0 (2 × HCarom); 115.0 (HCarom); 119.5 (HCarom); 127.5 
(HCarom); 128.5 (Carom,quat); 129.4 (2 × HCarom); 129.5 (Carom,quat); 132.5 (Carom,quat); 142.8 (HCarom); 152.0 
(HCarom); 153.6 (Carom,quat); 158.8 (Carom,quat). IR (cm
-1): νNH = 3323, νmax = 1583, 1511, 1276, 1245, 1173, 
1108, 1033, 828, 802, 749. MS m/z (%): 353 (M++1, 100). HRMS (ESI) calcd for C21H25N2O3: 353.1865 
[M+H]+, found: 353.1870.  
 
1-(Isoquinolin-5-yloxy)-3-methoxy-N-(2-methoxybenzyl)propane-2-amine 197h (75%)   
Orange oil. Rf (SiO2) = 0.25 (CH2Cl2/MeOH 95/5). 
1H NMR (300 MHz, CDCl3): δ 
2.67 (1H, br s, NH); 3.33 (1H, quint, J = 5.5 Hz, CHNH); 3.37 (3H, s, CH3OCH2); 3.62 
(2H, d, J = 5.5 Hz, CH2OMe); 3.75 (3H, s, CH3OCq); 3.96 (2H, d, J = 3.9 Hz, CH2NH); 
4.18 (2H, d, J = 5.5 Hz, CH2O); 6.82-6.99 (3H, m, 3 × CHarom); 7.21-7.31 (2H, m, 2 × 
CHarom); 7.43-7.52 (2H, m, 2 × CHarom); 7.93 (1H, d, J = 5.5 Hz, CHarom); 8.52 (1H, d, 
J = 5.5 Hz, CHarom); 9.19 (1H, s, CHarom). 
13C NMR (75.6 MHz, ref = CDCl3): δ 47.5 
(CH2NH); 55.3 (CH3OCq); 55.8 (CHNH); 59.2 (CH3O); 68.5 (CH2O); 72.6 (CH2OMe); 
108.6 (HCarom); 110.4 (HCarom); 115.1 (HCarom); 119.4 (HCarom); 120.6 (HCarom); 127.5 (HCarom); 128.2 
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(Carom,quat); 128.49 (Carom,quat); 128.54 (HCarom); 129.5 (Carom,quat); 129.9 (HCarom); 142.6 (HCarom); 152.0 
(HCarom); 153.6 (Carom,quat); 157.7 (Carom,quat). IR (cm
-1): νmax = 1584, 1492, 1276, 1241, 1110, 908, 829, 
750, 726. MS (70 eV): m/z (%): 353 (M++1, 100). HRMS (ESI) calcd for C19H21ClF3N4O2 353.1860 
[M+H]+, found 353.1864.  
 
3.2.7.14. Synthesis of N2-arylmethyl-3-(isoquinolin-5-yloxy)-N1-phenylpropane-1,2-diamines 
General procedure: To a solution of 5-[(1-arylmethylaziridin-2-yl)methoxy]isoquinoline 195 (1 mmol) 
in dichloromethane (4 mL) in a microwave recipient of 6 mL, boron trifluoride diethyl etherate (0.5 
mmol, 0.5 equiv) and aniline (1.1 mmol, 1.1 equiv) were slowly added. After microwave irradiation 
for 60 min at 65 °C, the product was observed as a precipitate in the recipient. After removal of the 
solvent in vacuo, the precipitate was dissolved in DMSO (5 mL), to which water (10 mL) was added, 
followed by extraction with diethyl ether (3 × 10 mL). The combined organic layers were washed with 
distilled water (3 × 10 mL) and subsequently dried over anhydrous magnesium sulfate. Filtration of 
the drying agent and removal of the solvent in vacuo afforded the crude products 198a-b, which 
were purified by means of column chromatography on silica gel. 
 
N2-Benzyl-3-(isoquinolin-5-yloxy)-N1-phenylpropane-1,2-diamine 198a (92%)  
 Brown viscous oil. Rf (SiO2) = 0.31 (EtOAc/MeOH 9/1). 
1H NMR (300 MHz, 
CDCl3): δ 3.29-3.36 (1H, m, HN(HCH)CHNH); 3.45-3.50 (2H, m, HN(HCH)CHNH + 
CHNH); 3.95 (2H, s, CH2Cq); 4.25 (2H, d, J = 4.4 Hz, CH2O); 6.64-6.75 (3H, m, 3 × 
CHarom); 6.98 (1H, d, J = 7.2 Hz, CHarom); 7.15-7.38 (7H, m, 7 × CHarom); 7.45-7.55 
(2H, m, 2 × CHarom); 7.94 (1H, d, J = 5.5 Hz, CHarom); 8.53 (1H, d, J = 5.5 Hz, 
CHarom); 9.20 (1H, s, CHarom). 
13C NMR (75.6 MHz, Ref = CDCl3): δ 44.9 
(CHCH2NH); 51.4 (CH2Cq); 55.4 (CHNH); 69.1 (CH2O); 108.7 (HCarom); 113.2 (2 × 
HCarom); 114.9 (HCarom); 117.8 (HCarom); 119.9 (HCarom); 127.4 (HCarom); 127.5 
(HCarom); 128.2 (2 × HCarom); 128.4 (Carom,quat); 128.7 (2 × HCarom); 129.4 (2 × HCarom); 129.5 (Carom,quat); 
140.0 (Carom,quat); 142.9 (HCarom); 148.4 (Carom,quat); 152.1 (HCarom); 153.4 (Carom,quat). IR (cm
-1): νNH = 3327, 
νmax = 1493, 1276, 1248, 746, 730, 695. MS m/z (%): 384 (M
++1, 100). HRMS (ESI) calcd for C25H26N3O: 
384.2075 [M+H]+, found: 384.2078.  
 
N2-(4-Chlorobenzyl)-3-(isoquinolin-5-yloxy)-N1-phenylpropane-1,2-diamine 198b (91%)  
Orange viscous oil. Rf (SiO2) = 0.30 (EtOAc/MeOH 9/1). 
1H NMR (300 MHz, 
CDCl3): δ 1.98 (1H, br s, NH); 3.29-3.34 (1H, m, HN(HCH)CHNH); 3.39-3.49 
(2H, m, HN(HCH)CHNH + CHNH); 3.91 (2H, d, J = 2.2 Hz, CH2Cq); 4.24 (2H, d, 
J = 5.0 Hz, CH2O); 6.65 (2H, dd, J = 8.8, 1.1 Hz, 2 × CHarom); 6.71-6.75 (1H, m, 
CHarom); 6.98 (1H, d, J = 6.1 Hz, CHarom); 7.15-7.30 (6H, m, 6 × CHarom); 7.45-
7.56 (2H, m, 2 × CHarom); 7.92 (1H, d, J = 5.5 Hz, CHarom); 8.54 (1H, d, J = 5.5 
Hz, CHarom); 9.21 (1H, s, CHarom). 
13C NMR (75.6 MHz, Ref = CDCl3): δ 45.0 
(CHCH2NH); 50.7 (CH2Cq); 55.4 (CHNH); 69.0 (CH2O); 108.7 (HCarom); 113.2 (2 
× HCarom); 114.8 (HCarom); 117.9 (HCarom); 120.0 (HCarom); 127.5 (HCarom); 
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128.4 (Carom,quat); 128.8 (2 × HCarom); 129.47 (2 × HCarom); 129.50 (2 × HCarom); 129.50 (Carom,quat); 133.0 
(Carom,quat); 138.7 (Carom,quat); 142.9 (HCarom); 148.4 (Carom,quat); 152.1 (HCarom); 153.3 (Carom,quat). IR (cm
-1): 
νNH = 3320, νmax = 1602, 1584, 1492, 1276, 1248, 828, 801, 748, 729, 693. MS m/z (%): 418 (M
++1, 
100). HRMS (ESI) calcd for C25H25ClN3O: 418.1686 [M+H]
+, found: 418.1687.  
 
3.2.7.15. Synthesis of 2-benzyl-5-[(1-benzylaziridin-2-yl)methoxy]-2-isoquinolinium bromide 
To a solution of 5-[(1-benzylaziridin-2-yl)methoxy]isoquinoline 195 (1 mmol) in acetonitrile (25 mL) 
was added benzyl bromide (1 mmol, 1 equiv). After stirring for 5 h at reflux temperature, the solvent 
was removed in vacuo affording crude product 199, which was purified by means of recrystallization 
from methanol. 
 
2-Benzyl-5-[(1-benzylaziridin-2-yl)methoxy]isoquinolinium bromide 199 (97%)  
 Brown crystals. Mp = 62.3 °C. Recrystallization from methanol. 1H NMR (300 
MHz, CDCl3): δ 1.71 (1H, d, J = 6.6 Hz, (HCH)CHN); 1.94 (1H, d, J = 3.3 Hz, 
(HCH)CHN); 2.06-2.19 (1H, m, CHN); 3.17 (1H, d, J = 13.2 Hz, N(HCH)Cq); 3.78 
(1H, d, J = 13.2 Hz, N(HCH)Cq); 3.85 (1H, dd, J = 10.5, 8.3 Hz, (HCH)O); 4.37 (1H, 
dd, J = 10.5, 3.9 Hz, (HCH)O); 6.34 (2H, s, N+CH2Cq); 7.21-7.38 (10H, m, 10 × 
CHarom); 7.68-7.74 (2H, m, 2 × CHarom); 7.97 (1H, d, J = 7.7 Hz, CHarom); 8.12 (1H, 
d, J = 7.7 Hz, CHarom); 8.62 (1H, dd, J = 7.7, 1.1 Hz, CHarom); 11.05 (1H, s, CHarom). 
13C NMR (75.6 MHz, Ref = CDCl3): δ 31.8 (NCH2CH); 37.1 (CHN); 63.8 (CH2N
+); 
64.5 (NCH2Cq); 71.6 (CH2O); 115.2 (HCarom); 121.5 (HCarom); 122.4 (HCarom); 127.5 (HCarom); 128.3 
(Carom,quat); 128.4 (Carom,quat); 128.6 (3 × HCarom); 129.5 (HCarom); 129.57 (2 × HCarom); 129.62(2 × HCarom); 
129.8 (HCarom); 132.2 (HCarom); 133.2 (Carom,quat); 133.4 (HCarom); 138.6 (Carom,quat); 149.5 (HCarom); 153.3 
(Carom,quat). IR (cm
-1): νmax = 3026, 2999, 1401, 1290, 747, 718, 699. MS m/z (%): 381/3 (M
++1, 100). 
HRMS (ESI) calcd for C26H25N2O: 381.1961 [M]
+, found: 381.1963.  
 
3.2.7.16. Synthesis of 2-benzyl-5-[2-bromo-3-(dibenzylamino)propyloxy]-2-isoquinolinium   
         bromide 
To a solution of 2-benzyl-5-[(1-benzylaziridin-2-yl)methoxy]-2-isoquinolinium bromide 199 (1 mmol) 
in acetonitrile (25 mL) was added benzyl bromide (1 mmol, 1 equiv). After stirring for 5 h at reflux 
temperature, the solvent was removed in vacuo affording crude product 200, which was purified by 
means of recrystallization from methanol. 
 
2-Benzyl-5-[2-bromo-3-(dibenzylamino)propoxy]isoquinolinium bromide 200 (98%)  
Brown crystals. Mp = 54.1 °C. Recrystallization from methanol. 1H NMR (300 MHz, CDCl3): δ 2.94 (1H, 
dd, J = 13.2, 5.0 Hz, N(HCH)CH); 3.15 (1H, dd, J = 13.2, 9.9 Hz, N(HCH)CH); 3.47 (1H, d, J = 13.2 Hz, 2 × 
N(HCH)Cq); 3.77 (1H, d, J = 13.2 Hz, 2 × N(HCH)Cq); 4.21 (1H, quint, J = 4.4 Hz, CHBr); 4.32 (2H, m, 
CH2O); 6.34 (1H, d, J = 13.8 Hz, N
+(HCH)Cq); 6.42 (1H, d, J = 13.8 Hz, N
+(HCH)Cq); 6.91 (2H, t, J = 7.7 Hz, 
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2 × CHarom); 7.05 (3H, t, J = 7.7 Hz, 3 × CHarom); 7.12 (1H, d, J = 7.7 Hz, CHarom); 
7.23 (3H, d, J = 7.7 Hz, 3 × CHarom); 7.29-7.42 (5H, m, 5 × CHarom); 7.75-7.83 (3H, 
m, 3 × CHarom); 8.04 (1H, d, J = 7.2 Hz, CHarom); 8.24 (1H, d, J = 7.7 Hz, CHarom); 
8.55 (1H, d, J = 7.2 Hz, CHarom); 11.34 (1H, s, CHarom). 
13C NMR (75 MHz, Ref = 
CDCl3): δ 47.4 (CHBr); 57.1 (CHCH2N); 59.9 (2 × NCH2Cq); 63.9 (N
+CH2Cq); 69.6 
(CH2O); 114.7 (HCarom); 121.3 (HCarom); 122.8 (HCarom); 127.2 (2 × HCarom); 128.4 
(4 × HCarom); 128.5 (HCarom); 128.7 (HCarom); 128.9 (HCarom); 129.0 (2 × HCarom); 
129.1 (HCarom); 129.5 (Carom,quat); 129.7 (4 × HCarom); 130.0 (HCarom); 132.1 (Carom,quat); 133.1 (Carom,quat); 
133.4 (Carom,quat); 138.7 (HCarom); 149.8 (Carom,quat); 152.9 (Carom,quat). IR (cm
-1): νmax = 1604, 1452, 1400, 
1290, 1262, 1104, 748, 718, 698. MS m/z (%): 551/3/5 (M++1, 100). HRMS (ESI) calcd for C33H32BrN2O: 
551.1698 [M]+, found: 551.1692.  
 
3.2.7.17. Antiplasmodial and cytotoxicity testing procedures 
Antiplasmodial assessment 
All samples were tested against a CQS strain of P. falciparum (NF54). Continuous in vitro cultures of 
asexual erythrocyte stages of P. falciparum were maintained using a modified method of Trager and 
Jensen,343 and quantitative assessment of antiplasmodial activity in vitro was determined via the 
parasite lactate dehydrogenase assay using a modified method described by Makler.344 The samples 
were tested in triplicate on one occasion. The test samples were prepared to a 20 mg/mL stock 
solution in 100% DMSO. Stock solutions were stored at -20 °C. Further dilutions were prepared in 
complete medium on the day of the experiment. Samples were tested as a suspension if not 
completely dissolved. CQ was used as the reference. A full dose-response was performed for all 
compounds to determine the concentration inhibiting 50% of parasite growth (IC50 value). Test 
samples were tested at a starting concentration of 100 µg/mL, which was then serially diluted 
twofold in complete medium to give 10 concentrations; with the lowest concentration being 0.2 
µg/mL. The same dilution technique was used for all samples. CQ was tested at a starting 
concentration of 100 ng/mL against a CQS strain and 1000 ng/mL against the CQR strain. The highest 
concentration of solvent to which the parasites were exposed to had no measurable effect on the 
parasite viability. 
Cytotoxicity assessment 
The test samples were tested in triplicate on one occasion. The test samples were prepared to a 2 
mg/mL stock solution in 10% DMSO and were tested as a suspension. Test compounds were stored 
at -20 °C until use. Dilutions were prepared on the day of the experiment. Emetine was used as the 
reference drug in all experiments. The initial concentration of emetine was 100 µg/mL, which was 
serially diluted in complete medium with 10-fold dilutions to give 6 concentrations, the lowest being 
0.001 µg/mL. The same dilution technique was applied to all test samples. The highest concentration 
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of solvent to which the cells were exposed to had no measurable effect on the cell viability. The 50% 
inhibitory concentration (IC50) values were obtained from full dose-response curves, using a non-
linear dose-response curve fitting analysis via GraphPad Prism v.4 software. 
3.2.7.18. Immunological testing procedures 
B-cells were isolated from peripheral blood mononucleated cells (PBMCs) of healthy donors by 
positive magnetic selection using CD19 MicroBeads technology according the manufacturer’s 
protocol. C19+ cells were incubated in 50 µL of culture medium in the presence of ODN2006 and 5 µL 
of compound dilution. After 7 days incubation at 37 °C in 5% CO2, supernatants were collected and 
Immunoglobulin G (IgG) concentration was determined using the Human IgG immunoassay kit 
according to the manufacturer’s protocol. For the MLR protocol385 PBMCs were isolated from 
heparinized blood of healthy donors and then were suspended in culture medium. RPMI1788 cells 
were treated with mitomycin C for 20 min at 37 °C, washed and finally suspended in culture medium. 
An amount of 100 µL of each cell suspension was mixed with 20 µL of diluted compound. The mixed 
cells were cultured at 37 °C for 6 days in 5% CO2. DNA synthesis was analyzed by the addition of 1µCi 
(methyl-3H)thymidine per well during the last 18h in culture, Thereafter, the cells were harvested on 
glass filter paper and the counts per minute determined in a liquid scintillation counter. 
 
3.2.7.19. Antimicrobial testing procedures 
Disk diffusion susceptibility test 
These strains were subcultured onto potato dextro medium (Oxoid) at 25 °C and the inocula were 
prepared by suspending and diluting a fresh and mature culture of each strain in a 0.85% sterile 
saline solution for desired density, equivalent to 0.5 McFarland standard (stock inocula). The fungal 
inocula were spread out on a PDA (Oxaid) plate by a sterile glass hockey. The empty 6 mm disc (BBLTM 
Sensi-DiscTM) containing 0.2 mg of the antifungal compound dissolved in DMSO was dispensed on the 
plate. The control disk was dispensed with 2 µL of the pure solvent (DMSO). All the plates were 
incubated at 25 °C and antifungal activity was measured after 24 h of incubation for yeasts and after 
48 h of incubation for filamentous fungi. The microbial inhibition was determined by measuring the 
diameter of the clear zone around microbial colonies. These experiments were repeated three times. 
  
 
 
3.3.  
Synthesis of N-functionalized 3-, 5-, 6- and  
8-aminoquinolines via intermediate (3-pyrrolin-1-yl)- and  
(2-oxopyrrolidin-1-yl)quinolines and evaluation of their 
biological activity 
 
 
 
Abstract: (3-Pyrrolin-1-yl)- and (2-oxopyrrolidin-1-yl)quinolines were prepared via cyclization of 
diallylaminoquinolines and 4-chloro-N-(quinolinyl)butanamides, respectively, as novel synthetic 
intermediates en route to functionalized 3-, 5-, 6- and 8-aminoquinolines with potential 
antiplasmodial activity. (3-Pyrrolin-1-yl)quinolines were subjected to bromination reactions, and the 
reactivity of (2-oxopyrrolidin-1-yl)quinolines toward lithium aluminium hydride and methyllithium 
was assessed, providing an entry to a broad range of novel functionalized (pyrrolidin-1-yl)- and 
(hydroxyalkylamino)quinolines. Antimalarial evaluation of these novel (3-pyrrolin-1-yl)- and (2-
oxopyrrolidin-1-yl)quinolines and their functionalized derivatives revealed moderate micromolar 
potency (13-50 µM) for all representatives against a chloroquine-sensitive strain of the malaria 
parasite Plasmodium falciparum. The two most potent compounds also showed micromolar activity 
against a chloroquine-resistant strain of P. falciparum with IC50 values ranging between 38 and 49 
µM. Antifungal assessment of the (hydroxyalkylamino)quinolines revealed three compounds with 
promising MIC values against Rhodotorula bogoriensis and one compound with potent activity 
against Aspergillus flavus. 
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3.3.1. Introduction 
In the previous section of this PhD thesis molecular hybridization was utilized as a convenient 
method to functionalize the quinoline skeleton. This appeared to be an efficient approach to further 
explore the chemical space around the quinoline core (substitutions at the 3- and 4-position of the 
quinoline ring). The reactive entity within these hybrid systems comprised the small heterocyclic 
aziridine ring, resulting in 1,2,3-trifunctionalized propanes after ring opening. In order to further 
elaborate this concept, larger heterocycles could be incorporated as a chemically reactive moiety in 
quinoline dual systems as well. On the one hand, conjugation between a quinoline moiety and 3-
pyrroline could allow further functionalization of the conjugate molecule by modifying the pyrroline 
moiety, thereby affording novel quinoline chimeras with potential biological activitiy. On the other 
hand, a pyrrolidin-2-one entity could be linked to quinoline scaffolds at different positions, after 
which subsequent ring opening could provide potentially bioactive chloroquine (CQ) analogs. Hence, 
the objective of this chapter consists of the design, synthesis and biological evaluation of a set of 
novel (pyrrolidin-1-yl)quinoline systems (with substitutions around the quinoline core) and their 
functionalized derivatives. 
 
3.3.2. Synthesis and functionalization of (3-pyrrolin-1-yl)quinoline derivatives 
3.3.2.1. Synthesis of (3-pyrrolin-1-yl)quinolines 
The first synthetic approach envisioned the synthesis of (3-pyrrolin-1-yl)quinolines starting from 
aminoquinolines via intermediate diallylaminoquinolines. Diallylaminoquinolines had only been 
reported as (minor) side products of the monoallylation of aminoquinolines,386-389 and thus 
optimization of the reaction conditions was required to realize selective diallylation. Several bases 
(K2CO3, NaH, LiHMDS), solvents (DMF/acetone 1:1, CH3CN, toluene, THF) and reaction temperatures 
were evaluated in order to achieve this objective. Eventually, complete diallylation of 
aminoquinolines 12 could only be accomplished by sequential addition of lithium 
bis(trimethylsilyl)amide (LiHMDS, 2 × 1 equiv, with an interval of 1 h) to a mixture of aminoquinoline 
12 and 4 equiv of allyl bromide in tetrahydrofuran after stirring for 2 h under reflux conditions. These 
diallylaminoquinolines 171 were obtained in good to excellent yields (50-99%) and purities, and 
could be used for further reactions as such (Scheme 15 and Table 12). The lower yields (50%) are 
probably due to loss of ammonium salts in the water phase during work-up. Diallylamines 171 were 
subsequently treated with 10 mol% of 1st or 2nd generation Grubbs catalyst in tetrahydrofuran or 
dichloromethane to produce the desired novel (3-pyrrolin-1-yl)quinolines 201a-d via ring-closing 
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metathesis after stirring for 24 h under inert atmosphere (N2) at room temperature. 1
st Generation 
Grubbs catalyst was preferred over 2nd generation since it is cheaper, and especially since it was 
shown to be more active toward 3-diallylaminoquinoline derivatives. However, 1st generation Grubbs 
catalyst was unable to effect ring closure of 8-diallylaminoquinolines, and it appeared that 2nd 
generation Grubbs catalyst was required in that case. The different reaction conditions tested are 
summarized in Table 11. Low yields are probably due to small-scale reactions, resulting in a rather 
broad yield-range. 
 
Table 11: Grubbs-catalysed RCM of quinolines 171 under different reaction conditions 
Quinolin- equiv catalyst Grubbs Solvent Temperture Time (h) Yield (%) 
3-yl 0.05 1
st
 generation CH2Cl2 r.t. 24 20-53 
3-yl 0.05 1
st
 generation THF r.t. 24 58 
5-yl 0.05 1
st
 generation CH2Cl2 r.t. 24 40 
5-yl 0.05 2
nd
 generation CH2Cl2 r.t. 24 32 
5-yl 0.10 1
st
 generation 2-Me-THF r.t. 24 0 
5-yl 0.10 1
st
 generation THF r.t. 24 54-82 
5-yl 0.10 2
nd
 generation THF r.t. 24 48-65 
6-yl 0.05 1
st
 generation CH2Cl2 r.t. 24 30-80 
8-yl 0.05 1
st
 generation CH2Cl2 r.t. 24 0 
8-yl 0.05 2
nd
 generation CH2Cl2 r.t. 24 0 
8-yl 0.10 1
st
 generation THF r.t. 24 0 
8-yl 0.10 2
nd
 generation THF r.t. 24 16-31 
 
 
Conversion rates of diallylaminoquinolines 171 to (3-pyrrolinyl)quinolines 201 varied between 50 and 
100%, but 3-pyrrolines 201 could be isolated in pure form in yields of 16-82% by preparative thin 
layer chromatography (Scheme 15 and Table 12).  
 
 
Scheme 15 
 
The ring-closing metathesis taking place in this second step is an intramolecular alkene metathesis 
reaction where a metallocarbene intermediate 203 is formed, which subsequently undergoes [2+2]-
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cycloaddition, furnishing metallacyclobutane 204. Finally, a retro-[2+2]-cycloaddition of 
metallocylobutane 204 affords the desired alkene 201 and the initial carbene (Scheme 16). 
 
Scheme 16 
 
3.3.2.2. Derivatization of (3-pyrrolin-1-yl)quinolines 
The reactivity of the (3-pyrrolin-1-yl)quinoline intermediates 201a-c was then evaluated by adding 2 
equiv of bromine to a solution of quinolines 201a-c in tetrahydrofuran or dichloromethane, which 
was stirred for 1 h at 0 °C. Surprisingly, next to the anticipated anti-addition of bromine across the 
pyrroline double bond, bromination of the quinoline core occurred as well. The position of quinoline 
bromination was dependent on the substitution pattern; seemingly bromination of the quinoline 
core took place in α-position with respect to the pyrrolinyl side chain. Apparently, the nitrogen atom 
of the pyrroline ring donated electron density to the aromatic quinoline ring, stimulating electrophilic 
aromatic substitution at the neighboring positions. For the 3- and 5-substituted quinolines 205a-b 
this resulted in an extra bromination at the 4- and 6- position of the quinoline core, respectively. 6-
Substituted quinolines 205c, however, yielded two products in a 3/1 ratio, with the major product 
brominated at the 5-position of the quinoline core and the minor product brominated at the 7-
position. Unfortunately, these regioisomers could not be isolated. The small scale synthesis and 
troublesome purification step(s) affected the overall yields (14-34%) of the final obtained products 
(Scheme 17 and Table 12).  
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Scheme 17 
 
When (3-pyrrolin-1-yl)quinoline 201c was treated with 2 equiv bromine in dichloromethane and 
stirred for 2 h at room temperature, a complex reaction mixture was obtained. However, after two 
purification steps over silica gel (column chromatography followed by pTLC), a pure fraction could be 
isolated. Analysis of this compound revealed that only quinoline hydrogen atoms and five bromo 
atoms were present. Further analysis proved that 1-(5-bromoquinolin-6-yl)-2,3,4,5-
tetrabromopyrrole 206 was obtained in 9% yield (Scheme 18, Table 12). The very low yield of the 
reaction can be attributed to different reasons; firstly, the reaction was performed at a very small 
scale (0.5 mmol) which made the correct dosage of bromine difficult. Secondly, the cumbersome 
purification of the reaction mixture also accounted for a substantial loss of yield. Lastly, insufficient 
bromine (2 equiv) was added to the reaction to get full conversion to compound 206 bearing 5 
bromo atoms. The different reaction steps are illustrated in Scheme 19.  
 
Scheme 18 
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Table 12: Substitution pattern and isolated yields of quinolines 171, 201, 205 and 206 
 
a
 Crude yields, purity >90% (NMR) 
 
 
Scheme 19 
 
3.3.3. Synthesis and functionalization of (2-oxo-pyrrolidin-1-yl)quinoline derivatives 
3.3.3.1. Synthesis of (2-oxo-pyrrolidin-1-yl)quinolines 
A second approach toward pyrrolidinylquinoline hybrids as intermediates in the synthesis of 
potentially novel antimalarials was based on the use of a pyrrolidinone moiety as reactive entity 
within the hybrid structure. The synthesis of 1-quinolinylpyrrolidin-2-ones commenced from 
aminoquinolines 12 as building blocks. The first step in the synthesis of these intermediates 
comprised the N-acylation of aminoquinolines 12 with 1 equiv of 4-chlorobutyryl chloride in the 
presence of 3 equiv of potassium carbonate in dichloromethane. After stirring for 2 h at room 
Compound Quinolin- Position Br Yield (%) 
171a 8-yl - 71
 
171h 6-yl - 50-70
a 
171i 5-yl - 79-95 
171j 3-yl - 90-99
a 
201a 3-yl - 20-53 
201b 5-yl - 48-82 
201c 6-yl - 50-80 
201d 8-yl - 16-53 
205a 3-yl 4-Br 28 
205b 5-yl 6-Br 28-34 
206 6-yl 5-Br 9 
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temperature under inert atmosphere, this approach afforded the required N-
(quinolinyl)butanamides 207a-d in excellent yields (71-99%) and high purities. When a purification 
step (column chromatography) was performed to remove an accidental excess of 4-chlorobutyryl 
chloride, the yields dropped immensely (36-45%) due to the high polarity of the compounds (Scheme 
20 and Table 13). Therefore, the crude products 207a-d were immediately modified as such through 
intramolecular ring closure by adding 1.5 equiv of potassium tert-butoxide to the acetonitrile 
solution of butanamides 207. After stirring for 2 h at reflux temperatures, this method yielded the 
desired and novel 1-quinolinyl-2-pyrrolidinones 208a-d in good yields (60-62%) (Scheme 20 and Table 
13). In an attempt to further optimize these reactions, various one-pot alternatives in acetonitrile 
were evaluated. However, prolonging reaction times, adding more base (KOtBu), adding base 
sequentially or even adding potassium iodide to stimulate the intramolecular nucleophilic 
substitution, all resulted in mixtures of compounds 12, 207 and 208. The one-pot approach was 
discarded as it did not offer an added value over the stepwise pathway. 
 
Scheme 20 
 
3.3.3.2. Derivatization of (2-oxopyrrolidin-1-yl)quinolines 
Different strategies for further derivatization of the 2-pyrrolidinone moiety were evaluated. Firstly, 
1.5 equiv of lithium aluminium hydride was added to lactams 208b-c in tetrahydrofuran under inert 
atmosphere under reflux, mediating the reductive removal of the carbonyl group and thus furnishing 
(pyrrolidin-1-yl)quinolines 213b-c in moderate to good yields (37-68%) (Scheme 22 and Table 13). 
Secondly, pyrrolidinones 208a-d were reduced to the corresponding intermediate aldehydes by 
treating pyrrolidinones 208a-d with 1.5 equiv of lithium aluminium hydride in tetrahydrofuran for 2.5 
h at room temperature under inert atmosphere. Next, methanol and 1.5 equiv of sodium 
borohydride were added to the mixture and stirred for 3 more hours at room temperature, affording 
further reduction towards primary alcohols 214. These 4-(quinolinylamino)butanols 214a-d were 
obtained in good crude yields (94-97%), but purification accounted for reduced yields (12-40%) 
(Scheme 22 and Table 13). Thirdly, lactams 208a-d were sequentially treated with a methyllithium 
solution (4 × 1 equiv, with an interval of 1 h) in tetrahydrofuran for 4 h at 0 °C under inert 
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atmosphere, providing 5-quinolinylamino-2-methylpentan-2-ols 215a-d in good yields, but again a 
troublesome purification step resulted in reduced yields (23-43%). It should be noted that when this 
method was applied to 1-(quinolin-3-yl)pyrrolidin-2-one 208a, an additional methylation occurred at 
the 2-position of the quinoline scaffold affording 2-methylquinoline 215a’ (R = Me). This reaction 
proceeded via the 2-methyl-1,2-dihydroquinoline intermediate 211 and is followed by reconstruction 
of aromaticity (Scheme 21). This type of nucleophilic alkyllithium addition onto quinoline has been 
described in the literature.390  
 
Scheme 21 
 
Lastly, when lactams 208a-c were sequentially treated with 2 equiv of a methyllithium solution (2 × 1 
equiv, with an interval of 1 h) in tetrahydrofuran for 2 h at 0 °C under inert atmosphere, 5-
(quinolinylamino)pentan-2-ones 216a-c were obtained in good to excellent yields (70-99%) and high 
purities (Scheme 22 and Table 13). Again, methylation of the 2-position of the quinoline core took 
place when applying this method to 1-(quinolin-3-yl)pyrrolidin-2-ones 208a, yielding the formation of 
5-(2-methylquinolin-3-ylamino)pentan-2-one 216a’ (R = Me). Temperature control appeared to be 
crucial in this reaction step, since the intermediate lithiate is only stable at temperatures below 0 °C. 
When the reaction was performed at higher temperatures, mixtures of methylketone 216 and 
tertiary alcohol 215 were obtained. However, this was not the case when 1-(quinolin-8-yl)-2-
pyrrolidinone 208d was used as substrate, as this reaction always resulted in the synthesis of 5-
(quinolin-8-ylamino)-2-methylpentan-2-ol 215d, even at reaction temperatures as low as -78 °C. This 
difference in reactivity could be explained by considering the formation of a coordination complex 
between the metal and 8-aminoquinolines.391, 392 Furthermore, the newly synthesized methylketones 
216a-c were rather unstable and could not be purified over silica gel. Fortunately, these ketones 
were obtained in sufficiently high purities (>90%, NMR), allowing for direct further synthetic 
modification. The first modification strategy consisted of intramolecular ring closure by adding 5 
equiv of acetic acid and 2 equiv of sodium cyanoborohydride to methylketones 216a-c in methanol 
and stirring for 3 h at room temperature. This afforded the novel 1-quinolinyl-2-methylpyrrolidines 
217a-c in excellent yields (89-92%), and column chromatography provided analytically pure samples 
in low to good yields (27-61%) (Scheme 22 and Table 13). In order to get the full range of 4-
aminobutanol side chains, 5-(quinolinylamino)pentan-2-ones 216a-c were treated with 1.5 equiv of 
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sodium borohydride in methanol for 2 h at room temperature, affording 5-(quinolinylamino)pentan-
2-ols 218a-c in very good yields (91-93%). Finally, column chromatography on silica gel was 
performed to provide analytically pure samples, but again this resulted in reduced yields (15-50%) 
(Scheme 22 and Table 13). 
 
Scheme 22 
 
It should be noted that 5-(quinolinylamino)pentan-2-ols 218a-c could also be obtained in a one-pot 
synthesis by treating lactams 208a-c with 2 equiv of a methyllithium solution (2 × 1 equiv, with an 
interval of 1h) in tetrahydrofuran for 2h at 0 °C under inert atmosphere, whereafter 1.5 equiv of 
sodium borohydride and methanol were added and the mixture was stirred for an additional 2h at 
room temperature. 5-Quinolinylamino-2-methylpentan-2-ols 215a-b could also be obtained through 
an alternative route where methylketones 216a-b in tetrahydrofuran were treated with 2 equiv of 
methylmagnesium iodide for 2 h at 0 °C. 
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Table 13: Substitution pattern and isolated yields of quinolines 207, 208, 213, 214, 215, 216, 217 and 218 
Compound Quinolin- R Yield (%) Compound Quinolin- R Yield (%) 
207a 3-yl - 71-97
a 
215b 5-yl H 23 
207b 5-yl - 92-99
a 
215c 6-yl H 43 
207c 6-yl - 92-94
a 
215d 8-yl H 26-43 
207d 8-yl - 96-99
a 
216a 3-yl H 70-97
a 
208a 3-yl - 60-90
a 
216a’ 3-yl CH3 75-95
a 
208b 5-yl - 62 216b 5-yl H 84-92
a 
208c 6-yl - 70-90
a 
216c 6-yl H 90-99
a 
208d 8-yl - 72 217a 3-yl H 61 
213b 5-yl - 37 217a’ 3-yl CH3 33 
213c 6-yl - 68 217b 5-yl H 31 
214a 3-yl - 40 217c 6-yl H 27 
214b 5-yl - 12-17 218a 3-yl H 20 
214c 6-yl - 40 218a’ 3-yl CH3 20 
214d 8-yl - 25 218b 5-yl H 15-18 
215a’ 3-yl CH3 15 218c 6-yl H 50 
a
 Crude yields 
 
Finally, the reactivity of methylketones 216a-c was assessed by subjecting them to a reductive 
amination, which would give access to diaminobutane side chains, similar to that of chloroquine 
(Scheme 23). Different reaction conditions were evaluated and are presented in Table 14.  
 
 
Scheme 23 
 
Table 14: Different reaction conditions for the reductive amination of methylketones 216 
A Activator B Amine C Reductant Solvent T Time (h) Yield (%) 
5 AcOH 2 Et2NH 2 NaCNBH3 MeOH r.t. 2 + 20 0 
2 AcOH 2 iPrNH2 2 NaCNBH3 MeOH r.t. 2 + 20 Complex mixture 
2 AcOH 10 iPrNH2 2 NaCNBH3 MeOH r.t. 2 + 20 Complex mixture 
0.6 
 
TiCl4 
 
4 
 
iPrNH2 - 
1.5 
- 
NaBH4 
THF 
MeOH 

r.t. 
2 
23 
Complex mixture 
0.05 
 
pTsOH 
 
1.2 
 
Et2NH - 
2 
- 
NaCNBH3 
Toluene 
MeOH 

r.t. 
18 
18 
Complex mixture 
0.05 
 
pTsOH 
 
1 
 
2-Cl-BnNH2 - 
2 
- 
NaBH4 
Toluene 
MeOH 


18 
1 
Complex mixture 
 
However, none of these reaction conditions resulted in the formation of the desired amines 219. 
Since methylketones 216 could also undergo intramolecular ring closure, this could be (partly) the 
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cause of the obtained complex mixtures. Therefore, it was opted to protect the amino group, but 
protection with di-tert-butyl dicarbonate or benzyl bromide resulted in the formation of the 
corresponding quinolinium salts. Since the quinoline nitrogen is slightly more basic than the amino 
group,393 and the positive charge is more delocalized, the quinolinium salts are favored.  
 
3.3.4. Antiplasmodial assessment of (pyrrolidin-1-yl)quinolines and their ring-opened derivatives 
This small library of (pyrrolidin-1-yl)quinolines 201a-d, 205a-c, 206, 208a-d, 213c, 217a-c and their 
ring-opened derivatives 214a-d, 215a-d, 218a-c (30 compounds in total) were subjected to an 
antiplasmodial assessment at the University of Cape Town, South Africa (Prof. P. J. Smith and Prof. K. 
Chibale). All samples were tested in triplicate against a chloroquine-sensitive (CQS) strain of 
Plasmodium falciparum (NF54). Subsequently, only those samples showing promising antiplasmodial 
activity were tested against a chloroquine-resistant (CQR) strain of P. falciparum (Dd2) and screened 
for in vitro cytotoxicity against a mammalian cell-line, Chinese Hamster Ovarian (CHO), using the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)-assay. The MTT-assay was used to 
measure all growth and survival, and compares well with other available assays.309, 310 The 
tetrazolium salt MTT was used to measure growth and chemosensitivity.  
 
Table 15: IC50 values of (pyrrolidin-1-yl)quinolines 201a-d, 205a-c, 206, 208a-d, 213c, 217a-c and their ring-
opened derivatives 214a-d, 215a-d, 218a-c tested for in vitro antimalarial activity and cytotoxicity 
Compound NF54: IC50 (µM) Dd2: IC50 (µM) CHO: IC50 (µM) SI
a 
RI
b 
201a >51 ND ND ND ND 
201b >51 ND ND ND ND 
201c >51 ND ND ND ND 
201d >51 ND ND ND ND 
205a >23 ND ND ND ND 
205b >23 ND ND ND ND 
206 >17 ND ND ND ND 
208a >47 ND ND ND ND 
208b >47 ND ND ND ND 
208c >47 ND ND ND ND 
208d >47 ND ND ND ND 
213a >50 ND ND ND ND 
213b >50 ND ND ND ND 
213c >50 ND ND ND ND 
214a >46 ND ND ND ND 
214b 19.88 49.01 >100 >5 2.47 
214c >46 ND ND ND ND 
214d >46 ND ND ND ND 
215a’ >39 ND ND ND ND 
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215b 28.24 ND ND ND ND 
215c >41 ND ND ND ND 
215d >41 ND ND ND ND 
217a 31.09 ND ND ND ND 
217a’ 13.26 38.00 293 22 2.87 
217b >47 ND ND ND ND 
217c 41.92 ND ND ND ND 
218a >43 ND ND ND ND 
218a’ >41 ND ND ND ND 
218b 32.56 ND ND ND ND 
218c >43 ND ND ND ND 
CQ (n=14) 0.0209 0.2739 ND ND 13.07 
Artunesate (n=8) 0.0052 0.0114 ND ND 2.19 
Emetine ND ND 0.1248 ND ND 
ND = not determined; CQ = chloroquine; n = number of replicates; 
a
 SI (Selectivity Index) = IC50 CHO/IC50 NF54; 
b
 
RI (Resistance Index) = IC50 Dd2/IC50 NF54. 
 
The results of the biological evaluation are summarized in Table 15. All compounds exhibited 
micromolar potencies against a chloroquine-sensitive NF54 strain of P. falciparum, with IC50 values 
varying beween 13 and 60 µM. Subsequently, the activity of the two most potent compounds (IC50 < 
20 µM) was determined against a chloroquine-resistant strain of P. falciparum (Dd2), again resulting 
in micromolar activities with IC50 values ranging between 38 and 49 µM. 
 
3.3.5. Antifungal evaluation of (pyrrolidin-1-yl)quinolines and ring-opened derivatives 
Finally, the antimicrobial activity of (hydroxyalkylamino)quinoline derivatives 214, 215 and 218 was 
tested against two yeast strains (Candida albicans (IHEM 374) and Rhodotorula bogoriensis 
(MUCL11796)) and one mold strain (Aspergillus flavus (IHEM5785)) at the Centre of Expertise for 
Industrial Biotechnology and Biocatalysis, Ghent University (Prof. T. Desmet). In a preliminary 
screening test, the antifungal activity of these 12 compounds was studied on the aforementioned 
fungi by using the Disk Diffusion susceptibility test.331 This test revealed an interesting profile for six 
compounds (214c, 214d, 215b, 215d, 218a and 218c), displaying antimicrobial activity against all 3 
microorganisms. These compounds were subsequently subjected to a Minimum Inhibitory 
Concentration (MIC) determination test via microdilution 394. The MIC values are reported in Table 
16. 
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Table 16: MIC values 
Compound Candida albicans Rhodotorula bogoriensis       Aspergillus flavus 
 (mg/L) (mM) (mg/L) (mM) (mg/L) (mM) 
214c 250 1.156 250 1.156 1.95 0.009 
214d 250 1.156 7.81 0.036 31.60 0.146 
215b 500 2.048 3.91 0.016 62.50 0.256 
215d 250 1.024 7.81 0.032 15.63 0.064 
218a 250 1.086 62.50 0.272 31.25 0.136 
218c 250 1.086 250 1.086 62.50 0.272 
Amphotericin B <0.195 <0.0002 <0.195 <0.0002 3.125 0.034 
 
The obtained MIC values confirm compounds 214d, 215b and 215d to display promising activity 
against the Rhodotorula bogoriensis yeast strain (MIC values between 0.016 and 0.036 mM) and can 
be considered as promising hit compounds. Furthermore, all (hydroxyalkylamino)quinoline 
derivatives exhibit activity toward the Aspergillus flavus strain, but particularly interesting is the fact 
that compound 214c displays antifungal activity toward A. flavus comparable to Amphotericin B, the 
best-known commercially available antifungal agent. Therefore, compound 214c can be considered 
as a promising novel antifungal (anti-Aspergillus flavus) lead structure.  
 
3.3.6. Immunological testing 
A selection of 5 compounds was assessed for their immunological properties against B-cells and T-
cells by previously described MLR- and B-cell-assays, but all of them were inactive, displaying IC50 
values > 10 µM.  
 
3.3.7. Conclusions 
The approach to functionalize quinolines via molecular hybridization with a chemically reactive 
heterocycle was further elaborated in this chapter. Instead of aziridines, functionalized pyrrolidinyl 
moieties were introduced in novel quinoline chimeras. Subsequently, the reactivity of novel (3-
pyrrolin-1-yl)quinolines was assessed by bromination with molecular bromine, affording tri- and 
pentabrominated derivatives. Reactivity evaluation of (2-oxopyrrolidin-1-yl)quinolines with lithium 
aluminium hydride, sodium borohydride and methyllithium afforded various 
(quinolinylamino)butanols and (quinolinylamino)pentan-2-ones by ring opening of the lactam entity, 
but also reductive removal of the carbonyl group of (2-oxopyrrolidin-1-yl)quinolines to 
pyrrolidinylquinolines took place. It is also clear that the reactivity varies between the different 
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regioisomers, and unique reaction conditions are required for different regioisomers. Furthermore, 
the antiplasmodial activity and cytotoxicity of the novel pyrrolidine-quinoline hybrid class of 
compounds and their functionalized derivatives was evaluated. All tested compounds displayed 
micromolar activity against a chloroquine-sensitive strain of P. falciparum, and two compounds also 
showed micromolar activity against a chloroquine-resistant strain of P. falciparum. Finally, antifungal 
assessment of (hydroxyalkylamino)quinolines resulted in the identification of three compounds 
displaying considerable activity against R. bogoriensis and one compound showing siginificant 
potency against A. flavus. 
 
3.3.8. Experimental section 
3.3.8.1. General methods 
All reagents were purchased from commercial suppliers (Sigma-Aldrich, Acros, TCI), and were used as 
received without any purification, unless otherwise noted. Solvents were dried with sodium (THF) or 
calcium hydride (dichloromethane), and distilled before use. Other solvents were purchased from 
commercial suppliers and used as supplied. The petroleum ether used during product purification 
steps had a boiling range of 40-60 °C. Crude reaction mixtures were analysed by LC/MS/UV. Thin-
layer chromatography was carried out on silica gel 60F254 plates (Merck). Column chromatography 
was performed in a glass column with silica gel (particle size 70-200 µm, pore diameter 60Å). 
Preperative TLC was executed with 2000 µm 20 × 20 cm TLC plates. High-resolution 1H and 13C 
magnetic resonance (NMR) spectra were recorded with Jeol Eclipse+ 300 or Brücker AVANCE-III 400 
MHz NMR spectrometers in CDCl3, unless otherwise noted. Chemical shifts were calibrated using 
tetramethylsilane, which was used as an internal reference, unless otherwise indicated. Peak 
assignments were obtained with the aid of APT and HSQC spectra. Attenuated total reflection (ATR) 
IR spectra were recorded with a Perkin-Elmer Spectrum BX spectrometer, equipped with a ZnSe 
crystal, at room temperature (neat). Low-resolution mass spectra were recorded with an Agilent 
Technologies 1100 series VL mass spectrometer (ESI, 70 eV). High resolution mass spectra were 
obtained with an HPLC coupled to an Agilent Technologies 6210 series time-of-flight mass 
spectrometer equipped with an ESI/APCI-multimode source. Melting points were measured with a 
Büchi B-540 apparatus or Koflerbench, type WME Heizbank of Wagner & Munz. 
 
3.3.8.2. Synthesis of diallylaminoquinolines  
General procedure: To a solution of aminoquinoline 12 (3.5 mmol) in dry tetrahydrofuran (50 mL), 
5.3 mL lithium bis(trimethylsilyl)amide (1M in THF) (3.5 mmol; 1 equiv) and 1.2 mL allyl bromide (14.0 
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mmol, 4 equiv) were added at 0 °C. After stirring for 1 h at reflux conditions under inert atmosphere, 
the flask was cooled to 0 °C and again lithium bis(trimethylsilyl)amide (1M in THF) (5.3 mmol; 1.5 
equiv) was slowly added to the solution. The mixture was again stirred for 1 h at reflux conditions. 
The reaction mixture was quenched with 10 mL of a saturated ammonium chloride solution, poured 
into water (30 mL) and extracted with ethyl acetate (3 × 20 mL). The combined organic layers were 
dried over anhydrous magnesium sulfate and filtration of the drying agent and removal of the 
solvent in vacuo afforded diallylaminoquinolines 171a,h-j in high purities (>90%, 1H NMR). 
 
8-Diallylaminoquinoline 171a (71%) 
Orange-brown oil. Rf (SiO2) = 0.28 (Petroleum ether/EtOAc 9/1). 
1H NMR (300 MHz, 
CDCl3): δ 4.07 (4H, d, J = 6.1 Hz, 2 × CH2N); 5.04 (2H, d, J = 10.5 Hz, 2 × (HCH)=CH); 5.09 
(2H, d, J = 17.6 Hz, 2 × (HCH)=CH); 5.78-5.92 (2H, m, 2 × CH2=CH); 7.00 (1H, dd, J = 7.2, 
1.7 Hz, CHarom); 7.21 (1H, dd, J = 8.3, 3.9 Hz, CHarom); 7.25 (1H, dd, J = 7.2, 1.7 Hz, 
CHarom); 7.29 (1H, t, J = 7.2 Hz, CHarom); 7.94 (1H, dd, J = 8.3, 1.7 Hz, CHarom); 8.80 (1H, 
dd, J = 3.9, 1.7 Hz, CHarom). 
13C NMR (75.6 MHz, ref = CDCl3): δ 55.6 (2 × CH2N); 117.5 (2 
× CH2=CH); 118.5 (HCarom); 120.8 (HCarom); 120.9 (HCarom); 126.4 (HCarom); 129.8 (Carom,quat); 135.2 (2 × 
CH2=CH); 136.5 (HCarom); 143.1 (Carom,quat); 147.4 (Carom,quat); 147.9 (HCarom). IR (cm
-1): νmax = 2976, 1565, 
1498, 1469, 1389, 1241, 1098, 915, 822, 805, 788, 749. MS (70 eV): m/z (%): 225 (M++1, 100). HRMS 
(ESI) calcd for C15H17N2 225.1386 [M+H]
+, found 225.1386.  
 
6-Diallylaminoquinoline 171h (50-70%) 
Brown-yellow oil. Rf (SiO2) = 0.3 (Petroleum ether/EtOAc 9/1). 
1H NMR (400 
MHz, CDCl3): δ 3.89 (4H, d, J = 4.7 Hz, 2 × CH2N); 5.03-5.09 (4H, m, 2 × CH2=CH); 
5.71-5.80 (2H, m, 2 × CH2=CH); 6.65 (1H, d, J = 2.9 Hz, CHarom); 7.08 (1H, dd, J = 
8.2, 4.2 Hz, CHarom); 7.13 (1H, dd, J = 9.3, 2.9 Hz, CHarom); 7.75 (1H, dd, J = 8.2, 
1.6 Hz, CHarom); 7.76 (1H, d, J = 9.3, CHarom); 8.44 (1H, dd, J = 4.2, 1.6 Hz, CHarom). 
13C NMR (100.6 MHz, ref = CDCl3): δ 52.9 (2 × NCH2); 104.8 (HCarom); 116.4 (2 × CH2=CH); 119.2 
(HCarom); 121.3 (HCarom); 129.8 (Carom,quat); 130.0 (HCarom); 133.4 (2 × CH2=CH); 134.0 (HCarom); 142.3 
(Carom,quat); 146.2 (HCarom); 146.8 (Carom,quat). IR (cm
-1): νmax = 3078, 1618, 1589, 1507, 1388, 1356, 1227, 
920, 822. MS (70 eV): m/z (%): 225 (M++1, 100) HRMS (ESI) calcd for C15H17N2 225.1386 [M+H]
+, found 
225.1396.  
 
5-Diallylaminoquinoline 171i (79-95%) 
Orange-brown oil. Rf (SiO2) = 0.27 (Petroleum ether/EtOAc 4/1). 
1H NMR (300 MHz, 
CDCl3): δ 3.78 (4H, d, J = 6.1 Hz, 2 × CH2N); 5.16 (2H, d, J = 10.5 Hz, 2 × (HCH)=CH); 5.24 
(2H, d, J = 17.1 Hz, 2 × (HCH)=CH); 5.78-5.91 (2H, m, 2 × CH2=CH); 7.13 (1H, d, J = 8.3 
Hz, CHarom); 7.38 (1H, dd, J = 8.3, 4.4 Hz, CHarom); 7.60 (1H, t, J = 8.3 Hz, CHarom); 7.80 
(1H, d, J = 8.3 Hz, CHarom); 8.60 (1H, d, J = 8.3 Hz, CHarom); 8.89 (1H, d, J = 4.4 Hz, 
CHarom). 
13C NMR (75.6 MHz, ref = CDCl3): δ 56.4 (2 × CH2N); 117.6 (2 × CH2=CH); 118.0 
(HCarom); 120.3 (HCarom); 124.4 (HCarom); 125.2 (Carom,quat); 129.0 (HCarom); 132.6 (HCarom); 134.5 (2 × 
CH2=CH); 147.9 (Carom,quat); 149.5 (Carom,quat); 150.0 (HCarom). IR (cm
-1): νmax = 3074, 2818, 1588, 1572, 
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1397, 986, 918, 799. MS (70 eV): m/z (%): 225 (M++1, 100). HRMS (ESI) calcd for C15H17N2 225.1386 
[M+H]+, found 225.1392. 
 
3-Diallylaminoquinoline 171j (90-99%) 
Spectral data of 3-diallylaminoquinoline 171j corresponded with data described in the literature.386 
 
3.3.8.3. Synthesis of (3-pyrrolin-1-yl)quinolines 
General procedure: To a solution of diallylaminoquinoline 171 (1.6 mmol) in dry dichloromethane or 
tetrahydrofuran (25 mL), 1st generation Grubbs catalyst (0.2 mmol, 10 mol%) was added (for 8-
diallylaminoquinoline 171a 2nd generation Grubbs catalyst was necessary). After stirring for 24 h at 
room temperature under nitrogen atmosphere, the solvent was removed in vacuo and the crude 
reaction mixture was purified by means of preparative thin layer chromatoghraphy (pTLC) or column 
chromatography on silica gel, affording (3-pyrrolin-1-yl)quinolines 201a-d.  
 
3-(3-pyrrolin-1-yl)quinoline 201a (20-53%) 
Brown crystals. Mp = 134 °C. Rf (SiO2) = 0.39 (Petroleum ether/EtOAc 1/1). 
1H 
NMR (300 MHz, CDCl3): δ 4.29 (4H, s, 2 × CH2N); 6.03 (2H, s, 2 × CHCH2); 6.96 (1H, 
d, J = 2.8 Hz, CHarom); 7.36-7.45 (2H, m, 2 × CHarom); 7.64 (1H, dd, J = 7.2, 2.8 Hz, 
CHarom); 7.96 (1H, dd, J = 7.2, 2.8 Hz, CHarom); 8.54 (1H, d, J = 2.8 Hz, CHarom). 
13C 
NMR (75.6 MHz, ref = CDCl3): δ 54.5 (2 × CH2N); 110.6 (HCarom); 124.5 (HCarom); 125.9 (HCarom); 126.2 (2 
× CH2CH); 126.9 (HCarom); 129.1 (HCarom); 129.7 (Carom,quat); 140.1 (HCarom); 140.5 (Carom,quat); 141.3 
(Carom,quat). IR (cm
-1): νmax = 3028, 2922, 2834, 1597, 1437, 1402, 834, 740, 674, 673. MS (70 eV): m/z 
(%): 197 (M++1, 100). HRMS (ESI) calcd for C13H13N2 197.1073 [M+H]
+, found 197.1073.  
 
5-(3-pyrrolin-1-yl)quinoline 201b (48-82%) 
Orange-brown oil. Rf (SiO2) = 0.13-0.31 (Petroleum ether/EtOAc 4/1). 
1H NMR (400 MHz, 
CDCl3): δ 4.37 (4H, s, 2 × CH2N); 5.98 (2H, s, 2 × CHCH2); 6.98 (1H, dd, J = 7.6, 0.9 Hz, 
CHarom); 7.31 (1H, dd, J = 8.7, 4.1 Hz, CHarom); 7.59 (1H, dd, J = 8.3, 7.6 Hz, CHarom); 7.65 
(1H, dd, J = 8.3, 0.9 Hz, CHarom); 8.64 (1H, dd, J = 8.7, 1.7 Hz, CHarom); 8.85 (1H, dd, J = 4.1, 
1.7 Hz, CHarom). 
13C NMR (100.6 MHz, ref = CDCl3) δ 59.0 (2 × CH2N); 111.5 (HCarom); 118.8 
(HCarom); 121.4 (HCarom); 122.4 (Carom,quat); 126.5 (2 × CH2CH); 129.6 (HCarom); 133.4 
(HCarom); 147.0 (Carom,quat); 149.7 (HCarom); 149.9 (Carom,quat). IR (cm
-1): νmax = 2848, 1570, 1461, 1410, 
1307, 907, 784, 727, 674. MS (70 eV): m/z (%): 197 (M++1, 100). HRMS (ESI) calcd for C13H13N2 
197.1073 [M+H]+, found 197.1076.  
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6-(3-pyrrolin-1-yl)quinoline 201c (50-80%) 
Brown-yellow oil. Rf (SiO2) = 0.15 (Petroleum ether/EtOAc 2/1). 
1H NMR (400 
MHz, CDCl3): δ 4.22 (4H, s, 2 × CH2N); 5.99 (2H, s, 2 × CHCH2); 6.59 (1H, d, J = 2,7 
Hz, CHarom); 7.15 (1H, dd, J = 9.2, 2.7 Hz, CHarom); 7.25 (1H, dd, J = 8.4, 4.1 Hz, 
CHarom); 7.93 (1H, dd, J = 8.4, 1.5 Hz, CHarom); 7.97 (1H, d, J = 9.2 Hz, CHarom); 8.59 
(1H, dd, J = 4.1, 1.5 Hz, CHarom). 
13C NMR (100.6 MHz, ref = CDCl3): δ 54.6 (2 × 
NCH2); 103.1 (HCarom); 118.5 (HCarom); 121.4 (HCarom); 126.3 (2 × CH2CH); 130.1 (HCarom); 130.2 
(Carom,quat); 133.9 (HCarom); 141.8 (Carom,quat); 145.1 (Carom,quat); 145.5 (HCarom). IR (cm
-1): νmax = 3030, 
1629, 1615, 1588, 1508, 1467, 1438, 1375, 1346, 1173, 1124, 672. MS (70 eV): m/z (%): 197 (M++1, 
100). HRMS (ESI) calcd for C13H13N2 197.1073 [M+H]
+, found 197.1077.  
 
8-(3-pyrrolin-1-yl)quinoline 201d (16-53%) 
Orange viscous oil. Rf (SiO2) = 0.59-0.67 (Petroleum ether/EtOAc 4/1). 
1H NMR (400 MHz, 
CDCl3): δ 4.72 (4H, s, 2 × CH2N); 5.99 (2H, s, 2 × CHCH2); 6.68 (1H, dd, J = 7.9, 0.9 Hz, 
CHarom); 7.09 (1H, dd, J = 7.9, 0.9 Hz, CHarom); 7.29 (1H, dd, J = 8.3, 4.1 Hz, CHarom); 7.38 
(1H, t, J = 7.9 Hz, CHarom); 8.02 (1H, dd, J = 8.3, 1.9 Hz, CHarom); 8.72 (1H, dd, J = 4.1, 1.9 
Hz, CHarom). 
13C NMR (100.6 MHz, ref = CDCl3) δ 58.3 (2 × NCH2); 109.4 (HCarom); 115.2 
(HCarom); 120.6 (HCarom); 126.2 (2 × CH2CH); 127.3 (HCarom); 130.1 (Carom,quat); 135.6 (HCarom); 140.6 
(Carom,quat); 145.4 (Carom,quat); 145.5 (HCarom). IR (cm
-1): νmax = 2853, 1561, 1503, 1476, 1461, 1426, 1398, 
1363, 1336, 1166, 1121, 810, 784, 747, 733, 674. MS (70 eV): m/z (%): 197 (M++1, 100). HRMS (ESI) 
calcd for C13H13N2 197.1073 [M+H]
+, found 197.1075. 
 
3.3.8.4. Synthesis of 1-bromoquinolinyl-3,4-dibromopyrrolidines 
General procedure: To a solution of (3-pyrrolin-1-yl)quinolines 201 (0.5 mmol) in dry 
dichloromethane or tetrahydrofuran (25 mL) at 0 °C, bromine (1.0 mmol, 2 equiv) was slowly added. 
After stirring for 1 h at 0 °C under inert atmosphere, the reaction mixture was poured into water (20 
mL) and extracted with ethyl acetate (3 × 15 mL). The combined organic layers were washed with a 
saturated sodium bicarbonate solution (20 mL) and subsequently dried over anhydrous magnesium 
sulfate. Filtration of the drying agent and removal of the solvent in vacuo afforded the crude 
products 205a-c, which were purified by means of column chromatography on silica gel followed by 
purification by means of pTLC. 
 
1-(4-Bromoquinolin-3-yl)-trans-3,4-dibromopyrrolidine 205a (28%) 
Light-yellow powder. Mp = 118.5 °C. Rf (SiO2) = 0.51 (Petroleum ether/EtOAc 
3/1). 1H NMR (300 MHz, CDCl3): δ 3.91 (2H, d, J = 11.6 Hz, 2 × N(HCH)); 4.73 
(2H, d, J = 3.9 Hz, 2 × CHBr); 4.93 (2H, dd, J = 11.6, 3.9 Hz, 2 × N(HCH)); 7.59-
7.61 (2H, m, 2 × CHarom); 8.02 (1H, dd, J = 6.1, 3.3 Hz, CHarom); 8.19 (1H, dd, J = 
6.1, 3.3 Hz, CHarom); 8.70 (1H, s, CHarom). 
13C NMR (75.6 MHz, ref = CDCl3): δ 
51.2 (2 × CHBr); 58.0 (2 × CH2N); 120.3 (Carom,quat); 126.0 (HCarom); 127.6 (HCarom); 128.4 (HCarom); 129.0 
(Carom,quat); 129.5 (HCarom); 140.6 (Carom,quat); 143.1 (HCarom); 144.4 (Carom,quat). IR (cm
-1): νNH = 3330, νmax = 
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2924, 1552, 1368, 1343, 1316, 759, 732. MS (70 eV): m/z (%): 433/435/437/439 (M++1, 100). HRMS 
(ESI) calcd for C13H12Br3N2 432.8545 [M+H]
+, found 432.8543.  
 
1-(6-Bromoquinolin-5-yl)-trans-3,4-dibromopyrrolidine 205b (28-34%) 
Orange-red powder. Mp = 145.5 °C. Rf (SiO2) = 0.24-0.38 (Petroleum ether/EtOAc 
4/1). 1H NMR (400 MHz, CDCl3): δ 3.75 (2H, dt, J = 11.7, 1.1 Hz, 2 × N(HCH)); 4.58 (2H, 
dd, J = 11.7, 4.1 Hz, 2 × N(HCH)); 4.71 (2H, dt, J = 4.1, 1.1 Hz, 2 × CHBr); 6.95 (1H, d, J 
= 8.3 Hz, CHarom); 7.44 (1H, dd, J = 8.6, 4.2 Hz, CHarom); 7.92 (1H, d, J = 8.3 Hz, CHarom); 
8.48 (1H, dd, J = 8.6, 1.6 Hz, CHarom); 9.03 (1H, dd, J = 4.2, 1.6 Hz, CHarom). 
13C NMR 
(100.6 MHz, ref = CDCl3) δ 50.8 (2 × CHBr); 59.5 (2 × CH2N); 113.3 (HCarom); 120.0 
(HCarom); 124.2 (Carom,quat); 128.2 (Carom,quat); 134.8 (HCarom); 136.7 (HCarom); 143.1 (Carom,quat); 146.3 
(Carom,quat); 149.6 (HCarom). IR (cm
-1): νmax = 2922, 1577, 1558, 1453, 1407, 1389, 1361, 1312, 1269, 
1219, 1212, 1148, 786, 764. MS (70 eV): m/z (%): 433/435/437/439 (M++1, 100). HRMS (ESI) calcd for 
C13H12Br3N2 432.8545 [M+H]
+, found 432.8530.  
 
1-(5-Bromoquinolin-6-yl)-trans-3,4-dibromopyrrolidine 205c (14%)  
Brown-yellow oil. Rf (SiO2) = 0.32 (Petroleum ether/EtOAc 3/1). 
1H NMR (400 
MHz, CDCl3): δ 3.83 (2H, d, J = 12.0 Hz, 2 × N(HCH)); 4.69 (2H, dt, J = 3.9, 1.0 
Hz, 2 × CHBr); 4.84 (2H, dd, J = 12.0, 3.9 Hz, 2 × N(HCH)); 7.43 (1H, dd, J = 8.6, 
4.2 Hz, CHarom); 7.52 (1H, d, J = 9.2 Hz, CHarom); 8.01 (1H, d, J = 9.2 Hz, CHarom); 
8.55 (1H, dd, J = 8.6, 1.5 Hz, CHarom); 8.76 (1H, dd, J = 4.2, 1.5 Hz, CHarom). 
13C 
NMR (100.6 MHz, ref = CDCl3): δ 51.3 (2 × CHBr); 58.2 (2 × NCH2); 109.7 
(Carom,quat); 122.0 (HCarom); 122.4 (HCarom); 129.5 (Carom,quat); 129.6 (HCarom); 134.7 (HCarom); 144.8 
(Carom,quat); 145.4 (Carom,quat); 148.4 (HCarom). IR (cm
-1): νmax = 2850, 1610, 1498, 1356, 800. MS (70 eV): 
m/z (%): 433/435/437/439 (M++1, 100). HRMS (ESI) calcd for C13H12Br3N2 432.8545 [M+H]
+, found 
432.8545. . 
 
3.3.8.5. Synthesis of 1-(5-bromoquinolin-6-yl)-2,3,4,5-tetrabromopyrrole 
To an ice-cooled solution of 6-(3-pyrrolin-1-yl)quinoline 201c (0.5 mmol) in dry dichloromethane (25 
mL), bromine (2.0 mmol, 2 equiv) was slowly added. After stirring for 2 h at room temperature, the 
reaction mixture was poured into water (20 mL) and extracted with ethyl acetate (3 × 15 mL). The 
combined organic layers were washed with a saturated sodium bicarbonate solution (20 mL) and 
subsequently dried over anhydrous magnesium sulfate. Filtration of the drying agent and removal of 
the solvent in vacuo afforded the crude mixture, and 1-(5-bromoquinolin-6-yl)-2,3,4,5-
tetrabromopyrrole 206 was isolated after column chromatography on silica gel followed by 
purification by means of pTLC. 
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1-(5-Bromoquinolin-6-yl)-2,3,4,5-tetrabromopyrrolidine 206 (9%) 
Yellow oil. Rf (SiO2) = 0.4 (Petroleum ether/EtOAc 4/1). 
1H NMR (400 MHz, 
CDCl3): δ 7.56 (1H, d, J = 8.9 Hz, CHarom); 7.64 (1H, dd, J = 8.6, 4.2 Hz, CHarom); 
8.24 (1H, dd, J = 8.9, 0.7 Hz, CHarom); 8.68 (1H, ddd, J = 8.6, 1.6, 0.7 Hz, CHarom); 
9.07 (1H, dd, J = 4.2, 1.6 Hz, CHarom). 
13C NMR (100.6 MHz, ref = CDCl3): δ 
103.1 (2 × CquatN); 104.2 (2 × Cquat); 123.2 (HCarom); 124.8 (Carom,quat); 128.2 
(Carom,quat); 130.0 (HCarom); 130.6 (HCarom); 135.8 (Carom,quat); 136.5 (HCarom); 148.7 (Carom,quat); 152.6 
(HCarom). IR (cm
-1): νmax = 2922, 1490, 1458, 1367, 1318, 1297, 1284, 955, 833, 808, 770. MS (70 eV): 
m/z (%): 585/587/589/591/593/595 (M++1, 100). HRMS (ESI) calcd for C13H6Br5N2 584.6442 [M+H]
+, 
found 584.6452.  
 
3.3.8.6. Synthesis of 4-chloro-N-(quinolinyl)butanamides 
General procedure: To a solution of aminoquinoline 12 (3.5 mmol) in dry dichloromethane (40 mL) 
under nitrogen atmosphere were added potassium carbonate (10.5 mmol, 3 equiv) and butyryl 
chloride (3.5 mmol, 1 equiv). After stirring for 2 h at room temperature, the reaction mixture was 
poured into water (30 mL) and extracted with dichloromethane (3 × 15 mL). The combined organic 
layers were subsequently dried over anhydrous magnesium sulfate. Filtration of the drying agent and 
removal of the solvent in vacuo afforded the crude 4-chloro-N-(quinolinyl)butanamides 207a-d, 
which were used as such for the next reaction. 
 
4-Chloro-N-(quinolin-3-yl)butanamide 207a (71-97%) 
 Light-yellow crystals. Mp = 138 °C. Rf (SiO2) = 0.27 (Petroleum 
ether/EtOAc 1/2). 1H NMR (300 MHz, CDCl3): δ 2.27 (2H, quint, J = 6.6 Hz, 
CH2CH2Cl); 2.69 (2H, t, J = 6.6 Hz, CH2CO); 3.71 (2H, t, J = 6.6 Hz, CH2Cl); 
7.55 (1H, t, J = 7.2 Hz, CHarom); 7.55 (1H, s (broad), NH); 7.65 (1H, t, J = 7.2 
Hz, CHarom); 7.81 (1H, d, J = 7.2 Hz, CHarom); 8.05 (1H, d, J = 7.2 Hz, CHarom); 8.75 (1H, d, J = 2.2 Hz, 
CHarom); 8.78 (1H, d, J = 2.2 Hz, CHarom). 
13C NMR (75.6 MHz, ref = CDCl3): δ 27.9 (CH2CH2Cl); 34.0 
(CH2CO); 44.5 (CH2Cl); 124.8 (HCarom); 127.6 (HCarom); 127.9 (HCarom); 128.2 (HCarom); 128.4 (Carom,quat); 
128.8 (HCarom); 131.9 (Carom,quat); 143.6 (HCarom); 144.4 (Carom,quat); 171.3 (C=O). IR (cm
-1): νNH = 3324, 
νC=O = 1549, νmax = 2964, 1695, 1676, 1581, 1532, 1384, 746. MS (70 eV): m/z (%): 249/251 (M
++1, 
100). HRMS (ESI) calcd for C13H14ClN2O 249.0789 [M+H]
+, found 249.0792.  
 
4-Chloro-N-(quinolin-5-yl)butanamide 207b (44-98%) 
Light yellow powder. Mp = 115 °C. Rf (SiO2) = 0.25 (100% EtOAc). 
1H NMR (300 
MHz, CDCl3): δ 2.26 (2H, quint, J = 6.6 Hz, CH2CH2Cl); 2.71 (2H, t, J = 6.6 Hz, CH2CO); 
3.71 (2H, t, J = 6.6 Hz, CH2Cl); 7.40 (1H, dd, J = 8.3, 4.4 Hz, CHarom); 7.67 (1H, t, J = 
8.3 Hz, CHarom); 7.78 (1H, d, J = 8.3 Hz, CHarom); 7.80 (1H, d, J = 4.4 Hz, CHarom); 7.97 
(1H, d, J = 8.3 Hz, CHarom); 8.18 (1H, d, J = 8.2 Hz, CHarom); 8.91 (1H, s (broad), NH). 
13C NMR (75.6 MHz, ref = CDCl3) δ 28.0 (CH2CH2Cl); 33.8 (CH2CO); 44.6 (CH2Cl); 
121.2 (HCarom); 122.4 (HCarom); 123.2 (Carom,quat); 127.8 (HCarom); 129.3 (HCarom); 130.2 (HCarom); 132.2 
(Carom,quat); 148.5 (Carom,quat); 150.5 (HCarom); 171.1 (C=O). IR (cm
-1): νNH = 3283, νC=O = 1660, νmax = 1524, 
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1492, 796, 698, 644. MS (70 eV): m/z (%): 249/251 (M++1, 100). HRMS (ESI) calcd for C13H14ClN2O 
249.0789 [M+H]+, found 249.0797.  
 
4-Chloro-N-(quinolin-6-yl)butanamide 207c (65-99%) 
 Light-yellow crystals. Mp = 144 °C. Rf (SiO2) = 0.19 (Petroleum 
ether/EtOAc 1/2). 1H NMR (300 MHz, CDCl3): δ 2.25 (2H, quint, J = 6.6 
Hz, CH2CH2Cl); 2.65 (2H, t, J = 6.6 Hz, CH2CO); 3.69 (2H, t, J = 6.6 Hz, 
CH2Cl); 7.40 (1H, dd, J = 8.8, 4.4 Hz, CHarom); 7.57 (1H, dd, J = 8.8, 2.8 Hz, 
CHarom); 7.98 (1H, s (broad), NH); 8.04 (1H, d, J = 8.8 Hz, CHarom); 8.12 (1H, d, J = 8.8 Hz, CHarom); 8.41 
(1H, s, CHarom); 8.84 (1H, d, J = 4.4 Hz, CHarom). 
13C NMR (75.6 MHz, ref = CDCl3): δ 27.9 (CH2CH2Cl); 
34.2 (CH2CO); 44.5 (CH2Cl); 116.3 (HCarom); 121.8 (HCarom); 123.3 (HCarom); 128.9 (Carom,quat); 130.1 
(HCarom); 135.9 (Carom,quat); 136.2 (HCarom); 145.4 (Carom,quat); 149.4 (HCarom); 170.6 (C=O). IR (cm
-1): νNH = 
3259, νC=O = 1684, νmax = 2922, 1581, 1561, 1382, 1239, 1233, 828, 802. MS (70 eV): m/z (%): 249/251 
(M++1, 100). HRMS (ESI) calcd for C13H14ClN2O 249.0789 [M+H]
+, found 249.0794.  
 
4-Chloro-N-(quinolin-8-yl)butanamide 207d (37-99%) 
Beige powder. Mp = 64 °C. Rf (SiO2) = 0.25 (Petroleum ether/EtOAc 9/1). 
1H NMR 
(300 MHz, CDCl3): δ 2.29 (2H, quint, J = 6.6 Hz, CH2CH2Cl); 2.78 (2H, t, J = 6.6 Hz, 
CH2CO); 3.72 (2H, t, J = 6.6 Hz, CH2Cl); 7.47 (1H, dd, J = 8.3, 4.4 Hz, CHarom); 7.52 
(1H, t, J = 6.6 Hz, CHarom); 7.53 (1H, d, J = 6.6 Hz, CHarom); 8.18 (1H, d, J = 8.3 Hz, 
CHarom); 8.76 (1H, d, J = 6.6 Hz, CHarom); 8.82 (1H, d, J = 4.4 Hz, CHarom); 9.87 (1H, s 
(broad), NH). 13C NMR (75.6 MHz, ref = CDCl3) δ 28.1 (CH2CH2Cl); 34.7 (CH2CO); 
44.6 (CH2Cl); 116.7 (HCarom); 121.70 (HCarom); 121.74 (HCarom); 127.5 (HCarom); 128.1 (Carom,quat); 134.4 
(Carom,quat); 136.6 (HCarom); 138.2 (Carom,quat); 148.2 (HCarom); 170.5 (C=O). IR (cm
-1): νC=O = 1695, νNH = 
3355, νmax = 1519, 1483, 1322, 1144, 826, 790, 661. MS (70 eV): m/z (%): 249 /251 (M
++1,100). HRMS 
(ESI) calcd for C13H14ClN2O 249.0789 [M+H]
+, found 249.0790.  
 
3.3.8.7. Synthesis of (2-oxopyrrolidin-1-yl)quinolines 
General procedure: To a solution of 1-quinolinyl-4-chlorobutyramides 207 (2.7 mmol) in acetonitrile 
(40 mL) was added potassium tert-butoxide (4.1 mmol, 1.5 equiv). After stirring for 2 h at reflux 
conditions the reaction mixture was poured into brine (30 mL) and extracted with ethyl acetate (3 × 
15 mL). The combined organic layers were subsequently dried over anhydrous magnesium sulfate. 
Filtration of the drying agent and removal of the solvent in vacuo afforded (2-oxopyrrolidin-1-
yl)quinolines 208a-d, which were purified by means of column chromatography on silica gel. 
 
3-(2-oxopyrrolidin-1-yl)quinoline 208a (60-90%) 
Spectral data of 3-(2-oxopyrrolidin-1-yl)quinoline 208 corresponded with data described in the 
literature.395  
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5-(2-oxopyrrolidin-1-yl)quinoline 208b (62%) 
 Yellow oil. Rf (SiO2) = 0.03 (100% EtOAc). 
1H NMR (300 MHz, CDCl3): δ 2.35 (2H, quint, J = 
7.7 Hz, CH2CH2CO); 2.72 (2H, t, J = 7.7 Hz, CH2CO); 3.89 (2H, t, J = 7.7 Hz, CH2N); 7.44 (1H, 
dd, J = 8.3, 2.9 Hz, CHarom); 7.45 (1H, d, J = 8.3 Hz, CHarom); 7.73 (1H, t, J = 8.3 Hz, CHarom); 
8.10 (2H, d, J = 8.3 Hz, 2 × CHarom); 8.94 (1H, d, J = 2.8 Hz, CHarom). 
13C NMR (75.6 MHz, ref 
= CDCl3) δ 19.4 (CH2CH2CO); 31.6 (CH2CO); 52.0 (CH2N); 121.6 (HCarom); 124.4 (HCarom); 
125.0 (Carom,quat); 129.1 (HCarom); 129.7 (HCarom); 131.8 (HCarom); 135.7 (Carom,quat); 149.0 
(Carom,quat); 150.9 (HCarom); 175.5 (C=O). IR (cm
-1): νC=O = 1678, νmax = 1595, 1416, 1402, 1297, 1246, 802, 
726, 668. MS (70 eV): m/z (%): 213 (M++1,100). HRMS (ESI) calcd for C13H13N2O 213.1022 [M+H]
+, 
found 213.1032.  
 
6-(2-oxopyrrolidin-1-yl)quinoline 208c (70-90%) 
Brown-red crystals. Mp = 125 °C. Rf (SiO2) = 0.10 (100% EtOAc). 
1H NMR (300 MHz, 
CDCl3): δ 2.20 (2H, quint, J = 7.7 Hz, CH2CH2CO); 2.66 (2H, t, J = 7.7 Hz, CH2CO); 
3.96 (2H, t, J = 7.7 Hz, CH2N); 7.73 (1H, dd, J = 7.7, 3.9 Hz, CHarom); 7.96 (1H, s, 
CHarom); 8.07-8.15 (3H, m, 3 × CHarom); 8.84 (1H, d, J = 3.9 Hz, CHarom).
 13C NMR (75.6 
MHz, ref = CDCl3): δ 17.9 (NCH2CH2); 32.8 (CH2CO); 48.8 (NCH2); 116.2 (HCarom); 
121.6 (HCarom); 122.9 (HCarom); 128.4 (Carom,quat); 129.9 (HCarom); 135.8 (HCarom); 137.6 (Carom,quat); 145.4 
(Carom,quat); 149.7 (HCarom); 174.6 (C=O). IR (cm
-1): νC=O = 1689, νmax = 2924, 1505, 1402, 1370, 1332, 
1295, 1242, 1219, 879, 838. MS (70 eV): m/z (%): 213 (M++1, 100). HRMS (ESI) calcd for C13H13N2O 
213.1022 [M+H]+, found 213.1029.  
 
8-(2-oxopyrrolidin-1-yl)quinoline 208d (72%) 
Spectral data of 8-(2-oxopyrrolidin-1-yl)quinoline 208d corresponded with data described in the 
literature.396 
 
3.3.1.1. Synthesis of 6-(pyrrolidin-1-yl)quinoline  
To a solution of (2-oxopyrrolidin-1-yl)quinolines 208 (0.5 mmol) in dry tetrahydrofuran (25 mL), a 
lithium aluminium hydride solution (1M in THF) (0.8 mmol, 1.5 equiv) was added slowly under inert 
atmosphere at 0 °C. After stirring for 3 h at reflux conditions, the reaction mixture was quenched 
with 10 mL of saturated ammonium chloride solution, poured into water (20 mL) and extracted with 
ethyl acetate (3 × 15 mL). The combined organic layers were dried over anhydrous magnesium 
sulfate. Filtration of the drying agent and removal of the solvent in vacuo afforded (pyrrolidin-1-
yl)quinoline 213a-c, which was purified by means of column chromatography on silica gel. 
 
3-(Pyrrolidin-1-yl)quinoline 213a (40%) 
Spectral data of 3-(pyrrolidin-1-yl)quinoline 123a corresponded with data described in the 
literature.397 
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5-(Pyrrolidin-1-yl)quinoline 213b (37%) 
Spectral data of 5-(pyrrolidin-1-yl)quinoline 213b corresponded with data described in the 
literature.398 
 
6-(Pyrrolidin-1-yl)quinoline 213c (68%) 
Spectral data of 6-(pyrrolidin-1-yl)quinoline 213c corresponded with data described in the 
literature.399  
 
3.3.8.8. Synthesis of 4-(quinolinylamino)butanols 
General procedure: To a solution of (2-oxopyrrolidin-1-yl)quinolines 208 (0.5 mmol) in dry 
tetrahydrofuran (25 mL) lithium aluminium hydride solution (1M in THF) (0.8 mmol, 1.5 equiv) was 
added slowly under inert atmosphere at 0 °C. After stirring for 2.5 h at room temperature, methanol 
(25 mL) and sodium borohydride (0.8 mmol, 1.5 equiv) were added to the mixture. The solution was 
stirred for three additional hours at room temperature. Finally the reaction mixture was poured into 
water (20 mL) and extracted with ethyl acetate (3 × 15 mL). The combined organic layers were dried 
over anhydrous magnesium sulfate. Filtration of the drying agent and removal of the solvent in vacuo 
afforded 4-(quinolinylamino)butanols 214a-d, which were purified by means of pTLC. 
 
4-(Quinolin-3-ylamino)butanol 214a (40%) 
 Yellow oil. Mp = 122 °C. Rf (SiO2) = 0.11 (100% EtOAc). 
1H NMR (300 
MHz, CDCl3): δ 1.70-1.87 (4H, m, CH2CH2CH2OH); 3.27 (2H, t, J = 6.6 Hz, 
CH2NH); 3.75 (2H, t, J = 6.6 Hz, CH2OH); 7.03 (1H, d, J = 2.2 Hz, CHarom); 
7.38-7.45 (2H, m, 2 × CHarom); 7.62 (1H, d, J = 7.7 Hz, CHarom); 7.94 (1H, d, 
J = 7.7 Hz, CHarom); 8.84 (1H, d, J = 2.2 Hz, CHarom). 
13C NMR (75.6 MHz, ref = CDCl3): δ 25.7 
(CH2CH2NH); 30.3 (CH2CH2OH); 43.6 (CH2NH); 62.5 (CH2OH); 110.1 (HCarom); 125.0 (HCarom); 126.0 
(HCarom); 127.1 (HCarom); 128.9 (HCarom); 129.7 (Carom,quat); 141.8 (Carom,quat); 141.9 (Carom,quat); 143.4 
(HCarom). IR (cm
-1): νOH,NH = 3328, 3162, νmax = 2941, 2859, 1612, 1537, 1060, 1017, 778, 753. MS (70 
eV): m/z (%): 217 (M++1, 100). HRMS (ESI) calcd for C13H17N2O 217.1335 [M+H]
+, found 217.1343.  
 
4-(Quinolin-5-ylamino)butanol 214b (12-17%) 
Yellow crystals. Mp = 124 °C. Rf (SiO2) = 0.11-0.30 (100% EtOAc). 
1H NMR (400 
MHz, (CD3)2CO): δ 1.58 (2H, quint, J = 6.7 Hz, CH2CH2OH); 1.74 (2H, quint, J = 6.7 
Hz, CH2CH2NH); 2.78 (2H, s (broad), NH + OH); 3.20 (2H, t, J = 6.7 Hz, CH2NH); 3.51 
(2H, t, J = 6.7 Hz, CH2OH); 6.50 (1H, d, J = 8.1 Hz, CHarom); 7.18 (1H, d, J = 8.1 Hz, 
CHarom); 7.21 (1H, dd, J = 8.6, 4.2 Hz, CHarom); 7.39 (1H, t, J = 8.1 Hz, CHarom); 8.56 
(1H, dd, J = 8.6, 1.7 Hz, CHarom); 8.66 (1H, dd, J = 4.2, 1.7 Hz, CHarom). 
13C NMR (100.6 MHz, ref = CDCl3) 
δ 23.9 (CH2CH2N); 28.5 (CH2CH2OH); 42.2 (CH2NH); 60.6 (CH2OH); 102.6 (HCarom); 116.2 (HCarom); 116.6 
(Carom,quat); 117.3 (HCarom); 127.0 (HCarom); 128.6 (HCarom); 141.9 (Carom,quat); 147.2 (Carom,quat); 147.9 
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(HCarom). IR (cm
-1): νNH, OH = 3353, νmax = 2925, 15.86, 1418, 1351, 1329, 1050, 1025, 793. MS (70 eV): 
m/z (%): 217 (M++1,100). HRMS (ESI) calcd for C13H17N2O 217.1335 [M+H]
+, found 217.1338.  
 
4-(Quinolin-6-ylamino)butanol 214c (40%) 
Yellow oil. Rf (SiO2) = 0.17 (CH3CN/CH2Cl2 1/3). 
1H NMR (400 MHz, CDCl3): 
δ 1.69-1.83 (4H, m, CH2CH2CH2OH); 3.23 (2H, t, J = 6.7 Hz, CH2NH); 3.73 
(2H, t, J = 6.1 Hz, CH2OH); 6.66 (1H, d, J = 2.6 Hz, CHarom); 7.05 (1H, dd, J = 
9.1, 2.6 Hz, CHarom); 7.25 (1H, dd, J = 8.2, 4.3 Hz, CHarom); 7.85 (1H, d, J = 
9.1 Hz, CHarom); 7.91 (1H, dd, J = 8.2, 1.6 Hz, CHarom); 8.57 (1H, dd, J = 4.3, 1.6 Hz, CHarom). 
13C NMR 
(100.6 MHz, Ref = CDCl3): δ 25.8 (CH2CH2N); 30.3 (CH2CH2OH); 43.7 (CH2NH); 62.4 (CH2OH); 102.7 
(HCarom); 121.3 (HCarom); 121.7 (HCarom); 129.8 (HCarom); 130.3 (Carom,quat); 134.1 (HCarom); 142.7 
(Carom,quat); 145.6 (HCarom); 146.4 (Carom,quat). IR (cm
-1): νOH, NH = 3313, νmax = 2935, 2864, 1624, 1523, 
1383, 1247, 828. MS (70 eV) m/z (%): 217 (M++1, 100). HRMS (ESI) calcd for C13H17N2O: 217.1335 
[M+H]+, found: 217.1337.  
 
4-(Quinolin-8-ylamino)butanol 214d (25%) 
 Light yellow-green oil. Rf (SiO2) = 0.23-0.32 (Petroleum ether/EtOAc 1/1). 
1H NMR 
(400 MHz, CDCl3): δ 1.71-1.78 (2H, m, CH2CH2OH); 1.81-1.88 (2H, m, CH2CH2NH); 
1.96 (1H, s (broad), OH); 3.32 (2H, t, J = 6.2 Hz, CH2NH); 3.70 (2H, t, J = 6.2 Hz, 
CH2OH); 6.13 (1H, s (broad), NH); 6.66 (1H, dd, J = 7.9, 0.9 Hz, CHarom); 7.03 (1H, 
dd, J = 7.9, 0.9 Hz, CHarom); 7.34 (1H, dd, J = 8.3, 4.2 Hz, CHarom); 7.37 (1H, t, J = 7.9 
Hz, CHarom); 8.03 (1H, dd, J = 8.3, 1.7 Hz, CHarom); 8.69 (1H, dd, J = 4.4, 1.7 Hz, CHarom). 
13C NMR (100.6 
MHz, ref = CDCl3) δ 25.7 (CH2CH2NH); 30.5 (CH2CH2OH); 43.2 (CH2NH); 62.6 (CH2OH); 104.7 (HCarom); 
113.7 (HCarom); 121.4 (HCarom); 127.8 (HCarom); 128.7 (Carom,quat); 136.1 (HCarom); 138.2 (Carom,quat); 144.8 
(Carom,quat); 146.8 (HCarom). IR (cm
-1): νNH, OH = 3400, νmax = 2936, 1575, 1519, 1476, 1379, 1337, 907, 
817, 789, 728. MS (70 eV): m/z (%): 217 (M++1,100). HRMS (ESI) calcd for C13H17N2O 217.1335 
[M+H]+, found 217.1333. 
 
3.3.8.9. Synthesis of 5-quinolinylamino-2-methylpentan-2-ols 
1st method: To a solution of 6-(2-oxopyrrolidin-1-yl)quinoline 208c (0.5 mmol) in dry tetrahydrofuran 
(25 mL), a methyllithium solution (1.6M in Et2O) (0.5 mmol, 1 equiv) was added slowly under inert 
atmosphere at 0 °C. After stirring for 1 h at 0 °C, again methyllithium solution (1.6M in Et2O) (0.5 
mmol, 1 equiv) was added slowly to the mixture, which was stirred for one additional hour at 0 °C. 
This step is repeated two more times until a total of 4 equiv of methyllithium has been added. Finally 
the reaction mixture was quenched with 20 mL of saturated ammonium chloride solution, poured 
into water (30 mL) and extracted with ethyl acetate (3 × 15 mL). The combined organic layers were 
washed with a saturated sodium bicarbonate solution (20 mL) and subsequently dried over 
anhydrous magnesium sulfate. Filtration of the drying agent and removal of the solvent in vacuo 
afforded 5-quinolin-6-ylamino-2-methylpentan-2-ol 215c, which was purified by means of pTLC. 
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2nd method: To a solution of 5-(quinolinylamino)pentan-2-ones 216a-b (0.5 mmol) in dry 
tetrahydrofuran (25 mL), a methylmagnesium iodide (3M in THF) (1.0 mmol, 2 equiv) was added 
under inert atmosphere at 0 °C. After stirring for 2 h at 0 °C the reaction mixture was quenched with 
a solution of saturated ammonium chloride (10 mL) and extracted with ethyl acetate (3 × 15 mL). The 
combined organic layers were dried over anhydrous magnesium sulfate. Filtration of the drying agent 
and removal of the solvent in vacuo afforded 5-(quinolinylamino)-2-methylpentan-2-ols 215a-b, 
which were purified by means of pTLC. 
3rd method: To a solution of 8-(2-oxopyrrolidin-1-yl)quinoline 208d (0.5 mmol) in dry tetrahydrofuran 
(25 mL), a methyllithium solution (1.6M in Et2O) (0.5 mmol, 1 equiv) was added slowly under inert 
atmosphere at 0 °C. After stirring for 1 h at 0 °C, again a methyllithium solution (1.6M in Et2O) (0.5 
mmol, 1 equiv) was added slowly to the mixture. Afterward, the solution was stirred for one 
additional hour at 0 °C. Finally the reaction mixture was quenched with 10 mL of saturated 
ammonium chloride solution, poured into water (30 mL) and extracted with ethyl acetate (3 × 15 
mL). The combined organic layers were washed with a saturated sodium bicarbonate solution (15 
mL) and subsequently dried over anhydrous magnesium sulfate. Filtration of the drying agent and 
removal of the solvent in vacuo afforded 5-(quinolin-8-ylamino)-2-methylpentan-2-ol 215d, which 
was purified by means of pTLC. 
 
5-(2-Methylquinolin-3-ylamino)-2-methylpentan-2-ol 215a’ (15%) 
Yellow oil. Rf (SiO2)= 0.21; (100% EtOAc). 
1H NMR (400 MHz, CDCl3): δ 
1.28 (6H, s, 2 × CH3); 1.63-1.68 (2H, m, CqCH2); 1.82-1.92 (2H, m, 
CH2CH2NH); 2.59 (3H, s, CH3CqN); 3.25 (2H, t, J = 7.0 Hz, CH2NH); 7.00 
(1H, s, CHarom); 7.35-7.41 (2H, m, 2 × CHarom); 7.59-7.63 (1H, m, CHarom); 
7.87-7.90 (1H, m, CHarom). 
13C NMR (100.6 MHz, Ref = CDCl3): δ 19.5 (CH3CqN); 22.1 (CH2CH2NH); 27.6 
(2 × CH3); 39.2 (CqCH2); 42.3 (CH2NH); 58.5 (OCquat); 107.3 (HCarom); 122.8 (HCarom); 123.7 (HCarom); 
124.1 (HCarom); 126.2 (HCarom); 127.2 (Carom,quat); 138.6 (Carom,quat); 139.1 (Carom,quat); 147.4 (Carom,quat). IR 
(cm-1): νOH, NH = 3346, νmax = 2965, 2929, 1608, 1515, 1487, 1467, 1486, 1438, 1386, 1360, 1331, 1243, 
1183, 749. MS (70 eV) m/z (%): 259 (M++1, 100). HRMS (ESI) calcd for C16H23N2O 259.1805 [M+H]
+, 
found 259.1810.  
 
5-(Quinolin-5-ylamino)-2-methylpentan-2-ol 215b (23%) 
Green oil. Rf (SiO2) = 0.09-0.15 (Petroleum ether/EtOAc 4/1). 
1H NMR (400 MHz, 
CDCl3): δ 1.25 (6H, s, 2 × CH3); 1.63-1.68 (2H, m, CH2CH2NH); 1.83-1.90 (2H, m, 
CqCH2); 3.33 (2H, t, J = 6.9 Hz, CH2NH); 6.15 (1H, s (broad), NH); 6.67 (1H, dd, J = 
7.9, 0.9 Hz, CHarom); 7.03 (1H, dd, J = 7.9, 0.9 Hz, CHarom); 7.35 (1H, dd, J = 8.2, 4.3 
Hz, CHarom); 7.37 (1H, t, J = 7.9 Hz, CHarom); 8.04 (1H, dd, J = 8.2, 1.7 Hz, CHarom); 
8.70 (1H, dd, J = 4.3, 1.7 Hz, CHarom). 
13C NMR (100.6 MHz, ref = CDCl3) δ 24.3 (CH2Cq); 29.3 (2 × CH3); 
41.4 (CH2CH2N); 43.9 (CH2NH); 70.8 (CqOH); 104.6 (HCarom); 113.7 (HCarom); 121.4 (HCarom); 127.8 
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(HCarom); 128.7 (Carom,quat); 136.0 (HCarom); 138.2 (Carom,quat); 144.9 (Carom,quat); 146.8 (HCarom). IR (cm
-1): 
νNH, OH = 3401, νmax = 2967, 1575, 1520, 1378, 13.36, 817, 789, 731. MS (70 eV): m/z (%): 245 
(M++1,100). HRMS (ESI) calcd for C15H21N2O 245.1648 [M+H]
+, found 245.1650.  
 
5-(Quinolin-6-ylamino)-2-methylpentan-2-ol 215c (43%) 
Yellow oil. Rf (SiO2) = 0.21 (100% EtOAc). 
1H NMR (400 MHz, CDCl3): δ 
1.26 (6H, s, 2 × CH3); 1.59-1.65 (2H, m, CqCH2); 1.76-1.83 (2H, m, 
CH2CH2NH); 3.23 (2H, t, J = 7.0 Hz, CH2NH); 6.68 (1H, d, J = 2.6 Hz, 
CHarom); 7.07 (1H, dd, J = 9.1, 2.6 Hz, CHarom); 7.25 (1H, dd, J = 8.4, 4.2 Hz, 
CHarom); 7.86 (1H, d, J = 9.1 Hz, CHarom); 7.91 (1H, dd, J = 8.4, 1.6 Hz, CHarom); 8.59 (1H, dd, J = 4.2, 1.6 
Hz, CHarom). 
13C NMR (100.6 MHz, Ref = CDCl3): δ 24.1 (CH2CH2NH); 29.5 (2×CH3); 41.1 (NHCH2CH2CH2); 
44.4 (CH2NH); 70.7 (CqOH); 102.7 (HCarom); 121.4 (HCarom); 121.5 (HCarom); 130.0 (HCarom); 130.2 
(Carom,quat); 133.9 (HCarom); 143.0 (Carom,quat); 145.9 (HCarom); 146.3 (Carom,quat). IR (cm
-1): νOH, NH = 3314, 
νmax = 2966, 1624, 1523, 1469, 1381, 1243, 828. MS (70 eV) m/z (%): 245 (M
++1, 100). HRMS (ESI) 
calcd for C15H21N2O 245.1648 [M+H]
+, found 245.1657.  
 
5-(Quinolin-8-ylamino)-2-methylpentan-2-ol 215d (26-43%) 
Yellow oil. Rf (SiO2) = 0.29 (Petroleum ether/EtOAc 1/1). 
1H NMR (300 MHz, 
CDCl3): δ 1.24 (6H, s, 2 × CH3); 1.64 (2H, t, J = 7.7 Hz, CqCH2); 1.86 (2H, quint, J = 
7.7 Hz, CH2CH2NH); 3.32 (2H, t, J = 7.7 Hz, CH2NH); 6.15 (1H, s (broad), NH); 6.66 
(1H, d, J = 7.7 Hz, CHarom); 7.03 (1H, d, J = 7.7 Hz, CHarom); 7.34 (1H, dd, J = 8.3, 4.4 
Hz, CHarom); 7.38 (1H, t, J = 7.7 Hz, CHarom); 8.04 (1H, d, J = 8.3 Hz, CHarom); 8.70 (1H, d, J = 4.4 Hz, 
CHarom). 
13C NMR (75.6 MHz, ref = CDCl3) δ 24.4 (CH2CH2NH); 29.4 (2 × CH3); 41.5 (CqCH2); 44.0 (CH2N); 
70.9 (CqOH); 104.7 (HCarom); 113.7 (HCarom); 121.5 (HCarom); 127.9 (HCarom); 128.8 (Carom,quat); 136.1 
(HCarom); 138.2 (Carom,quat); 144.9 (Carom,quat); 146.9 (HCarom). IR (cm
-1): νNH/OH = 3400, νmax = 2965, 1574, 
1519, 1378, 1336, 817, 789, 739. MS (70 eV): m/z (%): 245 (M++1,100). HRMS (ESI) calcd for 
C15H21N2O 245.1648 [M+H]
+, found 245.1654. 
 
3.3.8.10. Synthesis of 5-(quinolinylamino)pentan-2-ones 
General procedure: To a solution of 1-quinolinylpyrrolidin-2-one 208 (0.5 mmol) in dry 
tetrahydrofuran (25 mL), a methyllithium solution (1.6M in Et2O) (0.5 mmol, 1 equiv) was added 
slowly under inert atmosphere at 0 °C. After stirring for 1 h at 0 °C, again a methyllithium solution 
(1.6M in Et2O) (0.5 mmol, 1 equiv) was added slowly to the mixture. Afterward, the solution was 
stirred for one additional hour at 0 °C. Finally the reaction mixture was quenched with 10 mL of 
saturated ammonium chloride solution and poured into water (30 mL) and extracted with ethyl 
acetate (3 × 15 mL). The combined organic layers were washed with a saturated sodium bicarbonate 
solution (15 mL) and subsequently dried over anhydrous magnesium sulfate. Filtration of the drying 
agent and removal of the solvent in vacuo afforded 5-(quinolinylamino)pentan-2-ones 216a-c. These 
methylketones were not stable enough to purify over silica gel and were thus used as such for 
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further reactions. For the synthesis of 5-(2-methylquinolin-3-yl)pentan-2-one 216a’, the reaction was 
performed at room temperature instead of at 0 °C. 
 
5-(Quinolin-3-ylamino)pentan-2-one 216a (70-97%) 
Yellow-orange oil. Rf (SiO2) = 0.51 (CH3CN/CH2Cl2 3/1). 
1H NMR (300 MHz, 
CDCl3): δ 1.97 (2H, quint, J = 6.6 Hz, CH2CH2CO); 2.18 (3H, s, CH3); 2.62 (2H, 
t, J = 6.6 Hz, CH2CO); 3.21 (2H, t, J = 6.6 Hz, CH2NH); 4.19 (1H, s (broad), 
NH); 7.01 (1H, d, J = 2.2 Hz, CHarom); 7.37-7.44 (2H, m, 2 × CHarom); 7.61 
(1H, d, J = 7.7 Hz, CHarom); 7.93 (1H, d, J = 7.7 Hz, CHarom); 8.41 (1H, d, J = 2.2 Hz, CHarom). 
13C NMR (75.6 
MHz, ref = CDCl3): δ 22.8 (CH2CH2CO); 30.1 (CH3); 41.1 (CH2CO); 43.0 (CH2NH); 109.7 (HCarom); 124.8 
(HCarom); 126.0 (HCarom); 127.0 (HCarom); 127.7 (Carom,quat); 128.6 (Carom,quat); 128.8 (HCarom); 129.7 
(Carom,quat); 143.5 (HCarom); 208.7 (C=O). IR (cm
-1): νNH = 3362, νC=O = 1709, νmax = 2949, 1608, 1389, 
1368, 1350, 780, 748. MS (70 eV): m/z (%): 229 (M++1, 100). HRMS (ESI) calcd for C14H17N2O 229.1335 
[M+H]+, found 229.1340. 
 
5-(Quinolin-3-ylamino)pentan-2-one 216a’ (75-95%) 
Due to the instability of this compound complete characterization was not 
possible, and only the 1H NMR data are depicted below. 
1H NMR (400 MHz, CDCl3): δ 2.05 (2H, t, J = 6.6 Hz, CH2CH2CO); 2.05 (1H, s 
(broad), NH); 2.21 (3H, s, CH3CO); 2.63-2.70 (5H, m, CH2CO + CH3Carom,quat); 
3.25 (2H, t, J = 6.6 Hz, CH2NH); 7.04 (1H, s, CHarom); 7.39-7.42(2H, m, 2 × CHarom); 7.61-7.64 (1H, m, 
CHarom); 7.94-7.99 (1H, m, CHarom).  
 
5-(Quinolin-5-ylamino)pentan-2-one 216b (84-92%) 
Yellow oil. Rf (SiO2) = 0.30 (100% EtOAc). 
1H NMR (300 MHz, CDCl3): δ 2.03 (2H, 
quint, J = 6.6 Hz, CH2CH2CO); 2.16 (3H, s, CH3); 2.65 (2H, t, J = 6.6 Hz, CH2CO); 3.23 
(2H, t, J = 6.6 Hz, CH2NH); 4.85 (1H, s (broad), NH); 6.55 (1H, d, J = 8.3 Hz, CHarom); 
7.30 (1H, dd, J = 8.3, 4.4 Hz, CHarom); 7.45 (1H, d, J = 8.3 Hz, CHarom); 7.54 (1H, t, J = 
8.3 Hz, CHarom); 8.18 (1H, d, J = 8.3 Hz, CHarom); 8.84 (1H, d, J = 4.4 Hz, CHarom). 
13C 
NMR (75.6 MHz, ref = CDCl3) δ 22.5 (CH2CH2CO); 30.2 (CH3); 41.9 (CH2CO); 44.1 (CH2NH); 104.0 
(HCarom); 117.9 (HCarom); 118.5 (Carom,quat); 119.4 (HCarom); 129.2 (HCarom); 130.6 (HCarom); 144.0 
(Carom,quat); 149.2 (Carom,quat); 149.9 (HCarom); 209.7 (C=O). IR (cm
-1): νC=O = 1707, νNH = 3368, νmax = 2360, 
1586, 1576, 1415, 1327, 788, 731. MS (70 eV): m/z (%): 229 (M++1,100). HRMS (ESI) calcd for 
C14H17N2O 229.1335 [M+H]
+, found 229.1340.  
 
5-(Quinolin-6-ylamino)pentan-2-one 216c (90-99%) 
Brown-yellow oil. Rf (SiO2) = 0.15 (Petroleum ether/EtOAc 1/2). 
1H NMR 
(400 MHz, CDCl3): δ 1.99 (2H, quint, J = 6.8 Hz, CH2CH2CO); 2.18 (3H, s, 
CH3); 2.63 (2H, t, J = 6.8 Hz, CH2CO); 3.24 (2H, t, J = 6.8 Hz, CH2NH); 6.69 
(1H, d, J = 2.6 Hz, CHarom); 7.07 (1H, dd, J = 9.1, 2.6 Hz, CHarom); 7.26 (1H, 
dd, J = 8.0, 4.2 Hz, CHarom); 7.86 (1H, d, J = 9.1 Hz, CHarom); 7.91 (1H, dd, J = 8,0, 1.6 Hz, CHarom); 8.61 
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(1H, dd, J = 4.2, 1.6 Hz, CHarom). 
13C NMR (100.6 MHz, ref = CDCl3): δ 22.9 (CH2CH2CO); 30.0 (CH3); 41.1 
(CH2CO); 43.3 (CH2NH); 102.6 (HCarom); 121.3 (HCarom); 121.5 (HCarom); 130.0 (HCarom); 130.2 (Carom,quat); 
133.8 (HCarom); 143.0 (Carom,quat); 145.9 (HCarom); 146.2 (Carom,quat); 208.5 (C=O). IR (cm
-1): νNH = 3342, 
νC=O = 1708, νmax = 2928, 1608, 1504, 1378, 1292, 1244, 828, 208,5. MS (70 eV): m/z (%): 229 (M
++1, 
100). HRMS (ESI) calcd for C14H17N2O 229.1335 [M+H]
+, found 229.1343.  
 
3.3.8.11. Synthesis of (2-methylpyrrolidin-1-yl)quinolines 
General procedure: To a solution of 5-(quinolinylamino)pentan-2-ones 216 (0.5 mmol) in methanol 
(25 mL), acetic acid (2.5 mmol, 5 equiv) and sodium cyanoborohydride (1.0 mmol, 2 equiv) were 
added. After stirring for 3 h at room temperature, the reaction mixture was poured into water (20 
mL) and extracted with dichloromethane (3 × 15 mL). The combined organic layers were dried over 
anhydrous magnesium sulfate and filtration of the drying agent and removal of the solvent in vacuo 
afforded the crude products 217a-c, which were purified by means of column chromatography on 
silica gel or pTLC. 
 
3-(2-Methylpyrrolidin-1-yl)quinoline 217a (61%)  
 Yellow oil. Rf (SiO2) = 0.55 (Petroleum ether/EtOAc 1/2). 
1H NMR (300 MHz, 
CDCl3): δ 1.25 (3H, d, J = 6.6 Hz, CH3); 1.75-1.85 (1H, m, CH(HCH)); 2.05-2.21 (3H, 
m, CH(HCH) + CH2CH2N); 3.27-3.35 (1H, m, N(HCH)); 3.56-3.61 (1H, m, N(HCH)); 
4.08 (1H, quint, J = 6.6 Hz, NCH); 6.98 (1H, d, J = 2.2 Hz, CHarom); 7.34-7.42 (2H, m, 
2 × CHarom); 7.61 (1H, d, J = 7.7 Hz, CHarom); 7.94 (1H, d, J = 7.7 Hz, CHarom); 8.57 
(1H, d, J = 2.2 Hz, CHarom). 
13C NMR (75.6 MHz, ref = C6D6): δ 18.8 (CH3); 22.8 (NCH2CH2); 32.7 (CHCH2); 
47.5 (NCH2); 53.2 (NCH); 110.6 (HCarom); 124.2 (HCarom); 125.8 (HCarom); 126.7 (HCarom); 129.8 (HCarom); 
130.1 (Carom,quat); 140.6 (Carom,quat); 141.1 (HCarom); 141.9 (Carom,quat). IR (cm
-1): νmax = 2963, 1594, 1432, 
1393, 1379, 1370, 745. MS (70 eV): m/z (%): 213 (M++1, 100). HRMS (ESI) calcd for C14H17N2 213.1386 
[M+H]+, found 213.1393.  
 
2-Methyl-3-(2-methylpyrrolidin-1-yl)quinoline 217a’ (33%) 
Brown-yellow oil. Rf (SiO2) = 0.5 (100% EtOAc). 
1H NMR (400 MHz, CDCl3): δ 1.05 
(3H, d, J = 6.0 Hz, CHCH3); 1.61-1.71 (1H, m, CH(HCH)); 1.80-1.91 (1H, m, 
NCH2(HCH)); 1.95-2.04 (1H, m, NCH2(HCH)); 2.19-2.29 (1H, m, CH(HCH)); 2.71 (3H, 
s, CH3Cq); 2.89 (1H, td, J = 8.7, 3.8 Hz, N(HCH)); 3.66-3.73 (1H, m, N(HCH)); 3.79-
3.87 (1H, m, CHCH3); 7.39-7.43 (1H, m, CHarom); 7.43 (1H, s, CHarom); 7.47-7.51 (1H, 
m, CHarom); 7.66 (1H, dd, J = 8.0, 1.2 Hz, CHarom); 7.95 (1H, d, J = 8.3 Hz, CHarom). 
13C NMR (100.6 MHz, 
ref=CDCl3): δ 18.7 (CHCH3); 23.7 (CH3Cq); 23.8 (NCH2CH2); 33.9 (CHCH2); 53.1 (NCH2); 55.0 (NCH); 
120.6 (HCarom); 125.8 (HCarom); 126.2 (HCarom); 126.6 (HCarom); 127.9 (HCarom); 142.71 (Carom,quat); 142.72 
(Carom,quat); 143.0 (Carom,quat); 156.5 (Carom,quat). IR (cm
-1): νmax = 2964, 1594, 1424, 1375, 1362, 1347, 
1325, 749. MS (70 eV): m/z (%): 227 (M++1, 100). HRMS (ESI) calcd for C15H19N2 227.1543 [M+H]
+, 
found 227.1541.  
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5-(2-methylpyrrolidin-1-yl)quinoline 217b (31%)   
Yellow oil. Rf (SiO2) = 0.13 (Petroleum ether/EtOAc 4/1). 
1H NMR (400 MHz, CDCl3): δ 
1.08 (3H, d, J = 6.0 Hz, CH3); 1.65-1.74 (1H, m, (HCH)CH); 1.79-1.90 (1H, m, (HCH)CH2N); 
1.96-2.04 (1H, m, (HCH)CH2N); 2.20-2.27 (1H, m, (HCH)CH); 2.99 (2H, td, J = 8.8, 4.7 Hz, 
CH2N); 3.74 (1H, m, CHCH3); 7.03 (1H, d, J = 7.5 Hz, CHarom); 7.32 (1H, dd, J = 8.6, 4.2 Hz, 
CHarom); 7.59 (1H, dd, J = 8.4, 7.6 Hz, CHarom); 7.72 (1H, d, J = 8.4, CHarom); 8.54 (1H, dd, J = 
8.5, 1.6 Hz, CHarom); 8.85 (1H, dd, J = 4.2, 1.6 Hz, CHarom). 
13C NMR (100.6 MHz, ref = 
CDCl3): δ 18.7 (CH3); 23.8 (CH2CH2N); 33.8 (CH2CH); 55.7 (CH2N); 56.0 (CHCH3); 114.0 (HCarom); 119.3 
(HCarom); 122.8 (HCarom); 124.9 (Carom,quat); 129.4 (HCarom); 133.4 (HCarom); 147.2 (Carom,quat); 149.6 
(Carom,quat); 149.9 (HCarom). IR (cm
-1): νmax = 2963, 1587, 1570, 1464, 1398, 1315, 1286, 1089, 794. MS 
(70 eV): m/z (%): 213 (M++1,100). HRMS (ESI) calcd for C14H17N2 213.1386 [M+H]
+, found 213.1389.  
 
6-(2-methylpyrrolidin-1-yl)quinoline 217c (27%)  
Brown-yellow oil. Rf (SiO2) = 0.3 (Petroleum ether/EtOAc 1/2). 
1H NMR (400 MHz, 
CDCl3): δ 1.24 (3H, d, J = 6.2 Hz, CH3); 1.76-1.79 (1H, m, CH(HCH)); 2.03-2.18 (3H, 
m, CH(HCH) + NCH2CH2); 3.26-3.33 (1H, m, N(HCH)); 3.51-3.56 (1H, m, N(HCH)); 
4.01-4.07 (1H, m, NCH); 6.63 (1H, d, J = 2.7 Hz, CHarom); 7.21-7.25 (2H, m, 2 × 
CHarom); 7.91 (1H, dd, J = 8.1, 1.4 Hz, CHarom); 7.93 (1H, d, J = 9.4 Hz, CHarom); 8.57 
(1H, dd, J = 4.2, 1.4 Hz, CHarom). 
13C NMR (100.6 MHz, ref=CDCl3): δ 19.3 (CH3); 23.3 (NCH2CH2); 33.1 
(CHCH2); 48.3 (NCH2); 53.8 (NCH); 103.6 (HCarom); 119.4 (HCarom); 121.2 (HCarom); 129.7 (HCarom); 130.3 
(Carom,quat); 133.9 (HCarom); 141.5 (Carom,quat); 145.1 (HCarom); 145.3 (Carom,quat). IR (cm
-1): νmax = 2962, 
1618, 1589, 1380, 1364, 1124, 1076, 823. MS (70 eV): m/z (%): 213 (M++1, 100). HRMS (ESI) calcd for 
C14H17N2 213.1386 [M+H]
+, found 213.1394.  
 
3.3.8.12. Synthesis of 5-(quinolinylamino)pentan-2-ols 
General procedure: To a solution of 5-(quinolinylamino)pentan-2-ones 216 (0.5 mmol) in methanol 
(25 mL), sodium borohydride (0.8 mmol, 1.5 equiv) was added. After stirring for 2 h at room 
temperature, the reaction mixture was poured into water (20 mL) and extracted with 
dichloromethane (3 × 15 mL). The combined organic layers were dried over anhydrous magnesium 
sulfate, and filtration of the drying agent and removal of the solvent in vacuo afforded the crude 5-
(quinolinylamino)pentan-2-ols 218a-c, which were purified by means of pTLC. 
 
5-(Quinolin-3-ylamino)pentan-2-ol 218a (32%)  
Yellow oil. Rf (SiO2) = 0.13 (100% EtOAc). 
1H NMR (400 MHz, CDCl3): δ 
1.23 (3H, d, J = 6.2 Hz, CH3); 1.57-1.62 (2H, m, CHCH2); 1.70-1.88 (2H, m, 
NHCH2CH2); 3.20 (2H, t, J = 7.1 Hz, NHCH2); 3.88 (1H, sext, J = 6.2 Hz, 
CH3CH); 6.98 (1H, d, J = 2.8 Hz, CHarom); 7.36-7.43 (2H, m, 2×CHarom); 7.59 
(1H, dd, J = 7.3, 2.3 Hz, CHarom); 7.93 (1H, dd, J = 7.3, 2.3 Hz, CHarom); 8.40 (1H, d, J = 2.8 Hz, CHarom). 
13C 
NMR (100.6 MHz, ref = CDCl3): δ 23.8 (CH3); 25.4 (CH2CH2NH); 36.6 (CH2CH); 43.6 (CH2NH); 67.6 
(CHOH); 109.9 (HCarom); 124.8 (HCarom); 125.9 (HCarom); 126.9 (HCarom); 128.8 (HCarom); 129.6 (Carom,quat); 
141.77 (Carom,quat); 141.81 (Carom,quat); 143.3 (HCarom). IR (cm
-1): νOH, NH = 3306, νmax = 2962, 2930, 1611, 
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1535, 1488, 1473, 1392, 1372, 1350, 1223, 779, 748. MS (70 eV): m/z (%): 231 (M++1, 100). HRMS 
(ESI): calcd for C14H19N2O 231.1492 [M+H]
+, found 231.1491.  
 
5-(2-Methylquinolin-3-ylamino)pentan-2-ol 218a’ (20%)  
Yellow oil. Rf (SiO2) = 0.18 (100% EtOAc). 
1H NMR (400 MHz, CDCl3): δ 
1.25 (3H, d, J = 6.2 Hz, CHCH3); 1.59-1.66 (2H, m, CHCH2); 1.77-1.91 (2H, 
m, CH2CH2NH); 2.57 (3H, s, CH3Cq); 3.24 (2H, t, J = 7.0 Hz, CH2NH); 3.91 
(1H, sext, J = 6.2 Hz, CH3CH); 6.99 (1H, s, CHarom); 7.35-7.40 (2H, m, 2 × 
CHarom); 7.58-7.62 (1H, m, CHarom); 7.87-7.91 (1H, m, CHarom). 
13C NMR (100.6 MHz, ref=CDCl3): δ 21.3 
(CH3CH); 23.9 (CqCH3); 25.3 (CH2CH2NH); 36.7 (CH2CH); 43.8 (CH2NH); 67.7 (CHOH); 109.3 (HCarom); 
124.7 (HCarom); 125.5 (HCarom); 126.0 (HCarom); 128.0 (HCarom); 129.1 (Carom,quat); 140.5 (Carom,quat); 140.9 
(Carom,quat); 149.3 (Carom,quat). IR (cm
-1): νOH, NH = 3337, νmax = 2962, 2929, 1608, 1517, 1488, 1436, 1418, 
1387, 1372, 1359, 1245, 749. MS (70 eV): m/z (%): 245 (M++1, 100). HRMS (ESI): calcd for C15H21N2O 
245.1648 [M+H]+, found 245.1655.  
 
5-(Quinolin-5-ylamino)pentan-2-ol 218b (15-18%)  
Yellow oil. Rf (SiO2) = 0.19-0.36 (100% EtOAc). 
1H NMR (400 MHz, CDCl3): δ 1.26 
(3H, d, J = 6.2 Hz, CH3); 1.63-1.68 (2H, m, CH2CH); 1.83-1.95 (2H, m, CH2CH2NH); 
3.30 (2H, t, J = 6.8 Hz, CH2NH); 3.92 (1H, sext, J = 6.2 Hz, CHOH); 6.62 (1H, dd, J = 
7.8, 0.7 Hz, CHarom); 7.30 (1H, dd, J = 8.5, 4.2 Hz, CHarom); 7.47 (1H, dd, J = 8.4, 0.7 
Hz, CHarom); 7.56 (1H, dd, J = 8.4, 7.8 Hz, CHarom); 8.17 (1H, dd, J = 8.5, 1.6 Hz, CHarom); 8.85 (1H, dd, J = 
4.2, 1.6 Hz, CHarom). 
13C NMR (100.6 MHz, ref = CDCl3): δ 23.9 (CH3); 25.5 (CH2CH2NH); 36.8 (CH2CH); 
44.3 (CH2NH); 67.9 (CHOH); 104.5 (HCarom); 118.1 (HCarom); 118.4 (Carom,quat); 119.2 (HCarom); 128.8 
(HCarom); 130.5 (HCarom); 143.8 (Carom,quat); 149.1 (Carom,quat); 149.9 (HCarom). IR (cm
-1): νNH, OH = 3344, νmax 
= 2925, 1610, 1585, 1579, 1535, 1484, 1463, 1417, 1371, 1350, 1328, 1284, 1118, 789. MS (70 eV): 
m/z (%): 231 (M++1,100). HRMS (ESI) calcd for C14H19N2O 231.1492 [M+H]
+, found 231.1499.  
 
5-(Quinolin-6-ylamino)pentan-2-ol 218c (50%) 
Yellow oil. Rf (SiO2) = 0.13 (100% EtOAc). 
1H NMR (400 MHz, CDCl3): δ 
1.22 (3H, d, J = 6.2 Hz, CH3); 1.55-1.62 (2H, m, CHCH2); 1.67-1.85 (2H, m, 
CH2CH2NH); 3.17 (2H, t, J = 6.9 Hz, CH2NH); 3.87 (1H, sext, J = 6.2 Hz, 
CH3CH); 6.62 (1H, d, J = 2.6 Hz, CHarom); 7.01 (1H, dd, J = 9.1, 2.6 Hz, 
CHarom); 7.21 (1H, dd, J = 8.3, 4.2 Hz, CHarom); 7.83 (1H, d, J = 9.1 Hz, CHarom); 7.87 (1H, dd, J = 8.3, 1.4 
Hz, CHarom); 8.55 (1H, dd, J = 4.2, 1.4 Hz, CHarom). 
13C NMR (100.6 MHz, ref = CDCl3): δ 23.8 (CH3); 25.5 
(NHCH2CH2); 36.7 (CH2CHOH); 43.9 (CH2NH); 67.4 (CHOH); 102.6 (HCarom); 121.3 (HCarom); 121.6 
(HCarom); 129.8 (HCarom); 130.3 (Carom,quat); 133.9 (HCarom); 142.8 (Carom,quat); 145.6 (HCarom); 146.4 
(Carom,quat). IR (cm
-1): νOH, NH = 3318, νmax = 2926, 1623, 1521, 1468, 1381, 1247, 1124, 826. MS (70 eV): 
m/z (%): 231 (M++1, 100). HRMS (ESI): calcd for C14H19N2O 231.1492 [M+H]
+, found 231.1503. 
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3.3.8.13. Antiplasmodial and cytotoxicity testing procedures 
Antiplasmodial assessment 
All samples were tested against a CQS strain of P. falciparum (NF54). Continuous in vitro cultures of 
asexual erythrocyte stages of P. falciparum were maintained using a modified method of Trager and 
Jensen,343 and quantitative assessment of antiplasmodial activity in vitro was determined via the 
parasite lactate dehydrogenase assay using a modified method described by Makler.344 The samples 
were tested in triplicate on one occasion. The test samples were prepared to a 20 mg/mL stock 
solution in 100% DMSO. Stock solutions were stored at -20 °C. Further dilutions were prepared in 
complete medium on the day of the experiment. Samples were tested as a suspension if not 
completely dissolved. CQ was used as the reference. A full dose-response was performed for all 
compounds to determine the concentration inhibiting 50% of parasite growth (IC50 value). Test 
samples were tested at a starting concentration of 100 µg/mL, which was then serially diluted 
twofold in complete medium to give 10 concentrations; with the lowest concentration being 0.2 
µg/mL. The same dilution technique was used for all samples. CQ was tested at a starting 
concentration of 100 ng/mL against a CQS strain and 1000 ng/mL against the CQR strain. The highest 
concentration of solvent to which the parasites were exposed to had no measurable effect on the 
parasite viability. 
Cytotoxicity assessment 
The test samples were tested in triplicate on one occasion. The test samples were prepared to a 2 
mg/mL stock solution in 10% DMSO and were tested as a suspension. Test compounds were stored 
at -20 °C until use. Dilutions were prepared on the day of the experiment. Emetine was used as the 
reference drug in all experiments. The initial concentration of emetine was 100 µg/mL, which was 
serially diluted in complete medium with 10-fold dilutions to give 6 concentrations, the lowest being 
0.001 µg/mL. The same dilution technique was applied to all test samples. The highest concentration 
of solvent to which the cells were exposed to had no measurable effect on the cell viability. The 50% 
inhibitory concentration (IC50) values were obtained from full dose-response curves, using a non-
linear dose-response curve fitting analysis via GraphPad Prism v.4 software. 
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3.3.8.14. Antimicrobial testing procedures 
Disk diffusion susceptibility test 
These strains were subcultured onto potato dextro medium (Oxoid) at 25 °C and the inocula were 
prepared by suspending and diluting a fresh and mature culture of each strain in a 0.85% sterile 
saline solution for desired density, equivalent to 0.5 McFarland standard (stock inocula). The fungal 
inocula were spread out on a PDA (Oxaid) plate by a sterile glass hockey. The empty 6 mm disc (BBLTM 
Sensi-DiscTM) containing 0.2 mg of the antifungal compound dissolved in DMSO was dispensed on the 
plate. The control disk was dispensed with 2 µL of the pure solvent (DMSO). All the plates were 
incubated at 25 °C and antifungal activity was measured after 24 h of incubation for yeasts and after 
48 h of incubation for filamentous fungi. The microbial inhibition was determined by measuring the 
diameter of the clear zone around microbial colonies. These experiments were repeated three times. 
MIC determination via microdilution 
The MIC values of antifungal reagents were determined by a microdilution test which was performed 
in 96-well microtiter plates. The RPMI-1640 medium supplemented with glutamine and a pH 
indicatior, but without bicarbonate, was employed to prepare a dilution series (0-500 mg/L) of the 
antifungal agents. The previously prepared inoculi were diluted ten times in distilled water. Each well 
of the microtiter plate contained 100 µL of antifungal dilution and 100 µL inoculum. The 
microdilution plates were subsequently incubated without agitation at 37 °C for 24h, 48h or 72h for 
yeast, A. flavus or F. solani, respectively. The plates were read with a microtiter plate 
spectrophotometer (Bio-rad) at 530 nm. The MIC value evalution was based on the guidelines of 
EUCAST protocols. 
 
3.3.8.15. Immunological testing procedures 
B-cells were isolated from peripheral blood mononucleated cells (PBMCs) of healthy donors by 
positive magnetic selection using CD19 MicroBeads technology according the manufacturer’s 
protocol. C19+ cells were incubated in 50 µL of culture medium in the presence of ODN2006 and 5 µL 
of compound dilution. After 7 days incubation at 37 °C in 5% CO2, supernatants were collected and 
Immunoglobulin G (IgG) concentration was determined using the Human IgG immunoassay kit 
according to the manufacturer’s protocol. For the MLR protocol385 PBMCs were isolated from 
heparinized blood of healthy donors and then were suspended in culture medium. RPMI1788 cells 
were treated with mitomycin C for 20 min at 37 °C, washed and finally suspended in culture medium. 
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An amount of 100 µL of each cell suspension was mixed with 20 µL of diluted compound. The mixed 
cells were cultured at 37 °C for 6 days in 5% CO2. DNA synthesis was analyzed by the addition of 1µCi 
(methyl-3H)thymidine per well during the last 18h in culture, Thereafter, the cells were harvested on 
glass filter paper and the counts per minute determined in a liquid scintillation counter. 
 
  
 
 
3.4.  
Synthesis and antimalarial/antimicrobial  
assessment of halogenated 4-quinolones 
 
 
 
 
Abstract: Treatment of 4-hydroxyquinolines with (2-methyl)allyl bromide in the presence of K2CO3 
resulted in the unexpected formation of novel N-[(2-methyl)allyl]-4-quinolones through 
chemoselective N-alkylation. Further reaction of N-[(2-methyl)allyl]-4-quinolones with bromine or N-
bromosuccinimide yielded the corresponding 3-bromo-1-(2,3-dibromo-2-methylpropyl)-4-quinolones 
and 3-bromo-1-[(2-methyl)allyl]-4-quinolones, respectively. Furthermore, a copper-catalyzed C-N 
coupling of the latter 3-bromo-4-quinolones with (5-chloro)indole afforded novel 3-[(5-chloro)indol-1-
yl]-4-quinolone hybrids. Antifungal and antiplasmodial assays of all new 4-quinolones were 
performed and revealed no antifungal properties but moderate antiplasmodial activities. All 15 
compounds displayed micromolar activities against a chloroquine-sensitive strain of Plasmodium 
falciparum, and the five most potent compounds also showed micromolar activities against a 
chloroquine-resistant strain of P. falciparum with IC50 values ranging between 4 and 70 µM. 
 
 
 
 
 
 
 
Parts of the work described in this chapter have been published: 
Stéphanie Vandekerckhove, Tom Desmet, Hai Giang Tran, Carmen de Kock, Peter J. Smith, Kelly Chibale, Matthias 
D’hooghe. Synthesis of halogenated 4-quinolones and evaluation of their antiplasmodial activity. Bioorg. Med. Chem. Lett. 
2014, 24, 1214-1217. 
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3.4.1. Introduction 
Diverse studies in medicinal chemistry research have shown that the presence of halogens in organic 
molecules often improves their biological activity. A broad variety of halogenated compounds with 
diverse biological activities are known to date, such as anticancer, antiviral, antituberculosis, 
antimalarial and antifungal agents.8, 43, 296, 400-402 A tangible example is chloroquine (and many of its 
derivatives) used in malaria treatment, as it contains a chlorine atom at the 7-position of the 
quinoline core. Another point of attention in medicinal chemistry programs involves the use of 4-
quinolones as privileged building blocks. These scaffolds are among the most frequently encountered 
frameworks in recent drug development and have a broad and potent activity spectrum. 4-
Quinolones, and more specifically 4-quinolone-3-carboxylic acid derivatives, are widely used as 
antibacterial agents,403-407 but 4-quinolones are also known as second-line drugs in tuberculosis 
treatment.408, 409 Some lesser known biological activities of 4-quinolones include anticancer,410 
antiviral,411-413 and antimalarial activity,414-416 pointing to the versatility of these structures with 
regard to bioactive compound development. The objective of this chapter comprises the evaluation 
of the biological activity of novel 4-quinolones, unexpectedly recovered after attempted O-allylation 
of 4-hydroxyquinolines, bearing halogens positioned directly on the 4-quinolone core as well as on 
the side chain.  
 
3.4.2. Synthesis and functionalization of 4-quinolones 
3.4.2.1. Synthesis of N-substituted-4-quinolones 
N-[(2-methyl)allyl]-4-quinolones (4(1H)-quinolinones according to IUPAC) were serendipitously 
recovered when O-(2-methyl)allylation of 4-hydroxyquinolines was envisioned in Chapter 1 of this 
PhD thesis. However, when 4-hydroxyquinolines 13 were treated with 1.5 equiv of (2-methyl)allyl 
bromide in the presence of 3 equiv of potassium carbonate in acetone, N-[(2-methyl)allyl]-4-
quinolones 219 were obtained instead as the major products after stirring for 24 h under reflux 
conditions. The reaction mixtures contained both N- and O-(2-methyl)allylquinolines 219 and 169 
(ratios 6:4 to >99:1), and column chromatography on silica gel afforded the pure and novel N-[(2-
methyl)allyl]-4-quinolones 219a-e in moderate to good yields (56-85%) (Scheme 24, Table 17). The 
difference between the N- and O-allylated regioisomers could be clearly seen in the NMR spectra. In 
13C spectra, a peak appeared around 180 ppm what indicated the presence of a carbonyl group, while 
in 1H spectra the coupling constant between the quinoline hydrogens on the 2- and 3-position shifted 
from about 4 Hz (N-allylated) to around 8 Hz (O-allylated). 
PART III  RESULTS AND DISCUSSION 
171 
 
 
Scheme 24 
 
Table 17: Substitution pattern and yieds of 4-quinolones 219 
Compound R
1
 R
2 
Yield (%) 
219a H H 75 
219b H CH3 79 
219c 7-Cl H 70 
219d 7-Cl CH3 56 
219e 3-COOCH2CH3,8-F H 85 
 
This reactivity stands in contrast with the (2-methyl)allylation of other hydroxyquinolines, as 
demonstrated in Chapter 1 where reaction of 5-, 6- and 8-hydroxyquinolines with (2-methyl)allyl 
bromide under the same reaction conditions resulted in selective O-(2-methyl)allylation. For 4-
hydroxyquinolines, however, N-(2-methyl)allylation is known to be favored over O-(2-
methyl)allylation due to O to N charge delocalisation.417 This appeared to be an appealing method to 
introduce a side chain on 4-quinolones, and therefore some halogenated alkyl chains were evaluated 
as electrophiles in such reactions. 4-Hydroxyquinolines were treated with 1.1 equiv of potassium 
tert-butoxide in tetrahydrofuran at room temperature, and subsequently electrophiles (such as 2-(2-
bromoethyl)-1,3-dioxolane, methyl 4-chlorobutanoate, 1-benzyl-2-(bromomethyl)aziridine and 4-
bromobutyronitrile) were added to the reaction mixture, which was stirred for 6h at reflux 
temperature. These reactions, however, mostly resulted in the recovery of the starting material. 
Adjusting the reaction conditions, such as changing bases (sodium hydride instead of potassium tert-
butoxide), changing solvent (acetone instead of tetrahydrofuran) or using stronger electrophiles 
(methyl 4-iodobutanoate instead of methyl 4-chlorobutanoate) did not result in the premised N-
alkylation either. Only varying the solvent seemed to influence the product formation; employing 
acetone in the reaction with the 4-bromobutyronitrile yielded selective O-alkylation. Since this 
method did not furnish the proposed results, this route was abandoned and the reactivity of the 
obtained N-(2-methyl)allylquinolones 219 was assessed. 
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3.4.2.2. Reactivity evaluation of N-(2-methyl)allyl-4-quinolones 
Having introduced this (2-methyl)allyl group on the 1-position of the quinolone ring, functionalization 
of the exocyclic double bond provided an opportunity to move away from the N-substituents already 
described in the literature for 4-quinolones (e.g. ethyl, cyclopropyl, aryl groups, etc). In addition, also 
direct functionalization of the 4-quinolone nucleus could give acces to novel derivatives. In a first 
approach, selective bromine introduction at the 3-position of the quinolone ring was achieved in a 
very efficient way by treating 4-quinolone 219 with 1.5 equiv of N-bromosuccinimide (NBS) in 
dichloromethane for 24 h at room temperature, thereby affording 3-bromo-4-quinolones 220a-d in 
high to very high yields (89-99%) and purities (Scheme 25 and Table 18). The position of the bromine 
insertion (3-position of the quinolone ring) was confirmed by comparing the NMR spectra with 
literature data.418, 419  
 
Scheme 25 
 
The latter 3-bromo-4-quinolones 220 appeared to be excellent substrates for molecular hybridization 
reactions, which is, as stated before, an emerging strategy used in drug discovery programs.36, 38, 45 In 
accordance with a procedure recently described in the literature, a copper-catalyzed C-N coupling of 
3-bromo-4-quinolones 220 with (5-chloro)indole was performed.418 Thus, quinolones 220 were 
treated with 10 mol% of a Cu(0)-catalyst and 20 mol% of N,N’-dimethylethylenediamine (DMEDA) as 
a ligand in toluene in the presence of 1.5 equiv of potassium carbonate and 1.2 equiv of (5-
chloro)indole for 48 h at 135 °C under an inert atmosphere (N2). This resulted in the formation of 3-
[(5-chloro)indol-1-yl]-4-quinolones 221a-d in good yields (61-84%) (Scheme 26 and Table 18). The 
decision to utilize an indole ring in this coupling reaction was based upon literature data confirming 
antiplasmodial activity of various indole alkaloids and indoloquinolines.420-423  
PART III  RESULTS AND DISCUSSION 
173 
 
 
Scheme 26 
Different mechanisms for Ullmann-type reactions have been proposed, however, aryl radical 
intermediates in the reaction mechanism have been ruled out by a study of Bowman,424 while aryl-
copper intermediates have been proposed by Cohen.425 Most importantly, it was demonstrated that 
the active catalytic species in the Ullmann coupling is copper(I).425-427 Keeping this in mind, a possible 
mechanism is presented in Scheme 27.  
 
Scheme 27 
 
A second approach was based on a halogenation reaction with molecular bromine. In contrast to the 
bromination with NBS, both the exocyclic double bond and the 3-position of the quinolone ring were 
brominated, thus resulting in the simultaneous introduction of three bromine atoms in one step. 
Optimal results were achieved by dissolving N-(2-methylallyl)-4-quinolone 219 in dry 
dichloromethane followed by treatment with 2 equiv of Br2 for 1 h at room temperature. This 
procedure afforded multiple halo-substituted 3-bromo-1-(2,3-dibromo-2-methylpropyl)-4-quinolones 
222a-b in high yields (98-99%) and purities (Scheme 28 and Table 18). 
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Scheme 28 
 
Table 18: Substitution pattern and yieds of 4-quinolones 220, 221 and 222 
Compound R
1
 R
2 
R
3 
Yield (%) Compound R
1
 R
2 
R
3 
Yield (%) 
220a H H - 89 221b H - Cl 61 
220b H CH3 - 98 221c 7-Cl - H 84 
220c 7-Cl H - 89 221d 7-Cl - Cl 71 
220d 7-Cl CH3 - 99 222a H - - 98 
221a H - H 84 222b 7-Cl - - 99 
  
A final approach to evaluate the reactivity of (3-bromo-)N-(2-methyl)allyl-4-quinolones 220 involved 
a vinylation or allylation via a 1,4-nucleophilic conjugate addition of a Grignard reagent. Based on a 
similar literature procedure,428 3-bromo-N-(2-methyl)allyl-4-quinolones 220 were treated with 2.1 
equiv of copper iodide and 9 equiv of vinyl magnesiumbromide in tetrahydrofuran under an inert 
atmosphere. Vinyl magnesiumbromide was added sequentially (3 × 3 equiv) to the reaction mixture, 
which was stirred for 1.5 h at -78 °C and subsequently 2 × 45 min at -40 °C (Scheme 29). No 
conversion was observed when R = Me, however, when R = H, conversion to the desired compound 
223 was observed (40-50%). Unfortunately, product 223 could not be isolated and no analytically 
pure compound was obtained. 
 
Scheme 29 
Alternatively, these reaction conditions were also evaluated on N-(2-methyl)allyl-4-quinolones 219, 
but did not result in conversion toward compound 224 (Scheme 30). Varying nucleophile (allyl 
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magnesiumbromide instead of vinyl magnesiumbromide), replacing copper iodide by copper 
bromide or chloride, increasing reaction temperature or adding a Lewis acid to the reaction mixture 
did not result in conversion toward compound 224 either. 
 
Scheme 30 
 
3.4.3. Antiplasmodial evaluation 
Having obtained novel (halogenated) 4-quinolones 219, 220, 222 and 4-quinolone-indole hybrids 
221, they were assessed for their in vitro antiplasmodial activity at the University of Cape Town, 
South Africa (Prof. P. J. Smith and Prof. K. Chibale). All samples were screened against a chloroquine-
sensitive (CQS) strain of Plasmodium falciparum (NF54). Subsequently, those samples showing 
promising antiplasmodial activity were tested against a chloroquine-resistant (CQR) strain of P. 
falciparum (Dd2) and screened for in vitro cytotoxicity against a mammalian cell-line, Chinese 
Hamster Ovarian (CHO) cells, using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT)-assay. The results of the antiplasmodial assessment are summarized in Table 19.  
These results show that all tested compounds exhibit micromolar potencies against a CQS strain of P. 
falciparum (NF54), with 8 of the 15 samples having IC50 values beween 3 and 50 µM. Subsequently, 
the activity of the five most potent compounds (IC50 <35 µM) was determined against a CQR strain of 
P. falciparum (Dd2), again resulting in micromolar activities with IC50 values ranging between 4 and 
70 µM. With regard to structure-activity relationships, this assay confirms that the presence of a 
chlorine atom at the 7-position of the 4-quinolone ring is advantageous for antiplasmodial activity. By 
comparing the activities of compounds 219 and 220, it becomes clear that the introduction of a 
bromo atom to the quinolone skeleton causes a large increase in antiplasmodial activity. Further 
support for the statement that adding halogen atoms to a pharmacophore is beneficial for its 
bioactivity results from the comparison of the antiplasmodial activities of 220a-b and 220c-d (3-
bromo-4-quinolones without and with a 7-chloro atom, respectively) and those of 219 and 222 (not 
brominated vs. tribrominated 4-quinolones, respectively). The assay also proved compound 222b to 
be the most potent one, having low micromolar activity against both the CQS and CQR strain of 
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malaria parasite P. falciparum (3 and 4 µM, respectively). The molecular hybridization of the 4-
quinolone pharmacophore with an indole also increases the antiplasmodial activity, this is apparent 
when comparing IC50 values of 3-bromo-4-quinolones 220b and 220d (109 and 46 µM, respectively) 
with those of 4-quinolone-indole hybrids 221a-b (38 and 9 µM, respectively) and 221c-d (7 and 20 
µM, respectively). Also noteworthy are the good selectivity indices (SI>12) of hybrid molecules 221, 
which postulate the potential of these compounds as novel templates in antimalarial drug design. 
Table 19: IC50 values of 4-quinolones 219, 220, 221 and 222 tested for in vitro antimalarial activity and cytotoxicity
a
 
Compound NF54: IC50 (µM) Dd2: IC50 (µM) CHO: IC50 (µM) SI
c 
RI
b 
219a 539.89 ND ND ND ND 
219b 501.89 ND ND ND ND 
219c 399.24 ND ND ND ND 
219d 260.17 ND ND ND ND 
219e 207.43 ND ND ND ND 
220a 197.64 ND ND ND ND 
220b 108.58 ND ND ND ND 
220c 32.15 69.33 48.90 1.52 2.16 
220d 46.39 ND ND ND ND 
221a 38.17 ND ND ND ND 
221b
* 
8.89 26.09 248.84 28.00 2.94 
221c 6.88 17.20 >286.68 >41.67 2.50 
221d 20.35 24.26 >260.91 >12.82 1.19 
222a 35.16 ND ND ND ND 
222b 3.18 4.02 31.75 10.00 1.27 
CQ 0.016 0.378 ND ND 23.73 
Artesunate 0.005 0.046 ND ND 8.75 
Emetine ND ND 0.092 ND ND 
a
 ND = not determined; CQ = chloroquine. 
b 
RI (Resistance Index) = IC50
 
(Dd2)/IC50
 
(NF54).  
c
 SI (Selectivity Index) = IC50
 
(CHO)/IC50
 
(NF54). 
*
Contains 15% of 5-chloroindole as a contaminant. 
 
3.4.4. Antimicrobial assessment 
In light of the well-known antimicrobial activity of quinolones,403-407 the activity of the novel 4-
quinolones 219, 220, 221 and 222 was also tested against two bacteria strains (Staphylococcus 
aureus and Escherichia coli), a yeast strain (Candida albicans) and a fungus strain (Aspergillus flavus) 
at the Centre of Expertise for Industrial Biotechnology and Biocatalysis, Ghent University (Prof. T. 
Desmet). However, no antimicrobial activity was observed for any of the 15 compounds.  
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3.4.5. Conclusion 
The preparation of novel halogenated 4-quinolones and 4-quinolone-indole hybrids was established 
by N-(2-methyl)allylation of 4-hydroxyquinolines, followed by bromination with either NBS or 
molecular bromine and finally hybrid formation via a copper-catalyzed coupling between 3-bromo-4-
quinolones and (5-chloro)indole. Furthermore, the in vitro antiplasmodial activity and cytotoxicity of 
the novel 4-quinolone compounds was assessed. All tested compounds displayed micromolar activity 
against a chloroquine-sensitive strain of P. falciparum and five new compounds also displayed 
micromolar activity against a chloroquine-resistant strain of P. falciparum. Good selectivity indices 
asserted the low cytotoxicity of the 4-quinolone-indole hybrids, pointing to the promising potential 
of these compounds as novel antimalarial lead structures. 
 
3.4.6. Experimental section 
3.4.6.1. General methods 
All reagents were purchased from commercial suppliers (Sigma-Aldrich, Acros, TCI), and were used as 
received without any purification, unless otherwise noted. Solvents were dried with sodium (THF) or 
calcium hydride (dichloromethane), and distilled before use. Other solvents were purchased from 
commercial suppliers and used as supplied. The petroleum ether used during product purification 
steps had a boiling range of 40-60 °C. Crude reaction mixtures were analysed by LC/MS/UV. Thin-
layer chromatography was carried out on silica gel 60F254 plates (Merck). Column chromatography 
was performed in a glass column with silica gel (particle size 70-200 µm, pore diameter 60Å). 
Preperative TLC was executed with 2000 µm 20 × 20 cm TLC plates. High-resolution 1H and 13C 
magnetic resonance (NMR) spectra were recorded with Jeol Eclipse+ 300, Brücker AVANCE-III 400 
MHz or Brücker AVANCE-II 500 MHz NMR spectrometers in CDCl3, unless otherwise noted. Chemical 
shifts were calibrated using tetramethylsilane, which was used as an internal reference, unless 
otherwise indicated. Peak assignments were obtained with the aid of APT or HSQC spectra. 
Attenuated total reflection (ATR) IR spectra were recorded with a Perkin-Elmer Spectrum BX 
spectrometer, equipped with a ZnSe crystal, at room temperature (neat). Low-resolution mass 
spectra were recorded with an Agilent Technologies 1100 series VL mass spectrometer (ESI, 70 eV). 
High resolution mass spectra were obtained with an HPLC coupled to an Agilent Technologies 6210 
series time-of-flight mass spectrometer equipped with an ESI/APCI-multimode source. Melting points 
were measured with a Büchi B-540 apparatus or Koflerbench, type WME Heizbank of Wagner & 
Munz. 
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3.4.6.2. Synthesis of 1-[(2-methyl)allyl]-4-quinolones 
General procedure: To a solution of 4-hydroxyquinoline 13 (15 mmol) and (2-methyl)allyl bromide 
(22.5 mmol, 1.5 equiv) in acetone (50 mL) was added potassium carbonate (45 mmol, 3 equiv). After 
stirring for 24 h at reflux temperature, the reaction mixture was poured into water (50 mL) and 
extracted with dichloromethane (3 × 20 mL). The combined organic extracts were dried over 
anhydrous magnesium sulfate. Filtration of the drying agent and removal of the solvent in vacuo 
afforded the crude products 219a-e, which were purified by means of column chromatography over 
silica gel. 
 
1-Allyl-4-quinolone 219a (75%) 
Beige powder. Mp = 45 °C. Rf (SiO2) = 0.13 (100% EtOAc). 
1H NMR (300 MHz, CDCl3): δ 
4.73 (2H, d, J = 5.0 Hz, CH2N); 5.13 (1H, d, J = 17.6 Hz, (HCH)=CH); 5.31 (1H, d, J = 10.5 Hz, 
(HCH)=CH); 5.94-6.06 (1H, m, CH2=CH); 6.29 (1H, d, J = 7.7 Hz, CHarom); 7.37 (1H, t, J = 8.3 
Hz, CHarom); 7.39 (1H, d, J = 8.3 Hz, CHarom); 7.54 (1H, d, J = 7.7 Hz, CHarom); 7.64 (1H, td, J = 
8.3, 1.1 Hz, CHarom); 8.46 (1H, dd, J = 8.3, 1.1 Hz, CHarom). 
13C NMR (100.6 MHz, ref = 
CDCl3) δ 54.8 (CH2N); 109.9 (HCarom); 116.0 (HCarom); 118.3 (CH2=CH); 123.6 (HCarom); 126.5 
(HCarom); 126.9 (Carom,quat); 131.2 (CH2=CH); 132.1 (HCarom); 139.8 (Carom,quat); 143.4 (HCarom); 178.1 
(C=O). IR (cm-1): νC=O = 1609, νmax = 1563,1546, 1488,1470, 1426, 1392, 1232, 1040, 947, 832, 760. MS 
(70 eV): m/z (%): 186 (M++1, 100). HRMS (ESI) calcd for C12H12NO 186.0913 [M+H]
+, found 186.0921.  
 
1-(2-Methylallyl)-4-quinolone 219b (79%) 
Beige powder. Mp = 54 °C. Rf (SiO2) = 0.11 (100% EtOAc). 
1H NMR (300 MHz, CDCl3): δ 
1.79 (3H, s, CH3); 4.62 (2H, s, CH2N); 4.69 (1H, s, (HCH)=Cq), 5.00 (1H, s, (HCH)=Cq); 6.29 
(1H, d, J = 7.7 Hz, CHarom); 7.33 (1H, d, J = 8.8 Hz, CHarom); 7.38 (1H, d, J = 7.2 Hz, 
CHarom); 7.52 (1H, d, J = 7.7 Hz, CHarom); 7.62 (1H, ddd, J = 8.8, 7.2, 1.7 Hz, CHarom); 8.46 
(1H, dd, J = 7.2, 1.7 Hz, CHarom). 
13C NMR (100.6 MHz, ref = CDCl3) δ 20.0 (CH3); 58.4 
(CH2N); 110.3 (HCarom); 113.5 (CH2=Cq); 116.0 (HCarom); 123.8 (HCarom); 127.0 (HCarom); 
127.2 (Carom,quat); 132.1 (HCarom); 138.8 (CH2=Cq); 140.3 (Carom,quat); 143.7 (HCarom); 178.4 (C=O). IR (cm
-
1): νC=O = 1610, νmax = 1619, 1556, 1546, 1487, 1471, 1455, 1231, 762. MS (70 eV): m/z (%): 200 (M
++1, 
100). HRMS (ESI) calcd for C13H14NO 200.1070 [M+H]
+, found 200.1071.  
 
1-Allyl-7-chloro-4-quinolone 219c (70%)  
Off-white powder. Mp = 139 °C. Rf (SiO2) = 0.21 (100% EtOAc). 
1H NMR (500 MHz, 
CDCl3): δ 4.68 (2H, d, J = 4.0 Hz, CH2N); 5.14 (1H, d, J = 17.4 Hz, (HCH)=CH); 5.35 (1H, 
d, J = 10.4 Hz, (HCH)=CH); 5.95-6.03 (1H, m, CH2=CH); 6.27 (1H, d, J = 7.6 Hz, CHarom); 
7.31 (1H, d, J = 8.5 Hz, CHarom); 7.36 (1H, s, CHarom); 7.51 (1H, d, J = 7.6 Hz, CHarom); 
8.37 (1H, d, J = 8.5 Hz, CHarom). 
13C NMR (125.8 MHz, ref = CDCl3) δ 54.9 (CH2N); 111.0 
(HCarom); 115.6 (HCarom); 118.9 (CH2=CH); 124.3 (HCarom); 125.5 (Carom,quat); 128.7 
(HCarom); 130.7 (CH2=CH); 138.6 (Carom,quat); 140.7 (Carom,quat); 143.3 (HCarom); 177.5 (C=O). IR (cm
-1): νC=O 
= 1582, νmax = 1622, 1600, 1478, 1454, 1217, 860, 808. MS (70 eV): m/z (%): 220/222 (M
++1, 100). 
HRMS (ESI) calcd for C12H11ClNO 220.0524 [M+H]
+, found 220.0532.  
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7-Chloro-1-(2-methylallyl)-4-quinolone 219d (56%)  
Beige powder. Mp = 108 °C. Rf (SiO2) = 0.08 (Petroleum ether/EtOAc 1/1). 
1H NMR 
(300 MHz, CDCl3): δ 1.80 (3H, s, CH3); 4.56 (2H, s, CH2N); 4.71 (1H, s, (HCH)=Cq), 
5.03 (1H, s, (HCH)=Cq); 6.27 (1H, d, J = 7.7 Hz, CHarom); 7.30-7.33 (2H, m, 2 × CHarom); 
7.49 (1H, d, J = 7.7 Hz, CHarom); 8.38 (1H, d, J = 9.4 Hz CHarom). 
13C NMR (75.6 MHz, 
ref = CDCl3) δ 19.9 (CH3); 58.5 (CH2N); 110.9 (HCarom); 113.9 (CH2=Cq); 115.7 
(HCarom); 124.4 (HCarom); 125.6 (Carom,quat); 128.8 (HCarom); 138.4 (CH2=Cq); 138.6 
(Carom,quat); 141.0 (Carom,quat); 143.9 (HCarom); 177.6 (C=O). IR (cm
-1): νC=O = 1583, νmax = 1622, 1456, 1225, 
860, 808. MS (70 eV): m/z (%): 234 (M++1, 100). HRMS (ESI) calcd for C13H13ClNO 234.0680 [M+H]
+, 
found 234.0688.  
 
Ethyl (1-allyl-8-fluoro-4-oxo-1,4-dihydroquinolin-3-yl)formate 219e (85%)  
Light-yellow crystals. Mp = 112 °C. Rf (SiO2) = 0.10 (Petroleum ether/EtOAc 
1/1). 1H NMR (300 MHz, CDCl3): δ 1.42 (3H, t, J = 7.2 Hz, CH3); 4.40 (2H, q, J = 
7.2 Hz, CH2O); 4.95 (2H, d, J = 5.0 Hz, CH2N); 5.16 (1H, d, J = 17.1 Hz, (HCH)=CH); 
5.30 (1H, d, J = 10.5 Hz, (HCH)=CH); 6.00-6.13 (1H, m, CH2=CH); 7.35-7.40 (2H, 
m, 2 × CHarom); 8.35 (1H, dd, J = 7.2, 1.1 Hz, CHarom); 8.39 (1H, s, CHarom). 
13C 
NMR (75.6 MHz, ref = CDCl3) δ 14.5 (CH3); 59.6 (CH2N); 61.1 (CH2O); 111.4 
(Carom,quat); 118.5 (CH2=CH); 119.8 (HCarom); 123.9 (HCarom); 125.5 (HCarom); 128.5 (Carom,quat); 131.8 
(CH2=CH); 132.0 (Carom,quat); 151.1 (HCarom); 151.9 (d, J = 249.2 Hz, CF), 165.5 (C=O, ester); 176.0 (C=O, 
ketone). 19F NMR (282.8 MHz, Ref = CDCl3) -122.061 (1F, s, CF). IR (cm
-1): νC=O = 1683, 1649, νmax = 
1606, 1556, 1312, 1246, 1239, 1174, 1149, 780. MS (70 eV): m/z (%): 276 (M++1, 100). HRMS (ESI) 
calcd for C15H15FNO3 276.1031 [M+H]
+, found 276.1036.  
 
3.4.6.3. Synthesis of 1-[(2-methyl)allyl]-3-bromo-4-quinolones 
General procedure: N-bromosuccinimide (1.5 mmol, 1.5 equiv) was added to a solution of N-[(2-
methyl)allyl]-4-quinolone 219 (1 mmol) in dry dichloromethane (50 mL) at 0 °C and was subsequently 
stirred for 24 h at room temperature. The reaction mixture was finally poured into a 1M NaOH-
solution (50 mL) and extracted with dichloromethane (3 × 20 mL). The combined organic extracts 
were washed with brine (3 × 20 mL) and dried over anhydrous magnesium sulfate. Filtration of the 
drying agent and removal of the solvent in vacuo afforded compounds 220a-d in high purity (>95% 
based on NMR). 
 
1-Allyl-3-bromo-4-quinolone 220a (89%)  
Beige powder. Mp = 140 °C. Rf (SiO2) = 0.13 (Petroleum ether/EtOAc 1/1). 
1H NMR 
(300 MHz, CDCl3): δ 4.76 (2H, d, J = 4.4 Hz, CH2N); 5.18 (1H, d, J = 17.1 Hz, (HCH)=CH); 
5.36 (1H, d, J = 10.5 Hz, (HCH)=CH); 5.94-6.07 (1H, m, CH2=CH); 7.40 (1H, d, J = 8.8 Hz, 
CHarom); 7.41 (1H, t, J = 8.8 Hz, CHarom); 7.66 (1H, dd, J = 8.8, 1.7 Hz, CHarom); 7.97 (1H, 
s, CHarom); 8.50 (1H, dd, J = 8.8, 1.7 Hz, CHarom). 
13C NMR (100.6 MHz, ref = CDCl3) δ 
55.1 (CH2N); 105.5 (Carom,quat); 116.0 (HCarom); 119.2 (CH2=CH); 124.4 (HCarom); 125.4 
(Carom,quat); 127.4 (HCarom); 130.8 (CH2=CH); 132.3 (HCarom); 139.2 (Carom,quat); 143.1 (HCarom); 172.6 
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(C=O). IR (cm-1): νC=O = 1586, νmax = 1612, 1545, 1486, 1226, 759, 691. MS (70 eV): m/z (%): 264/266 
(M++1, 100). HRMS (ESI) calcd for C12H11BrNO 264.0019 [M+H]
+, found 264.0030.  
 
3-Bromo-1-(2-methylallyl)-4-quinolone 220b (98%)  
Off-white powder. Mp = 152 °C. Rf (SiO2) = 0.19 (Petroleum ether/EtOAc 1/1). 
1H 
NMR (300 MHz, CDCl3): δ 1.80 (3H, s, CH3); 4.64 (2H, s, CH2N); 4.71 (1H, s, (HCH)=Cq), 
5.04 (1H, s, (HCH)=Cq); 7.34 (1H, d, J = 8.8 Hz, CHarom); 7.42 (1H, t, J = 7.7 Hz, CHarom); 
7.64 (1H, ddd, J = 8.8, 7.7, 1.7 Hz, CHarom); 7.96 (1H, s, CHarom); 8.51 (1H, dd, J = 7.7, 
1.7 Hz, CHarom). 
13C NMR (100.6 MHz, ref = CDCl3) δ 19.9 (CH3); 58.5 (CH2N); 105.5 
(Carom,quat); 113.8 (CH2=Cq); 116.0 (HCarom); 124.4 (HCarom); 125.4 (Carom,quat); 127.4 
(HCarom); 132.2 (HCarom); 138.4 (CH2=Cq); 139.4 (Carom,quat); 143.5 (HCarom); 172.6 (C=O). IR (cm
-1): νC=O = 
1589, νmax = 1614, 1548, 1488, 1472, 1266, 1218, 885, 844, 757, 689. MS (70 eV): m/z (%): 278/280 
(M++1, 100). HRMS (ESI) calcd for C13H13BrNO 278.0175 [M+H]
+, found 278.0186.  
 
1-Allyl-3-bromo-7-chloro-4-quinolone 220c (89%)  
Off-white powder. Mp = 209 °C. Rf (SiO2) = 0.25 (Petroleum ether/EtOAc 1/1). 
1H 
NMR (500 MHz, CDCl3): δ 4.73 (2H, d, J = 4.3 Hz, CH2N); 5.20 (1H, d, J = 17.1 Hz, 
(HCH)=CH), 5.41 (1H, d, J = 10.4 Hz, (HCH)=CH); 5.97-6.05 (1H, m, CH2=CH); 7.35 
(1H, d, J = 8.5 Hz, CHarom); 7.38 (1H, s, CHarom); 7.96 (1H, s, CHarom); 8.40 (1H, d, J = 
8.5 Hz, CHarom).
 13C NMR (100.6 MHz, ref = CDCl3) δ 55.2 (CH2N); 106.2 (Carom,quat); 
115.8 (HCarom); 119.7 (CH2=CH); 123.8 (Carom,quat); 125.1 (HCarom); 129.2 (CH2=CH); 
130.3 (HCarom); 138.9 (Carom,quat); 139.9 (Carom,quat); 143.4 (HCarom); 172.0 (C=O). IR (cm
-1): νC=O = 1584, 
νmax = 1613, 1472,1455, 1210, 1076, 1016, 940, 878, 862, 826, 766. MS (70 eV): m/z (%): 298/300/302 
(M++1, 100). HRMS (ESI) calcd for C12H10BrClNO 297.9629 [M+H]
+, found 297.9632.  
 
3-Bromo-7-chloro-1-(2-methylallyl)-4-quinolone 220d (99%)  
Off-white powder. Mp = 176 °C. Rf (SiO2) = 0.12 (Petroleum ether/EtOAc 4/1). 
1H 
NMR (300 MHz, CDCl3) 1.81 (3H, s, CH3); 4.59 (2H, s, CH2N); 4.72 (1H, s, 
(HCH)=Cq), 5.07 (1H, s, (HCH)=Cq); 7.32 (1H, s, CHarom); 7.36 (1H, d, J = 8.8 Hz, 
CHarom); 7.93 (1H, s, CHarom); 8.44 (1H, d, J = 8.8 Hz, CHarom).
 13C NMR (100.6 MHz, 
ref = CDCl3) δ 19.9 (CH3); 58.6 (CH2N); 106.1 (Carom,quat); 114.1 (CH2=Cq); 115.8 
(HCarom); 123.7 (Carom,quat); 125.1 (HCarom); 129.1 (HCarom); 138.0 (CH2=Cq); 138.8 
(Carom,quat); 140.1 (Carom,quat); 143.8 (HCarom); 172.0 (C=O). IR (cm
-1): νC=O = 1587, νmax = 1617, 1460, 1222, 
881, 848, 765. MS (70 eV): m/z (%): 312/314/316 (M++1, 100). HRMS (ESI) calcd for C13H12BrClNO 
311.9785 [M+H]+, found 311.9795.  
 
3.4.6.4. Synthesis of (7-chloro-)3-[(5-chloro)indol-1-yl]-1-(2-methylallyl)-4-quinolones 
General procedure: A flame-dried flask of 25 mL was charged with Cu powder (0.05 mmol, 10 mol%), 
N-(2-methylallyl)-3-bromo-4-quinolones 220 (0.5 mmol), (5-chloro)indole (0.6 mmol, 1.2 equiv) and 
potassium carbonate (0.75 mmol, 1.5 equiv). The flask was put under inert atmosphere (N2) and 
subsequently DMEDA (0.1 mmol, 20 mol%) and toluene (2 mL) were added through the septum. The 
mixture was stirred for 48 h at 135 °C. The resulting suspension was cooled to room temperature and 
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filtered through celite, which was washed with an excess of ethyl acetate (50 mL). The filtrate was 
finally washed with water (3 × 20 mL) (in order to remove the inorganic salts) and dried over 
anhydrous magnesium sulphate. Filtration of the drying agent and concentration of the filtrate 
yielded compounds 221a-d in high purity (>95% based on NMR). 
 
3-(Indol-1-yl)-1-(2-methylallyl)-4-quinolone 221a (84%)  
Light yellow powder. Mp = 161 °C. Rf (SiO2) = 0.38 (Petroleum ether/EtOAc 1/1). 
1H NMR (300 MHz, CDCl3): δ 1.84 (3H, s, CH3); 4.70 (2H, s, CH2N); 4.82 (1H, s, 
(HCH)=Cq), 5.08 (1H, s, (HCH)=Cq); 6.68 (1H, d, J = 3.3 Hz, CHarom); 7.13 (1H, td, J = 
7.2, 1.1 Hz, CHarom); 7.17 (1H, td, J = 7.2, 1.1 Hz, CHarom); 7.25 (1H, d, J = 7.2 Hz, 
CHarom); 7.38 (1H, d, J = 3.3 Hz, CHarom); 7.446 (1H, t, J = 7.2 Hz, CHarom); 7.450 (1H, 
d, J = 7.2 Hz, CHarom); 7.68 (1H, ddd, J = 7.2, 1.1 Hz, CHarom); 7.72 (1H, dd, J = 7.2, 
1.1 Hz, CHarom); 7.88 (1H, s, CHarom); 8.59 (1H, dd, J = 7.2, 1.1 Hz, CHarom).
 13C NMR 
(75.6 MHz, ref = CDCl3) δ 20.0 (CH3); 58.6 (CH2N); 103.0 (HCarom); 110.2 (HCarom); 
113.9 (CH2=Cq); 116.1 (HCarom); 120.1 (HCarom); 121.0 (HCarom); 121.5 (Carom,quat); 122.1 (HCarom); 124.2 
(HCarom); 127.57 (HCarom); 127.64 (CH2=Cq); 128.8 (Carom,quat); 130.0 (HCarom); 132.5 (HCarom); 137.1 
(Carom,quat); 138.7 (Carom,quat); 139.5 (Carom,quat); 141.4 (HCarom); 173.5 (C=O). IR (cm
-1): νC=O = 1591, νmax = 
1553, 1453, 1389, 1362, 1221, 760, 737, 718, 702. MS (70 eV): m/z (%): 315 (M++1, 100). HRMS (ESI) 
calcd for C21H19N2O 315.1492 [M+H]
+, found 315.1502.  
 
3-(5-Chloroindol-1-yl)-1-(2-methylallyl)-4-quinolone 221b (61%)  
Orange crystals. Mp = 161 °C. Rf (SiO2) = 0.47 (Petroleum ether/EtOAc 1/1). 
1H 
NMR (400 MHz, CDCl3): δ 1.79 (3H, s, CH3); 4.62 (2H, s, CH2N); 4.73 (1H, s, 
(HCH)=Cq), 5.05 (1H, s, (HCH)=Cq); 6.54 (1H, d, J = 3.2 Hz, CHarom); 7.02 (1H, dd, J = 
8.7, 1.9 H, CHarom); 7.08 (1H, d, J = 8.7 Hz, CHarom); 7.25 (1H, d, J = 3.2 Hz CHarom); 
7.40-7.44 (2H, m, 2 × CHarom); 7.56 (1H, d, J = 1.8 Hz, CHarom); 7.67-7.72 (1H, m, 
CHarom); 7.83 (1H, s, CHarom); 8.50 (1H, dd, J = 8.7, 1.6 Hz, CHarom). 
13C NMR (100.6 
MHz, ref = CDCl3) δ 19.9 (CH3); 58.4 (CH2N); 102.5 (HCarom); 111.4 (HCarom); 113.7 
(CH2=Cq); 116.2 (HCarom); 120.2 (HCarom); 120.9 (Carom,quat); 122.2 (HCarom); 124.3 
(HCarom); 125.5 (Carom,quat); 127.3 (HCarom); 127.4 (Carom,quat); 129.6 (Carom,quat); 130.8 
(HCarom); 132.5 (HCarom); 135.4 (Carom,quat); 138.6 (CH2=Cq); 139.4 (Carom,quat); 141.5 (HCarom); 173.2 (C=O). 
IR (cm-1): νC=O = 1579, νmax = 1556, 1492, 1450, 1379, 1231, 1222, 904, 756, 721, 701. MS (70 eV): m/z 
(%): 349/351 (M++1, 100). HRMS (ESI) calcd for C21H18ClN2O 349.1102 [M+H]
+, found 349.1118.  
 
7-Chloro-3-(indol-1-yl)-1-(2-methylallyl)-4-quinolone 221c (84 %)  
Orange powder. Mp = 168 °C. Rf (SiO2) = 0.48 (Petroleum ether/EtOAc 1/1). 
1H 
NMR (300 MHz, CDCl3): δ 1.84 (3H, s, CH3); 4.63 (2H, s, CH2N); 4.82 (1H, s, 
(HCH)=Cq), 5.11 (1H, s, (HCH)=Cq); 6.68 (1H, d, J = 3.3 Hz, CHarom); 7.14 (1H, dd, 
J = 5.5, 1.7 Hz, CHarom); 7.16 (1H, dd, J = 5.5, 1.7 Hz, CHarom); 7.21 (1H, dd, J = 
5.5, 1.7 Hz, CHarom); 7.35 (1H, d, J = 3.3 Hz, CHarom); 7.38 (1H, dd, J = 8.8, 1.7 Hz, 
CHarom); 7.42 (1H, d, J = 1.7 Hz, CHarom); 7.66 (1H, dd, J = 5.5, 1.7 H, CHarom); 
7.84 (1H, s, CHarom); 8.50 (1H, d, J = 8.8 Hz, CHarom).
 13C NMR (100.6 MHz, ref = 
CDCl3) δ 19.9 (CH3); 58.4 (CH2N); 103.1 (HCarom); 110.1 (CHarom); 114.0 (CH2=Cq); 
115.9 (HCarom); 120.1 (HCarom); 121.0 (HCarom); 121.8 (Carom,quat); 122.1 (HCarom); 124.9 (HCarom); 125.8 
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(Carom,quat); 128.7 (Carom,quat); 129.1 (HCarom); 129.3 (HCarom); 136.9 (Carom,quat); 138.2 (Carom,quat); 138.9 
(CH2=Cq); 140.1 (Carom,quat); 141.7 (HCarom); 172.8 (C=O). IR (cm
-1): νC=O = 1586, νmax = 1624, 1609, 1455, 
1220, 760, 741, 718. MS (70 eV): m/z (%): 349/351 (M++1, 100). HRMS (ESI) calcd for C21H18ClN2O 
349.1102 [M+H]+, found 349.1107.  
 
7-Chloro-3-(5-chloroindol-1-yl)-1-(2-methylallyl)-4-quinolone 221d (71%)  
Yellow-orange powder. Mp = 81 °C. Rf (SiO2) = 0.15 (Petroleum ether/EtOAc 
4/1). 1H NMR (300 MHz, CDCl3): δ 1.86 (3H, s, CH3); 4.66 (2H, s, CH2N); 4.82 
(1H, s, (HCH)=Cq), 5.13 (1H, s, (HCH)=Cq); 6.62 (1H, d, J = 3.3 Hz, CHarom); 7.13 
(1H, d, J = 1.7 Hz, CHarom); 7.13 (1H, s, CHarom); 7.34 (1H, d, J = 3.3 Hz, CHarom); 
7.40 (1H, dd, J = 8.3, 1.7 Hz, CHarom); 7.42 (1H, d, J = 3.3 Hz, CHarom); 7.62 (1H, 
d, J = 3.3 Hz, CHarom); 7.83 (1H, s, CHarom); 8.50 (1H, d, J = 8.3 Hz, CHarom). 
13C 
NMR (100.6 MHz, ref = CDCl3) δ 19.9 (CH3); 58.5 (CH2N); 102.7 (HCarom); 111.3 
(HCarom); 114.1 (CH2=Cq); 115.9 (HCarom); 120.3 (HCarom); 121.5 (Carom,quat); 122.9 
(HCarom); 125.1 (HCarom); 125.70 (Carom,quat); 125.73 (Carom,quat); 129.0 (HCarom); 
129.7 (Carom,quat); 130.6 (HCarom); 135.3 (Carom,quat); 138.1 (Carom,quat); 139.2 (CH2=Cq); 140.1 (Carom,quat); 
141.7 (HCarom); 172.6 (C=O). IR (cm
-1): νC=O = 1593, νmax = 1626, 1453, 1220, 880, 789, 774, 754, 719. 
MS (70 eV): m/z (%): 383/385/387 (M++1, 100). HRMS (ESI) calcd for C21H17Cl2N2O 383.0712 [M+H]
+, 
found 383.0727.  
 
3.4.6.5. Synthesis of 3-bromo-(7-chloro-)1-(2,3-dibromo-2-methylpropyl)-4-quinolones 
General procedure: Bromine (2 mmol, 2 equiv) was added to a solution of N-(2-methylallyl)-4-
quinolone 219 (1 mmol) in dry dichloromethane (25 mL) at 0 °C and was subsequently stirred for 1 h 
at room temperature. The reaction mixture was poured in a sodium bicarbonate solution (25 mL) and 
extracted with dichloromethane (3 × 10 mL). The combined organic fractions were dried over 
anhydrous magnesium sulfate. Filtration of the drying agent and removal of the solvent in vacuo 
afforded compounds 222a-b in high purity (>95% based on NMR). 
 
3-Bromo-1-(2,3-dibromo-2-methylpropyl)-4-quinolone 222a (98%)  
Beige powder. Mp = 155 °C. Rf (SiO2) = 0.34 (Petroleum ether/EtOAc 1/1). 
1H NMR 
(300 MHz, CDCl3): δ 1.82 (3H, s, CH3); 3.99 (2H, s, CH2N); 4.41 (1H, d, J = 16.0 Hz, 
(HCH)Br), 4.96 (1H, d, J = 16.0 Hz, (HCH)Br); 7.43 (1H, t, J = 8.8 Hz, CHarom); 7.64 (1H, t, 
J = 8.8 Hz, CHarom); 7.70 (1H, dd, J = 8.8, 1.7 Hz, CHarom); 8.30 (1H, s, CHarom); 8.51 (1H, 
d, J = 8.8 Hz, CHarom). 
13C NMR (75.6 MHz, ref = CDCl3) δ 28.6 (CH3); 40.8 (CH2N); 58.8 
(CH2Br); 63.4 (CH2CqBr); 105.9 (Carom,quat); 115.9 (HCarom); 124.7 (HCarom); 125.6 
(Carom,quat); 128.0 (HCarom); 132.3 (HCarom); 140.2 (Carom,quat); 144.0 (HCarom); 172.7 (C=O). 
IR (cm-1): νC=O = 1592, νmax = 1614, 1547, 1484, 1376, 1266, 1223, 761. MS (70 eV): m/z (%): 
436/438/440/442 (M++1, 100). HRMS (ESI) calcd for C13H13Br3NO 435.8542 [M+H]
+, found 435.8542.  
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3-Bromo-7-chloro-1-(2,3-dibromo-2-methylpropyl)-4-quinolone 222b (99%)  
Off-white powder. Mp = 182 °C. Rf (SiO2) = 0.15 (Petroleum ether/EtOAc 4/1). 
1H 
NMR (500 MHz, CDCl3): δ 1.89 (3H, s, CH3); 3.97 (1H, d, J = 11.0 Hz, (HCH)N); 4.01 
(1H, d, J = 11.0 Hz, (HCH)N); 4.44 (1H, d, J = 16.2 Hz, (HCH)Br), 4.83 (1H, d, J = 
16.2 Hz, (HCH)Br); 7.39 (1H, dd, J = 8.5, 1.8 Hz, CHarom); 7.67 (1H, d, J = 1.8 Hz, 
CHarom); 8.28 (1H, s, CHarom); 8.44 (1H, d, J = 8.5 Hz, CHarom). 
13C NMR (125.8 MHz, 
ref = CDCl3) δ 28.6 (CH3); 40.4 (CH2Br); 58.8 (CH2N); 62.9 (CH2CqBr); 106.4 
(Carom,quat); 115.9 (HCarom); 123.7 (Carom,quat); 125.3 (HCarom); 129.5 (HCarom); 138.8 
(Carom,quat); 140.8 (Carom,quat); 144.1 (HCarom); 172.0 (C=O). IR (cm
-1): νC=O = 1592, νmax = 1618, 1466, 1265, 
1219, 1073, 880, 769. MS (70 eV): m/z (%): 469/471/473/475 (M++1, 100). HRMS (ESI) calcd for 
C13H12Br3ClNO 469.8152 [M+H]
+, found 469.8150.  
 
3.4.6.6. Antiplasmodial and cytotoxicity testing procedures 
Antiplasmodial assessment 
All samples were tested against a CQS strain of P. falciparum (NF54). Continuous in vitro cultures of 
asexual erythrocyte stages of P. falciparum were maintained using a modified method of Trager and 
Jensen,343 and quantitative assessment of antiplasmodial activity in vitro was determined via the 
parasite lactate dehydrogenase assay using a modified method described by Makler.344 The samples 
were tested in triplicate on one occasion. The test samples were prepared to a 20 mg/mL stock 
solution in 100% DMSO. Stock solutions were stored at -20 °C. Further dilutions were prepared in 
complete medium on the day of the experiment. Samples were tested as a suspension if not 
completely dissolved. CQ was used as the reference. A full dose-response was performed for all 
compounds to determine the concentration inhibiting 50% of parasite growth (IC50 value). Test 
samples were tested at a starting concentration of 100 µg/mL, which was then serially diluted 
twofold in complete medium to give 10 concentrations; with the lowest concentration being 0.2 
µg/mL. The same dilution technique was used for all samples. CQ was tested at a starting 
concentration of 100 ng/mL against a CQS strain and 1000 ng/mL against the CQR strain. The highest 
concentration of solvent to which the parasites were exposed to had no measurable effect on the 
parasite viability. 
Cytotoxicity assessment 
The test samples were tested in triplicate on one occasion. The test samples were prepared to a 2 
mg/mL stock solution in 10% DMSO and were tested as a suspension. Test compounds were stored 
at -20 °C until use. Dilutions were prepared on the day of the experiment. Emetine was used as the 
reference drug in all experiments. The initial concentration of emetine was 100 µg/mL, which was 
serially diluted in complete medium with 10-fold dilutions to give 6 concentrations, the lowest being 
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0.001 µg/mL. The same dilution technique was applied to all test samples. The highest concentration 
of solvent to which the cells were exposed to had no measurable effect on the cell viability. The 50% 
inhibitory concentration (IC50) values were obtained from full dose-response curves, using a non-
linear dose-response curve fitting analysis via GraphPad Prism v.4 software. 
 
3.4.6.7. Antimicrobial testing procedures 
Disk diffusion susceptibility test 
These strains were subcultured onto potato dextro medium (Oxoid) at 25 °C and the inocula were 
prepared by suspending and diluting a fresh and mature culture of each strain in a 0.85% sterile 
saline solution for desired density, equivalent to 0.5 McFarland standard (stock inocula). The fungal 
inocula were spread out on a PDA (Oxaid) plate by a sterile glass hockey. The empty 6 mm disc (BBLTM 
Sensi-DiscTM) containing 0.2 mg of the antifungal compound dissolved in DMSO was dispensed on the 
plate. The control disk was dispensed with 2 µL of the pure solvent (DMSO). All the plates were 
incubated at 25 °C and antifungal activity was measured after 24 h of incubation for yeasts and after 
48 h of incubation for filamentous fungi. The microbial inhibition was determined by measuring the 
diameter of the clear zone around microbial colonies. These experiments were repeated three times. 
MIC determination via microdilution 
The MIC values of antifungal reagents were determined by a microdilution test which was performed 
in 96-well microtiter plates. The RPMI-1640 medium supplemented with glutamine and a pH 
indicatior, but without bicarbonate, was employed to prepare a dilution series (0-500 mg/L) of the 
antifungal agents. The previously prepared inoculi were diluted ten times in distilled water. Each well 
of the microtiter plate contained 100 µL of antifungal dilution and 100 µL inoculum. The 
microdilution plates were subsequently incubated without agitation at 37 °C for 24h, 48h or 72h for 
yeast, A. flavus or F. solani, respectively. The plates were read with a microtiter plate 
spectrophotometer (Bio-rad) at 530 nm. The MIC value evalution was based on the guidelines of 
EUCAST protocols. 
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The literature review of this PhD thesis emphasizes the attention that scientists have recently 
devoted to quinoline-containing hybrid structures and their importance in antimalarial drug research. 
In the research part of this work, the concept of pharmacophore hybridization was approached from 
a more synthetic viewpoint, since molecular hybridization can deliver a synthetic advantage through 
selective chemical modification of the more reactive entity within hybrid systems as well. This was 
illustrated by linking a quinoline core to chemically reactive heterocycles such as aziridines, 3-
pyrrolines or 2-oxopyrrolidines. The reactivity of the heterocycles in these chimeric structures was 
subsequently evaluated and allowed for selective transformations. This strategy can be further 
expanded toward other reactive heterocycles; for example, recently, β-lactam-purine chimeras have 
been described as synthetic intermediates for antiviral applications.38 In that regard, hybridization of 
a quinoline core with heterocycles such as azetidines, β-lactams, oxiranes, oxetanes, etc. could result 
in compelling intermediates, which might be eligible substrates for further elaboration toward 
functionalized quinolines with potential biological potency. A first proposal includes the introduction 
of fluorine, since fluorine is known to be advantageous for a compounds’ bioavailability because of 
its unique chemical and physical properties.429-432 Moreover, fluorine-containing antimalarials have 
been reported in the literature.433 Employing a recently described pathway,434 [(2-
(trifluoromethyl)azetidin-1-yl]quinolines 225 could be obtained via imination, hydride reduction, 
chlorination and base-induced ring closure. Subsequent regioselective ring opening of the 
heterocyclic azetidine moiety by various nucleophiles could furnish functionalized, fluorinated 
quinolines 226 (Scheme 31). 
 
Scheme 31 
As a second example, the oxygen analog of 2-(bromomethyl)aziridines, i.e. 2-(bromomethyl)oxirane, 
could be linked to a hydroxyquinoline core, affording (oxiran-2-ylmethyloxy)quinoline 227.435-437 
Subsequent ring opening of the epoxide would afford a triheteroatom-substituted propane (C3 unit) 
side chain on a quinoline core 228 (Scheme 32). Functionalized C3 units are also known for their wide 
biological activity,361, 362, 364, 369, 438-441 including antimalarial potency.307, 308 This synthetic pathway 
could thus afford biologically appealing hybrid compounds. 
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Scheme 32 
Based on the same methodology, aminoquinolines could be linked to 2-(bromomethyl)oxirane.442 
Unlike the oxygen analogs of this hybrid, an intramolecular substitution reaction with the secondary 
amino group could open the epoxide ring, affording [2-(hydroxymethyl)aziridin-1-yl]quinoline 230 
which in turn could serve as a substrate for further side chain functionalization (Scheme 33). 
 
Scheme 33 
As a final example of hybridization of quinolines with a reactive small heterocycle, the connection of 
a quinoline core with an oxetane moiety is proposed. The Paternò-Büchi reaction involves a 
stereoselective intramolecular [2+2]-photocycloaddition reaction between a carbonyl compound and 
an alkene. In this respect, a quinoline-carbaldehyde 17 could be treated with an alkene, furnishing a 
quinoline-oxetane chimera 231 under irradiation conditions. This hybrid 231 could be ring opened to 
afford functionalized quinolines 232 (Scheme 34). 
 
Scheme 34 
Exploring the chemical space around the quinoline core was the main objective of this PhD thesis, 
and an incentive was given in this direction with the synthesis of various 3-, 4-, 5-, 6- and 8-
functionalized quinolines. These structures seemed to (at least partially) have retained their 
antiplasmodial potency, indicating that varying a side chain around the quinoline core is a valuable 
method to obtain active quinoline derivatives. Keeping this in mind, the design of 2-, 3-, 5-, 6-, 7- or 
8-derivatives of quinoline-containing drugs could provide valid alternatives which could be less prone 
to cross-resistance. It should be noted though that synthetic procedures are not always applicable on 
all derivatives since reactivity can differ significantly between the various regioisomers. 
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Exploration of functionalized aminoisoquinolines and their corresponding isoquinolinium salts as the 
nitrogen analogs of the oxyisoquinolines (which were discussed in  Part II of this manuscript) may 
afford valuable new biologically active compounds and thereby broaden the scope of this work. In 
analogy with the quinoline derivatives, varying the side chain around the isoquinoline core might 
yield interesting compounds as well.  
Finally, 8-hydroxyquinolines are known to be fungistatic compounds, and bulky (halo-)substituents 
have been reported to augment their antifungal activity.11, 321, 323-327 In this PhD, the promising 
potential of 8-(4-diethylaminobutyloxy)quinolines as antifungal agents was described, and one of 
these novel compounds can even be considered as a promising novel broad-spectrum antifungal lead 
compound. These results ask for the further elaboration of substituted 8-alkoxyquinolines as novel 
antifungal agents. 
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Quinolines comprise a very interesting class of compounds, since these scaffolds are well-known 
“privileged structures” that are present in many pharmacophores with diverse biological activities 
such as antimalarial, anticancer, antipsychotic, anti-inflammatory, anti-HIV, antituberculosis, 
antimicrobial, antileishmanial and antifungal activity. Quinoline derivatives, like quinine and 
chloroquine, were the antimalarial drugs of choice until chloroquine resistance occurred, and 
synthetic antiplasmodial agents like pyrimethamine, sulfadoxine, artemisinin and artemether have 
been introduced in the second half of the twentieth century as a result. However, recently a renewed 
interest in quinolines flared up when resistance against these novel synthetic drugs arose as well. 
Quinolines were evaluated as active entities within novel drug development programs such as drug 
combination therapies or hybrid drug design. In that respect, the synthesis and biological evaluation 
of various novel classes of quinolines, i.e. (4-aminobutyloxy)quinolines, (iso)quinoline-aziridine 
conjugates and their ring-opened derivatives, pyrrolidinylquinolines and halogenated quinolones, 
was achieved in this PhD thesis, resulting in the identification of several promising hit compounds 
with auspicious biological activities. Hereby focusing on the exploration of the chemical space around 
the quinoline building block.  
In a first approach, (4-aminobutyloxy)quinolines iv and v were prepared starting from 
hydroxyquinolines i, which were O-alkylated with 1.5 equiv of (2-methyl)allyl bromide in the 
presence of 3 equiv potassium carbonate, affording the corresponding (2-methyl)allyloxyquinolines ii 
in 57-92% yield. The latter derivatives ii were subsequently assessed as novel substrates for a 
rhodium-catalyzed hydroformylation applying syngas (20 bar CO/H2, 1:1), using 
(acetylacetonato)dicarbonylrhodium(I) [Rh(acac)(CO)2] as a catalyst precursor (substrate/Rh = 500) 
and pyrrole-containing phosphordiamidite DPBO as a ligand (ligand/Rh = 4) in toluene at 80 °C (2h 
preformation, 20 h reaction). This method provided a number of novel (4-oxobutyloxy)quinolines iii 
in a selective and efficient way (59-98%). Finally, the obtained aldehydes iii were converted to 
amines by reductive amination with diethylamine or 4-chlorobenzylamine, affording the desired 
functionalized quinolines iv and v (48-95%).  
In addition, biological assessment of these novel compounds revealed micromolar antimalarial 
potency for all representatives against a CQS strain of P. falciparum and three compounds displayed 
submicromolar activity against a CQR strain of P. falciparum, pointing to the promising potential of 
these structures as novel antimalarial hit compounds. Antifungal testing resulted in the identification 
of six 8-(4-aminobutyloxy)quinolines displaying considerable antifungal activity, with one compound 
showing a significant potential as a novel broad-spectrum antifungal candidate. 
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In a second part of this work, quinoline-aziridine chimeras viii were prepared through imination of 
quinoline-carboxaldehydes vi with 2,3-dibromopropylamine hydrobromide in dichloromethane in the 
presence of magnesium sulphate and triethylamine. The recovered imines vii were subsequently 
treated with sodium borohydride in methanol affording novel {[2-(bromomethyl)aziridin-1-
yl]methyl}quinolines viii. Substitution of these quinoline-aziridines with heteroaromatic nucleophiles 
afforded quinoline-aziridine-pyrazole/pyrimidinone/pyridazinone hybrid compound ix, x and xi. 
Further selective ring opening of the reactive aziridine moiety was achieved by activating the three-
membered ring with para-toluenesulfonic acid or a Lewis acid (e.g. BF3∙Et2O), after which nucleophilic 
attack by water or methanol furnished regioselective ring opening toward novel functionalized 
quinolines xii and xiii. 
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A second approach toward aziridine-containing hybrids as intermediates for the synthesis of 
potential novel antimalarials was based on the use of the isoquinoline scaffold. The readily available 
5-hydroxyisoquinoline xiv was deprotonated using sodium hydroxide, and nucleophilic substitution 
occurred after adding 1 equiv of an 1-arylmethyl-2-(bromomethyl)aziridine, which afforded 5-
(aziridin-2-ylmethoxy)isoquinolines xv in good yields (65-90%). 
 
Different strategies for the opening of the constrained ring in the aziridine-isoquinoline chimeras xv 
were assessed. The aziridine system in compound xv was activated by protonation by para-
toluenesulfonic acid, by complexation with a Lewis acid (e.g. BF3·Et2O) in a THF/water (1/1) solvent 
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mixture or in methanol, affording isoquinoline-aminopropanols xvi and xvii. In addition to the 
oxygen-based nucleophiles water and methanol, aniline was employed as a nitrogen-based 
nucleophile to induce ring opening of aziridines xv furnishing 1,2-diaminopropanes xviii in excellent 
yields (91-92%). Finally, the aziridine moiety was activated by alkylation of the aziridine nitrogen 
atom by benzyl bromide. However, the first equiv of benzyl bromide led to selective alkylation of the 
isoquinoline nitrogen atom, resulting in the formation of isoquinolinium salt xix. The aziridine entity 
of this salt was subsequently opened by adding another equiv of benzyl bromide, affording the 
desired β-bromoamine xx in excellent yield (98%). 
 
Antiplasmodial potency and cytotoxicity of the novel aziridine-(iso)quinolines and their ring-opening 
products was demonstrated; all compounds displayed micromolar activity against a CQS strain of P. 
falciparum, and six compounds also showed micromolar activity against a chloroquine-resistant 
strain of P. falciparum. The low cytotoxicity of these functionalized (iso)quinolines was affirmed by 
their high selectivity indices, which also demonstrated the promising potential of these novel 
compounds as potential antimalarial lead structures. 
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In a third part of this work, the principle of molecular hybridization of a quinoline core with a reactive 
heterocycle was further explored and evolved around the synthesis of N-functionalized 3-,  
5-, 6- and 8-aminoquinolines via intermediate (3-pyrrolin-1-yl)quinolines xxiii and (2-oxopyrrolidin-1-
yl)quinolines xxv. (3-Pyrrolin-1-yl)quinolines xxiii were obtained via intermediate 
diallylaminoquinolines xxii, which were synthesized by treating aminoquinolines xxi with 4 equiv of 
allyl bromide and sequentially adding 2 equiv of lithium bis(trimethylsilyl)amide. The 
diallylaminoquinolines xxii were subsequently subjected to ring-closing metathesis by adding 10 
mol% of 1st or 2nd generation Grubbs catalyst, affording the desired (3-pyrrolin-1-yl)quinoline 
intermediates xxiii. The (2-oxopyrrolidin-1-yl)quinoline intermediates xxv were acquired by treating 
aminoquinolines xxi with 1 equiv of 4-chlorobutyryl chloride in the presence of potassium carbonate, 
which furnished 4-chloro-N-quinolinylbutanamides xxiv. Subsequent intramolecular nucleophilic 
substitution within these butanamides xxiv resulted in the formation of (2-oxopyrrolidin-1-
yl)quinoline intermediates xxv.  
 
In a second phase, the more reactive entity of intermediate hybrids xxiii and xxv was explored 
synthetically in order to obtain N-functionalized 3-, 5-, 6- and 8-aminoquinolines. The reactivity of 
the (3-pyrrolin-1-yl)quinolines xxiii was evaluated by adding 2 equiv of bromine. When the reaction 
temperature was controlled at 0 °C, anti-addition of bromine on the 3-pyrroline double bond took 
place, as well as bromination of the quinoline core at the position next to the pyrrolidinyl side chain. 
This resulted in 3- and 6-substituted quinolines xxvi in moderate yields (14-34%). However, when 6-
(3-pyrrolin-1-yl)quinoline xxiii was used as substrate for this reaction performed at room 
temperature, a complex reaction mixture was obtained, although, after purification, a small fraction 
of 1-(5-bromoquinolin-6-yl)-2,3,4,5-tetrabromopyrrole xxvii could be isolated (9%).  
Different strategies for the further elaboration of (2-oxopyrrolidin-1-yl)quinolines xxv were 
evaluated. Firstly, the addition of 1.5 equiv of lithium aluminium hydride to lactams xxv in 
tetrahydrofuran and stirring for 3 h under reflux conditions mediated the reductive removal of the 
carbonyl group, furnishing (pyrrolidin-1-yl)quinolines xxviii. Secondly, pyrrolidinones xxv were 
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reduced to the corresponding intermediate aldehydes by treating them with 1.5 equiv of lithium 
aluminium hydride in tetrahydrofuran for 2.5 h under inert atmosphere at room temperature. 
Subsequent addition of methanol and 1.5 equiv of sodium borohydride to the reaction mixture, 
which was stirred for an additional 3 hours at room temperature, resulted in further reduction 
toward primary alcohols 4-(quinolinylamino)butanols xxix. Thirdly, lactams xxv were sequentially 
treated with a methyllithium solution (4 × 1 equiv, with an interval of 1 h) in tetrahydrofuran for 4 h 
at 0 °C under inert atmosphere, providing 5-(quinolinylamino)-2-methylpentan-2-ols xxx. Lastly, the 
sequential addition of 2 equiv of methyllithium (2 × 1 equiv, with an interval of 1 h) to lactams xxv in 
tetrahydrofuran and stirring for 2 h at 0 °C under inert atmosphere, furnished 5-
(quinolinylamino)pentan-2-ones xxxi in good to excellent yields (79-91%). Furthermore, the newly 
synthesized methylketones xxxi were rather unstable but could be modified directly to 1-quinolinyl-
2-methylpyrrolidines xxxii via intramolecular ring closure by adding 5 equiv of acetic acid and 2 equiv 
of sodium cyanoborohydride to methylketones xxxi in methanol and stirring for 3 h at room 
temperature. Finally, in order to get the full range of 4-aminobutanol side chains, 5-
(quinolinylamino)pentan-2-ones xxxi were treated with 1.5 equiv of sodium borohydride in methanol 
for 2 h at room temperature, affording the corresponding 5-(quinolinylamino)pentan-2-ols xxxiii. 
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It should be noted that 5-(quinolinylamino)pentan-2-ols xxxiii could also be obtained in a one-pot 
synthesis starting from lactams xxv, and also 5-quinolinylamino-2-methylpentan-2-ols xxx could be 
obtained via an alternative route where methylketones xxxi in tetrahydrofuran were treated with 2 
equiv of methylmagnesium iodide for 2 h at 0 °C. 
Antiplasmodial assessment of these pyrrolidinylquinolines and their derivatives revealed that all 
compounds exhibited micromolar antimalarial potency against a chloroquine-sensitive NF54 strain of 
P. falciparum, with IC50 values varying between 13 and 60 µM. The two most potent compounds 
were also tested against a chloroquine-resistant Dd2 strain of P. falciparum and displayed moderate 
activity (IC50 between 38 and 49 µM) as well. 
In a final part of this PhD thesis, novel halogenated 4-quinolones were evaluated, and their synthesis 
proceeded through an initial N-allylation of 4-hydroxyquinolines i with (2-methyl)allyl bromide in the 
presence of potassium carbonate, resulting in the unexpected formation of N-[(2-methyl)allyl]-4-
quinolones xxxiv. Subsequent reaction of these 4-quinolones xxxiv with 1.5 equiv of N-
bromosuccinimide yielded selective bromination to 3-bromo-1-[(2-methyl)allyl]-4-quinolones xxxv. A 
copper-catalyzed C-N coupling of the latter 3-bromo-4-quinolones xxxv with (5-chloro)indole 
afforded novel 3-[(5-chloro)indol-1-yl]-4-quinolone hybrids xxxvi. The bromination of N-(2-
methylallyl)-4-quinolones xxxiv with molecular bromine resulted in the bromination of both the 
exocyclic double bond and the 3-position of the quinolone ring, giving rise to the formation of 3-
bromo-1-(2,3-dibromo-2-methylpropyl)-4-quinolones xxxvii in high yields (98-99%). 
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Furthermore, in vitro antimalarial assessment of these halogenated quinolones revealed that all 
tested compounds displayed micromolar potencies against a CQS strain of P. falciparum. Five novel 
compounds also exhibited micromolar activity agains a CQR strain of P. falciparum. Good selectivity 
indices asserted the low cytotoxicity of the 4-quinolone-indole hybrids xxxvi, pointing to the 
promising potential of these compounds as novel antimalarial lead structures. 
In this PhD thesis, a variety of functionalized (iso)quinolines, in which the side chain is connected to 
the (iso)quinoline core at different positions, has been synthesized. The biological potency of in total 
101 novel functionalized (iso)quinolines and 4-quinolones has been determined by several biological 
assays, including antiplasmodial, antimicrobial and immunosuppressant assessments. The most 
promising compounds are summarized below (IC50 values indicate their antiplasmodial activity, MIC 
values represent the antimicrobial potency). 
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It is clear that the synthetic elaboration of the chemical space around the quinoline core has resulted 
in a variety of diverse and biologically active compounds, which can be considered as valuable lead 
compounds in antimalarial and antimicrobial drug research.  
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Chinolinen worden beschouwd als een zeer interessante klasse van chemische verbindingen 
aangezien dit organisch skelet aanwezig is in talrijke farmacoforen met zeer diverse activiteiten, zoals 
antimalaria, antikanker, antipsychotische, anti-inflammatoire, anti-HIV, antituberculose, 
antimicrobiële, antileishmania en antifungale activiteit. Chinolinederivaten, zoals kinine en 
chloroquine (CQ), werden gebruikt als dé antimalariageneesmiddelen bij uitstek totdat chloroquine- 
resistentie de kop opstak en synthetische antiplasmodiumagentia zoals pyrimethamine, sulfadoxine, 
artemisinine en artemether geïntroduceerd werden op de markt in de tweede helft van de twintigste 
eeuw. Aangezien recentelijk echter resistentie werd waargenomen tegen deze nieuwe synthetische 
geneesmiddelen wakkerde de interesse voor chinolinen terug op. Chinolinen werden reeds 
geëvalueerd als actieve eenheden in de ontwikkeling van geneesmiddelen, zoals in verschillende 
combinatietherapieën of in de ontwikkeling van hybride medicijnen. In dat opzicht werd de synthese 
en biologische evaluatie van verscheidene nieuwe chinoline klassen, zoals (4-
aminobutyloxy)chinolinen, (iso)chinoline-aziridinehybriden en hun ringgeopende derivaten, 
pyrrolidinylchinolinen en gehalogeneerde chinolonen, uitgevoerd in het kader van deze 
doctoraatsthesis. Dit resulteerde in de identificatie van meerdere veelbelovende “hit” verbindingen 
die gunstige biologische activiteiten vertoonden. De focus lag hierbij op de exploratie van de 
chemische ruimte rond de chinolinebouwsteen. 
In een eerste luik werden (4-aminobutyloxy)chinolinen iv en v gesynthetiseerd. De syntheseroute 
begon met de O-alkylering van hydroxychinolinen i met 1,5 equiv (2-methyl)allylbromide in de 
aanwezigheid van 3 equiv kaliumcarbonaat, hetgeen resulteerde in omzetting tot de 
overeenkomstige (2-methyl)allyloxychinolinen ii in rendementen van 57-92%. Laatstgenoemde 
derivativen ii werden vervolgens geëvalueerd als nieuwe substraten voor een rhodium-
gekatalyseerde hydroformylering. Syngas (20 bar CO/H2, 1:1) werd aangewend, 
(acetylacetonato)dicarbonylrhodium(I) [Rh(acac)(CO)2], de katalysator-precursor, werd net als het 
pyrrool-bevattende fosfordiamidiet DPBO-ligand toegevoegd aan de substraatoplossing in tolueen en 
geroerd voor 20-24u bij 80 °C (substraat/Rh-ratio = 500, ligand/Rh-ratio = 4, 2u katalysator activatie, 
20-22u reactie). Deze methode leverde een aantal nieuwe (4-oxobutyloxy)chinolinen iii op een 
selectieve en efficiënte wijze (59-98%). Uiteindelijk werden de bekomen aldehyden iii omgezet tot 
aminen aan de hand van reductieve aminering met diëthylamine of 4-chloorbenzylamine, hetgeen 
resulteerde in de vorming van de gewenste, gefunctionaliseerde chinolinen iv en v (48-95%).  
Bovendien onthulde biologische analyse dat alle nieuwe verbindingen micromolaire antimalaria- 
activiteit vertoonden tegen een CQ-gevoelige D10 stam van P. falciparum, en drie verbindingen 
vertoonden bovendien submicromolaire werking tegen een CQ-resistente Dd2 P. falciparum stam. 
Deze resultaten wezen op het veelbelovende potentieel van deze nieuwe structuren als nieuwe 
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antimalaria “hit” verbindingen. Antifungale analyse resulteerde in de identificatie van zes 8-(4-
aminobutyloxy)chinolinen die beschikken over een goede antifungale werking, en één verbinding 
vertoonde zelfs een significant potentieel als nieuwe breed-spectrum antifungale kandidaat.  
 
In een tweede deel van dit werk werden chinoline-aziridinechimeren viii aangemaakt door chinoline-
carboxaldehyden vi te imineren met 2,3-dibroompropylaminehydrobromide in dichloormethaan in 
de aanwezigheid van magnesiumsulfaat en triëthylamine. De bekomen iminen vii werden vervolgens 
opgelost in methanol en behandeld met natriumboorhydride, hetgeen resulteerde in de vorming van 
nieuwe {[2-(broommethyl)aziridin-1-yl]methyl}chinolinen viii.  
 
Substitutie van deze chinoline-aziridinen met een heteroaromatisch nucleofiel leverde chinoline-
aziridine-pyrazool/pyrimidinon/pyridazinon-hybride verbindingen ix, x en xi op. Selectieve 
ringopening van de reactieve aziridine-eenheid werd vervolgens bekomen door activering van de 
driering met para-tolueensulfonzuur of een Lewiszuur (bv. BF3∙Et2O), waarna een nucleofiele aanval 
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door water of methanol regioselectieve ringopening tot nieuwe gefunctionaliseerde chinolinen xii en 
xiii bewerkstelligde. 
 
Een tweede benadering omtrent aziridine-bevattende hybriden die dienen als intermediairen voor de 
synthese van potentieel nieuwe antimalariamiddelen was gebaseerd op het gebruik van 
isochinolinen. Commercieel beschikbaar 5-hydroxyisochinoline xiv werd gedeprotoneerd door 
natriumhydroxide, waarna nucleofiele substitutie optrad na het toevoegen van 1 equiv 1-arylmethyl-
2-(broommethyl)aziridine, hetgeen resulteerde in de vorming van 5-(aziridin-2-
ylmethoxy)isochinolinen xv in goede rendementen (65-90%). 
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Verschillende strategieën om de gespannen aziridine-ring in de aziridine-isochinolinechimeren xv te 
openen, werden geëvalueerd. De aziridine-eenheid in verbinding xv werd geactiveerd door 
protonering met para-tolueensulfonzuur of door complexering met een Lewiszuur (bv. BF3·Et2O) in 
een THF/water (1/1) solventmengsel of in methanol. Het solvent (water of methanol) zorgde 
vervolgens voor aziridine-ringopening hetgeen isochinoline-aminopropanolen xvi en xvii opleverde. 
Bovendien werd naast de zuurstof-gebaseerde nucleofielen water en methanol ook een stikstof-
gebaseerd nucleofiel (nl. aniline) aangewend om ringopening van aziridinen xv te induceren. Dit 
leverde 1,2-diaminopropanen xviii op in uitstekende rendementen (91-92%). Tot slot werd de 
aziridine-eenheid ook geactiveerd door alkylering van het aziridinestikstofatoom door 
benzylbromide. Het eerste equiv benzylbromide dat werd toegevoegd leidde echter tot selectieve 
alkylering van het isochinolinestikstofatoom, hetgeen resulteerde in de vorming van 
isochinoliniumzout xix. De aziridine-eenheid van dit zout werd vervolgens geopend door een extra 
equiv benzylbromide toe te voegen, hetgeen het gewenste β-broomamine xx opleverde in 
uitstekende rendementen (98%). 
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De antiplasmodiumactiviteit en cytotoxiciteit van de nieuwe aziridine-(iso)chinolinen en hun 
ringgeopende derivaten werden onderzocht en alle verbindingen vertoonden micromolaire activiteit 
tegen een CQ-gevoelige NF54 P. falciparum stam. Zes verbindingen vertoonden eveneens 
micromolaire activiteit tegen een CQ-resistente Dd2 P. falciparum stam. De lage cytotoxiciteit van 
deze gefunctionaliseerde (iso)chinolinen werd bevestigd door hun hoge selectiviteitsindices, hetgeen 
eveneens het veelbelovende potentieel van deze nieuwe verbindingen als antimalaria “lead” 
structuren illustreerde.  
In een derde deel van dit werk werd het principe van moleculaire hybridizatie van een chinolinekern 
en een reactieve heterocyclische verbinding verder onderzocht. De synthese van N-
gefunctionaliseerde 3-, 5-, 6- en 8-aminochinolinen werd bekomen via intermediaire (3-pyrrolin-1-
yl)chinolinen xxiii en (2-oxopyrrolidin-1-yl)chinolinen xxv. (3-Pyrrolin-1-yl)chinolinen xxiii werden 
bekomen door aminochinolinen xxi te behandelen met 4 equiv allylbromide en sequentieel 2 equiv 
lithium bis(trimethylsilyl)amide toe te voegen, hetgeen resulteerde in de vorming van intermediaire 
diallylaminochinolinen xxii. Deze diallylaminochinolinen xxii werden vervolgens onderworpen aan 
een ringsluiting via alkeenmetathese door de toevoeging van 10 mol% 1ste of 2de generatie Grubbs-
katalysator, hetgeen leidde tot (3-pyrrolin-1-yl)chinoline-intermediairen xxiii. (2-Oxopyrrolidin-1-
yl)chinoline-intermediairen xxv werden op hun beurt bekomen door aminochinolinen xxi te 
behandelen met 1 equiv 4-chloorbutyrylchloride in de aanwezigheid van kaliumcarbonaat, hetgeen 
4-chloor-N-chinolinylbutanamiden xxiv opleverde. Een intramoleculaire nucleofiele substitutie in 
deze butanamiden xxiv resulteerde vervolgens in de vorming van (2-oxopyrrolidin-1-yl)chinolinen 
xxv.  
 
Tijdens een tweede fase werd de meest reactieve eenheid van hybriden xxiii and xxv synthetisch 
onderzocht, teneinde N-gefunctionaliseerde 3-, 5-, 6- en 8-aminochinolinen te verkrijgen. De 
reactiviteit van (3-pyrrolin-1-yl)chinolinen xxiii werd geëvalueerd door 2 equiv broom toe te voegen. 
Wanneer de reactietemperatuur op 0 °C werd gehouden, was naast anti-additie van broom op de 3-
pyrroline dubbele binding ook bromering van de chinolinekern waar te nemen op de positie naast de 
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pyrrolidinylzijketen. Dit leverde 3- en 6-gesubstitueerde chinolinen xxvi in matige rendementen (14-
34%). Wanneer 6-(3-pyrrolin-1-yl)chinoline xxiii echter werd gebruikt als substraat en de reactie 
werd uitgevoerd bij karmertemperatuur, werd een complex reactiemengsel bekomen, hoewel na 
zuivering een kleine fractie 1-(5-broomchinolin-6-yl)-2,3,4,5-tetrabroompyrrool xxvii kon geïsoleerd 
worden (9%).  
Verschillende strategiën voor verdere uitwerking van (2-oxopyrrolidin-1-yl)chinolinen xxv werden 
eveneens onderzocht. Ten eerste zorgde het toevoegen van 1,5 equiv lithiumaluminiumhydride aan 
lactamen xxv in tetrahydrofuran na een reactie van 3u onder refluxomstandigheden voor de 
reductieve verwijdering van de carbonylgroep, hetgeen aanleiding gaf tot de vorming van (pyrrolidin-
1-yl)chinolinen xxviii. Ten tweede werden pyrrolidinonen xxv in tetrahydrofuran gereduceerd tot de 
overeenkomstige intermediaire aldehyden door hen te behandelen met 1,5 equiv 
lithiumaluminiumhydride en 2,5u te laten reageren bij kamertemperatuur onder een inerte 
atmosfeer. Methanol werd vervolgens samen met 1,5 equiv natriumboorhydride aan het 
reactiemengsel toegevoegd, dit resulteerde, na 3u additioneel roeren bij kamertemperatuur, in de 
verdere reductie tot primaire alcoholen 4-(chinolinylamino)butanolen xxix. Ten derde werd 
methyllithium sequentieel (4 × 1 equiv, met een interval van 1u) toegevoegd aan lactamen xxv in 
tetrahydrofuran en werd geroerd voor 4u bij 0 °C onder inerte atmosfeer, hetgeen 5-
chinolinylamino-2-methylpentan-2-olen xxx opleverde. Ten laatste werden 2 equiv methyllithium 
sequentieel (2 × 1 equiv, met een interval van 1u) toegevoegd aan lactamen xxv in tetrahydrofuran, 
hetgeen na roeren voor 2u bij 0 °C onder inerte atmosfeer resulteerde in de vorming van 5-
(chinolinylamino)pentan-2-onen xxxi in zeer goede rendementen (79-91%). De nieuw-
gesynthetiseerde methylketonen xxxi bleken echter onstabiel te zijn, maar konden onmiddellijk 
gemodificeerd worden tot 1-chinolinyl-2-methylpyrrolidinen xxxii aan de hand van intramoleculaire 
ringsluiting. Dit werd bewerkstelligd door 5 equiv azijnzuur en 2 equiv natriumcyaanboorhydride toe 
te voegen aan methylketonen xxxi in methanol en te roeren voor 3u bij kamertemperatuur. Om tot 
slot het volledige overzicht van 4-aminobutanolzijketens te bekomen werd 1,5 equiv 
natriumboorhydride toegevoegd aan 5-(chinolinylamino)pentan-2-onen xxxi in methanol, waarna 
roeren voor 2u bij kamertemperatuur de overeenkomstige 5-(chinolinylamino)pentan-2-olen xxxiii 
bekomen werden. 
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Het dient opgemerkt dat 5-(chinolinylamino)pentan-2-olen xxxiii ook kunnen bekomen worden 
volgens een één-potsynthese die uitgaat van lactamen xxv, terwijl ook 5-chinolinylamino-2-
methylpentan-2-olen xxx kunnen bekomen worden via een alternatieve route waarbij 
methylketonen xxxi in tetrahydrofuran behandeld worden met 2 equiv methylmagnesiumjodide voor 
2u bij 0 °C. 
Antiplasmodiumanalyse van deze pyrrolidinylchinolinen en hun derivaten toonde aan dat alle 
verbindingen micromolaire antimalaria-activiteit vertonen tegen een CQ-gevoelige NF54 P. 
falciparum stam (IC50 waarden tussen 13 en 60 µM). De twee actiefste verbindingen werden ook 
getest tegen een CQ-resistente Dd2 P. falciparum stam en vertoonden eveneens matige activiteit 
(IC50 tussen 38 en 49 µM).  
In een laatste deel van deze PhD thesis werden nieuwe gehalogeneerde 4-chinolonen onderzocht. 
Hun synthese begon met een initiële N-(2-methyl)allylering van 4-hydroxychinolinen i met (2-
methyl)allylbromide in de aanwezigheid van kaliumcarbonaat, hetgeen resulteerde in de vorming van 
N-[(2-methyl)allyl]-4-chinolonen xxxiv. Vervolgens werd 1,5 equiv N-broomsuccinimide toegevoegd 
aan deze 4-chinolonen xxxiv hetgeen een selectieve bromering tot 3-broom-1-[(2-methyl)allyl]-4-
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chinolonen xxxv opleverde. Een koper-gekatalyseerde C-N-koppeling van laatstgenoemde 3-broom-
4-chinolonen xxxv met (5-chloor)indool leverde nieuwe 3-[(5-chloor)indol-1-yl]-4-chinolonhybriden 
xxxvi. De bromering van N-(2-methylallyl)-4-chinolonen xxxiv met moleculaire broom resulteerde in 
de bromering van zowel de exocyclische dubbele binding als de 3-positie van de chinolonring, 
hetgeen leidde tot de vorming van 3-broom-1-(2,3-dibroom-2-methylpropyl)-4-chinolonen xxxvii in 
hoge rendementen (98-99%). 
 
In vitro antimalaria-analysen van deze gehalogeneerde chinolonen onthulde dat alle geteste 
verbindingen micromolaire activiteiten vertoonden tegen een CQ-gevoelige NF54 P. falciparum stam. 
Vijf nieuwe verbindingen vertoonden ook micromolaire activiteit tegen een CQ-resistente Dd2 P. 
falciparum stam. Goede selectiviteitsindices verzekerden de lage cytotoxiciteit van 4-chinolon-
indool-hybriden xxxvi, hetgeen opnieuw wijst op het veelbelovende potentieel van deze 
verbindingen als nieuwe antiplasmodium “hit” verbindingen.  
In deze doctoraatsthesis werd een assortiment aan gefunctionaliseerde (iso)chinolinen 
gesynthetiseerd waarvan de zijketen verbonden is met de (iso)chinolinekern op verschillende 
posities. De biologische activiteit van in totaal 101 nieuwe gefunctionalieerde (iso)chinolinen en 4-
chinolonen werd geëvalueerd aan de hand van verschillende biologische analysen, waaronder 
antiplasmodium, antimicrobiële en immunologische tests. De meest veelbelovende verbindingen 
worden hieronder samengevat (IC50 waarden duiden op hun antiplasmodium activiteit, terwijl MIC 
waarden de antimicrobiële activiteit weergeven). 
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Het is duidelijk dat de synthetische exploratie van de chemische ruimte rondom de chinolinekern 
heeft geleid tot een variëteit aan diverse biologisch actieve verbindingen, die kunnen beschouwd 
worden als waardevolle “hit” verbindingen in antimalaria en antimicrobieel onderzoek. 
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